{"PMC7397966": [["IntroductionThe World Health Organization (WHO) on March 11th, 2020 has declared that we are in an exceptional situation of pandemic due to the new SARS-CoV-2 or COVID-19 virus (https://www.who.int/es/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19%2D%2D-11-march-2020).IntroductionManagement of SARS-CoV-2 virus disease or COVID-19 disease has no proven effective treatments to date.", [["SARS-CoV-2 virus disease", "DISEASE", 340, 364], ["COVID-19 disease", "DISEASE", 368, 384], ["SARS-CoV-2", "ORGANISM", 148, 158], ["COVID-19 virus", "ORGANISM", 162, 176], ["SARS-CoV-2 virus", "ORGANISM", 340, 356], ["CoV-2 virus", "SPECIES", 345, 356], ["SARS-CoV", "SPECIES", 148, 156], ["COVID-19 virus", "SPECIES", 162, 176], ["SARS-CoV-2 virus", "SPECIES", 340, 356], ["COVID-19", "SPECIES", 368, 376], ["pandemic", "PROBLEM", 124, 132], ["the new SARS", "PROBLEM", 140, 152], ["CoV", "TEST", 153, 156], ["COVID", "TEST", 162, 167], ["SARS", "PROBLEM", 340, 344], ["CoV", "PROBLEM", 345, 348], ["2 virus disease", "PROBLEM", 349, 364], ["COVID-19 disease", "PROBLEM", 368, 384]]], ["In fact, the Spanish Ministry of Health, in the Technical document entitled \u201cClinical Management of COVID-19: Hospital Care\u201d states that there is currently no evidence from controlled clinical trials to recommend a specific treatment for the SARS-CoV-2 infection in patients with suspected or confirmed COVID-19.", [["SARS-CoV-2 infection", "DISEASE", 242, 262], ["SARS-CoV-2", "ORGANISM", 242, 252], ["patients", "ORGANISM", 266, 274], ["patients", "SPECIES", 266, 274], ["SARS-CoV", "SPECIES", 242, 250], ["a specific treatment", "TREATMENT", 213, 233], ["the SARS", "PROBLEM", 238, 246], ["CoV-2 infection", "PROBLEM", 247, 262], ["COVID", "TEST", 303, 308], ["infection", "OBSERVATION", 253, 262]]], ["However, this information could change rapidly due to the results of several ongoing clinical trials (https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Protocolo_manejo_clinico_ah_COVID-19.pdf).IntroductionOn the other hand, the pandemic situation means that there is a real risk of saturation of the health system with the need to reorganize it and a probable shortage of material and human resources is expected (https://www.eldiario.es/sociedad/coronavirus-sobrecarga-sanidad-Comunidad-Madrid_0_1004050083.html).IntroductionCurrently, about 80 clinical trials are being carried out that seek to define the best therapy for the management of SARS-CoV-2 infection, of which only 3 are dedicated to the study of ozone on this disease and its potential therapeutic use [1].", [["SARS-CoV-2 infection", "DISEASE", 689, 709], ["ozone", "CHEMICAL", 757, 762], ["ozone", "CHEMICAL", 757, 762], ["human", "ORGANISM", 431, 436], ["SARS-CoV-2", "ORGANISM", 689, 699], ["ozone", "SIMPLE_CHEMICAL", 757, 762], ["human", "SPECIES", 431, 436], ["human", "SPECIES", 431, 436], ["SARS-CoV-2", "SPECIES", 689, 699], ["the management", "TREATMENT", 671, 685], ["SARS", "PROBLEM", 689, 693], ["CoV-2 infection", "PROBLEM", 694, 709], ["the study", "TEST", 744, 753], ["this disease", "PROBLEM", 766, 778]]], ["None of the clinical trials consider rectal ozone as a therapeutic option for the management of COVID-19 infection.IntroductionThe current treatment for COVID-19 is supporting, and respiratory failure due to acute respiratory distress syndrome (ARDS) is the main cause of mortality.", [["rectal", "ANATOMY", 37, 43], ["respiratory", "ANATOMY", 181, 192], ["respiratory", "ANATOMY", 214, 225], ["ozone", "CHEMICAL", 44, 49], ["COVID-19", "CHEMICAL", 96, 104], ["infection", "DISEASE", 105, 114], ["respiratory failure", "DISEASE", 181, 200], ["acute respiratory distress syndrome", "DISEASE", 208, 243], ["ARDS", "DISEASE", 245, 249], ["ozone", "CHEMICAL", 44, 49], ["rectal", "ORGAN", 37, 43], ["COVID-19", "ORGANISM", 96, 104], ["COVID-19", "SPECIES", 96, 104], ["rectal ozone", "TREATMENT", 37, 49], ["a therapeutic option", "TREATMENT", 53, 73], ["the management", "TREATMENT", 78, 92], ["COVID-19 infection", "PROBLEM", 96, 114], ["The current treatment", "TREATMENT", 127, 148], ["COVID", "TEST", 153, 158], ["respiratory failure", "PROBLEM", 181, 200], ["acute respiratory distress syndrome", "PROBLEM", 208, 243], ["ARDS", "PROBLEM", 245, 249], ["infection", "OBSERVATION", 105, 114], ["respiratory failure", "OBSERVATION", 181, 200], ["acute", "OBSERVATION_MODIFIER", 208, 213], ["respiratory distress", "OBSERVATION", 214, 234], ["main", "OBSERVATION_MODIFIER", 258, 262], ["mortality", "OBSERVATION", 272, 281]]], ["A subgroup of patients with severe COVID-19 could develop a hyperinflammation or \u201ccytokine storm\u201d syndrome [2].", [["hyperinflammation", "DISEASE", 60, 77], ["patients", "ORGANISM", 14, 22], ["cytokine", "PROTEIN", 82, 90], ["patients", "SPECIES", 14, 22], ["severe COVID", "PROBLEM", 28, 40], ["a hyperinflammation", "PROBLEM", 58, 77], ["\u201ccytokine storm\u201d syndrome", "PROBLEM", 81, 106], ["cytokine storm", "OBSERVATION", 82, 96]]], ["Early identification and treatment of hyperinflammation using all existing therapies with acceptable safety profiles is of paramount importance in order to reduce mortality [3].IntroductionSeveral studies (from Cuba, Italy, Germany, Russia, and Spain) and years of experience have shown that ozone (O3) is capable of modulating inflammation and pain, in addition to having demonstrated a bactericidal, fungicidal, virucidal, and antiparasitic effect [4, 5].", [["hyperinflammation", "DISEASE", 38, 55], ["ozone", "CHEMICAL", 292, 297], ["O3", "CHEMICAL", 299, 301], ["inflammation", "DISEASE", 328, 340], ["pain", "DISEASE", 345, 349], ["ozone", "CHEMICAL", 292, 297], ["O3", "CHEMICAL", 299, 301], ["ozone", "SIMPLE_CHEMICAL", 292, 297], ["O3", "SIMPLE_CHEMICAL", 299, 301], ["hyperinflammation", "PROBLEM", 38, 55], ["all existing therapies", "TREATMENT", 62, 84], ["IntroductionSeveral studies", "TEST", 177, 204], ["modulating inflammation", "PROBLEM", 317, 340], ["pain", "PROBLEM", 345, 349], ["a bactericidal, fungicidal, virucidal", "PROBLEM", 386, 423], ["antiparasitic effect", "PROBLEM", 429, 449], ["inflammation", "OBSERVATION", 328, 340], ["bactericidal", "OBSERVATION_MODIFIER", 388, 400]]], ["These antimicrobial properties have made ozone recognized as a disinfectant so effective that it is used in many water purification plants worldwide [4].", [["ozone", "CHEMICAL", 41, 46], ["ozone", "CHEMICAL", 41, 46], ["ozone", "SIMPLE_CHEMICAL", 41, 46]]], ["In this context, in a recent review, Fern\u00e1ndez-Cuadros et al. reasonably considered that ozone has a place in the management of the present SARS-CoV-2 pandemic, due to its virucidal, immunomodulatory, stimulating cellular and humoral immunity properties, and as a facilitator of O2 transport in hypoxemic tissues [6].IntroductionIn the SARS-CoV-2 infection, three evolutionary stages are recognized (early infection (stage 1), normoxic and hypoxic lung phase (Stage 2a and b), and systemic hyperinflammation or cytokine storm (stage 3)), with characteristic signs and clinical symptoms [6].", [["cellular", "ANATOMY", 213, 221], ["tissues", "ANATOMY", 305, 312], ["lung", "ANATOMY", 448, 452], ["ozone", "CHEMICAL", 89, 94], ["SARS-CoV-2 pandemic", "DISEASE", 140, 159], ["O2", "CHEMICAL", 279, 281], ["SARS-CoV-2 infection", "DISEASE", 336, 356], ["infection", "DISEASE", 406, 415], ["hyperinflammation", "DISEASE", 490, 507], ["ozone", "CHEMICAL", 89, 94], ["O2", "CHEMICAL", 279, 281], ["ozone", "SIMPLE_CHEMICAL", 89, 94], ["SARS-CoV-2", "ORGANISM", 140, 150], ["cellular", "CELL", 213, 221], ["O2", "SIMPLE_CHEMICAL", 279, 281], ["tissues", "TISSUE", 305, 312], ["SARS-CoV-2", "ORGANISM", 336, 346], ["lung", "ORGAN", 448, 452], ["cytokine", "PROTEIN", 511, 519], ["SARS-CoV-2", "SPECIES", 336, 346], ["the management", "TREATMENT", 110, 124], ["the present SARS", "PROBLEM", 128, 144], ["CoV", "TEST", 145, 148], ["pandemic", "PROBLEM", 151, 159], ["its virucidal", "PROBLEM", 168, 181], ["immunomodulatory", "TREATMENT", 183, 199], ["humoral immunity properties", "TREATMENT", 226, 253], ["O2 transport", "TREATMENT", 279, 291], ["hypoxemic tissues", "PROBLEM", 295, 312], ["the SARS-CoV-2 infection", "PROBLEM", 332, 356], ["early infection (stage 1)", "PROBLEM", 400, 425], ["normoxic and hypoxic lung phase", "PROBLEM", 427, 458], ["Stage 2a and b)", "PROBLEM", 460, 475], ["systemic hyperinflammation", "PROBLEM", 481, 507], ["cytokine storm", "PROBLEM", 511, 525], ["characteristic signs", "PROBLEM", 543, 563], ["clinical symptoms", "PROBLEM", 568, 585], ["ozone", "OBSERVATION", 89, 94], ["hypoxemic tissues", "OBSERVATION", 295, 312], ["SARS", "OBSERVATION", 336, 340], ["infection", "OBSERVATION", 347, 356], ["early", "OBSERVATION_MODIFIER", 400, 405], ["infection", "OBSERVATION", 406, 415], ["hypoxic", "OBSERVATION_MODIFIER", 440, 447], ["lung", "ANATOMY", 448, 452], ["phase", "OBSERVATION_MODIFIER", 453, 458], ["systemic", "ANATOMY", 481, 489], ["hyperinflammation", "OBSERVATION", 490, 507], ["cytokine storm", "OBSERVATION", 511, 525]]], ["In this scenario, Fern\u00e1ndez-Cuadros et al. consider that at least 4 biological properties of O3 could allow its use as adjuvant therapy in the different phases of SARS-CoV-2 infection.", [["O3", "CHEMICAL", 93, 95], ["SARS-CoV-2 infection", "DISEASE", 163, 183], ["O3", "CHEMICAL", 93, 95], ["O3", "SIMPLE_CHEMICAL", 93, 95], ["SARS-CoV-2", "ORGANISM", 163, 173], ["SARS-CoV-2", "SPECIES", 163, 173], ["O3", "TREATMENT", 93, 95], ["adjuvant therapy", "TREATMENT", 119, 135], ["SARS", "PROBLEM", 163, 167], ["CoV", "PROBLEM", 168, 171], ["2 infection", "PROBLEM", 172, 183], ["infection", "OBSERVATION", 174, 183]]], ["Ozone could inactivate the virus by direct (O3) or indirect oxidation (ROS (reactive oxygen species) and LOPs (lipid oxidative products)) and could stimulate the cellular and humoral immune system being useful in the early COVID-19 infection phase (stage 1 and 2a).", [["cellular", "ANATOMY", 162, 170], ["Ozone", "CHEMICAL", 0, 5], ["O3", "CHEMICAL", 44, 46], ["ROS", "CHEMICAL", 71, 74], ["oxygen", "CHEMICAL", 85, 91], ["infection", "DISEASE", 232, 241], ["Ozone", "CHEMICAL", 0, 5], ["O3", "CHEMICAL", 44, 46], ["oxygen", "CHEMICAL", 85, 91], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["O3", "SIMPLE_CHEMICAL", 44, 46], ["ROS", "SIMPLE_CHEMICAL", 71, 74], ["reactive oxygen species", "SIMPLE_CHEMICAL", 76, 99], ["LOPs", "SIMPLE_CHEMICAL", 105, 109], ["lipid", "SIMPLE_CHEMICAL", 111, 116], ["cellular", "CELL", 162, 170], ["Ozone", "TREATMENT", 0, 5], ["the virus", "PROBLEM", 23, 32], ["indirect oxidation (ROS (reactive oxygen species", "PROBLEM", 51, 99], ["LOPs (lipid oxidative products", "TREATMENT", 105, 135], ["the early COVID", "TEST", 213, 228]]], ["Ozone improves gas exchange, reduces inflammation, and modulates the antioxidant system, making it useful in the hyper inflammation or cytokine storm phase, and in the hypoxemia and / or multi-organ failure phase (stage 2b and stage 3) [6] (Table 1).IntroductionThe objective of this article is to show the preliminary results on the effectiveness of rectal O3 in a small series of COVID-19 patients with severe bilateral pneumonia admitted at the Santa Cristina University Hospital in Madrid, Spain.Material and MethodsA prospective quasi-experimental before-and-after study was performed.", [["multi-organ", "ANATOMY", 187, 198], ["rectal", "ANATOMY", 351, 357], ["Ozone", "CHEMICAL", 0, 5], ["inflammation", "DISEASE", 37, 49], ["inflammation", "DISEASE", 119, 131], ["hypoxemia", "DISEASE", 168, 177], ["multi-organ failure", "DISEASE", 187, 206], ["O3", "CHEMICAL", 358, 360], ["pneumonia", "DISEASE", 422, 431], ["Ozone", "CHEMICAL", 0, 5], ["O3", "CHEMICAL", 358, 360], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["rectal", "ORGANISM_SUBDIVISION", 351, 357], ["O3", "SIMPLE_CHEMICAL", 358, 360], ["patients", "ORGANISM", 391, 399], ["cytokine", "PROTEIN", 135, 143], ["patients", "SPECIES", 391, 399], ["inflammation", "PROBLEM", 37, 49], ["the hyper inflammation", "PROBLEM", 109, 131], ["the hypoxemia", "PROBLEM", 164, 177], ["multi-organ failure phase", "PROBLEM", 187, 212], ["stage 2b and stage 3)", "PROBLEM", 214, 235], ["rectal O3", "TREATMENT", 351, 360], ["severe bilateral pneumonia", "PROBLEM", 405, 431], ["study", "TEST", 570, 575], ["gas exchange", "OBSERVATION", 15, 27], ["reduces", "OBSERVATION_MODIFIER", 29, 36], ["inflammation", "OBSERVATION", 37, 49], ["hyper", "OBSERVATION_MODIFIER", 113, 118], ["inflammation", "OBSERVATION", 119, 131], ["cytokine storm", "OBSERVATION", 135, 149], ["hypoxemia", "OBSERVATION", 168, 177], ["multi-organ", "ANATOMY", 187, 198], ["failure", "OBSERVATION", 199, 206], ["rectal", "ANATOMY", 351, 357], ["severe", "OBSERVATION_MODIFIER", 405, 411], ["bilateral", "ANATOMY_MODIFIER", 412, 421], ["pneumonia", "OBSERVATION", 422, 431]]], ["The study included 4 severe COVID-19 patients admitted at the Santa Cristina University Hospital, with clinical symptoms and RT-PCR (reverse transcriptase polymerase chain reaction) positive for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).", [["COVID", "DISEASE", 28, 33], ["acute respiratory syndrome coronavirus", "DISEASE", 214, 252], ["patients", "ORGANISM", 37, 45], ["SARS-CoV-2", "ORGANISM", 195, 205], ["reverse transcriptase", "PROTEIN", 133, 154], ["patients", "SPECIES", 37, 45], ["SARS-CoV-2 (severe acute respiratory syndrome coronavirus", "SPECIES", 195, 252], ["The study", "TEST", 0, 9], ["clinical symptoms", "PROBLEM", 103, 120], ["RT-PCR", "TEST", 125, 131], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 133, 180], ["SARS", "PROBLEM", 195, 199], ["CoV", "TEST", 200, 203], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 207, 252], ["severe", "OBSERVATION_MODIFIER", 207, 213], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["respiratory syndrome", "OBSERVATION", 220, 240]]], ["The study was conducted from April to May 2020, and the Hospital\u2019s Health Care Ethics Committee (CEAS Report 15/4/2020) authorized the study and ozone treatment for compassionate use.Material and MethodsInclusion criteria were the following: (1) man or woman, from 18 to 87 years old; (2) with positive detection of new coronavirus nucleic acid (RT-PCR SARS-CoV-2; (3) diagnosed with moderate-severe pneumonia (SpO2 < 93% or PaO2/FiO2 < 300 mmHg), with fever or moderate/severe respiratory symptoms; (4) confirmation of lung lesions with chest X-ray (according to Taylor\u2019s scale) [7]; (5) hospitalized patients with fever and moderate or severe respiratory symptoms; (6) the participant/legal representative must be willing to be given informed consent to participate in the trial.Material and MethodsExclusion criteria were the following: (1) pregnancy or lactation; (2) G-6PD (glucose 6-phosphate dehydrogenase) deficiency (favism) rare in Spain; (3) Patients who have not participated in other clinical studies.Material and MethodsIn the initial evaluation, the objectives of the treatment, the procedure, the indications, and the contraindications were explained to the patients and/or legal representative; the initial biochemical evaluation (leucocytes and lymphocytes count, ferritin, D-Dimer, fibrinogen, procalcitonin, CRP, and IL-6) and the initial radiography of the chest were performed; and informed consent was signed.Material and MethodsThe proposed technique, according to the Madrid International Ozone Therapy Declaration, was to administer intra rectally a volume of 100 mL of rectal ozone, at a concentration of 35 \u03bcg/mL for 5 to 10 days, according to the severity of the patients.Material and MethodsThe supplies needed to perform the technique were as follows: (a) OZONOSAN \u03b1-PLUS \u00ae (Ozone Generator); (b) rectal probe, and (c) two silicone syringes of 50-mL capacity.Material and MethodsFor administration, the patient was placed in the supine or lateral decubitus position with the lower limbs flexed, depending on their collaboration, two 50-mL syringes of Ozone were loaded with the corresponding concentration (35 \u03bcg/mL), and were slowly injected rectally through a 14-French rectal tube, after lubrication with medical gel-type solution.", [["respiratory", "ANATOMY", 478, 489], ["lung lesions", "ANATOMY", 520, 532], ["respiratory", "ANATOMY", 645, 656], ["leucocytes", "ANATOMY", 1248, 1258], ["lymphocytes", "ANATOMY", 1263, 1274], ["chest", "ANATOMY", 1378, 1383], ["rectal", "ANATOMY", 1596, 1602], ["rectal", "ANATOMY", 1828, 1834], ["lateral decubitus", "ANATOMY", 1970, 1987], ["lower limbs", "ANATOMY", 2006, 2017], ["ozone", "CHEMICAL", 145, 150], ["nucleic acid", "CHEMICAL", 332, 344], ["pneumonia", "DISEASE", 400, 409], ["fever", "DISEASE", 453, 458], ["respiratory symptoms", "DISEASE", 478, 498], ["fever", "DISEASE", 616, 621], ["respiratory symptoms", "DISEASE", 645, 665], ["glucose 6-phosphate", "CHEMICAL", 879, 898], ["Ozone", "CHEMICAL", 1514, 1519], ["ozone", "CHEMICAL", 1603, 1608], ["Ozone", "CHEMICAL", 2082, 2087], ["ozone", "CHEMICAL", 145, 150], ["glucose 6-phosphate", "CHEMICAL", 879, 898], ["Ozone", "CHEMICAL", 1514, 1519], ["ozone", "CHEMICAL", 1603, 1608], ["Ozone", "CHEMICAL", 2082, 2087], ["man", "ORGANISM", 246, 249], ["woman", "ORGANISM", 253, 258], ["coronavirus", "ORGANISM", 320, 331], ["lung", "ORGAN", 520, 524], ["lesions", "PATHOLOGICAL_FORMATION", 525, 532], ["patients", "ORGANISM", 602, 610], ["G-6PD", "GENE_OR_GENE_PRODUCT", 872, 877], ["glucose 6-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 879, 912], ["Patients", "ORGANISM", 953, 961], ["patients", "ORGANISM", 1174, 1182], ["leucocytes", "CELL", 1248, 1258], ["lymphocytes", "CELL", 1263, 1274], ["ferritin", "GENE_OR_GENE_PRODUCT", 1282, 1290], ["D-Dimer", "GENE_OR_GENE_PRODUCT", 1292, 1299], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 1301, 1311], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 1313, 1326], ["CRP", "GENE_OR_GENE_PRODUCT", 1328, 1331], ["IL-6", "GENE_OR_GENE_PRODUCT", 1337, 1341], ["chest", "ORGAN", 1378, 1383], ["rectal", "ORGANISM_SUBDIVISION", 1596, 1602], ["patients", "ORGANISM", 1692, 1700], ["rectal", "ORGAN", 1828, 1834], ["patient", "ORGANISM", 1934, 1941], ["lateral decubitus", "ORGANISM_SUBDIVISION", 1970, 1987], ["lower limbs", "ORGANISM_SUBDIVISION", 2006, 2017], ["Ozone", "SIMPLE_CHEMICAL", 2082, 2087], ["rectal tube", "MULTI-TISSUE_STRUCTURE", 2203, 2214], ["glucose 6-phosphate dehydrogenase", "PROTEIN", 879, 912], ["leucocytes", "CELL_TYPE", 1248, 1258], ["lymphocytes", "CELL_TYPE", 1263, 1274], ["ferritin", "PROTEIN", 1282, 1290], ["D-Dimer", "PROTEIN", 1292, 1299], ["fibrinogen", "PROTEIN", 1301, 1311], ["procalcitonin", "PROTEIN", 1313, 1326], ["CRP", "PROTEIN", 1328, 1331], ["IL", "PROTEIN", 1337, 1339], ["man", "SPECIES", 246, 249], ["woman", "SPECIES", 253, 258], ["patients", "SPECIES", 602, 610], ["participant", "SPECIES", 675, 686], ["Patients", "SPECIES", 953, 961], ["patients", "SPECIES", 1174, 1182], ["patients", "SPECIES", 1692, 1700], ["patient", "SPECIES", 1934, 1941], ["The study", "TEST", 0, 9], ["the study", "TEST", 131, 140], ["ozone treatment", "TREATMENT", 145, 160], ["new coronavirus nucleic acid", "TEST", 316, 344], ["RT", "TEST", 346, 348], ["PCR SARS", "TEST", 349, 357], ["CoV", "TEST", 358, 361], ["moderate-severe pneumonia", "PROBLEM", 384, 409], ["SpO2", "TEST", 411, 415], ["PaO2", "TEST", 425, 429], ["FiO2", "TEST", 430, 434], ["fever", "PROBLEM", 453, 458], ["moderate/severe respiratory symptoms", "PROBLEM", 462, 498], ["lung lesions", "PROBLEM", 520, 532], ["chest X-ray", "TEST", 538, 549], ["fever", "PROBLEM", 616, 621], ["moderate or severe respiratory symptoms", "PROBLEM", 626, 665], ["pregnancy or lactation", "PROBLEM", 844, 866], ["G", "TEST", 872, 873], ["glucose", "TEST", 879, 886], ["phosphate dehydrogenase) deficiency (favism)", "PROBLEM", 889, 933], ["other clinical studies", "TEST", 991, 1013], ["the initial evaluation", "TEST", 1037, 1059], ["the treatment", "TREATMENT", 1079, 1092], ["the procedure", "TREATMENT", 1094, 1107], ["the initial biochemical evaluation", "TEST", 1212, 1246], ["leucocytes", "TEST", 1248, 1258], ["lymphocytes count", "TEST", 1263, 1280], ["ferritin", "TEST", 1282, 1290], ["D-Dimer", "TEST", 1292, 1299], ["fibrinogen", "TEST", 1301, 1311], ["procalcitonin", "TEST", 1313, 1326], ["CRP", "TEST", 1328, 1331], ["IL", "TEST", 1337, 1339], ["the initial radiography of the chest", "TEST", 1347, 1383], ["The proposed technique", "TREATMENT", 1452, 1474], ["the Madrid International Ozone Therapy", "TREATMENT", 1489, 1527], ["intra rectally a volume", "TREATMENT", 1559, 1582], ["rectal ozone", "TREATMENT", 1596, 1608], ["the technique", "TEST", 1752, 1765], ["a) OZONOSAN \u03b1-PLUS \u00ae (Ozone Generator)", "TREATMENT", 1784, 1822], ["rectal probe, and (c) two silicone syringes", "TREATMENT", 1828, 1871], ["administration", "TREATMENT", 1914, 1928], ["Ozone", "TREATMENT", 2082, 2087], ["the corresponding concentration", "TREATMENT", 2105, 2136], ["a 14-French rectal tube", "TREATMENT", 2191, 2214], ["lubrication", "TREATMENT", 2222, 2233], ["medical gel-type solution", "TREATMENT", 2239, 2264], ["moderate", "OBSERVATION_MODIFIER", 384, 392], ["severe", "OBSERVATION_MODIFIER", 393, 399], ["pneumonia", "OBSERVATION", 400, 409], ["moderate", "OBSERVATION_MODIFIER", 462, 470], ["severe", "OBSERVATION_MODIFIER", 471, 477], ["respiratory", "ANATOMY", 478, 489], ["lung", "ANATOMY", 520, 524], ["lesions", "OBSERVATION", 525, 532], ["chest", "ANATOMY", 538, 543], ["moderate", "OBSERVATION_MODIFIER", 626, 634], ["severe", "OBSERVATION_MODIFIER", 638, 644], ["respiratory", "ANATOMY", 645, 656], ["chest", "ANATOMY", 1378, 1383], ["rectal", "ANATOMY", 1828, 1834], ["lower limbs", "ANATOMY", 2006, 2017], ["rectal", "ANATOMY", 2203, 2209], ["tube", "OBSERVATION", 2210, 2214]]], ["The insufflation time will be a few minutes, at an administration rate of 1 mL/s.Material and MethodsAfter five to ten sessions of the ozone protocol (O3), the final evaluation was performed; clinical and biochemical analysis and chest radiographies were performed and evaluated; and adverse effects (if any) were recorded.Material and MethodsSince COVID-19 produces an acute and severe respiratory infection, with the lungs being the main target organs affected, chest radiography was the instrument used to grade severity and to confirm diagnosis.", [["chest", "ANATOMY", 230, 235], ["respiratory", "ANATOMY", 387, 398], ["lungs", "ANATOMY", 419, 424], ["organs", "ANATOMY", 447, 453], ["chest", "ANATOMY", 464, 469], ["ozone", "CHEMICAL", 135, 140], ["O3", "CHEMICAL", 151, 153], ["respiratory infection", "DISEASE", 387, 408], ["ozone", "CHEMICAL", 135, 140], ["O3", "SIMPLE_CHEMICAL", 151, 153], ["lungs", "ORGAN", 419, 424], ["organs", "ORGAN", 447, 453], ["The insufflation time", "TREATMENT", 0, 21], ["MethodsAfter", "TREATMENT", 94, 106], ["the ozone protocol", "TREATMENT", 131, 149], ["the final evaluation", "TEST", 156, 176], ["clinical and biochemical analysis", "TEST", 192, 225], ["chest radiographies", "TEST", 230, 249], ["MethodsSince COVID", "TEST", 336, 354], ["an acute and severe respiratory infection", "PROBLEM", 367, 408], ["chest radiography", "TEST", 464, 481], ["grade severity", "PROBLEM", 509, 523], ["insufflation", "OBSERVATION", 4, 16], ["chest", "ANATOMY", 230, 235], ["acute", "OBSERVATION_MODIFIER", 370, 375], ["severe", "OBSERVATION_MODIFIER", 380, 386], ["respiratory", "OBSERVATION_MODIFIER", 387, 398], ["infection", "OBSERVATION", 399, 408], ["lungs", "ANATOMY", 419, 424], ["main", "OBSERVATION_MODIFIER", 435, 439], ["chest", "ANATOMY", 464, 469]]], ["Taylor has proposed a severity scale for severe acute respiratory infection, ranging from 1 to 5 degrees.", [["respiratory", "ANATOMY", 54, 65], ["respiratory infection", "DISEASE", 54, 75], ["a severity scale", "TREATMENT", 20, 36], ["severe acute respiratory infection", "PROBLEM", 41, 75], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["respiratory", "ANATOMY", 54, 65], ["infection", "OBSERVATION", 66, 75]]], ["Grade 1 is considered normal.", [["normal", "OBSERVATION", 22, 28]]], ["Grade 2 shows patchy atelectasis or hyper inflammation or thickening of the bronchial wall.", [["bronchial wall", "ANATOMY", 76, 90], ["atelectasis", "DISEASE", 21, 32], ["inflammation", "DISEASE", 42, 54], ["bronchial wall", "MULTI-TISSUE_STRUCTURE", 76, 90], ["patchy atelectasis", "PROBLEM", 14, 32], ["hyper inflammation", "PROBLEM", 36, 54], ["thickening of the bronchial wall", "PROBLEM", 58, 90], ["patchy", "OBSERVATION_MODIFIER", 14, 20], ["atelectasis", "OBSERVATION", 21, 32], ["hyper", "OBSERVATION_MODIFIER", 36, 41], ["inflammation", "OBSERVATION", 42, 54], ["thickening", "OBSERVATION", 58, 68], ["bronchial", "ANATOMY", 76, 85], ["wall", "ANATOMY_MODIFIER", 86, 90]]], ["Grade 3 includes focal alveolar consolidation but without involving more than one segment or lobe.", [["alveolar", "ANATOMY", 23, 31], ["lobe", "ANATOMY", 93, 97], ["alveolar", "MULTI-TISSUE_STRUCTURE", 23, 31], ["lobe", "ORGAN", 93, 97], ["Grade 3 includes focal alveolar consolidation", "PROBLEM", 0, 45], ["focal", "OBSERVATION_MODIFIER", 17, 22], ["alveolar", "ANATOMY_MODIFIER", 23, 31], ["consolidation", "OBSERVATION", 32, 45], ["without", "UNCERTAINTY", 50, 57], ["lobe", "ANATOMY_MODIFIER", 93, 97]]], ["Grade 4 shows multifocal consolidation and grade 5 includes diffuse alveolar consolidation [7].Material and MethodsStatistical analysis was performed using SPSS\u00ae version 20.0.", [["alveolar", "ANATOMY", 68, 76], ["alveolar", "MULTI-TISSUE_STRUCTURE", 68, 76], ["multifocal consolidation", "PROBLEM", 14, 38], ["grade 5", "PROBLEM", 43, 50], ["diffuse alveolar consolidation", "PROBLEM", 60, 90], ["MethodsStatistical analysis", "TEST", 108, 135], ["SPSS\u00ae version", "TEST", 156, 169], ["multifocal", "OBSERVATION_MODIFIER", 14, 24], ["consolidation", "OBSERVATION", 25, 38], ["grade 5", "OBSERVATION_MODIFIER", 43, 50], ["diffuse", "OBSERVATION_MODIFIER", 60, 67], ["alveolar", "ANATOMY_MODIFIER", 68, 76], ["consolidation", "OBSERVATION", 77, 90]]], ["Frequencies and percentages were used to evaluate qualitative variables, while for the evaluation of quantitative variables, means and standard deviation were used.", [["percentages", "TEST", 16, 27], ["the evaluation", "TEST", 83, 97]]], ["The Mann-Whitney U test was the tool used to evaluate a change before-and-after treatment in quantitative variables.", [["U test", "TEST", 17, 23], ["treatment", "TREATMENT", 80, 89]]], ["The level of significance was 95% (p < 0.05).First case ::: ResultsFifty-seven-year-old man, who after standard treatment already completed (hydroxychloroquine, lopinavir/ritonavir, and azithromycin), one cycle of descending corticosteroid therapy (methylprednisolone), and 26 days of hospital admission, persisted with ventilatory support (reservoir mask at a concentration of 100%) saturating 90%.", [["hydroxychloroquine, lopinavir/ritonavir", "CHEMICAL", 141, 180], ["azithromycin", "CHEMICAL", 186, 198], ["methylprednisolone", "CHEMICAL", 249, 267], ["hydroxychloroquine", "CHEMICAL", 141, 159], ["lopinavir", "CHEMICAL", 161, 170], ["ritonavir", "CHEMICAL", 171, 180], ["azithromycin", "CHEMICAL", 186, 198], ["methylprednisolone", "CHEMICAL", 249, 267], ["man", "ORGANISM", 88, 91], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 141, 159], ["lopinavir", "SIMPLE_CHEMICAL", 161, 170], ["ritonavir", "SIMPLE_CHEMICAL", 171, 180], ["azithromycin", "SIMPLE_CHEMICAL", 186, 198], ["methylprednisolone", "SIMPLE_CHEMICAL", 249, 267], ["man", "SPECIES", 88, 91], ["standard treatment", "TREATMENT", 103, 121], ["hydroxychloroquine", "TREATMENT", 141, 159], ["lopinavir", "TREATMENT", 161, 170], ["ritonavir", "TREATMENT", 171, 180], ["azithromycin", "TREATMENT", 186, 198], ["descending corticosteroid therapy", "TREATMENT", 214, 247], ["methylprednisolone)", "TREATMENT", 249, 268], ["ventilatory support", "TREATMENT", 320, 339], ["reservoir mask", "TREATMENT", 341, 355], ["ventilatory support", "OBSERVATION", 320, 339]]], ["The radiological diagnosis he presented was grade 5 bilateral viral pneumonitis (according to the Taylor\u2019s scale) [7], and he had biochemical signs of inflammation.", [["viral pneumonitis", "DISEASE", 62, 79], ["inflammation", "DISEASE", 151, 163], ["grade 5 bilateral viral pneumonitis", "PROBLEM", 44, 79], ["biochemical signs of inflammation", "PROBLEM", 130, 163], ["bilateral", "ANATOMY_MODIFIER", 52, 61], ["viral pneumonitis", "OBSERVATION", 62, 79], ["inflammation", "OBSERVATION", 151, 163]]], ["Given the clinical severity, compassionate treatment with rectal O3 was authorized.", [["rectal", "ANATOMY", 58, 64], ["O3", "CHEMICAL", 65, 67], ["O3", "CHEMICAL", 65, 67], ["rectal O3", "SIMPLE_CHEMICAL", 58, 67], ["the clinical severity", "PROBLEM", 6, 27], ["compassionate treatment", "TREATMENT", 29, 52], ["rectal O3", "TREATMENT", 58, 67], ["rectal", "ANATOMY", 58, 64]]], ["After 5 sessions, evident clinical improvement was observed, decreasing dyspnea and respiratory rate, starting to use O2 through nasal glasses (4 L flow), and presenting increasingly better saturation levels.", [["respiratory", "ANATOMY", 84, 95], ["nasal", "ANATOMY", 129, 134], ["dyspnea", "DISEASE", 72, 79], ["O2", "CHEMICAL", 118, 120], ["O2", "CHEMICAL", 118, 120], ["O2", "SIMPLE_CHEMICAL", 118, 120], ["decreasing dyspnea", "PROBLEM", 61, 79], ["respiratory rate", "PROBLEM", 84, 100], ["O2 through nasal glasses", "TREATMENT", 118, 142], ["decreasing", "OBSERVATION_MODIFIER", 61, 71], ["dyspnea", "OBSERVATION", 72, 79], ["respiratory rate", "OBSERVATION", 84, 100]]], ["Inflammation markers decreased (fibrinogen from 582 to 496 mg/dL, D-dimer from 626 to 347 ng/mL; urea from 54 to 39 mg/dL, LDH from 281 to 263 U/L, ferritin from 645 to 343 ng/mL, IL-6 from 22.91 to 6.81 pg/mL, and CRP from 0.6 to 0.2 mg/dL) and the radiological grade improved from 5 to 3 (according to the Taylor\u2019s scale) [7] (Fig. 3a).Second case ::: ResultsEighty-seven-year-old man, who after standard treatment already completed (hydroxychloroquine, azithromycin, meropenem due to bacterial infection and two cycles of descending corticosteroid therapy (methylprednisolone)), including tocilizumab (IL-6 inhibitor), persisted with dyspnea after 31 days of admission, requiring O2 by nasal glasses (4 L flow) and frequent episodes of desaturation of up to 87%.", [["nasal", "ANATOMY", 689, 694], ["urea", "CHEMICAL", 97, 101], ["hydroxychloroquine", "CHEMICAL", 436, 454], ["azithromycin", "CHEMICAL", 456, 468], ["meropenem", "CHEMICAL", 470, 479], ["bacterial infection", "DISEASE", 487, 506], ["methylprednisolone", "CHEMICAL", 560, 578], ["tocilizumab", "CHEMICAL", 592, 603], ["dyspnea", "DISEASE", 637, 644], ["O2", "CHEMICAL", 683, 685], ["desaturation", "DISEASE", 739, 751], ["urea", "CHEMICAL", 97, 101], ["hydroxychloroquine", "CHEMICAL", 436, 454], ["azithromycin", "CHEMICAL", 456, 468], ["meropenem", "CHEMICAL", 470, 479], ["methylprednisolone", "CHEMICAL", 560, 578], ["O2", "CHEMICAL", 683, 685], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 32, 42], ["D-dimer", "GENE_OR_GENE_PRODUCT", 66, 73], ["urea", "SIMPLE_CHEMICAL", 97, 101], ["LDH", "GENE_OR_GENE_PRODUCT", 123, 126], ["ferritin", "GENE_OR_GENE_PRODUCT", 148, 156], ["IL-6", "GENE_OR_GENE_PRODUCT", 180, 184], ["CRP", "GENE_OR_GENE_PRODUCT", 215, 218], ["man", "ORGANISM", 383, 386], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 436, 454], ["azithromycin", "SIMPLE_CHEMICAL", 456, 468], ["meropenem", "SIMPLE_CHEMICAL", 470, 479], ["methylprednisolone", "SIMPLE_CHEMICAL", 560, 578], ["tocilizumab", "SIMPLE_CHEMICAL", 592, 603], ["IL-6", "GENE_OR_GENE_PRODUCT", 605, 609], ["O2", "SIMPLE_CHEMICAL", 683, 685], ["Inflammation markers", "PROTEIN", 0, 20], ["fibrinogen", "PROTEIN", 32, 42], ["LDH", "PROTEIN", 123, 126], ["ferritin", "PROTEIN", 148, 156], ["CRP", "PROTEIN", 215, 218], ["man", "SPECIES", 383, 386], ["Inflammation markers", "PROBLEM", 0, 20], ["fibrinogen", "TEST", 32, 42], ["D-dimer", "TEST", 66, 73], ["urea", "TEST", 97, 101], ["LDH", "TEST", 123, 126], ["U/L", "TEST", 143, 146], ["ferritin", "TEST", 148, 156], ["IL", "TEST", 180, 182], ["CRP", "TEST", 215, 218], ["the radiological grade", "TEST", 246, 268], ["standard treatment", "TREATMENT", 398, 416], ["hydroxychloroquine", "TREATMENT", 436, 454], ["azithromycin", "TREATMENT", 456, 468], ["meropenem", "TREATMENT", 470, 479], ["bacterial infection", "PROBLEM", 487, 506], ["descending corticosteroid therapy", "TREATMENT", 525, 558], ["methylprednisolone)", "TREATMENT", 560, 579], ["tocilizumab (IL", "TREATMENT", 592, 607], ["dyspnea", "PROBLEM", 637, 644], ["O2", "TREATMENT", 683, 685], ["nasal glasses", "TREATMENT", 689, 702], ["desaturation", "PROBLEM", 739, 751], ["decreased", "OBSERVATION_MODIFIER", 21, 30], ["bacterial", "OBSERVATION_MODIFIER", 487, 496], ["infection", "OBSERVATION", 497, 506], ["descending", "OBSERVATION_MODIFIER", 525, 535], ["corticosteroid therapy", "OBSERVATION", 536, 558], ["desaturation", "OBSERVATION", 739, 751]]], ["The radiological diagnosis that he showed was bilateral viral pneumonitis grade 5 (according to the Taylor\u2019s scale) [7], and he had elevated inflammation markers.", [["pneumonitis", "DISEASE", 62, 73], ["inflammation", "DISEASE", 141, 153], ["inflammation markers", "PROTEIN", 141, 161], ["bilateral viral pneumonitis grade 5", "PROBLEM", 46, 81], ["elevated inflammation markers", "PROBLEM", 132, 161], ["bilateral", "ANATOMY_MODIFIER", 46, 55], ["viral", "OBSERVATION_MODIFIER", 56, 61], ["pneumonitis", "OBSERVATION", 62, 73], ["elevated", "OBSERVATION_MODIFIER", 132, 140], ["inflammation", "OBSERVATION", 141, 153]]], ["Given the clinical severity, compassionate treatment with rectal O3 was authorized.", [["rectal", "ANATOMY", 58, 64], ["O3", "CHEMICAL", 65, 67], ["O3", "CHEMICAL", 65, 67], ["rectal O3", "SIMPLE_CHEMICAL", 58, 67], ["the clinical severity", "PROBLEM", 6, 27], ["compassionate treatment", "TREATMENT", 29, 52], ["rectal O3", "TREATMENT", 58, 67], ["rectal", "ANATOMY", 58, 64]]], ["After 5 sessions, evident clinical improvement was observed, reducing dyspnea and respiratory rate, ceasing to present desaturation episodes.", [["respiratory", "ANATOMY", 82, 93], ["dyspnea", "DISEASE", 70, 77], ["desaturation", "DISEASE", 119, 131], ["dyspnea", "PROBLEM", 70, 77], ["respiratory rate", "PROBLEM", 82, 98], ["present desaturation episodes", "PROBLEM", 111, 140], ["respiratory rate", "OBSERVATION", 82, 98], ["desaturation episodes", "OBSERVATION", 119, 140]]], ["With the exception of IL-6, all other inflammation markers ameliorated (fibrinogen from 760 to 386 mg/dL, D-dimer from 4844 to 1496 ng/mL; urea from 59 to 57 mg/dL, LDH from 276 to 233 U/L, ferritin from 1222 to 343 ng/mL, IL-6 from 10.53 to 12.02 pg/mL, and CRP from 18.8 to 1.6 mg/dL) and the radiological grade decreased from 5 to 3 (according to the Taylor\u2019s scale) [7] (Fig. 3b).Third case ::: ResultsEighty-four-year-old woman, who after standard treatment already completed (hydroxychloroquine, lopinavir/ritonavir, ciprofloxacin due to bacterial infection, linezolid due to MRSA [+] in sputum, fluconazole due to candida [+] in sputum, amikacin due to Klebsiella [+] in sputum, trimethoprim/sulfamethoxazole due to E. coli BLEE [+], and a cycle of corticotherapy (methylprednisolone) with descending regimen), after 39 days of admission, persisted with dyspnea, requiring O2 through nasal glasses (4 L flow) and fluctuating episodes of desaturation up to 90%.", [["sputum", "ANATOMY", 594, 600], ["sputum", "ANATOMY", 636, 642], ["sputum", "ANATOMY", 678, 684], ["nasal", "ANATOMY", 891, 896], ["inflammation", "DISEASE", 38, 50], ["urea", "CHEMICAL", 139, 143], ["hydroxychloroquine", "CHEMICAL", 482, 500], ["lopinavir/ritonavir", "CHEMICAL", 502, 521], ["ciprofloxacin", "CHEMICAL", 523, 536], ["bacterial infection", "DISEASE", 544, 563], ["linezolid", "CHEMICAL", 565, 574], ["MRSA", "CHEMICAL", 582, 586], ["fluconazole", "CHEMICAL", 602, 613], ["amikacin", "CHEMICAL", 644, 652], ["Klebsiella", "CHEMICAL", 660, 670], ["trimethoprim/sulfamethoxazole", "CHEMICAL", 686, 715], ["methylprednisolone", "CHEMICAL", 772, 790], ["dyspnea", "DISEASE", 861, 868], ["O2", "CHEMICAL", 880, 882], ["desaturation", "DISEASE", 944, 956], ["urea", "CHEMICAL", 139, 143], ["hydroxychloroquine", "CHEMICAL", 482, 500], ["lopinavir", "CHEMICAL", 502, 511], ["ritonavir", "CHEMICAL", 512, 521], ["ciprofloxacin", "CHEMICAL", 523, 536], ["linezolid", "CHEMICAL", 565, 574], ["fluconazole", "CHEMICAL", 602, 613], ["amikacin", "CHEMICAL", 644, 652], ["trimethoprim", "CHEMICAL", 686, 698], ["sulfamethoxazole", "CHEMICAL", 699, 715], ["methylprednisolone", "CHEMICAL", 772, 790], ["O2", "CHEMICAL", 880, 882], ["IL-6", "GENE_OR_GENE_PRODUCT", 22, 26], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 72, 82], ["D-dimer", "GENE_OR_GENE_PRODUCT", 106, 113], ["urea", "SIMPLE_CHEMICAL", 139, 143], ["LDH", "GENE_OR_GENE_PRODUCT", 165, 168], ["ferritin", "GENE_OR_GENE_PRODUCT", 190, 198], ["IL-6", "GENE_OR_GENE_PRODUCT", 223, 227], ["CRP", "GENE_OR_GENE_PRODUCT", 259, 262], ["woman", "ORGANISM", 427, 432], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 482, 500], ["lopinavir", "SIMPLE_CHEMICAL", 502, 511], ["ritonavir", "SIMPLE_CHEMICAL", 512, 521], ["ciprofloxacin", "SIMPLE_CHEMICAL", 523, 536], ["linezolid", "SIMPLE_CHEMICAL", 565, 574], ["fluconazole", "SIMPLE_CHEMICAL", 602, 613], ["amikacin", "SIMPLE_CHEMICAL", 644, 652], ["trimethoprim/sulfamethoxazole", "SIMPLE_CHEMICAL", 686, 715], ["E. coli", "ORGANISM", 723, 730], ["BLEE", "ORGANISM", 731, 735], ["methylprednisolone", "SIMPLE_CHEMICAL", 772, 790], ["O2", "SIMPLE_CHEMICAL", 880, 882], ["IL-6", "PROTEIN", 22, 26], ["inflammation markers", "PROTEIN", 38, 58], ["fibrinogen", "PROTEIN", 72, 82], ["LDH", "PROTEIN", 165, 168], ["ferritin", "PROTEIN", 190, 198], ["CRP", "PROTEIN", 259, 262], ["woman", "SPECIES", 427, 432], ["MRSA", "SPECIES", 582, 586], ["E. coli", "SPECIES", 723, 730], ["E. coli", "SPECIES", 723, 730], ["IL", "TEST", 22, 24], ["all other inflammation markers", "PROBLEM", 28, 58], ["fibrinogen", "TEST", 72, 82], ["D-dimer", "TEST", 106, 113], ["urea", "TEST", 139, 143], ["LDH", "TEST", 165, 168], ["U/L", "TEST", 185, 188], ["ferritin", "TEST", 190, 198], ["IL", "TEST", 223, 225], ["CRP", "TEST", 259, 262], ["the radiological grade", "TEST", 291, 313], ["standard treatment", "TREATMENT", 444, 462], ["hydroxychloroquine", "TREATMENT", 482, 500], ["lopinavir", "TREATMENT", 502, 511], ["ritonavir", "TREATMENT", 512, 521], ["ciprofloxacin", "TREATMENT", 523, 536], ["bacterial infection", "PROBLEM", 544, 563], ["linezolid", "TREATMENT", 565, 574], ["MRSA", "PROBLEM", 582, 586], ["sputum", "PROBLEM", 594, 600], ["fluconazole", "TREATMENT", 602, 613], ["candida", "PROBLEM", 621, 628], ["sputum", "PROBLEM", 636, 642], ["amikacin", "TREATMENT", 644, 652], ["Klebsiella", "PROBLEM", 660, 670], ["sputum", "PROBLEM", 678, 684], ["trimethoprim", "TREATMENT", 686, 698], ["sulfamethoxazole", "TREATMENT", 699, 715], ["E. coli BLEE", "PROBLEM", 723, 735], ["corticotherapy (methylprednisolone)", "TREATMENT", 756, 791], ["descending regimen", "TREATMENT", 797, 815], ["dyspnea", "PROBLEM", 861, 868], ["O2", "TREATMENT", 880, 882], ["nasal glasses", "TREATMENT", 891, 904], ["fluctuating episodes of desaturation", "PROBLEM", 920, 956], ["inflammation", "OBSERVATION", 38, 50], ["decreased", "OBSERVATION_MODIFIER", 314, 323], ["infection", "OBSERVATION", 554, 563], ["dyspnea", "OBSERVATION", 861, 868], ["desaturation", "OBSERVATION_MODIFIER", 944, 956]]], ["The radiological diagnosis that she showed was bilateral viral pneumonitis grade 4 (according to the Taylor\u2019s scale) [7], and elevated inflammation markers.", [["pneumonitis", "DISEASE", 63, 74], ["inflammation", "DISEASE", 135, 147], ["inflammation markers", "PROTEIN", 135, 155], ["bilateral viral pneumonitis grade 4", "PROBLEM", 47, 82], ["elevated inflammation markers", "PROBLEM", 126, 155], ["bilateral", "ANATOMY_MODIFIER", 47, 56], ["viral", "OBSERVATION_MODIFIER", 57, 62], ["pneumonitis", "OBSERVATION", 63, 74], ["elevated", "OBSERVATION_MODIFIER", 126, 134], ["inflammation", "OBSERVATION", 135, 147]]], ["Given the clinical severity, compassionate treatment with rectal O3 was authorized.", [["rectal", "ANATOMY", 58, 64], ["O3", "CHEMICAL", 65, 67], ["O3", "CHEMICAL", 65, 67], ["rectal O3", "SIMPLE_CHEMICAL", 58, 67], ["the clinical severity", "PROBLEM", 6, 27], ["compassionate treatment", "TREATMENT", 29, 52], ["rectal O3", "TREATMENT", 58, 67], ["rectal", "ANATOMY", 58, 64]]], ["After 5 sessions, evident clinical improvement was observed, decreasing dyspnea and respiratory rate, without presenting episodes of desaturation, saturating up to 98% with O2 (4 L flow).", [["respiratory", "ANATOMY", 84, 95], ["dyspnea", "DISEASE", 72, 79], ["desaturation", "DISEASE", 133, 145], ["O2", "CHEMICAL", 173, 175], ["O2", "CHEMICAL", 173, 175], ["O2", "SIMPLE_CHEMICAL", 173, 175], ["decreasing dyspnea", "PROBLEM", 61, 79], ["respiratory rate", "TEST", 84, 100], ["desaturation", "PROBLEM", 133, 145], ["O2", "TREATMENT", 173, 175], ["decreasing", "OBSERVATION_MODIFIER", 61, 71], ["dyspnea", "OBSERVATION", 72, 79], ["respiratory rate", "OBSERVATION", 84, 100], ["desaturation", "OBSERVATION", 133, 145]]], ["Inflammation markers, except for urea, decreased significantly (fibrinogen from 619 to 590 mg/dL, D-dimer from 2303 to 398 ng/mL, urea from 49 to 61 mg/dL, LDH from 327 to 195 U/L, ferritin from 302 to 152 ng/mL, IL-6 from 136.1 to 9.28 pg/mL, and CRP from 2.3 to 1.6 mg/dL).", [["urea", "CHEMICAL", 33, 37], ["urea", "CHEMICAL", 130, 134], ["urea", "CHEMICAL", 33, 37], ["urea", "CHEMICAL", 130, 134], ["urea", "SIMPLE_CHEMICAL", 33, 37], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 64, 74], ["D-dimer", "GENE_OR_GENE_PRODUCT", 98, 105], ["urea", "SIMPLE_CHEMICAL", 130, 134], ["LDH", "GENE_OR_GENE_PRODUCT", 156, 159], ["ferritin", "GENE_OR_GENE_PRODUCT", 181, 189], ["IL-6", "GENE_OR_GENE_PRODUCT", 213, 217], ["CRP", "GENE_OR_GENE_PRODUCT", 248, 251], ["fibrinogen", "PROTEIN", 64, 74], ["LDH", "PROTEIN", 156, 159], ["ferritin", "PROTEIN", 181, 189], ["CRP", "PROTEIN", 248, 251], ["Inflammation markers", "TEST", 0, 20], ["urea", "TEST", 33, 37], ["fibrinogen", "TEST", 64, 74], ["D-dimer", "TEST", 98, 105], ["urea", "TEST", 130, 134], ["LDH", "TEST", 156, 159], ["U/L", "TEST", 176, 179], ["ferritin", "TEST", 181, 189], ["IL", "TEST", 213, 215], ["CRP", "TEST", 248, 251], ["decreased", "OBSERVATION_MODIFIER", 39, 48]]], ["Likewise, the patient presented radiological improvement, going from grade 4 to 3 (according to the Taylor\u2019s scale) [7] (Fig. 3c).Fourth case ::: ResultsThirty-seven-year-old woman, who after standard treatment already completed (hydroxychloroquine, azithromycin, a cycle of corticotherapy (methylprednisolone) with descending regimen; and anakinra (anti IL-1)), after 10 days of admission, persisted with dyspnea, and fluctuating episodes of desaturation up to 90%.", [["hydroxychloroquine", "CHEMICAL", 230, 248], ["azithromycin", "CHEMICAL", 250, 262], ["methylprednisolone", "CHEMICAL", 291, 309], ["anakinra", "CHEMICAL", 340, 348], ["dyspnea", "DISEASE", 406, 413], ["desaturation", "DISEASE", 443, 455], ["hydroxychloroquine", "CHEMICAL", 230, 248], ["azithromycin", "CHEMICAL", 250, 262], ["methylprednisolone", "CHEMICAL", 291, 309], ["patient", "ORGANISM", 14, 21], ["woman", "ORGANISM", 175, 180], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 230, 248], ["azithromycin", "SIMPLE_CHEMICAL", 250, 262], ["methylprednisolone", "SIMPLE_CHEMICAL", 291, 309], ["anakinra", "SIMPLE_CHEMICAL", 340, 348], ["IL-1", "GENE_OR_GENE_PRODUCT", 355, 359], ["patient", "SPECIES", 14, 21], ["woman", "SPECIES", 175, 180], ["standard treatment", "TREATMENT", 192, 210], ["hydroxychloroquine", "TREATMENT", 230, 248], ["azithromycin", "TREATMENT", 250, 262], ["corticotherapy (methylprednisolone)", "TREATMENT", 275, 310], ["descending regimen", "TREATMENT", 316, 334], ["anakinra (anti IL", "TREATMENT", 340, 357], ["dyspnea", "PROBLEM", 406, 413], ["fluctuating episodes of desaturation", "PROBLEM", 419, 455], ["descending", "ANATOMY", 316, 326], ["dyspnea", "OBSERVATION", 406, 413], ["fluctuating", "OBSERVATION_MODIFIER", 419, 430], ["desaturation", "OBSERVATION_MODIFIER", 443, 455]]], ["The radiological diagnosis that she showed was unilateral viral pneumonitis grade 3 (according to the Taylor\u2019s scale) [7], and elevated IL-6 markers.", [["pneumonitis", "DISEASE", 64, 75], ["IL-6", "GENE_OR_GENE_PRODUCT", 136, 140], ["IL-6 markers", "PROTEIN", 136, 148], ["unilateral viral pneumonitis grade 3", "PROBLEM", 47, 83], ["elevated IL", "PROBLEM", 127, 138], ["viral", "OBSERVATION_MODIFIER", 58, 63], ["pneumonitis", "OBSERVATION", 64, 75]]], ["Given the clinical symptoms, compassionate treatment with rectal O3 was authorized.", [["rectal", "ANATOMY", 58, 64], ["O3", "CHEMICAL", 65, 67], ["O3", "CHEMICAL", 65, 67], ["rectal O3", "SIMPLE_CHEMICAL", 58, 67], ["the clinical symptoms", "PROBLEM", 6, 27], ["compassionate treatment", "TREATMENT", 29, 52], ["rectal O3", "TREATMENT", 58, 67]]], ["After 5 sessions, evident clinical improvement was observed, decreasing dyspnea and respiratory rate, without presenting episodes of desaturation, saturating up to 99% without O2.", [["respiratory", "ANATOMY", 84, 95], ["dyspnea", "DISEASE", 72, 79], ["desaturation", "DISEASE", 133, 145], ["O2", "CHEMICAL", 176, 178], ["O2", "CHEMICAL", 176, 178], ["O2", "SIMPLE_CHEMICAL", 176, 178], ["decreasing dyspnea", "PROBLEM", 61, 79], ["respiratory rate", "TEST", 84, 100], ["desaturation", "PROBLEM", 133, 145], ["O2", "TREATMENT", 176, 178], ["decreasing", "OBSERVATION_MODIFIER", 61, 71], ["dyspnea", "OBSERVATION", 72, 79], ["respiratory rate", "OBSERVATION", 84, 100], ["desaturation", "OBSERVATION", 133, 145]]], ["Inflammation markers were on normal range.", [["Inflammation markers", "PROBLEM", 0, 20]]], ["IL-6 was the only variable that decreased after ozone protocol, the other variables increased slightly (fibrinogen from 242 to 250 mg/dL, D-dimer from 87 to 101 ng/mL; urea from 27 to 26 mg/dL, LDH from 128 to 149 U/L, ferritin from 54.5 to 60.5 ng/mL, IL-6 from 5.32 to 5.02 pg/mL, and CRP was 0 mg/dL and remained in 0 mg/dL).", [["ozone", "CHEMICAL", 48, 53], ["urea", "CHEMICAL", 168, 172], ["ozone", "CHEMICAL", 48, 53], ["urea", "CHEMICAL", 168, 172], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 104, 114], ["D-dimer", "GENE_OR_GENE_PRODUCT", 138, 145], ["urea", "SIMPLE_CHEMICAL", 168, 172], ["LDH", "GENE_OR_GENE_PRODUCT", 194, 197], ["ferritin", "GENE_OR_GENE_PRODUCT", 219, 227], ["IL-6", "GENE_OR_GENE_PRODUCT", 253, 257], ["CRP", "GENE_OR_GENE_PRODUCT", 287, 290], ["IL-6", "PROTEIN", 0, 4], ["fibrinogen", "PROTEIN", 104, 114], ["LDH", "PROTEIN", 194, 197], ["ferritin", "PROTEIN", 219, 227], ["CRP", "PROTEIN", 287, 290], ["IL", "TEST", 0, 2], ["ozone protocol", "TREATMENT", 48, 62], ["fibrinogen", "TEST", 104, 114], ["D-dimer", "TEST", 138, 145], ["urea", "TEST", 168, 172], ["LDH", "TEST", 194, 197], ["U/L", "TEST", 214, 217], ["ferritin", "TEST", 219, 227], ["IL", "TEST", 253, 255], ["CRP", "TEST", 287, 290], ["decreased", "OBSERVATION_MODIFIER", 32, 41]]], ["Likewise, the patient presented radiological improvement, going from grade 3 to 2 (according to the Taylor\u2019s scale) [7].DiscussionTo the best of authors\u2019 knowledge, this is the first report in the literature on the effectiveness of rectal ozone in patients with severe COVID-19 pneumonia treated in this new SARS-CoV-2 pandemic.", [["rectal", "ANATOMY", 232, 238], ["ozone", "CHEMICAL", 239, 244], ["COVID", "DISEASE", 269, 274], ["pneumonia", "DISEASE", 278, 287], ["SARS-CoV-2 pandemic", "DISEASE", 308, 327], ["ozone", "CHEMICAL", 239, 244], ["patient", "ORGANISM", 14, 21], ["rectal", "ORGANISM_SUBDIVISION", 232, 238], ["patients", "ORGANISM", 248, 256], ["SARS-CoV-2", "ORGANISM", 308, 318], ["patient", "SPECIES", 14, 21], ["patients", "SPECIES", 248, 256], ["rectal ozone", "TREATMENT", 232, 244], ["severe COVID", "PROBLEM", 262, 274], ["pneumonia", "PROBLEM", 278, 287], ["this new SARS", "PROBLEM", 299, 312], ["CoV", "TEST", 313, 316], ["pandemic", "PROBLEM", 319, 327], ["rectal", "ANATOMY", 232, 238], ["pneumonia", "OBSERVATION", 278, 287]]], ["Rectal ozone improved clinical, biochemical, and radiological symptoms in the preliminary results in a small series of patients.DiscussionTo date, from more than 80 studies that try to find effective therapeutic alternatives for the management of SARS-CoV-2 pandemic and COVID-19 infection, only three studies consider ozone, and all of them apply to autohemotherapy as biologically effective therapy [1].", [["Rectal", "ANATOMY", 0, 6], ["ozone", "CHEMICAL", 7, 12], ["SARS-CoV-2 pandemic", "DISEASE", 247, 266], ["infection", "DISEASE", 280, 289], ["ozone", "CHEMICAL", 319, 324], ["ozone", "CHEMICAL", 7, 12], ["ozone", "CHEMICAL", 319, 324], ["Rectal", "ORGAN", 0, 6], ["patients", "ORGANISM", 119, 127], ["SARS-CoV-2", "ORGANISM", 247, 257], ["COVID-19", "ORGANISM", 271, 279], ["ozone", "SIMPLE_CHEMICAL", 319, 324], ["patients", "SPECIES", 119, 127], ["COVID-19", "SPECIES", 271, 279], ["Rectal ozone", "PROBLEM", 0, 12], ["radiological symptoms", "PROBLEM", 49, 70], ["therapeutic alternatives", "TREATMENT", 200, 224], ["the management", "TREATMENT", 229, 243], ["SARS", "PROBLEM", 247, 251], ["CoV", "TEST", 252, 255], ["pandemic", "PROBLEM", 258, 266], ["COVID", "TREATMENT", 271, 276], ["infection", "PROBLEM", 280, 289], ["autohemotherapy", "TREATMENT", 351, 366], ["ozone", "OBSERVATION_MODIFIER", 7, 12], ["improved", "OBSERVATION_MODIFIER", 13, 21], ["infection", "OBSERVATION", 280, 289]]], ["As far as we are concerned, there are no studies that postulate rectal ozone as a useful alternative in the management of COVID-19 pneumonia [6].", [["rectal", "ANATOMY", 64, 70], ["ozone", "CHEMICAL", 71, 76], ["COVID", "DISEASE", 122, 127], ["pneumonia", "DISEASE", 131, 140], ["ozone", "CHEMICAL", 71, 76], ["rectal", "ORGAN", 64, 70], ["studies", "TEST", 41, 48], ["rectal ozone", "TREATMENT", 64, 76], ["COVID", "TEST", 122, 127], ["pneumonia", "PROBLEM", 131, 140], ["pneumonia", "OBSERVATION", 131, 140]]], ["The importance of the study subsides in the unpublished and innovative protocol.DiscussionOur study group has previously identified up to 4 properties that would be biologically useful to cope with the complications derived from this COVID-19 infection (viral replication, oxidative stress, hyperinflammation or cytokine storm and hypoxia) [6].", [["infection", "DISEASE", 243, 252], ["hyperinflammation", "DISEASE", 291, 308], ["hypoxia", "DISEASE", 331, 338], ["cytokine", "PROTEIN", 312, 320], ["the study", "TEST", 18, 27], ["innovative protocol", "TREATMENT", 60, 79], ["the complications", "PROBLEM", 198, 215], ["this COVID-19 infection", "PROBLEM", 229, 252], ["viral replication", "TREATMENT", 254, 271], ["oxidative stress", "PROBLEM", 273, 289], ["hyperinflammation", "PROBLEM", 291, 308], ["cytokine storm", "PROBLEM", 312, 326], ["hypoxia", "PROBLEM", 331, 338], ["infection", "OBSERVATION", 243, 252]]], ["The study protocol of these properties has been recently published, given the pandemic situation, due to the relevance of the study for the management of SARS-CoV-2 infection and pneumonia due to COVID-19 [6] (Table 1).DiscussionThe clinical improvement observed in the small series of patients confirms that the properties that we had reasonably postulated are effective in managing the complications of this infection (SARS-CoV-2) [6], and they come in line with ozone properties suggested by Martinez-Sanchez [8], Conti [9], and Marini [10].DiscussionOur observations come in line with reports on clinical cases observed in China, Italy, and Spain [11\u201315].", [["SARS-CoV-2 infection", "DISEASE", 154, 174], ["pneumonia", "DISEASE", 179, 188], ["infection", "DISEASE", 410, 419], ["SARS", "DISEASE", 421, 425], ["ozone", "CHEMICAL", 465, 470], ["ozone", "CHEMICAL", 465, 470], ["SARS-CoV-2", "ORGANISM", 154, 164], ["patients", "ORGANISM", 286, 294], ["ozone", "SIMPLE_CHEMICAL", 465, 470], ["patients", "SPECIES", 286, 294], ["SARS-CoV-2", "SPECIES", 154, 164], ["The study protocol", "TEST", 0, 18], ["the study", "TEST", 122, 131], ["the management", "TREATMENT", 136, 150], ["SARS", "PROBLEM", 154, 158], ["CoV-2 infection", "PROBLEM", 159, 174], ["pneumonia", "PROBLEM", 179, 188], ["COVID", "TEST", 196, 201], ["the complications", "PROBLEM", 384, 401], ["this infection", "PROBLEM", 405, 419], ["ozone properties", "TREATMENT", 465, 481], ["infection", "OBSERVATION", 165, 174], ["pneumonia", "OBSERVATION", 179, 188], ["infection", "OBSERVATION", 410, 419]]], ["All cases were treated by ozone autohemotherapy, and none of cases were treated by rectal ozone therapy.DiscussionIn Italy, improvement has been reported in 39 patients in a first report, and after 71 patients (in a second report), treated with ozone via autohemotherapy in the management of patients with COVID-19 pneumonia [11, 12].", [["rectal", "ANATOMY", 83, 89], ["ozone", "CHEMICAL", 26, 31], ["ozone", "CHEMICAL", 90, 95], ["ozone", "CHEMICAL", 245, 250], ["pneumonia", "DISEASE", 315, 324], ["ozone", "CHEMICAL", 26, 31], ["ozone", "CHEMICAL", 90, 95], ["ozone", "CHEMICAL", 245, 250], ["rectal", "ORGANISM_SUBDIVISION", 83, 89], ["patients", "ORGANISM", 160, 168], ["patients", "ORGANISM", 201, 209], ["ozone", "SIMPLE_CHEMICAL", 245, 250], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 160, 168], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 292, 300], ["rectal ozone therapy", "TREATMENT", 83, 103], ["ozone via autohemotherapy", "TREATMENT", 245, 270], ["COVID", "TEST", 306, 311], ["pneumonia", "PROBLEM", 315, 324], ["rectal", "ANATOMY", 83, 89], ["pneumonia", "OBSERVATION", 315, 324]]], ["The authors have reported improvement in the general clinical situation, temperature normalization, decreased CRP, improved O2 saturation and decreased O2 support [11, 12].DiscussionA report of a clinical case in China showed in a 49-year-old patient with severe pneumonia and admitted to the ICU (intensive care unit), after 5 sessions of ozone by autohemotherapy, clinical improvement evident from the outset, the effect of ozone therapy on tissue oxygenation (evaluated by arterial blood gas) lasted approximately 9 h, and the patient was successfully extubated and transferred to Internal Medicine Ward.", [["tissue", "ANATOMY", 443, 449], ["arterial blood", "ANATOMY", 476, 490], ["O2", "CHEMICAL", 124, 126], ["O2", "CHEMICAL", 152, 154], ["pneumonia", "DISEASE", 263, 272], ["ozone", "CHEMICAL", 340, 345], ["ozone", "CHEMICAL", 426, 431], ["O2", "CHEMICAL", 124, 126], ["O2", "CHEMICAL", 152, 154], ["ozone", "CHEMICAL", 340, 345], ["ozone", "CHEMICAL", 426, 431], ["CRP", "GENE_OR_GENE_PRODUCT", 110, 113], ["O2", "SIMPLE_CHEMICAL", 124, 126], ["O2", "SIMPLE_CHEMICAL", 152, 154], ["patient", "ORGANISM", 243, 250], ["ozone", "SIMPLE_CHEMICAL", 340, 345], ["ozone", "SIMPLE_CHEMICAL", 426, 431], ["tissue", "TISSUE", 443, 449], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 476, 490], ["patient", "ORGANISM", 530, 537], ["CRP", "PROTEIN", 110, 113], ["patient", "SPECIES", 243, 250], ["patient", "SPECIES", 530, 537], ["decreased CRP", "PROBLEM", 100, 113], ["O2 saturation", "TEST", 124, 137], ["decreased O2 support", "TREATMENT", 142, 162], ["severe pneumonia", "PROBLEM", 256, 272], ["ozone", "TREATMENT", 340, 345], ["ozone therapy", "TREATMENT", 426, 439], ["tissue oxygenation", "TREATMENT", 443, 461], ["arterial blood gas", "TEST", 476, 494], ["improvement", "OBSERVATION_MODIFIER", 26, 37], ["decreased", "OBSERVATION_MODIFIER", 100, 109], ["CRP", "OBSERVATION_MODIFIER", 110, 113], ["severe", "OBSERVATION_MODIFIER", 256, 262], ["pneumonia", "OBSERVATION", 263, 272]]], ["A significant decrease in D-dimer, fibrinogen, and CRP was observed, in addition to a decrease in IL-6 and negative PCR of SARS-CoV-2 obtained by nasal swab [13].DiscussionIn China, in another preliminary report from two severe COVID-19 patients treated by 7 sessions of autohemotherapy, Zheng et al. have stated that both patients remitted clinical symptoms, and abnormal laboratory and radiological signs.", [["nasal swab", "ANATOMY", 146, 156], ["D-dimer", "GENE_OR_GENE_PRODUCT", 26, 33], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 35, 45], ["CRP", "GENE_OR_GENE_PRODUCT", 51, 54], ["IL-6", "GENE_OR_GENE_PRODUCT", 98, 102], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 123, 133], ["patients", "ORGANISM", 237, 245], ["patients", "ORGANISM", 323, 331], ["D-dimer", "PROTEIN", 26, 33], ["fibrinogen", "PROTEIN", 35, 45], ["CRP", "PROTEIN", 51, 54], ["IL-6", "PROTEIN", 98, 102], ["patients", "SPECIES", 237, 245], ["patients", "SPECIES", 323, 331], ["SARS-CoV", "SPECIES", 123, 131], ["A significant decrease in D-dimer", "PROBLEM", 0, 33], ["fibrinogen", "TEST", 35, 45], ["CRP", "TEST", 51, 54], ["a decrease in IL", "PROBLEM", 84, 100], ["SARS", "PROBLEM", 123, 127], ["CoV", "TEST", 128, 131], ["nasal swab", "TEST", 146, 156], ["autohemotherapy", "TREATMENT", 271, 286], ["Zheng et al", "TREATMENT", 288, 299], ["clinical symptoms", "PROBLEM", 341, 358], ["abnormal laboratory", "PROBLEM", 364, 383], ["radiological signs", "TEST", 388, 406], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["decrease", "OBSERVATION_MODIFIER", 14, 22], ["D-dimer", "OBSERVATION_MODIFIER", 26, 33], ["decrease", "OBSERVATION_MODIFIER", 86, 94], ["nasal", "ANATOMY", 146, 151]]], ["Moreover, patients were discharged with negative RT-PCR testing for SARS-CoV-2.", [["SARS", "DISEASE", 68, 72], ["patients", "ORGANISM", 10, 18], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 68, 78], ["patients", "SPECIES", 10, 18], ["SARS-CoV", "SPECIES", 68, 76], ["PCR testing", "TEST", 52, 63], ["SARS", "TEST", 68, 72], ["CoV", "TEST", 73, 76]]], ["These two cases were matched and compared with two other subjects that were not treated by ozone.", [["ozone", "CHEMICAL", 91, 96], ["ozone", "CHEMICAL", 91, 96], ["ozone", "SIMPLE_CHEMICAL", 91, 96]]], ["Since all four patients followed the Chinese Guidelines for COVID-19 management, it is expected that ozone therapy is responsible for the good effects observed in the ozone autohemotherapy cases [14].DiscussionIn Spain, Dr. Alberto Hern\u00e1ndez has published the case of a 49-year-old patient with severe pneumonia who needed mechanical ventilation with an ICU admission, and in whom ozone (autohemotherapy) was prescribed as a last resort.", [["ozone", "CHEMICAL", 101, 106], ["ozone", "CHEMICAL", 167, 172], ["pneumonia", "DISEASE", 302, 311], ["ozone", "CHEMICAL", 381, 386], ["ozone", "CHEMICAL", 101, 106], ["ozone", "CHEMICAL", 167, 172], ["ozone", "CHEMICAL", 381, 386], ["patients", "ORGANISM", 15, 23], ["ozone", "SIMPLE_CHEMICAL", 101, 106], ["patient", "ORGANISM", 282, 289], ["patients", "SPECIES", 15, 23], ["patient", "SPECIES", 282, 289], ["COVID-19 management", "TREATMENT", 60, 79], ["ozone therapy", "TREATMENT", 101, 114], ["severe pneumonia", "PROBLEM", 295, 311], ["mechanical ventilation", "TREATMENT", 323, 345], ["severe", "OBSERVATION_MODIFIER", 295, 301], ["pneumonia", "OBSERVATION", 302, 311], ["mechanical ventilation", "OBSERVATION", 323, 345]]], ["The patient showed immediate improvement, to the point that after 2 sessions he did not require ICU admission, and after 5 sessions the need for O2 supply decreased markedly [15].", [["O2", "CHEMICAL", 145, 147], ["O2", "CHEMICAL", 145, 147], ["patient", "ORGANISM", 4, 11], ["O2", "SIMPLE_CHEMICAL", 145, 147], ["patient", "SPECIES", 4, 11], ["O2 supply", "TREATMENT", 145, 154], ["immediate", "OBSERVATION_MODIFIER", 19, 28], ["improvement", "OBSERVATION", 29, 40]]], ["Hern\u00e1ndez et al. have emphasized that the clinical improvement is due to the immunomodulatory, oxygenating and antioxidant role of ozone via autohemotherapy in this patient [15].DiscussionAs a summary, the experience in patients with COVID-19 treated in Italy, China, and Spain refers to ozone applied under the autohemotherapy technique [11\u201315].", [["ozone", "CHEMICAL", 131, 136], ["ozone", "CHEMICAL", 288, 293], ["ozone", "CHEMICAL", 131, 136], ["ozone", "CHEMICAL", 288, 293], ["ozone", "SIMPLE_CHEMICAL", 131, 136], ["patient", "ORGANISM", 165, 172], ["patients", "ORGANISM", 220, 228], ["ozone", "SIMPLE_CHEMICAL", 288, 293], ["patient", "SPECIES", 165, 172], ["patients", "SPECIES", 220, 228], ["ozone via autohemotherapy", "TREATMENT", 131, 156], ["COVID", "TEST", 234, 239], ["the autohemotherapy technique", "TREATMENT", 308, 337]]], ["To date, we are not aware of the existence of any study that has treated patients with COVID-19 with rectal ozone.", [["rectal", "ANATOMY", 101, 107], ["ozone", "CHEMICAL", 108, 113], ["COVID-19", "CHEMICAL", 87, 95], ["ozone", "CHEMICAL", 108, 113], ["patients", "ORGANISM", 73, 81], ["rectal", "ORGAN", 101, 107], ["patients", "SPECIES", 73, 81], ["any study", "TEST", 46, 55], ["COVID", "TREATMENT", 87, 92], ["rectal ozone", "TREATMENT", 101, 113], ["rectal", "ANATOMY", 101, 107]]], ["The number of sessions in autohemotherapy (5\u20137 sessions) [11\u201315] was similar to rectal ozone sessions applied in this study (6.75 sessions on average).DiscussionThe Ethics Committee of Santa Cristina Hospital (CEAS) that approved our study, although it recognized that there is controversy about ozone therapy, because there are no national laws or regulations that specifically refer to ozone therapy, but, taking into account the principles of bioethics (non-maleficence, beneficence, justice, and autonomy of the patient) and considering that the proposed technique (rectal ozone therapy) is cheap, simple to apply, and does not require excessive human or material resources, they considered reasonable its use in patients diagnosed with COVID-19, taking into account the 4 biological properties proposed by Fern\u00e1ndez-Cuadros et al., that could act on the pathophysiology of COVID-19 disease and on the SARS-CoV-2 virus [6] (Table 1).", [["rectal", "ANATOMY", 80, 86], ["rectal", "ANATOMY", 570, 576], ["ozone", "CHEMICAL", 87, 92], ["ozone", "CHEMICAL", 296, 301], ["ozone", "CHEMICAL", 388, 393], ["ozone", "CHEMICAL", 577, 582], ["COVID", "DISEASE", 878, 883], ["ozone", "CHEMICAL", 87, 92], ["ozone", "CHEMICAL", 296, 301], ["ozone", "CHEMICAL", 388, 393], ["ozone", "CHEMICAL", 577, 582], ["rectal", "ORGAN", 80, 86], ["ozone", "SIMPLE_CHEMICAL", 296, 301], ["ozone", "SIMPLE_CHEMICAL", 388, 393], ["patient", "ORGANISM", 516, 523], ["rectal", "ORGANISM_SUBDIVISION", 570, 576], ["human", "ORGANISM", 650, 655], ["patients", "ORGANISM", 717, 725], ["SARS-CoV-2 virus", "ORGANISM", 906, 922], ["patient", "SPECIES", 516, 523], ["human", "SPECIES", 650, 655], ["patients", "SPECIES", 717, 725], ["CoV-2 virus", "SPECIES", 911, 922], ["human", "SPECIES", 650, 655], ["SARS-CoV-2 virus", "SPECIES", 906, 922], ["rectal ozone sessions", "TREATMENT", 80, 101], ["this study", "TEST", 113, 123], ["our study", "TEST", 230, 239], ["ozone therapy", "TREATMENT", 296, 309], ["ozone therapy", "TREATMENT", 388, 401], ["the proposed technique (rectal ozone therapy", "TREATMENT", 546, 590], ["excessive human or material resources", "TREATMENT", 640, 677], ["COVID", "TEST", 741, 746], ["COVID-19 disease", "PROBLEM", 878, 894], ["the SARS", "TEST", 902, 910], ["CoV", "TEST", 911, 914], ["rectal", "ANATOMY", 80, 86], ["ozone", "OBSERVATION", 87, 92]]], ["In addition, ozone therapy is part of the Hospital Services portfolio, and has been used for 10 years in the Rehabilitation and Physical Medicine Department for the management of musculoskeletal pain.DiscussionApplying translational medicine, our study group has observed that ozone is able to decrease inflammation biomarkers, such as CRP, ESR (erythrocyte sedimentation rate), and uric acid, markers that play an important role in knee osteoarthritis [5].", [["musculoskeletal", "ANATOMY", 179, 194], ["erythrocyte", "ANATOMY", 346, 357], ["knee", "ANATOMY", 433, 437], ["ozone", "CHEMICAL", 13, 18], ["musculoskeletal pain", "DISEASE", 179, 199], ["ozone", "CHEMICAL", 277, 282], ["inflammation", "DISEASE", 303, 315], ["uric acid", "CHEMICAL", 383, 392], ["osteoarthritis", "DISEASE", 438, 452], ["ozone", "CHEMICAL", 13, 18], ["ozone", "CHEMICAL", 277, 282], ["uric acid", "CHEMICAL", 383, 392], ["ozone", "SIMPLE_CHEMICAL", 13, 18], ["ozone", "SIMPLE_CHEMICAL", 277, 282], ["CRP", "GENE_OR_GENE_PRODUCT", 336, 339], ["erythrocyte", "CELL", 346, 357], ["uric acid", "SIMPLE_CHEMICAL", 383, 392], ["knee", "ORGANISM_SUBDIVISION", 433, 437], ["CRP", "PROTEIN", 336, 339], ["ESR", "PROTEIN", 341, 344], ["ozone therapy", "TREATMENT", 13, 26], ["the management", "TREATMENT", 161, 175], ["musculoskeletal pain", "PROBLEM", 179, 199], ["our study", "TEST", 243, 252], ["inflammation biomarkers", "PROBLEM", 303, 326], ["CRP", "TEST", 336, 339], ["ESR", "TEST", 341, 344], ["erythrocyte sedimentation rate", "TEST", 346, 376], ["uric acid", "TEST", 383, 392], ["knee osteoarthritis", "PROBLEM", 433, 452], ["musculoskeletal", "ANATOMY", 179, 194], ["knee", "ANATOMY", 433, 437], ["osteoarthritis", "OBSERVATION", 438, 452]]], ["Therefore, we hypothesized and afterwards demonstrated that ozone decreased CRP in patients with COVID-19, as it was observed in knee osteoarthritis, although the route of application was different (intra-articular in the first case, rectal in the present study) [5].DiscussionFern\u00e1ndez-Cuadros et al., in a recent review on the fundamentals of ozone therapy, have established that ozone is a multi-target drug, being able to decrease inflammatory cytokines (IL-1\u03b2, IL-6, IFN-\u03b3, TNF-\u03b1), to stimulate anti-inflammatory cytokines (IL-4, IL-10), to stimulate the release of nitric oxide (vasodilator) and stem cells [16].", [["knee", "ANATOMY", 129, 133], ["articular", "ANATOMY", 205, 214], ["rectal", "ANATOMY", 234, 240], ["stem cells", "ANATOMY", 602, 612], ["ozone", "CHEMICAL", 60, 65], ["osteoarthritis", "DISEASE", 134, 148], ["ozone", "CHEMICAL", 345, 350], ["ozone", "CHEMICAL", 382, 387], ["nitric oxide", "CHEMICAL", 571, 583], ["ozone", "CHEMICAL", 60, 65], ["ozone", "CHEMICAL", 345, 350], ["ozone", "CHEMICAL", 382, 387], ["nitric oxide", "CHEMICAL", 571, 583], ["ozone", "SIMPLE_CHEMICAL", 60, 65], ["CRP", "GENE_OR_GENE_PRODUCT", 76, 79], ["patients", "ORGANISM", 83, 91], ["knee", "ORGANISM_SUBDIVISION", 129, 133], ["articular", "TISSUE", 205, 214], ["rectal", "ORGAN", 234, 240], ["ozone", "SIMPLE_CHEMICAL", 345, 350], ["ozone", "SIMPLE_CHEMICAL", 382, 387], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 459, 464], ["IL-6", "GENE_OR_GENE_PRODUCT", 466, 470], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 472, 477], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 479, 484], ["IL-4", "GENE_OR_GENE_PRODUCT", 529, 533], ["IL-10", "GENE_OR_GENE_PRODUCT", 535, 540], ["nitric oxide", "SIMPLE_CHEMICAL", 571, 583], ["vasodilator", "SIMPLE_CHEMICAL", 585, 596], ["stem cells", "CELL", 602, 612], ["CRP", "PROTEIN", 76, 79], ["inflammatory cytokines", "PROTEIN", 435, 457], ["IL-1\u03b2, IL-6", "PROTEIN", 459, 470], ["IFN", "PROTEIN", 472, 475], ["TNF", "PROTEIN", 479, 482], ["anti-inflammatory cytokines", "PROTEIN", 500, 527], ["IL-4, IL-10", "PROTEIN", 529, 540], ["stem cells", "CELL_TYPE", 602, 612], ["patients", "SPECIES", 83, 91], ["ozone decreased CRP", "PROBLEM", 60, 79], ["COVID", "TEST", 97, 102], ["knee osteoarthritis", "PROBLEM", 129, 148], ["ozone therapy", "TREATMENT", 345, 358], ["a multi-target drug", "TREATMENT", 391, 410], ["inflammatory cytokines", "TEST", 435, 457], ["IL", "TEST", 459, 461], ["IL", "TEST", 466, 468], ["IFN", "TEST", 472, 475], ["TNF", "TEST", 479, 482], ["anti-inflammatory cytokines", "TREATMENT", 500, 527], ["IL", "TEST", 529, 531], ["nitric oxide (vasodilator", "TREATMENT", 571, 596], ["stem cells", "TEST", 602, 612], ["ozone", "OBSERVATION_MODIFIER", 60, 65], ["decreased", "OBSERVATION_MODIFIER", 66, 75], ["CRP", "OBSERVATION_MODIFIER", 76, 79], ["knee", "ANATOMY", 129, 133], ["osteoarthritis", "OBSERVATION", 134, 148], ["rectal", "ANATOMY", 234, 240]]], ["In addition, in a very recent review, Fern\u00e1ndez-Cuadros et al. have observed that O3 is capable of inhibiting the inflammasome pathway (NF-\u03ba\u03b2 pathway) [17], a pathway that would play a major role in stimulating hyperinflammation or cytokine storm [2].", [["O3", "CHEMICAL", 82, 84], ["hyperinflammation", "DISEASE", 211, 228], ["O3", "CHEMICAL", 82, 84], ["O3", "SIMPLE_CHEMICAL", 82, 84], ["NF-\u03ba\u03b2", "GENE_OR_GENE_PRODUCT", 136, 141], ["NF-\u03ba\u03b2", "PROTEIN", 136, 141], ["cytokine", "PROTEIN", 232, 240]]], ["These findings would explain why inflammatory variables such as ferritin, IL-6, and CRP decreased in our COVID-19 patients treated with rectal ozone.DiscussionFrom an analysis of patients with SARS-CoV-2 new pandemic (Wuhan, China), it was observed that those patients with a higher viral load had a higher hyperinflammatory state, with an elevation of inflammatory cytokines (IL-2, IL-6, IL-7, IL-10, GCSF, INF-\u03b3, TNF-\u03b1, MCP-1, and MIP-1).", [["rectal", "ANATOMY", 136, 142], ["ozone", "CHEMICAL", 143, 148], ["SARS-CoV-2 new pandemic", "DISEASE", 193, 216], ["ozone", "CHEMICAL", 143, 148], ["ferritin", "GENE_OR_GENE_PRODUCT", 64, 72], ["IL-6", "GENE_OR_GENE_PRODUCT", 74, 78], ["CRP", "GENE_OR_GENE_PRODUCT", 84, 87], ["patients", "ORGANISM", 114, 122], ["rectal", "ORGAN", 136, 142], ["patients", "ORGANISM", 179, 187], ["SARS-CoV-2", "ORGANISM", 193, 203], ["patients", "ORGANISM", 260, 268], ["IL-2", "GENE_OR_GENE_PRODUCT", 377, 381], ["IL-6", "GENE_OR_GENE_PRODUCT", 383, 387], ["IL-7", "GENE_OR_GENE_PRODUCT", 389, 393], ["IL-10", "GENE_OR_GENE_PRODUCT", 395, 400], ["GCSF", "GENE_OR_GENE_PRODUCT", 402, 406], ["INF-\u03b3", "GENE_OR_GENE_PRODUCT", 408, 413], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 415, 420], ["MCP-1", "GENE_OR_GENE_PRODUCT", 422, 427], ["MIP-1", "GENE_OR_GENE_PRODUCT", 433, 438], ["ferritin", "PROTEIN", 64, 72], ["IL-6", "PROTEIN", 74, 78], ["CRP", "PROTEIN", 84, 87], ["inflammatory cytokines", "PROTEIN", 353, 375], ["IL", "PROTEIN", 395, 397], ["GCSF", "PROTEIN", 402, 406], ["INF", "PROTEIN", 408, 411], ["TNF", "PROTEIN", 415, 418], ["MCP", "PROTEIN", 422, 425], ["MIP", "PROTEIN", 433, 436], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 179, 187], ["patients", "SPECIES", 260, 268], ["inflammatory variables", "PROBLEM", 33, 55], ["ferritin", "TEST", 64, 72], ["IL", "TEST", 74, 76], ["CRP", "TEST", 84, 87], ["our COVID", "TEST", 101, 110], ["rectal ozone", "TREATMENT", 136, 148], ["an analysis", "TEST", 164, 175], ["SARS", "PROBLEM", 193, 197], ["a higher viral load", "PROBLEM", 274, 293], ["a higher hyperinflammatory state", "PROBLEM", 298, 330], ["an elevation of inflammatory cytokines", "PROBLEM", 337, 375], ["IL", "TEST", 377, 379], ["IL", "TEST", 383, 385], ["IL", "TEST", 389, 391], ["IL", "TEST", 395, 397], ["GCSF", "TEST", 402, 406], ["INF", "TEST", 408, 411], ["TNF", "TEST", 415, 418], ["MCP", "TEST", 422, 425], ["MIP", "TEST", 433, 436], ["inflammatory", "OBSERVATION", 33, 45], ["rectal", "ANATOMY", 136, 142], ["hyperinflammatory state", "OBSERVATION", 307, 330], ["elevation", "OBSERVATION_MODIFIER", 340, 349], ["inflammatory", "OBSERVATION_MODIFIER", 353, 365]]], ["In this series, the patients who died presented high levels of inflammation markers such as ferritin, IL-6, and ESR, suggesting that the severe inflammatory reaction could contribute to the severity and mortality of the disease [18].DiscussionIn this scenario of cytokine storm or hyperinflammation and given the high risk of mortality, it is necessary to reduce this severe inflammatory response, either with the use of corticosteroids [6], biological drugs (anti IL-1, anti-IL-6, anti-TNF-\u03b1, IFN-\u03b21, JAK inhibitors) [6], human immunoglobulin [6], extracorporeal cytokine clearance therapy [18], or through the use of ozone (due to its \u201cideal\u201d cytokine-inducing or immunomodulatory effect) [4\u20136, 15\u201317].", [["inflammation", "DISEASE", 63, 75], ["hyperinflammation", "DISEASE", 281, 298], ["ozone", "CHEMICAL", 619, 624], ["corticosteroids", "CHEMICAL", 421, 436], ["ozone", "CHEMICAL", 619, 624], ["patients", "ORGANISM", 20, 28], ["ferritin", "GENE_OR_GENE_PRODUCT", 92, 100], ["IL-6", "GENE_OR_GENE_PRODUCT", 102, 106], ["ESR", "GENE_OR_GENE_PRODUCT", 112, 115], ["IL-1", "GENE_OR_GENE_PRODUCT", 465, 469], ["IL-6", "GENE_OR_GENE_PRODUCT", 476, 480], ["anti-TNF-\u03b1", "SIMPLE_CHEMICAL", 482, 492], ["IFN-\u03b21", "GENE_OR_GENE_PRODUCT", 494, 500], ["JAK", "GENE_OR_GENE_PRODUCT", 502, 505], ["human", "ORGANISM", 523, 528], ["immunoglobulin [6]", "SIMPLE_CHEMICAL", 529, 547], ["ozone", "SIMPLE_CHEMICAL", 619, 624], ["inflammation markers", "PROTEIN", 63, 83], ["ferritin", "PROTEIN", 92, 100], ["IL-6", "PROTEIN", 102, 106], ["ESR", "PROTEIN", 112, 115], ["cytokine", "PROTEIN", 263, 271], ["anti-IL-6", "PROTEIN", 471, 480], ["anti", "PROTEIN", 482, 486], ["TNF", "PROTEIN", 487, 490], ["\u03b1", "PROTEIN", 491, 492], ["IFN", "PROTEIN", 494, 497], ["JAK", "PROTEIN", 502, 505], ["human immunoglobulin", "PROTEIN", 523, 543], ["cytokine", "PROTEIN", 564, 572], ["cytokine", "PROTEIN", 645, 653], ["patients", "SPECIES", 20, 28], ["human", "SPECIES", 523, 528], ["human", "SPECIES", 523, 528], ["inflammation markers", "PROBLEM", 63, 83], ["ferritin", "TEST", 92, 100], ["IL", "TEST", 102, 104], ["ESR", "TEST", 112, 115], ["the severe inflammatory reaction", "PROBLEM", 133, 165], ["the severity", "PROBLEM", 186, 198], ["the disease", "PROBLEM", 216, 227], ["cytokine storm", "PROBLEM", 263, 277], ["hyperinflammation", "PROBLEM", 281, 298], ["this severe inflammatory response", "PROBLEM", 363, 396], ["corticosteroids", "TREATMENT", 421, 436], ["biological drugs", "TREATMENT", 442, 458], ["anti IL", "TREATMENT", 460, 467], ["anti-IL", "TREATMENT", 471, 478], ["anti-TNF", "TREATMENT", 482, 490], ["IFN", "TREATMENT", 494, 497], ["JAK inhibitors", "TREATMENT", 502, 516], ["human immunoglobulin", "TREATMENT", 523, 543], ["extracorporeal cytokine clearance therapy", "TREATMENT", 549, 590], ["ozone", "TREATMENT", 619, 624], ["inflammation", "OBSERVATION", 63, 75], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["inflammatory", "OBSERVATION", 144, 156], ["cytokine storm", "OBSERVATION", 263, 277], ["severe", "OBSERVATION_MODIFIER", 368, 374], ["inflammatory", "OBSERVATION", 375, 387]]], ["For this reason, we have opted for ozone therapy in this study as compassionate use, since previous therapies had failed (corticosteroids, anakinra and tocilizumab).DiscussionInfection with SARS-CoV-2 or COVID-19 can produce a state of hyperinflammation or cytokine storm, as occurs in malaria, dengue, Ebola hemorrhagic fever, and in bacterial sepsis.", [["ozone", "CHEMICAL", 35, 40], ["anakinra", "CHEMICAL", 139, 147], ["tocilizumab", "CHEMICAL", 152, 163], ["SARS", "DISEASE", 190, 194], ["COVID-19", "CHEMICAL", 204, 212], ["hyperinflammation", "DISEASE", 236, 253], ["malaria", "DISEASE", 286, 293], ["dengue", "DISEASE", 295, 301], ["Ebola hemorrhagic fever", "DISEASE", 303, 326], ["sepsis", "DISEASE", 345, 351], ["ozone", "CHEMICAL", 35, 40], ["corticosteroids", "CHEMICAL", 122, 137], ["anakinra", "CHEMICAL", 139, 147], ["ozone", "SIMPLE_CHEMICAL", 35, 40], ["anakinra", "SIMPLE_CHEMICAL", 139, 147], ["tocilizumab", "SIMPLE_CHEMICAL", 152, 163], ["SARS-CoV-2", "ORGANISM", 190, 200], ["COVID-19", "SIMPLE_CHEMICAL", 204, 212], ["Ebola", "ORGANISM", 303, 308], ["COVID-19", "DNA", 204, 212], ["cytokine", "PROTEIN", 257, 265], ["Ebola hemorrhagic fever", "SPECIES", 303, 326], ["SARS-CoV", "SPECIES", 190, 198], ["ozone therapy", "TREATMENT", 35, 48], ["this study", "TEST", 52, 62], ["previous therapies", "TREATMENT", 91, 109], ["corticosteroids", "TREATMENT", 122, 137], ["anakinra", "TREATMENT", 139, 147], ["tocilizumab", "TREATMENT", 152, 163], ["SARS", "TEST", 190, 194], ["CoV", "TEST", 195, 198], ["COVID", "TEST", 204, 209], ["hyperinflammation", "PROBLEM", 236, 253], ["cytokine storm", "PROBLEM", 257, 271], ["malaria", "PROBLEM", 286, 293], ["dengue", "PROBLEM", 295, 301], ["Ebola hemorrhagic fever", "PROBLEM", 303, 326], ["bacterial sepsis", "PROBLEM", 335, 351], ["cytokine storm", "OBSERVATION", 257, 271], ["malaria", "OBSERVATION", 286, 293], ["Ebola", "OBSERVATION_MODIFIER", 303, 308], ["bacterial", "OBSERVATION_MODIFIER", 335, 344], ["sepsis", "OBSERVATION", 345, 351]]], ["In fact, it was Rowen who used this route (rectal ozone) for the first time in the management of 5 patients infected with Ebola (60% mortality), and after 5 treatment sessions, significant improvement was achieved without any deaths [19].", [["rectal", "ANATOMY", 43, 49], ["ozone", "CHEMICAL", 50, 55], ["Ebola", "DISEASE", 122, 127], ["deaths", "DISEASE", 226, 232], ["ozone", "CHEMICAL", 50, 55], ["rectal", "ORGANISM_SUBDIVISION", 43, 49], ["patients", "ORGANISM", 99, 107], ["Ebola", "ORGANISM", 122, 127], ["patients", "SPECIES", 99, 107], ["this route (rectal ozone", "TREATMENT", 31, 55], ["Ebola", "TREATMENT", 122, 127]]], ["We have postulated that this benefit could be extrapolated to patients with COVID-19 [6], a hypothesis that has been demonstrated with the presentation of this small series of patients.DiscussionCOVID-19 produces an acute and severe respiratory infection, with the lungs being the main target organs affected.", [["respiratory", "ANATOMY", 233, 244], ["lungs", "ANATOMY", 265, 270], ["organs", "ANATOMY", 293, 299], ["respiratory infection", "DISEASE", 233, 254], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 176, 184], ["lungs", "ORGAN", 265, 270], ["organs", "ORGAN", 293, 299], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 176, 184], ["COVID", "TEST", 76, 81], ["an acute and severe respiratory infection", "PROBLEM", 213, 254], ["acute", "OBSERVATION_MODIFIER", 216, 221], ["severe", "OBSERVATION_MODIFIER", 226, 232], ["respiratory", "ANATOMY", 233, 244], ["infection", "OBSERVATION", 245, 254], ["lungs", "ANATOMY", 265, 270]]], ["Taylor has proposed a severity scale for severe acute respiratory infection, ranging from 1 to 5 degrees [7].", [["respiratory", "ANATOMY", 54, 65], ["respiratory infection", "DISEASE", 54, 75], ["a severity scale", "TREATMENT", 20, 36], ["severe acute respiratory infection", "PROBLEM", 41, 75], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["respiratory", "ANATOMY", 54, 65], ["infection", "OBSERVATION", 66, 75]]], ["This scale is a valid tool to describe the overall severity in patients with acute and severe respiratory infection.", [["respiratory", "ANATOMY", 94, 105], ["respiratory infection", "DISEASE", 94, 115], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["acute and severe respiratory infection", "PROBLEM", 77, 115], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["respiratory", "ANATOMY", 94, 105], ["infection", "OBSERVATION", 106, 115]]], ["Furthermore, this scale allows an overall description of the respiratory characteristics to be provided and will allow comparisons over time in affected patients, in order to assess the evolution of the disease.", [["respiratory", "ANATOMY", 61, 72], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["the disease", "PROBLEM", 199, 210], ["disease", "OBSERVATION", 203, 210]]], ["In our study, this scale has allowed us to see an improvement between 1 and 2 degrees, in patients treated with rectal ozone.DiscussionA postmortem histopathological analysis has established that phase 3 (hyperinflammation or cytokine storm) of COVID-19 infection produces alveolar edema, hyalinosis, and fibrin deposition with infiltration of immune cells at the pulmonary level [18].", [["rectal", "ANATOMY", 112, 118], ["alveolar edema", "ANATOMY", 273, 287], ["immune cells", "ANATOMY", 344, 356], ["pulmonary", "ANATOMY", 364, 373], ["ozone", "CHEMICAL", 119, 124], ["COVID-19", "CHEMICAL", 245, 253], ["infection", "DISEASE", 254, 263], ["alveolar edema", "DISEASE", 273, 287], ["hyalinosis", "DISEASE", 289, 299], ["ozone", "CHEMICAL", 119, 124], ["patients", "ORGANISM", 90, 98], ["rectal", "ORGANISM_SUBDIVISION", 112, 118], ["COVID-19", "GENE_OR_GENE_PRODUCT", 245, 253], ["alveolar edema", "PATHOLOGICAL_FORMATION", 273, 287], ["fibrin", "GENE_OR_GENE_PRODUCT", 305, 311], ["immune cells", "CELL", 344, 356], ["pulmonary", "ORGAN", 364, 373], ["cytokine", "PROTEIN", 226, 234], ["immune cells", "CELL_TYPE", 344, 356], ["patients", "SPECIES", 90, 98], ["our study", "TEST", 3, 12], ["rectal ozone", "TREATMENT", 112, 124], ["postmortem histopathological analysis", "TEST", 137, 174], ["COVID", "TEST", 245, 250], ["infection", "PROBLEM", 254, 263], ["alveolar edema", "PROBLEM", 273, 287], ["hyalinosis", "PROBLEM", 289, 299], ["fibrin deposition", "PROBLEM", 305, 322], ["infiltration of immune cells", "PROBLEM", 328, 356], ["rectal", "ANATOMY", 112, 118], ["alveolar", "ANATOMY_MODIFIER", 273, 281], ["edema", "OBSERVATION", 282, 287], ["hyalinosis", "OBSERVATION", 289, 299], ["fibrin deposition", "OBSERVATION", 305, 322], ["infiltration", "OBSERVATION", 328, 340], ["immune cells", "OBSERVATION", 344, 356], ["pulmonary", "ANATOMY", 364, 373]]], ["The fact that rectal ozone has decreased edema and alveolar infiltrate, verified by radiological tests (Taylor\u2019s scale), added to the decrease in inflammation markers (LDH, ferritin, fibrinogen, D-dimer, IL-6, and CRP) and to the improvement in pulmonary oxygenation (O2 saturation), suggests that ozone is an alternative to consider in the management of severe acute respiratory distress syndrome caused by the SARS-CoV-2 or COVID-19 virus.DiscussionA limitation of this small series of patients is the small sample analyzed.", [["rectal", "ANATOMY", 14, 20], ["edema", "ANATOMY", 41, 46], ["alveolar infiltrate", "ANATOMY", 51, 70], ["pulmonary", "ANATOMY", 245, 254], ["respiratory", "ANATOMY", 368, 379], ["ozone", "CHEMICAL", 21, 26], ["edema", "DISEASE", 41, 46], ["inflammation", "DISEASE", 146, 158], ["ozone", "CHEMICAL", 298, 303], ["respiratory distress syndrome", "DISEASE", 368, 397], ["ozone", "CHEMICAL", 21, 26], ["O2", "CHEMICAL", 268, 270], ["ozone", "CHEMICAL", 298, 303], ["rectal", "ORGAN", 14, 20], ["edema", "PATHOLOGICAL_FORMATION", 41, 46], ["alveolar infiltrate", "PATHOLOGICAL_FORMATION", 51, 70], ["LDH", "GENE_OR_GENE_PRODUCT", 168, 171], ["ferritin", "GENE_OR_GENE_PRODUCT", 173, 181], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 183, 193], ["D-dimer", "GENE_OR_GENE_PRODUCT", 195, 202], ["IL-6", "GENE_OR_GENE_PRODUCT", 204, 208], ["CRP", "GENE_OR_GENE_PRODUCT", 214, 217], ["pulmonary", "ORGAN", 245, 254], ["O2", "SIMPLE_CHEMICAL", 268, 270], ["ozone", "SIMPLE_CHEMICAL", 298, 303], ["SARS-CoV-2", "ORGANISM", 412, 422], ["COVID-19 virus", "ORGANISM", 426, 440], ["patients", "ORGANISM", 488, 496], ["inflammation markers", "PROTEIN", 146, 166], ["LDH", "PROTEIN", 168, 171], ["ferritin", "PROTEIN", 173, 181], ["fibrinogen", "PROTEIN", 183, 193], ["D-dimer", "PROTEIN", 195, 202], ["IL-6", "PROTEIN", 204, 208], ["CRP", "PROTEIN", 214, 217], ["patients", "SPECIES", 488, 496], ["SARS-CoV", "SPECIES", 412, 420], ["COVID-19 virus", "SPECIES", 426, 440], ["rectal ozone", "PROBLEM", 14, 26], ["decreased edema", "PROBLEM", 31, 46], ["alveolar infiltrate", "PROBLEM", 51, 70], ["radiological tests", "TEST", 84, 102], ["the decrease in inflammation markers", "PROBLEM", 130, 166], ["LDH", "TEST", 168, 171], ["ferritin", "TEST", 173, 181], ["fibrinogen", "TEST", 183, 193], ["D-dimer", "TEST", 195, 202], ["IL", "TEST", 204, 206], ["CRP", "TEST", 214, 217], ["pulmonary oxygenation", "TEST", 245, 266], ["O2 saturation", "TEST", 268, 281], ["severe acute respiratory distress syndrome", "PROBLEM", 355, 397], ["the SARS", "PROBLEM", 408, 416], ["CoV", "TEST", 417, 420], ["COVID-19 virus", "PROBLEM", 426, 440], ["rectal", "ANATOMY", 14, 20], ["ozone", "OBSERVATION", 21, 26], ["decreased", "OBSERVATION_MODIFIER", 31, 40], ["edema", "OBSERVATION", 41, 46], ["alveolar", "ANATOMY_MODIFIER", 51, 59], ["infiltrate", "OBSERVATION", 60, 70], ["decrease", "OBSERVATION_MODIFIER", 134, 142], ["inflammation", "OBSERVATION", 146, 158], ["improvement", "OBSERVATION_MODIFIER", 230, 241], ["pulmonary", "ANATOMY", 245, 254], ["oxygenation", "OBSERVATION_MODIFIER", 255, 266], ["severe", "OBSERVATION_MODIFIER", 355, 361], ["acute", "OBSERVATION_MODIFIER", 362, 367], ["respiratory distress syndrome", "OBSERVATION", 368, 397], ["small", "OBSERVATION_MODIFIER", 504, 509]]], ["The fact that the improvement observed in the variables analyzed was nominal, but not statistical; it does not mean that there is not a benefit from this intervention.", [["this intervention", "TREATMENT", 149, 166], ["improvement", "OBSERVATION_MODIFIER", 18, 29]]], ["A greater sample is necessary to get a statistical improvement, although the clinical benefit was already observed in this preliminary study.DiscussionA one-group before-and-after study lacks of randomization and control group.", [["this preliminary study", "TEST", 118, 140], ["randomization and control group", "TREATMENT", 195, 226]]], ["A quasi-experimental study by definition is used to establish the causality (the effect of an independent variable over a dependent variable) in situations where researchers are not able to randomly assign groups to the subjects for various reasons [20].", [["A quasi-experimental study", "TEST", 0, 26]]], ["One of those reasons is sample size and another reason is ethical purposes.", [["size", "OBSERVATION_MODIFIER", 31, 35]]], ["In a pretest-posttest analysis, the effect of the intervention (rectal ozone treatment) is expected to be the change in a before-and-after evaluation [20].", [["rectal", "ANATOMY", 64, 70], ["ozone", "CHEMICAL", 71, 76], ["ozone", "CHEMICAL", 71, 76], ["rectal", "ORGANISM_SUBDIVISION", 64, 70], ["a pretest-posttest analysis", "TEST", 3, 30], ["the intervention", "TREATMENT", 46, 62], ["rectal ozone treatment", "TREATMENT", 64, 86], ["evaluation", "TEST", 139, 149], ["rectal", "ANATOMY", 64, 70]]], ["Quasi-experimental studies are used because they are more practical and feasible to conduct.", [["Quasi-experimental studies", "TEST", 0, 26]]], ["This design is preferred when sample size is small or the availability of control group because of ethical reasons is not possible [20].", [["small", "OBSERVATION_MODIFIER", 45, 50]]], ["This design is more suitable for a real natural world setting (rehabilitation setting) than true experimental designs.", [["rehabilitation setting", "TREATMENT", 63, 85]]], ["This design allows the researchers to evaluate the impact of a quasi-independent variable (rectal ozone) under naturally occurring conditions (natural history of COVID-19 disease) [20].However, neither the small sample size nor the lack of control group did not influence on the results observed in the current study.DiscussionThe strength of the study is that the patients have been evaluated taking into account clinical (O2 saturation and O2 supply), laboratory (systemic inflammation markers) and radiological characteristics, using instruments (pulse oximeter), laboratory equipment and radiological scales (Taylor\u2019s scale) that are clinically validated.DiscussionIn a cost/effectiveness analysis, Ozone is an anti-inflammatory technique capable of decreasing several markers of inflammation (as it was observed in this study), and ozone is cheaper and safer if compared to biological treatments (monoclonal antibodies) [9].", [["rectal", "ANATOMY", 91, 97], ["ozone", "CHEMICAL", 98, 103], ["Ozone", "CHEMICAL", 703, 708], ["inflammation", "DISEASE", 784, 796], ["ozone", "CHEMICAL", 837, 842], ["ozone", "CHEMICAL", 98, 103], ["O2", "CHEMICAL", 424, 426], ["O2", "CHEMICAL", 442, 444], ["Ozone", "CHEMICAL", 703, 708], ["ozone", "CHEMICAL", 837, 842], ["rectal", "ORGANISM_SUBDIVISION", 91, 97], ["patients", "ORGANISM", 365, 373], ["O2", "SIMPLE_CHEMICAL", 424, 426], ["O2", "SIMPLE_CHEMICAL", 442, 444], ["Ozone", "SIMPLE_CHEMICAL", 703, 708], ["ozone", "SIMPLE_CHEMICAL", 837, 842], ["monoclonal antibodies", "PROTEIN", 902, 923], ["patients", "SPECIES", 365, 373], ["a quasi-independent variable (rectal ozone", "TREATMENT", 61, 103], ["the small sample size", "PROBLEM", 202, 223], ["the current study", "TEST", 299, 316], ["the study", "TEST", 343, 352], ["O2 saturation", "TEST", 424, 437], ["O2 supply", "TEST", 442, 451], ["laboratory (systemic inflammation markers", "TEST", 454, 495], ["radiological characteristics", "TEST", 501, 529], ["instruments (pulse oximeter", "TREATMENT", 537, 564], ["laboratory equipment", "TEST", 567, 587], ["radiological scales", "TEST", 592, 611], ["a cost/effectiveness analysis", "TREATMENT", 672, 701], ["Ozone", "TREATMENT", 703, 708], ["an anti-inflammatory technique", "TREATMENT", 712, 742], ["inflammation", "PROBLEM", 784, 796], ["this study", "TEST", 820, 830], ["rectal", "ANATOMY", 91, 97], ["small", "OBSERVATION_MODIFIER", 206, 211], ["sample", "OBSERVATION_MODIFIER", 212, 218], ["size", "OBSERVATION_MODIFIER", 219, 223], ["inflammation", "OBSERVATION", 784, 796]]], ["This analysis makes this treatment option a valid alternative for low-middle-income countries, where patients have to pay for their medical bills.DiscussionFinally, our study group, given the effectiveness observed in these first cases treated in the world with rectal ozone, and taking into account the safety, simplicity of the technique and the low cost, has submitted to the AEMPS (Spanish Agency for Medicines and Medical Devices) request to conduct a clinical trial, in order to confirm these promising results, in a much larger sample of patients.ConclusionRectal ozone decreases O2 supply and improves O2 saturation, decreases inflammation biomarkers, and improves Taylor\u2019s radiological grade in patients with severe COVID-19 pneumonia.", [["rectal", "ANATOMY", 262, 268], ["ozone", "CHEMICAL", 269, 274], ["ozone", "CHEMICAL", 571, 576], ["O2", "CHEMICAL", 587, 589], ["O2", "CHEMICAL", 610, 612], ["inflammation", "DISEASE", 635, 647], ["COVID", "DISEASE", 725, 730], ["pneumonia", "DISEASE", 734, 743], ["ozone", "CHEMICAL", 269, 274], ["ozone", "CHEMICAL", 571, 576], ["O2", "CHEMICAL", 587, 589], ["O2", "CHEMICAL", 610, 612], ["patients", "ORGANISM", 101, 109], ["rectal", "ORGAN", 262, 268], ["patients", "ORGANISM", 545, 553], ["ozone", "SIMPLE_CHEMICAL", 571, 576], ["O2", "SIMPLE_CHEMICAL", 587, 589], ["O2", "SIMPLE_CHEMICAL", 610, 612], ["patients", "ORGANISM", 704, 712], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 545, 553], ["patients", "SPECIES", 704, 712], ["This analysis", "TEST", 0, 13], ["this treatment option", "TREATMENT", 20, 41], ["rectal ozone", "TREATMENT", 262, 274], ["the technique", "TREATMENT", 326, 339], ["ConclusionRectal ozone", "TREATMENT", 554, 576], ["O2 supply", "TREATMENT", 587, 596], ["O2 saturation", "TEST", 610, 623], ["decreases inflammation biomarkers", "PROBLEM", 625, 658], ["severe COVID", "PROBLEM", 718, 730], ["pneumonia", "PROBLEM", 734, 743], ["rectal", "ANATOMY", 262, 268], ["severe", "OBSERVATION_MODIFIER", 718, 724], ["pneumonia", "OBSERVATION", 734, 743]]], ["Rectal ozone is a safe, effective, cheap, and simple alternative capable of acting on the SARS-CoV-2 virus, and it is presented as an adjunctive therapeutic option to consider in the management of severe bilateral COVID-19 pneumonia.", [["Rectal", "ANATOMY", 0, 6], ["ozone", "CHEMICAL", 7, 12], ["pneumonia", "DISEASE", 223, 232], ["ozone", "CHEMICAL", 7, 12], ["Rectal", "ORGAN", 0, 6], ["SARS-CoV-2 virus", "ORGANISM", 90, 106], ["SARS-CoV-2 virus", "SPECIES", 90, 106], ["Rectal ozone", "PROBLEM", 0, 12], ["cheap", "TREATMENT", 35, 40], ["the SARS", "TEST", 86, 94], ["an adjunctive therapeutic option", "TREATMENT", 131, 163], ["severe bilateral COVID-19 pneumonia", "PROBLEM", 197, 232], ["ozone", "OBSERVATION", 7, 12], ["severe", "OBSERVATION_MODIFIER", 197, 203], ["bilateral", "ANATOMY_MODIFIER", 204, 213], ["COVID", "ANATOMY", 214, 219], ["pneumonia", "OBSERVATION", 223, 232]]]], "40ee23685395d5bca3db0f4946e5ce7b1c6003f5": [["IntroductionSevere Acute Respiratory Infection (SARI) is an important cause of morbidity and mortality worldwide, particularly in developing countries and among children under five years of age (GBD LRI Collaborators, 2017; GBD 2015 LRI Collaborators, 2017 World Health Organization, 2011) .", [["Acute Respiratory Infection", "DISEASE", 19, 46], ["SARI", "DISEASE", 48, 52], ["children", "ORGANISM", 161, 169], ["children", "SPECIES", 161, 169], ["Acute Respiratory Infection", "PROBLEM", 19, 46], ["morbidity", "PROBLEM", 79, 88], ["Acute", "OBSERVATION_MODIFIER", 19, 24], ["Respiratory", "ANATOMY", 25, 36], ["Infection", "OBSERVATION", 37, 46], ["morbidity", "OBSERVATION", 79, 88]]], ["SARI is associated with viral and bacterial agents.", [["SARI", "DISEASE", 0, 4], ["SARI", "PROBLEM", 0, 4], ["viral and bacterial agents", "TREATMENT", 24, 50], ["bacterial agents", "OBSERVATION", 34, 50]]], ["Common viral agents are influenza A (Infl A) and B (Infl B) viruses, parainfluenza viruses (PIV), coronaviruses, respiratory syncytial viruses (RSV), adenoviruses (AV), and rhinoviruses.", [["parainfluenza viruses", "DISEASE", 69, 90], ["respiratory syncytial viruses (RSV), adenoviruses (AV), and rhinoviruses", "DISEASE", 113, 185], ["influenza A", "ORGANISM", 24, 35], ["Infl A", "ORGANISM", 37, 43], ["B (Infl B) viruses", "ORGANISM", 49, 67], ["parainfluenza viruses", "ORGANISM", 69, 90], ["coronaviruses", "ORGANISM", 98, 111], ["respiratory syncytial viruses", "ORGANISM", 113, 142], ["RSV", "ORGANISM", 144, 147], ["adenoviruses", "ORGANISM", 150, 162], ["rhinoviruses", "ORGANISM", 173, 185], ["parainfluenza", "SPECIES", 69, 82], ["coronaviruses", "SPECIES", 98, 111], ["respiratory syncytial viruses", "SPECIES", 113, 142], ["parainfluenza viruses", "SPECIES", 69, 90], ["PIV", "SPECIES", 92, 95], ["respiratory syncytial viruses", "SPECIES", 113, 142], ["RSV", "SPECIES", 144, 147], ["AV", "SPECIES", 164, 166], ["influenza", "PROBLEM", 24, 33], ["B (Infl B) viruses", "PROBLEM", 49, 67], ["parainfluenza viruses", "PROBLEM", 69, 90], ["PIV", "TEST", 92, 95], ["coronaviruses", "PROBLEM", 98, 111], ["respiratory syncytial viruses", "PROBLEM", 113, 142], ["adenoviruses", "PROBLEM", 150, 162], ["rhinoviruses", "PROBLEM", 173, 185], ["viral agents", "OBSERVATION", 7, 19], ["parainfluenza viruses", "OBSERVATION", 69, 90], ["respiratory", "ANATOMY", 113, 124], ["syncytial viruses", "OBSERVATION", 125, 142], ["rhinoviruses", "OBSERVATION", 173, 185]]], ["Influenza virus infection, in particular, is very common followed by respiratory syncytial virus (RSV) infection (CDC, 2016; Laguna-Torres et al., 2011; Chakhunashvili et al., 2018; Kenmoe et al., 2016; Tjon-Kon-Fat et al., 2016) .", [["Influenza virus infection", "DISEASE", 0, 25], ["respiratory syncytial virus (RSV) infection", "DISEASE", 69, 112], ["Influenza virus", "ORGANISM", 0, 15], ["respiratory syncytial virus", "ORGANISM", 69, 96], ["RSV", "ORGANISM", 98, 101], ["Influenza virus", "SPECIES", 0, 15], ["syncytial virus (RSV", "SPECIES", 81, 101], ["Influenza virus", "SPECIES", 0, 15], ["respiratory syncytial virus", "SPECIES", 69, 96], ["RSV", "SPECIES", 98, 101], ["Influenza virus infection", "PROBLEM", 0, 25], ["respiratory syncytial virus (RSV) infection", "PROBLEM", 69, 112], ["Tjon", "TEST", 203, 207], ["virus infection", "OBSERVATION", 10, 25], ["respiratory", "ANATOMY", 69, 80], ["syncytial virus", "OBSERVATION", 81, 96]]], ["Newer respiratory pathogens are also emerging.", [["respiratory pathogens", "DISEASE", 6, 27], ["Newer respiratory pathogens", "PROBLEM", 0, 27], ["pathogens", "OBSERVATION", 18, 27]]], ["In view of this, we investigated the association of human PARV4 virus with SARI.IntroductionParvovirus 4 (PARV4) is a newly discovered human Parvovirus, first reported in 2005 in serum of intravenous drug users infected with hepatitis B virus (Jones et al., 2005) .", [["serum", "ANATOMY", 179, 184], ["intravenous", "ANATOMY", 188, 199], ["human Parvovirus", "DISEASE", 135, 151], ["hepatitis B", "DISEASE", 225, 236], ["human", "ORGANISM", 52, 57], ["PARV4 virus", "ORGANISM", 58, 69], ["IntroductionParvovirus 4", "ORGANISM", 80, 104], ["PARV4", "GENE_OR_GENE_PRODUCT", 106, 111], ["human", "ORGANISM", 135, 140], ["serum", "ORGANISM_SUBSTANCE", 179, 184], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 188, 199], ["hepatitis B virus", "ORGANISM", 225, 242], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 135, 140], ["hepatitis B virus", "SPECIES", 225, 242], ["human PARV4 virus", "SPECIES", 52, 69], ["human", "SPECIES", 135, 140], ["hepatitis B virus", "SPECIES", 225, 242], ["human PARV4 virus", "PROBLEM", 52, 69], ["SARI", "PROBLEM", 75, 79], ["IntroductionParvovirus", "TREATMENT", 80, 102], ["a newly discovered human Parvovirus", "PROBLEM", 116, 151], ["hepatitis B virus", "PROBLEM", 225, 242], ["Parvovirus", "OBSERVATION", 141, 151]]], ["PARV4 is a single stranded non-enveloped DNA virus belonging to the Parvoviridae family of genus Tetraparvovirus (Matthews et al., 2017) .", [["PARV4", "CHEMICAL", 0, 5], ["PARV4", "GENE_OR_GENE_PRODUCT", 0, 5], ["DNA", "CELLULAR_COMPONENT", 41, 44], ["PARV4", "DNA", 0, 5], ["a single stranded non-enveloped DNA virus", "PROBLEM", 9, 50]]], ["PARV4 infects a diverse range of hosts and has been classified into 3 genotypes; 1-3.", [["PARV4", "CHEMICAL", 0, 5], ["PARV4", "GENE_OR_GENE_PRODUCT", 0, 5], ["PARV4", "PROTEIN", 0, 5], ["PARV4", "SPECIES", 0, 5], ["diverse range", "OBSERVATION_MODIFIER", 16, 29]]], ["Generally genotypes 1 and 2 are found in North America, Europe, and Asia, and genotype 3 is found in sub-Saharan Africa.IntroductionPARV4 has been detected in blood/plasma, autopsy samples, stool, nasopharyngeal swab, the bone marrow and CSF; however, until now, there are no established clinical manifestations of PARV4 infection (Simmonds et al., 2007a) .", [["blood", "ANATOMY", 159, 164], ["plasma", "ANATOMY", 165, 171], ["autopsy samples", "ANATOMY", 173, 188], ["stool", "ANATOMY", 190, 195], ["nasopharyngeal swab", "ANATOMY", 197, 216], ["bone marrow", "ANATOMY", 222, 233], ["IntroductionPARV4", "CHEMICAL", 120, 137], ["PARV4 infection", "DISEASE", 315, 330], ["blood", "ORGANISM_SUBSTANCE", 159, 164], ["plasma", "ORGANISM_SUBSTANCE", 165, 171], ["autopsy samples", "ORGANISM_SUBSTANCE", 173, 188], ["stool", "ORGANISM_SUBSTANCE", 190, 195], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 197, 216], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 222, 233], ["CSF", "ORGANISM_SUBSTANCE", 238, 241], ["PARV4", "ORGANISM", 315, 320], ["IntroductionPARV4", "PROTEIN", 120, 137], ["PARV4", "SPECIES", 315, 320], ["IntroductionPARV4", "TREATMENT", 120, 137], ["blood/plasma", "TEST", 159, 171], ["autopsy samples", "TEST", 173, 188], ["stool, nasopharyngeal swab", "TEST", 190, 216], ["the bone marrow and CSF", "TEST", 218, 241], ["PARV4 infection", "PROBLEM", 315, 330], ["nasopharyngeal", "ANATOMY", 197, 211], ["bone marrow", "ANATOMY", 222, 233], ["infection", "OBSERVATION", 321, 330]]], ["It remains uncertain whether PARV4 actually causes the observed disease, or is a bystander that was coincidentally detected in a highly exposed population.", [["PARV4", "CHEMICAL", 29, 34], ["PARV4", "GENE_OR_GENE_PRODUCT", 29, 34], ["PARV4", "PROTEIN", 29, 34], ["PARV4", "PROBLEM", 29, 34], ["the observed disease", "PROBLEM", 51, 71], ["disease", "OBSERVATION", 64, 71]]], ["Seroprevalence of PARV4 in the general population has been varying in different parts of the world ranging from 0% to 25% Lavoie et al., 2012) .", [["PARV4", "CHEMICAL", 18, 23], ["PARV4", "GENE_OR_GENE_PRODUCT", 18, 23], ["PARV4", "PROTEIN", 18, 23], ["Seroprevalence of PARV4", "TREATMENT", 0, 23], ["varying", "OBSERVATION_MODIFIER", 59, 66]]], ["A study from Africa reports PARV4 in 0.8% of nasal swab specimens, whereas a study from Scotland did not observe PARV4in respiratory samples (Drexler et al., 2012; Manning et al., 2006) .IntroductionTo the best of our knowledge, no previous study has reported the association of PARV4 with severe acute respiratory illness (SARI).", [["nasal swab specimens", "ANATOMY", 45, 65], ["respiratory", "ANATOMY", 303, 314], ["acute respiratory illness", "DISEASE", 297, 322], ["SARI", "DISEASE", 324, 328], ["nasal swab specimens", "CANCER", 45, 65], ["PARV4", "GENE_OR_GENE_PRODUCT", 279, 284], ["A study", "TEST", 0, 7], ["PARV4", "TEST", 28, 33], ["nasal swab specimens", "TEST", 45, 65], ["a study", "TEST", 75, 82], ["previous study", "TEST", 232, 246], ["PARV4", "PROBLEM", 279, 284], ["severe acute respiratory illness", "PROBLEM", 290, 322], ["severe", "OBSERVATION_MODIFIER", 290, 296], ["acute", "OBSERVATION_MODIFIER", 297, 302], ["respiratory", "ANATOMY", 303, 314], ["illness", "OBSERVATION", 315, 322]]], ["It is also not clear whether PARV4 is transmitted by the respiratory route or causes respiratory infections.", [["respiratory", "ANATOMY", 57, 68], ["respiratory", "ANATOMY", 85, 96], ["PARV4", "CHEMICAL", 29, 34], ["respiratory infections", "DISEASE", 85, 107], ["PARV4", "GENE_OR_GENE_PRODUCT", 29, 34], ["PARV4", "PROTEIN", 29, 34], ["the respiratory route", "TREATMENT", 53, 74], ["respiratory infections", "PROBLEM", 85, 107], ["respiratory", "ANATOMY", 85, 96], ["infections", "OBSERVATION", 97, 107]]], ["Here, we aim to investigate the association of human PARV4 with SARI.Case definition (SARI)A person of any age who presented with difficulty in breathing accompanied with fever !38 C and cough with at least one of the following symptoms: poor general condition, thoracic pain, polypnoea or acute respiratory distress syndrome (ARDS) and required hospitalization (World Health Organization) (WHO, 2013) .", [["thoracic", "ANATOMY", 262, 270], ["respiratory", "ANATOMY", 296, 307], ["difficulty in breathing", "DISEASE", 130, 153], ["fever", "DISEASE", 171, 176], ["cough", "DISEASE", 187, 192], ["thoracic pain", "DISEASE", 262, 275], ["polypnoea", "DISEASE", 277, 286], ["acute respiratory distress syndrome", "DISEASE", 290, 325], ["ARDS", "DISEASE", 327, 331], ["human", "ORGANISM", 47, 52], ["PARV4", "GENE_OR_GENE_PRODUCT", 53, 58], ["thoracic", "ORGANISM_SUBDIVISION", 262, 270], ["human PARV4", "PROTEIN", 47, 58], ["SARI", "PROTEIN", 64, 68], ["human", "SPECIES", 47, 52], ["person", "SPECIES", 93, 99], ["human", "SPECIES", 47, 52], ["SARI", "PROBLEM", 64, 68], ["difficulty in breathing", "PROBLEM", 130, 153], ["fever", "PROBLEM", 171, 176], ["cough", "PROBLEM", 187, 192], ["the following symptoms", "PROBLEM", 214, 236], ["poor general condition", "PROBLEM", 238, 260], ["thoracic pain", "PROBLEM", 262, 275], ["polypnoea", "PROBLEM", 277, 286], ["acute respiratory distress syndrome", "PROBLEM", 290, 325], ["ARDS", "PROBLEM", 327, 331], ["cough", "OBSERVATION", 187, 192], ["thoracic", "ANATOMY", 262, 270], ["pain", "OBSERVATION", 271, 275], ["acute", "OBSERVATION_MODIFIER", 290, 295], ["respiratory distress", "OBSERVATION", 296, 316]]], ["This study was ethically approved by the Institutional ethics committee (ethical clearance reference code: Registration No.", [["This study", "TEST", 0, 10]]], ["ECR/262/Inst/UP/2013/RR/16).", [["ECR/262/Inst/UP/2013/RR/16", "SPECIES", 0, 26], ["ECR", "TEST", 0, 3], ["RR", "TEST", 21, 23]]], ["All cases and controls or their guardians provided written informed consent for participation in the study.", [["the study", "TEST", 97, 106]]], ["Consenting subjects were consecutively enrolled.", [["subjects", "ORGANISM", 11, 19]]], ["Demographic and clinical details were collected through a predesigned questionnaire.Laboratory diagnosisFor conducting this case control study, NS/TS from cases referred to Virology Laboratory, Department of Microbiology, King George's Medical University, Lucknow, Uttar Pradesh, India, with clinical diagnosis of SARI and healthy volunteer controls (matched for age and sex), over a period of 15 months, i.e. January 2017 to March 2018, were collected and tested for viral etiology (Influenza A/Subtype H1N1/Subtype H3N2/ Influenza B, Parainfluenza virus (PIV), Measles virus (MEV), Respiratory syncytial virus RSV, Adenovirus (AV), Bocavirus (BoV), as per previously reported method (Singh et al., 2014) ) and human house-keeping control RnaseP (Shu et al., 2011) .", [["SARI", "DISEASE", 314, 318], ["Influenza B", "DISEASE", 523, 534], ["Measles virus", "DISEASE", 563, 576], ["Respiratory syncytial virus RSV", "DISEASE", 584, 615], ["Influenza A/Subtype H1N1/Subtype H3N2", "ORGANISM", 484, 521], ["Influenza B", "ORGANISM", 523, 534], ["Parainfluenza virus", "ORGANISM", 536, 555], ["Measles virus", "ORGANISM", 563, 576], ["Respiratory syncytial virus RSV", "ORGANISM", 584, 615], ["Adenovirus", "ORGANISM", 617, 627], ["human", "ORGANISM", 712, 717], ["H3N2", "SPECIES", 517, 521], ["Influenza B", "SPECIES", 523, 534], ["Parainfluenza virus", "SPECIES", 536, 555], ["Measles virus", "SPECIES", 563, 576], ["syncytial virus RSV", "SPECIES", 596, 615], ["human", "SPECIES", 712, 717], ["Influenza A/Subtype H1N1/Subtype H3N2/ Influenza B", "SPECIES", 484, 534], ["Parainfluenza virus", "SPECIES", 536, 555], ["PIV", "SPECIES", 557, 560], ["Measles virus", "SPECIES", 563, 576], ["MEV", "SPECIES", 578, 581], ["Respiratory syncytial virus RSV", "SPECIES", 584, 615], ["Adenovirus", "SPECIES", 617, 627], ["AV", "SPECIES", 629, 631], ["human", "SPECIES", 712, 717], ["SARI", "PROBLEM", 314, 318], ["viral etiology", "PROBLEM", 468, 482], ["Influenza A/Subtype H1N1", "PROBLEM", 484, 508], ["Subtype H3N2", "PROBLEM", 509, 521], ["Influenza B", "PROBLEM", 523, 534], ["Parainfluenza virus (PIV)", "TREATMENT", 536, 561], ["Measles virus", "PROBLEM", 563, 576], ["Respiratory syncytial virus RSV", "PROBLEM", 584, 615], ["Adenovirus", "PROBLEM", 617, 627], ["Bocavirus", "PROBLEM", 634, 643], ["Respiratory syncytial", "ANATOMY", 584, 605]]], ["Each real time PCR consisted of positive, negative and extraction controls.", [["Each real time PCR", "TEST", 0, 18]]], ["All the samples of both cases (SARI) and controls were also tested for presence of PARV4-DNA using primers and probes described in patent no. PCT/IN2015/ 000409 and WO2016071926A9 by Jain and Prakash (2016) .", [["samples", "ANATOMY", 8, 15], ["PARV4", "GENE_OR_GENE_PRODUCT", 83, 88], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["PARV4-DNA", "DNA", 83, 92], ["PARV4-DNA using primers", "TREATMENT", 83, 106], ["probes", "TREATMENT", 111, 117], ["PCT", "TEST", 142, 145], ["patent", "OBSERVATION", 131, 137]]], ["Total viral nucleic acid was extracted from 200 ml NS/TS sample using PureLink DNA/RNA mini kit (Invitrogen, USA) as per manufacturer's instructions and processed for TaqMan real time PCR.", [["sample", "ANATOMY", 57, 63], ["nucleic acid", "CHEMICAL", 12, 24], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["PureLink DNA", "DNA", 70, 82], ["Total viral nucleic acid", "TREATMENT", 0, 24], ["TS sample", "TEST", 54, 63], ["PureLink DNA", "TREATMENT", 70, 82], ["TaqMan real time PCR", "TEST", 167, 187]]], ["The real time PCR reaction mix contained 12.5 ml 2\u00c2 master mix (LightCycler 480 Probes Master, Roche Diagnostics, Nederland BV, Almere, the Netherlands), 1 ml of Parv4 forward and reverse primer (10 pm/ml) and 0.5 ml taqmanprobe (10 pm/ml)(IDT, USA) and 5 ml H 2 O (DNAse and RNAse free).", [["H 2 O", "CHEMICAL", 259, 264], ["DNAse", "SIMPLE_CHEMICAL", 266, 271], ["RNAse", "GENE_OR_GENE_PRODUCT", 276, 281], ["DNAse", "PROTEIN", 266, 271], ["The real time PCR reaction", "TEST", 0, 26], ["Parv4", "TREATMENT", 162, 167], ["reverse primer", "TREATMENT", 180, 194]]], ["Finally, 5 ml extracted total nucleic acid was added to 20 ml of prepared mastermix, making it a final volume of 25 ml.", [["mastermix", "ANATOMY", 74, 83], ["nucleic acid", "CHEMICAL", 30, 42], ["nucleic acid", "SIMPLE_CHEMICAL", 30, 42], ["5 ml extracted total nucleic acid", "TREATMENT", 9, 42]]], ["Real time RT-PCR assays were performed on Quantstudio 7 (Life Technologies, USA).DNA sequencing and analysisPARV4 VP1 gene was amplified using an in-house designed nested PCR primer to yield a product size of 849-854 base pairs (bp).", [["DNA", "CELLULAR_COMPONENT", 81, 84], ["analysisPARV4 VP1", "GENE_OR_GENE_PRODUCT", 100, 117], ["analysisPARV4 VP1 gene", "DNA", 100, 122], ["Real time RT-PCR assays", "TEST", 0, 23], ["DNA sequencing", "TEST", 81, 95], ["analysisPARV4 VP1 gene", "TREATMENT", 100, 122], ["nested PCR primer", "TREATMENT", 164, 181], ["base pairs", "TEST", 217, 227], ["bp", "TEST", 229, 231], ["size", "OBSERVATION_MODIFIER", 201, 205]]], ["The amplified nested PCR product was purified using exonuclease I and Shrimp Alkaline phosphatase.", [["exonuclease I", "GENE_OR_GENE_PRODUCT", 52, 65], ["Shrimp Alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 70, 97], ["exonuclease I", "PROTEIN", 52, 65], ["Shrimp Alkaline phosphatase", "PROTEIN", 70, 97], ["The amplified nested PCR product", "TREATMENT", 0, 32], ["exonuclease I", "TREATMENT", 52, 65], ["Shrimp Alkaline phosphatase", "TEST", 70, 97]]], ["The amplicon was processed for sequencing PCR using BigDye Terminator (BDT) cycle sequencing kitv3.1 (Applied Biosystems, Foster City, CA).", [["The amplicon", "TREATMENT", 0, 12], ["sequencing PCR", "TEST", 31, 45], ["BigDye Terminator (BDT)", "TREATMENT", 52, 75], ["sequencing kit", "TEST", 82, 96]]], ["After sequencing PCR the product was purified using an ethanol purification method and sequenced on Genetic Analyzer 3130 (Applied Biosystems) according to the manufacturer's instructions.", [["ethanol", "CHEMICAL", 55, 62], ["ethanol", "CHEMICAL", 55, 62], ["ethanol", "SIMPLE_CHEMICAL", 55, 62], ["sequencing PCR", "TEST", 6, 20], ["an ethanol purification method", "TREATMENT", 52, 82], ["Genetic Analyzer", "TEST", 100, 116]]], ["Reference sequences were obtained from GenBank [genotype 1: EU546204.1, genotype 2: EU175855.1, genotype 3: JN183925.1].", [["Reference sequences", "TEST", 0, 19], ["genotype", "TEST", 72, 80], ["genotype", "TEST", 96, 104], ["JN", "TEST", 108, 110]]], ["Intergroup comparisons were done using Chi square test.", [["Intergroup comparisons", "TEST", 0, 22], ["Chi square test", "TEST", 39, 54]]], ["P value< 0.05 was regarded as statistically significant.ResultsA total of 241 cases of SARI and 146 normal healthy controls were included in the study.", [["SARI", "DISEASE", 87, 91], ["SARI", "CANCER", 87, 91], ["controls", "ORGANISM", 115, 123], ["P value", "TEST", 0, 7], ["SARI", "TEST", 87, 91], ["the study", "TEST", 141, 150]]], ["The mean age AE SD of cases was 23.26 AE 23.34 (Median 14; range 0-63) and of the control group was 18.0 AE 15.51 (median 4.5; range 0k62).", [["SD", "DISEASE", 16, 18], ["cases", "TEST", 22, 27], ["AE", "TEST", 38, 40], ["Median", "TEST", 48, 54], ["AE", "TEST", 105, 107]]], ["Peak positivity of PARV4 was noted among infants and young children (age, 0-10years) as 46.87% (n = 30/64) cases were younger than 5 years of age (Table 3 ).", [["PARV4", "GENE_OR_GENE_PRODUCT", 19, 24], ["infants", "ORGANISM", 41, 48], ["children", "ORGANISM", 59, 67], ["PARV4", "PROTEIN", 19, 24], ["infants", "SPECIES", 41, 48], ["children", "SPECIES", 59, 67], ["Peak positivity", "TEST", 0, 15]]], ["The seasonal distribution of PARV4 corresponds to the enrolled SARI cases.", [["SARI", "DISEASE", 63, 67], ["PARV4", "GENE_OR_GENE_PRODUCT", 29, 34], ["SARI", "CANCER", 63, 67], ["PARV4", "PROTEIN", 29, 34], ["The seasonal distribution of PARV4", "PROBLEM", 0, 34], ["the enrolled SARI cases", "PROBLEM", 50, 73], ["seasonal", "OBSERVATION_MODIFIER", 4, 12], ["distribution", "OBSERVATION_MODIFIER", 13, 25]]], ["There was an upsurge in PARV4 positive cases in the month of January (Figure 1 ).ResultsOf total 241 SARI cases, 64 (26.55%) were positive for at least one of the known tested respiratory pathogens.", [["respiratory pathogens", "DISEASE", 176, 197], ["PARV4", "GENE_OR_GENE_PRODUCT", 24, 29], ["SARI", "CANCER", 101, 105], ["SARI cases", "TEST", 101, 111], ["the known tested respiratory pathogens", "PROBLEM", 159, 197], ["respiratory pathogens", "OBSERVATION", 176, 197]]], ["RSV [n = 19 (7.88%)] was the most common aetiology detected in cases, followed by Influenza A/H1N1 [n = 12 (4.97%)] and MEV [n = 12 (4.97%)] (Table 1) .", [["Influenza A/H1N1", "DISEASE", 82, 98], ["MEV", "DISEASE", 120, 123], ["RSV", "ORGANISM", 0, 3], ["Influenza A/H1N1", "ORGANISM", 82, 98], ["RSV", "SPECIES", 0, 3], ["Influenza A/H1N1", "SPECIES", 82, 98], ["MEV", "SPECIES", 120, 123], ["RSV", "TEST", 0, 3], ["H1N1", "PROBLEM", 94, 98], ["MEV [n", "TEST", 120, 126]]], ["Four cases were positive for more than one virus [Influenza A/H1N1 + MEV (2), Influenza B + Adenovirus (1); PIV + MEV (1)].", [["Influenza B", "DISEASE", 78, 89], ["Influenza A/H1N1 + MEV", "ORGANISM", 50, 72], ["Influenza B + Adenovirus", "ORGANISM", 78, 102], ["Influenza B + Adenovirus", "SPECIES", 78, 102], ["Influenza A/H1N1 + MEV", "SPECIES", 50, 72], ["Four cases", "TEST", 0, 10], ["one virus", "PROBLEM", 39, 48], ["Influenza", "PROBLEM", 50, 59], ["H1N1", "PROBLEM", 62, 66], ["MEV", "PROBLEM", 69, 72], ["Influenza B", "PROBLEM", 78, 89], ["Adenovirus", "PROBLEM", 92, 102], ["PIV + MEV", "TREATMENT", 108, 117]]], ["PARV4-DNA was present in 64 cases.", [["PARV4", "GENE_OR_GENE_PRODUCT", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["PARV4-DNA", "DNA", 0, 9]]], ["A total of 44(18.2%) cases had PARV4 DNA alone, whereas in 20 cases (8.2%) PARV4 was co-detected with other known pathogenic viruses (Table 2) .", [["PARV4", "GENE_OR_GENE_PRODUCT", 31, 36], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["PARV4", "GENE_OR_GENE_PRODUCT", 75, 80], ["PARV4 DNA", "DNA", 31, 40], ["PARV4 DNA", "PROBLEM", 31, 40], ["PARV4", "TEST", 75, 80], ["other known pathogenic viruses", "PROBLEM", 102, 132], ["total", "OBSERVATION_MODIFIER", 2, 7], ["pathogenic", "OBSERVATION_MODIFIER", 114, 124], ["viruses", "OBSERVATION", 125, 132]]], ["Parvovirus 4 was significantly higher in cases as compared to controls (Relative risk 37.709595%; NNT (Harm) 3.868; 95% CI: 5.402 (Harm) to 3.013 (Harm); p value<0.0003).ResultsOf 146 healthy controls, three subjects were positive for RSV, one for PIV, whereas in a single individual PARV4-DNA was found (Tables 1 and 2) .ResultsOut of total viral causes tested, a final aetiology could be established in 108(44.81%) cases which were positive for at least one of the tested viral agents.", [["Parvovirus 4", "ORGANISM", 0, 12], ["subjects", "ORGANISM", 208, 216], ["RSV", "ORGANISM", 235, 238], ["DNA", "CELLULAR_COMPONENT", 290, 293], ["PARV4-DNA", "DNA", 284, 293], ["RSV", "SPECIES", 235, 238], ["Parvovirus", "TEST", 0, 10], ["CI", "TEST", 120, 122], ["Harm", "TEST", 131, 135], ["p value", "TEST", 154, 161], ["RSV", "PROBLEM", 235, 238], ["PIV", "TREATMENT", 248, 251], ["total viral causes", "PROBLEM", 336, 354]]], ["Of 64 PARV4 positive cases, 23 samples with high viremia (Ct value 30) could be amplified for the VP1 gene and sequenced.", [["samples", "ANATOMY", 31, 38], ["viremia", "DISEASE", 49, 56], ["PARV4", "CANCER", 6, 11], ["samples", "CANCER", 31, 38], ["VP1", "GENE_OR_GENE_PRODUCT", 98, 101], ["VP1 gene", "DNA", 98, 106], ["high viremia", "PROBLEM", 44, 56], ["Ct value", "TEST", 58, 66], ["the VP1 gene", "TEST", 94, 106]]], ["Phylogenetic analysis showed the presence of PARV4 genotype 2 in SARI cases (Figure 2) .", [["SARI", "CANCER", 65, 69], ["Phylogenetic analysis", "TEST", 0, 21], ["PARV4 genotype", "PROBLEM", 45, 59]]], ["One strain from a healthy control was sequenced and was similar to other strains detected in cases.", [["One strain", "PROBLEM", 0, 10], ["a healthy control", "TREATMENT", 16, 33], ["other strains", "PROBLEM", 67, 80], ["strain", "OBSERVATION", 4, 10]]], ["All the genetic sequences were submitted to GenBank (accession numbers MH939288 to MH939311).DiscussionThe present study described a high prevalence of PARV4 DNA in cases presenting with SARI.", [["SARI", "DISEASE", 187, 191], ["PARV4", "ORGANISM", 152, 157], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["PARV4 DNA", "DNA", 152, 161], ["PARV4", "SPECIES", 152, 157], ["The present study", "TEST", 103, 120], ["PARV4 DNA", "PROBLEM", 152, 161], ["SARI", "PROBLEM", 187, 191]]], ["An association of PARV4 positivity with SARI is also seen.", [["SARI", "DISEASE", 40, 44], ["PARV4", "GENE_OR_GENE_PRODUCT", 18, 23], ["SARI", "GENE_OR_GENE_PRODUCT", 40, 44], ["PARV4", "PROTEIN", 18, 23], ["SARI", "PROTEIN", 40, 44], ["PARV4 positivity", "PROBLEM", 18, 34], ["SARI", "PROBLEM", 40, 44], ["SARI", "OBSERVATION", 40, 44]]], ["Clinical impact of PARV4 infection is not well understood; still, a wide range of potential infection outcomes has been proposed.", [["infection", "DISEASE", 25, 34], ["infection", "DISEASE", 92, 101], ["PARV4", "GENE_OR_GENE_PRODUCT", 19, 24], ["PARV4 infection", "PROBLEM", 19, 34], ["potential infection outcomes", "PROBLEM", 82, 110], ["PARV4", "ANATOMY", 19, 24], ["infection", "OBSERVATION", 25, 34], ["infection", "OBSERVATION", 92, 101]]], ["In the past, studies have described an association of PARV4 with influenza-like symptoms, encephalitis (Benjamin et al., 2011; Prakash et al., 2015) , transient rash and hepatitis , foetal hydrops (Chen et al., 2011) and acceleration of progression to AIDS in HIV-infected adults (Simmons et al., 2012) .", [["influenza-like symptoms", "DISEASE", 65, 88], ["encephalitis", "DISEASE", 90, 102], ["rash", "DISEASE", 161, 165], ["hepatitis", "DISEASE", 170, 179], ["foetal hydrops", "DISEASE", 182, 196], ["AIDS", "DISEASE", 252, 256], ["HIV-infected", "DISEASE", 260, 272], ["PARV4", "GENE_OR_GENE_PRODUCT", 54, 59], ["HIV", "ORGANISM", 260, 263], ["adults", "ORGANISM", 273, 279], ["HIV", "SPECIES", 260, 263], ["HIV", "SPECIES", 260, 263], ["PARV4", "PROBLEM", 54, 59], ["influenza", "PROBLEM", 65, 74], ["like symptoms", "PROBLEM", 75, 88], ["encephalitis", "PROBLEM", 90, 102], ["transient rash", "PROBLEM", 151, 165], ["hepatitis", "PROBLEM", 170, 179], ["foetal hydrops", "PROBLEM", 182, 196], ["AIDS", "PROBLEM", 252, 256], ["HIV", "PROBLEM", 260, 263], ["influenza", "OBSERVATION", 65, 74], ["transient", "OBSERVATION_MODIFIER", 151, 160], ["rash", "OBSERVATION", 161, 165], ["hepatitis", "OBSERVATION", 170, 179], ["hydrops", "OBSERVATION", 189, 196]]], ["Transmission via respiratory secretions or faeces suggestive of respiratory tract infection or gastroenteritis is also suggested.", [["respiratory secretions", "ANATOMY", 17, 39], ["faeces", "ANATOMY", 43, 49], ["respiratory tract", "ANATOMY", 64, 81], ["respiratory tract infection", "DISEASE", 64, 91], ["gastroenteritis", "DISEASE", 95, 110], ["faeces", "ORGANISM_SUBDIVISION", 43, 49], ["respiratory tract", "ORGANISM_SUBDIVISION", 64, 81], ["Transmission via respiratory secretions", "TEST", 0, 39], ["faeces", "PROBLEM", 43, 49], ["respiratory tract infection", "PROBLEM", 64, 91], ["gastroenteritis", "PROBLEM", 95, 110], ["respiratory", "ANATOMY", 17, 28], ["secretions", "OBSERVATION", 29, 39], ["suggestive of", "UNCERTAINTY", 50, 63], ["respiratory tract", "ANATOMY", 64, 81], ["infection", "OBSERVATION", 82, 91], ["gastroenteritis", "OBSERVATION", 95, 110]]], ["13 Groups with risk factors for parenteral infection and those infected with either HBV or HCV or HIV have associated PARV4 infections, suggesting parenteral transmission.", [["parenteral infection", "DISEASE", 32, 52], ["HBV or HCV or HIV", "DISEASE", 84, 101], ["PARV4 infections", "DISEASE", 118, 134], ["HBV", "ORGANISM", 84, 87], ["HCV", "ORGANISM", 91, 94], ["HIV", "ORGANISM", 98, 101], ["PARV4", "GENE_OR_GENE_PRODUCT", 118, 123], ["HIV", "SPECIES", 98, 101], ["HBV", "SPECIES", 84, 87], ["HCV", "SPECIES", 91, 94], ["HIV", "SPECIES", 98, 101], ["PARV4", "SPECIES", 118, 123], ["risk factors", "PROBLEM", 15, 27], ["parenteral infection", "PROBLEM", 32, 52], ["HBV", "PROBLEM", 84, 87], ["HCV", "PROBLEM", 91, 94], ["HIV", "PROBLEM", 98, 101], ["PARV4 infections", "PROBLEM", 118, 134], ["parenteral transmission", "TREATMENT", 147, 170], ["infection", "OBSERVATION", 43, 52], ["HBV", "OBSERVATION", 84, 87], ["infections", "OBSERVATION", 124, 134], ["parenteral transmission", "OBSERVATION", 147, 170]]], ["Intravenous drug users and those with a history of multiple transfusions have a high positivity of PARV4 (Jones et al., 2005; Simmonds et al., 2007b; Fryer et al., 2007a) .DiscussionIn the present study, we have tested respiratory samples from many healthy individuals and except for one, all were negative.", [["respiratory samples", "ANATOMY", 219, 238], ["multiple transfusions", "TREATMENT", 51, 72], ["the present study", "TEST", 185, 202], ["respiratory samples", "TEST", 219, 238], ["negative", "OBSERVATION", 298, 306]]], ["Studies from Africa have reported the detection frequency of PARV4 IgG ranging from 30% to 50% in the general population, irrespective of their positivity for HBV/ HCV/ HIV (Lavoie et al., 2012; Drexler et al., 2012; Sharp et al., 2010) .", [["HBV/ HCV/ HIV", "DISEASE", 159, 172], ["PARV4 IgG", "GENE_OR_GENE_PRODUCT", 61, 70], ["HBV", "ORGANISM", 159, 162], ["HCV", "ORGANISM", 164, 167], ["HIV", "ORGANISM", 169, 172], ["PARV4 IgG", "PROTEIN", 61, 70], ["HIV", "SPECIES", 169, 172], ["PARV4", "SPECIES", 61, 66], ["HBV", "SPECIES", 159, 162], ["HCV", "SPECIES", 164, 167], ["HIV", "SPECIES", 169, 172], ["PARV4 IgG", "TEST", 61, 70], ["HBV", "PROBLEM", 159, 162], ["HCV", "PROBLEM", 164, 167], ["HIV", "PROBLEM", 169, 172]]], ["Acute infections with PARV4 DNA positivity were seen in 8.5% of young children in Ghana (Drexler et al., 2012) .DiscussionGenotype 2 was the only circulating genotype detected in the present study.", [["infections", "DISEASE", 6, 16], ["PARV4", "GENE_OR_GENE_PRODUCT", 22, 27], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["children", "ORGANISM", 70, 78], ["children", "SPECIES", 70, 78], ["PARV4", "SPECIES", 22, 27], ["Acute infections", "PROBLEM", 0, 16], ["PARV4 DNA positivity", "PROBLEM", 22, 42], ["the present study", "TEST", 179, 196], ["infections", "OBSERVATION", 6, 16]]], ["Genotype-2 (formerly known as PARV5) has been identified in European and North American cohorts (Matthews et al., 2017; Simmonds et al., 2008; Fryer et al., 2007b) .", [["PARV5", "GENE_OR_GENE_PRODUCT", 30, 35], ["PARV5", "PROTEIN", 30, 35]]], ["It was also the predominant strain reported from Asia (Matthews et al., 2017; Benjamin et al., 2011) .", [["predominant", "OBSERVATION_MODIFIER", 16, 27], ["strain", "OBSERVATION", 28, 34]]], ["In one of our earlier studies we also found genotype 2 in samples from cases of encephalitis (Prakash et al., 2015) .There is a high similarity in strains of genotype 2 identified the world over.DiscussionHigher positivity in children less than 5 years of age and during winter is demonstrable with the current data.", [["samples", "ANATOMY", 58, 65], ["encephalitis", "DISEASE", 80, 92], ["samples", "CANCER", 58, 65], ["children", "ORGANISM", 226, 234], ["children", "SPECIES", 226, 234], ["our earlier studies", "TEST", 10, 29], ["genotype 2", "PROBLEM", 44, 54], ["encephalitis", "PROBLEM", 80, 92], ["encephalitis", "OBSERVATION", 80, 92], ["high similarity", "OBSERVATION_MODIFIER", 128, 143]]], ["Most of the studies have commented on positivity in children; however, seasonality is not well described (Panning et al., 2010; Rosenfeldt et al., 2015; von Linstow et al., 2015) .", [["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["the studies", "TEST", 8, 19]]], ["Co-infection with other respiratory viruses is also seen in the present study.", [["Co-infection", "DISEASE", 0, 12], ["respiratory viruses", "DISEASE", 24, 43], ["Co-infection", "PROBLEM", 0, 12], ["other respiratory viruses", "PROBLEM", 18, 43], ["the present study", "TEST", 60, 77], ["respiratory viruses", "OBSERVATION", 24, 43]]], ["It may be possible that PARV4 exacerbated other viral infections.", [["PARV4", "CHEMICAL", 24, 29], ["viral infections", "DISEASE", 48, 64], ["PARV4", "SIMPLE_CHEMICAL", 24, 29], ["PARV4 exacerbated other viral infections", "PROBLEM", 24, 64], ["may be possible", "UNCERTAINTY", 3, 18], ["viral", "OBSERVATION_MODIFIER", 48, 53], ["infections", "OBSERVATION", 54, 64]]], ["However there is no supporting literature suggesting the same.", [["no supporting", "UNCERTAINTY", 17, 30]]], ["Our study has a limitation that it does not include the co-existence or presence of non viral Figure 2 .", [["Our study", "TEST", 0, 9], ["non viral Figure 2", "PROBLEM", 84, 102], ["viral", "OBSERVATION", 88, 93]]], ["Phylogenetic analysis of PARV4 genome.", [["PARV4", "GENE_OR_GENE_PRODUCT", 25, 30], ["PARV4 genome", "DNA", 25, 37], ["Phylogenetic analysis", "TEST", 0, 21], ["PARV4 genome", "PROBLEM", 25, 37], ["PARV4 genome", "OBSERVATION", 25, 37]]], ["The strains from the study cases are marked with red triangle and strain from one healthy control is marked as a green circle.", [["The strains", "PROBLEM", 0, 11], ["the study cases", "TEST", 17, 32], ["red triangle and strain", "PROBLEM", 49, 72], ["marked", "OBSERVATION_MODIFIER", 37, 43], ["red triangle", "OBSERVATION_MODIFIER", 49, 61], ["marked", "OBSERVATION_MODIFIER", 101, 107], ["green circle", "OBSERVATION", 113, 125]]], ["The optimal tree with the sum of branch length = 0.44876634 is shown.", [["optimal", "OBSERVATION_MODIFIER", 4, 11], ["tree", "OBSERVATION_MODIFIER", 12, 16], ["branch", "OBSERVATION_MODIFIER", 33, 39], ["length", "OBSERVATION_MODIFIER", 40, 46]]], ["The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) is shown next to the branches.", [["the bootstrap test", "TEST", 85, 103], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["replicate trees", "OBSERVATION", 18, 33], ["branches", "ANATOMY_MODIFIER", 143, 151]]], ["The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree.", [["tree", "OBSERVATION_MODIFIER", 4, 8], ["branch", "OBSERVATION_MODIFIER", 33, 39], ["lengths", "OBSERVATION_MODIFIER", 40, 47], ["phylogenetic tree", "OBSERVATION", 123, 140]]], ["The evolutionary distances were computed using the Maximum Composite Likelihood method and are in the units of the number of base substitutions per site.", [["base substitutions", "TREATMENT", 125, 143], ["base substitutions", "OBSERVATION", 125, 143]]], ["Evolutionary analyses were conducted in MEGA7.Discussionetiologies.", [["MEGA7", "DNA", 40, 45], ["Evolutionary analyses", "TEST", 0, 21]]], ["Our study also did not look at the prevalence in cases with milder illness for providing a comparison with prevalence in cases with SARI.ConclusionDetection of PARV4 in a significantly large number of SARI cases, in comparison with controls, suggests association of PARV4 with SARI.", [["SARI", "DISEASE", 132, 136], ["SARI", "DISEASE", 201, 205], ["SARI", "DISEASE", 277, 281], ["PARV4", "GENE_OR_GENE_PRODUCT", 160, 165], ["SARI", "CANCER", 201, 205], ["PARV4", "GENE_OR_GENE_PRODUCT", 266, 271], ["PARV4", "PROTEIN", 160, 165], ["PARV4", "PROTEIN", 266, 271], ["SARI", "PROTEIN", 277, 281], ["Our study", "TEST", 0, 9], ["milder illness", "PROBLEM", 60, 74], ["SARI", "PROBLEM", 132, 136], ["PARV4", "PROBLEM", 266, 271], ["SARI", "PROBLEM", 277, 281], ["significantly", "OBSERVATION_MODIFIER", 171, 184], ["large", "OBSERVATION_MODIFIER", 185, 190], ["number", "OBSERVATION_MODIFIER", 191, 197], ["SARI cases", "OBSERVATION", 201, 211], ["SARI", "OBSERVATION", 277, 281]]], ["PARV4 genotype 2 is the only circulating strain detected in our study.", [["circulating strain", "PROBLEM", 29, 47], ["our study", "TEST", 60, 69], ["circulating strain", "OBSERVATION", 29, 47]]]], "3b2ecf95d002afdfeb450f9775e30d80879074e5": [["IntroductionAlthough the Human Activity or Action Recognition (HAR) is an active field in the present era, there are still key aspects which should be taken into consideration in order to accurately realise how people interact with each other or while using digital devices [1] , [2] , [3] .", [["Human", "ORGANISM", 25, 30], ["people", "ORGANISM", 211, 217], ["Human", "SPECIES", 25, 30], ["people", "SPECIES", 211, 217], ["active", "OBSERVATION_MODIFIER", 74, 80]]], ["Human activity recognition is a sequence Corresponding Author: m.rezaei@leeds.ac.uk (M. Rezaei) of multiple and complex sub-actions.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["multiple and complex sub-actions", "TREATMENT", 99, 131]]], ["Automatic recognition of human activities using computer vision has been more effective and a result with a growing demand in many applications.", [["human", "ORGANISM", 25, 30], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["computer vision", "TREATMENT", 48, 63]]], ["These include health care systems, activities monitoring in smart homes, Autonomous Vehicles and Driver Assistance Systems [4] , [5] , security and environmental monitoring to automatic detection of abnormal activities to inform relevant authorities about criminal or terrorist behaviours, services such as intelligent meeting rooms, home automation, personal digital assistants and entertainment environments for improving human interaction with computers, and even in the new challenges of social distancing monitoring during the COVID-19 pandemic [6] .IntroductionIn general, we can obtain the required information from a given subject by using different types of sensors such as cameras and wearable sensors [7] , [8] , [9] .", [["human", "ORGANISM", 424, 429], ["human", "SPECIES", 424, 429], ["human", "SPECIES", 424, 429], ["environmental monitoring", "TEST", 148, 172], ["automatic detection", "TEST", 176, 195], ["abnormal activities", "PROBLEM", 199, 218]]], ["Cameras are more suitable sensors for security applications (such as intrusion detection) and other interactive applications.", [["security applications", "TREATMENT", 38, 59], ["intrusion detection", "TEST", 69, 88]]], ["The concept of action and movement recognition in video sequences are very interesting and challenging research topics to many researchers.", [["movement recognition", "TEST", 26, 46], ["video sequences", "TEST", 50, 65]]], ["For example, in walking action recognition using computer vision and wearable devices, the challenges could be visual limitation of sensory devises.", [["computer vision", "TREATMENT", 49, 64], ["wearable devices", "TREATMENT", 69, 85], ["sensory devises", "PROBLEM", 132, 147], ["sensory devises", "OBSERVATION", 132, 147]]], ["Accordingly, useful frames and frame index information can be exploited; In human pose estimation, the body pose is represented by a series of directional rectangles.", [["body", "ANATOMY", 103, 107], ["human", "ORGANISM", 76, 81], ["body", "ORGANISM_SUBDIVISION", 103, 107], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81]]], ["Combination of rectangles' directions and positions defines a histogram to create a state descriptor for each frame.", [["a histogram", "TEST", 60, 71]]], ["In the background subtraction methods (BGS), the background is considered as the offset and the methods such as histogram of oriented gradients (HOG), histogram of optical flow (HOF) and motion boundary histogram (MBH) can increase the efficiency of video based action recognition systems [14] , [15] .", [["the methods", "TEST", 92, 103], ["motion boundary histogram", "TEST", 187, 212]]], ["Skeletons models can capture the position of the body parts or the human hands/arms to be used for human activity classification [15] , [16] , [17] .", [["body parts", "ANATOMY", 49, 59], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["human", "ORGANISM", 67, 72], ["hands", "ORGANISM_SUBDIVISION", 73, 78], ["human", "ORGANISM", 99, 104], ["[16]", "SIMPLE_CHEMICAL", 136, 140], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 99, 104], ["the human hands/arms", "TREATMENT", 63, 83]]], ["Different machine learning methods have been proposed for action recognition and address the mentioned challenges, each of which has its own strengths, deficiencies and weaknesses.IntroductionConvolutional Neural Networks (CNNs) is a type of deep neural network that effectively classifies the objects using a combination of layers and filtering [18] .", [["neural network", "ANATOMY", 247, 261], ["neural network", "MULTI-TISSUE_STRUCTURE", 247, 261], ["Different machine learning methods", "TREATMENT", 0, 34], ["action recognition", "TREATMENT", 58, 76], ["weaknesses", "PROBLEM", 169, 179], ["Neural Networks", "OBSERVATION", 206, 221], ["deep", "ANATOMY_MODIFIER", 242, 246], ["neural", "ANATOMY", 247, 253]]], ["Recurrent Neural Network (RNN) can be used to address some of the challenges in activity recognition.", [["Neural Network", "OBSERVATION", 10, 24]]], ["In fact, RNNs include a recursive loop that retains the information obtained in the previous moments.", [["RNNs", "SIMPLE_CHEMICAL", 9, 13], ["RNNs", "PROTEIN", 9, 13], ["a recursive loop", "PROBLEM", 22, 38]]], ["The RNN only maintains a previous step that is considered as a disadvantage.", [["RNN", "DNA", 4, 7]]], ["Therefore, LSTM was introduced to maintain information of several sequential stages [19] .", [["LSTM", "PROTEIN", 11, 15]]], ["Theoretically, RNNs should be able to maintain long-term dependencies in order to solve two common problems of Exploding and Vanishing Gradients, while LSTM deals with the abovementioned issues more efficiently [7] , [12] , [20] , [21] .IntroductionIn the following sections we discuss in more details and provide further information about our ideas.", [["RNNs", "SIMPLE_CHEMICAL", 15, 19], ["[12]", "SIMPLE_CHEMICAL", 217, 221], ["[20]", "SIMPLE_CHEMICAL", 224, 228], ["long-term dependencies", "TREATMENT", 47, 69], ["Vanishing Gradients", "PROBLEM", 125, 144]]], ["In Section 4. we will review the experimental and evaluation results and compare them with six stateof-the-art methods.", [["the experimental and evaluation", "TEST", 29, 60]]], ["Finally, Section 5. concludes the paper and provides suggestions for future works.Related WorkIn the last decade, Human Action Recognition (HAR) has attracted the attention of many researchers from different disciplines and for various applications.", [["Human", "ORGANISM", 114, 119], ["Human", "SPECIES", 114, 119], ["various applications", "TREATMENT", 228, 248]]], ["Most of the existing methods use hand-crafted features, and thanks to the GPU and extended memory developments, the deep neural networks can also recognise the activities of subjects in the live videos.", [["hand", "ANATOMY", 33, 37], ["neural networks", "ANATOMY", 121, 136], ["neural networks", "MULTI-TISSUE_STRUCTURE", 121, 136], ["deep", "ANATOMY_MODIFIER", 116, 120], ["neural", "ANATOMY", 121, 127]]], ["Human action recognition in a sequence of image frames is one of the research topics of the machine vision that focuses on correct recognition of human activities using single view images [12] , [22] .", [["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 146, 151], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 146, 151], ["single view images", "TEST", 169, 187]]], ["In conventional hand-crafted approaches, the low-level features associated with an specific action were extracted from the video signal sequences, followed by labelling by a classifier, such as K-Nearest Neighbour (KNN), Support Vector Machine (SVM), decision tree, K-means, or Hidden Markov Models (HMMs) [12] , [23] .", [["hand", "ANATOMY", 16, 20], ["video signal sequences", "DNA", 123, 145], ["the low-level features", "PROBLEM", 41, 63], ["the video signal sequences", "TEST", 119, 145], ["low", "OBSERVATION_MODIFIER", 45, 48]]], ["Deep learning techniques for image classification, object detection, HAR, or sound recognition have also taken traditional hand-crafting techniques, but in a more automated manner than conventional approaches [24] .Related WorkIn [12] , the authors performed an analytical study on every six frames of input video sequences and tried to extract relevant features for action recognition using a pre-trained AlexNet Network.", [["hand", "ANATOMY", 123, 127], ["Deep learning techniques", "TREATMENT", 0, 24], ["image classification", "TEST", 29, 49], ["object detection", "TEST", 51, 67], ["an analytical study", "TEST", 259, 278], ["video sequences", "TEST", 308, 323], ["a pre-trained AlexNet Network", "TREATMENT", 392, 421]]], ["The method uses deep LSTM with two forward and backward layers to learn and extract the relevant features from a sequence of video frames.Related WorkIn [24] , a pretrained deep CNN is used to extract features, followed by the combination of SVM and KNN classifiers for action recognition.", [["pretrained deep CNN", "DNA", 162, 181], ["deep LSTM", "TREATMENT", 16, 25], ["a pretrained deep CNN", "PROBLEM", 160, 181], ["SVM", "TREATMENT", 242, 245], ["KNN classifiers", "TREATMENT", 250, 265], ["action recognition", "TEST", 270, 288]]], ["A pre-trained CNN on a large-scale annotation dataset can be transmitted for the action recognition with a small training dataset.", [["pre-trained CNN", "DNA", 2, 17], ["a small training dataset", "TREATMENT", 105, 129]]], ["So transfer learning using deep CNN would be a useful approach for training models where the dataset size is limited.", [["deep CNN", "TREATMENT", 27, 35], ["training models", "TREATMENT", 67, 82], ["size", "OBSERVATION_MODIFIER", 101, 105]]], ["By increasing the size of the dataset, the issue of overfitting will be eliminated; however, providing a large amount of annotated data is very difficult and expensive.", [["overfitting", "PROBLEM", 52, 63], ["size", "OBSERVATION_MODIFIER", 18, 22]]], ["The proposed technique in [24] aims to build a new architecture using a successful pre-trained model.Related WorkIn some research works, the human activity and hand gesture recognition problems are investigated using 3-D data sequence of the entire body and skeletons.", [["hand", "ANATOMY", 160, 164], ["body", "ANATOMY", 249, 253], ["human", "ORGANISM", 141, 146], ["hand", "ORGANISM_SUBDIVISION", 160, 164], ["body", "ORGANISM_SUBDIVISION", 249, 253], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 141, 146], ["a successful pre-trained model", "TREATMENT", 70, 100], ["skeletons", "ANATOMY", 258, 267]]], ["Also, a learning-based approach, which combines CNN and LSTM, is used for pose detection problems and 3-D temporal detection [12] .", [["CNN", "DNA", 48, 51], ["LSTM", "DNA", 56, 60], ["a learning-based approach", "TREATMENT", 6, 31]]], ["Singh et al. [22] propose a framework for background subtraction (BGS) along with a feature extraction function, and ultimately they use HMMs for action recognition.Related WorkIn [15] an action recognition system is presented using various feature extraction fusion techniques for UCF dataset.", [["background subtraction", "TEST", 42, 64], ["action recognition", "TEST", 146, 164], ["various feature extraction fusion techniques", "TREATMENT", 233, 277]]], ["The paper presents six different fusion models inspired by the early fusion, late fusion, and intermediate fusion schemes [25] .", [["six different fusion models", "TREATMENT", 19, 46], ["the early fusion", "TREATMENT", 59, 75], ["late fusion", "TREATMENT", 77, 88], ["intermediate fusion schemes", "TREATMENT", 94, 121], ["fusion models", "OBSERVATION", 33, 46], ["early", "OBSERVATION_MODIFIER", 63, 68], ["fusion", "OBSERVATION", 69, 75]]], ["In the first two models, the system utilises an early fusion technique.", [["an early fusion technique", "TREATMENT", 45, 70], ["early fusion", "OBSERVATION", 48, 60]]], ["The third and fourth models exploit intermediate fusion techniques.", [["third", "ANATOMY_MODIFIER", 4, 9], ["intermediate fusion", "OBSERVATION", 36, 55]]], ["In the fourth model, the system confront a kernel-based fusion scheme, which takes advantage of a kernel based SVM classifier.", [["a kernel-based fusion scheme", "TREATMENT", 41, 69], ["a kernel based SVM classifier", "TREATMENT", 96, 125], ["fusion scheme", "OBSERVATION", 56, 69]]], ["In the fifth and sixth models, late fusion techniques has been demonstrated.", [["late fusion techniques", "TREATMENT", 31, 53], ["late", "OBSERVATION_MODIFIER", 31, 35], ["fusion", "OBSERVATION", 36, 42]]], ["However, to capture the contextual relationships between distant frames, a simple aggregation of scores is insufficient.", [["a simple aggregation of scores", "PROBLEM", 73, 103], ["distant frames", "OBSERVATION", 57, 71], ["simple", "OBSERVATION_MODIFIER", 75, 81], ["aggregation", "OBSERVATION", 82, 93]]], ["Therefore, they feed the feature representations of distant frames into a 3-D network that learns the temporal context between the frames, so, it can improve significantly over the belief obtained from a single frame especially for complex long-term activities.Related Work[26] has proposed a Robust Non-Linear Knowledge Transfer Model (R-NKTM) for human action recognition from unseen viewing angles.", [["human", "ORGANISM", 349, 354], ["human", "SPECIES", 349, 354], ["human", "SPECIES", 349, 354], ["complex long-term activities", "TREATMENT", 232, 260]]], ["The proposed R-NKTM is a fully-connected deep neural network that transfers knowledge of human actions from any unknown view to a shared highlevel virtual view by finding a non-linear virtual path that interconnects different views together.", [["neural network", "ANATOMY", 46, 60], ["neural network", "MULTI-TISSUE_STRUCTURE", 46, 60], ["human", "ORGANISM", 89, 94], ["R-NKTM", "DNA", 13, 19], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["deep", "ANATOMY_MODIFIER", 41, 45], ["neural network", "OBSERVATION", 46, 60]]], ["The R-NKTM is trained by dense trajectories of synthetic 3-D human models fitted to capture real motion data, and then generalise them for real videos of human actions.", [["R-NKTM", "GENE_OR_GENE_PRODUCT", 4, 10], ["human", "ORGANISM", 61, 66], ["human", "ORGANISM", 154, 159], ["R-NKTM", "DNA", 4, 10], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 154, 159], ["dense", "OBSERVATION_MODIFIER", 25, 30], ["trajectories", "OBSERVATION_MODIFIER", 31, 43]]], ["The strength of the proposed technique is that it trains only one single R-NKTM for all action detections and all viewpoints for knowledge transfer of any human action video, without the requirement of re-training or fine-tuning the model.Related WorkIn [27] a probabilistic framework is proposed to infer the dynamic information associated with a human pose.", [["human", "ORGANISM", 155, 160], ["human", "ORGANISM", 348, 353], ["R-NKTM", "DNA", 73, 79], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 348, 353], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 348, 353], ["all action detections", "TEST", 84, 105], ["re-training", "TREATMENT", 202, 213]]], ["The model develops a data driven approach, by estimating the density of the test samples.", [["the test samples", "TEST", 72, 88]]], ["The statistical inference on the estimated density provides them with quantities of interests, such as the most probable future motion of the human and the amount of motion information conveyed by a pose.", [["human", "ORGANISM", 142, 147], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147], ["density", "OBSERVATION", 43, 50]]], ["[12] proposes a novel robust and efficient human activity recognition scheme called ReHAR which can be used to handle single person activities and group activities prediction.", [["human", "ORGANISM", 43, 48], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48]]], ["First, they generate an optical flow image for each video frame.", [["an optical flow image", "TEST", 21, 42]]], ["Then, both the original video frames and their corresponding optical flow images are fed into a single frame representation model to generate representations.", [["video frames", "DNA", 24, 36], ["their corresponding optical flow images", "TEST", 41, 80]]], ["Finally, an LSTM network is used to predict the forthcoming activities based on the generated representations.MethodologyThe architecture of our proposed method called Feature Reduction and Deep Learning (FR-DL) is shown in Figure 1 .", [["LSTM network", "DNA", 12, 24], ["an LSTM network", "TEST", 9, 24], ["Feature Reduction", "TREATMENT", 168, 185], ["Reduction", "OBSERVATION_MODIFIER", 176, 185], ["Deep", "OBSERVATION_MODIFIER", 190, 194]]], ["The proposed system consists of three main components: the input, the learning process, and the output.MethodologyThe learning process module includes Background Subtraction, Histogram of Oriented Gradients, and Skeletons (BGS-HOG-SKE), where we also call it feature reduction module; then we develope the CNN-LSTM model as deep learning module; and finally the KNN and Softmax layer as the human action classification sub-modules.", [["human", "ORGANISM", 391, 396], ["CNN", "DNA", 306, 309], ["human action classification sub-modules", "DNA", 391, 430], ["human", "SPECIES", 391, 396], ["human", "SPECIES", 391, 396], ["the output", "TEST", 92, 102], ["Background Subtraction", "TEST", 151, 173], ["Oriented Gradients", "TEST", 188, 206], ["BGS", "TEST", 223, 226], ["the CNN", "TEST", 302, 309], ["deep learning module", "PROBLEM", 324, 344], ["the KNN and Softmax layer", "TREATMENT", 358, 383], ["three", "OBSERVATION_MODIFIER", 32, 37], ["main", "OBSERVATION_MODIFIER", 38, 42], ["components", "OBSERVATION_MODIFIER", 43, 53], ["output", "OBSERVATION_MODIFIER", 96, 102], ["Skeletons", "ANATOMY", 212, 221]]], ["The UCF101 dataset and AlexNet are also utilized in the system, the former is a collection of large and complex video clips and the latter one is a pre-trained system designed to enhance the system action detection performance.", [["UCF101 dataset", "DNA", 4, 18], ["AlexNet", "TREATMENT", 23, 30], ["large and complex video clips", "PROBLEM", 94, 123], ["collection", "OBSERVATION_MODIFIER", 80, 90], ["large", "OBSERVATION_MODIFIER", 94, 99], ["complex", "OBSERVATION_MODIFIER", 104, 111], ["video clips", "OBSERVATION", 112, 123]]], ["In the preprocessing step, the video clips are converted to a sequence of frames.", [["video clips", "DNA", 31, 42], ["the video clips", "TREATMENT", 27, 42], ["clips", "OBSERVATION", 37, 42]]], ["However, the operations are performed only on selected frames which can have a positive impact on the cost and performance.", [["the operations", "TREATMENT", 9, 23], ["positive", "OBSERVATION_MODIFIER", 79, 87], ["impact", "OBSERVATION_MODIFIER", 88, 94]]], ["Two deep CNN and LSTM neural networks are used to select the features with optimised weights.", [["LSTM neural networks", "ANATOMY", 17, 37], ["neural networks", "MULTI-TISSUE_STRUCTURE", 22, 37], ["deep CNN and LSTM neural networks", "DNA", 4, 37], ["Two deep CNN and LSTM neural networks", "PROBLEM", 0, 37], ["deep", "ANATOMY_MODIFIER", 4, 8]]], ["Later in section experimental we will show the main advantage of RNNs and deep LSTM with a higher accuracy rate in complex action recognitions, comparing to other deep neural network models.", [["neural network", "ANATOMY", 168, 182], ["RNNs", "SIMPLE_CHEMICAL", 65, 69], ["neural network", "MULTI-TISSUE_STRUCTURE", 168, 182], ["RNNs", "PROTEIN", 65, 69], ["deep", "ANATOMY_MODIFIER", 163, 167], ["neural network", "ANATOMY", 168, 182]]], ["In the classification section, two methods of Softmax and KNN are used to label and classify the output as an action.MethodologyAfter the training phase of the developed action recognition system, the second phase is the system test and performance analysis, which specifies the system error and its accuracy.", [["Softmax", "TREATMENT", 46, 53], ["KNN", "TREATMENT", 58, 61], ["the output", "TEST", 93, 103], ["MethodologyAfter", "TREATMENT", 117, 133], ["the system test", "TEST", 217, 232], ["performance analysis", "TEST", 237, 257]]], ["The preprocessing stage is a very sensitive stage and the model performance highly depends on this stage and can lead to increased accuracy in the HAR output.", [["a very sensitive stage", "PROBLEM", 27, 49], ["increased accuracy", "PROBLEM", 121, 139], ["the HAR output", "TEST", 143, 157], ["very sensitive", "OBSERVATION_MODIFIER", 29, 43], ["increased", "OBSERVATION_MODIFIER", 121, 130]]], ["In this study, we removed the background of representative frames using BGS technique ( Figure 2 , bottom row).", [["this study", "TEST", 3, 13], ["BGS technique", "TREATMENT", 72, 85]]], ["After that we apply the deep and skeletal method on the representative frames, where depth motion maps explicitly create the motion representations from the raw frames.", [["skeletal", "ANATOMY", 33, 41], ["skeletal", "TISSUE", 33, 41], ["depth motion maps", "TEST", 85, 102], ["deep", "ANATOMY_MODIFIER", 24, 28], ["skeletal", "ANATOMY", 33, 41]]], ["Below we explain our model in an step-by-step manner:Learning ProcessingA) Video to frame conversion and frame selection: The input videos must first be converted to a set of frames [28] , each of which is represented by a matrix as shown in Eq.", [["matrix", "CELLULAR_COMPONENT", 223, 229]]], ["(1):Learning Processingwhere f k is the k th representative frame, which has n rows and m columns. f ij are the feature values (intensity of each pixel) for the corresponding frame k.", [["ij", "TREATMENT", 101, 103], ["ij", "ANATOMY", 101, 103]]], ["After converting a video to frames we face a high volume of still images and frames that decrease the overall efficiency of the system due to high computational cost.", [["high computational cost", "PROBLEM", 142, 165], ["overall", "OBSERVATION_MODIFIER", 102, 109], ["efficiency", "OBSERVATION_MODIFIER", 110, 120], ["high", "OBSERVATION_MODIFIER", 142, 146], ["computational cost", "OBSERVATION", 147, 165]]], ["In order to cope with the issue, we propose a simple yet effective solution to remove the redundant images.", [["effective solution", "TREATMENT", 57, 75], ["the redundant images", "TEST", 86, 106]]], ["This can be done by fixed-step jumps J to eliminate similar sequential frames [29] .", [["fixed-step jumps J", "TREATMENT", 20, 38]]], ["Therefore, instead of extracting all features of all frames, only N F frames [15] , [16] , [17] , [30] were used.", [["N F", "CHEMICAL", 66, 69], ["[17]", "SIMPLE_CHEMICAL", 91, 95]]], ["This makes our CNN network to perform more efficiently for the next steps.B) BGS and human action identification:A majority of the moving object recognition techniques include BGS, statistical methods, temporal differencing, and optical flow.", [["CNN network", "MULTI-TISSUE_STRUCTURE", 15, 26], ["human", "ORGANISM", 85, 90], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["statistical methods", "TEST", 181, 200], ["optical flow", "OBSERVATION", 229, 241]]], ["After separating the pixels from the static background of the scene, the regions can be classified into classes such as groups of humans.", [["humans", "ORGANISM", 130, 136], ["humans", "SPECIES", 130, 136], ["humans", "SPECIES", 130, 136]]], ["The classification algorithm depends on the comparison of the silhouettes of detected objects with pre-labelled templates in the database of an object silhouette.", [["The classification algorithm", "TEST", 0, 28], ["pre-labelled templates", "TREATMENT", 99, 121], ["object silhouette", "OBSERVATION", 144, 161]]], ["The template database is created by collecting samples of object silhouettes from samples of videos, labelled in appropriate categories.", [["The template database", "TEST", 0, 21]]], ["The silhouettes of the object regions are then extracted from the foreground pixel-map by using a contour tracing algorithm [28] , [31] .", [["a contour tracing algorithm", "TEST", 96, 123], ["silhouettes", "OBSERVATION_MODIFIER", 4, 15], ["object", "OBSERVATION_MODIFIER", 23, 29]]], ["In [33] , the BGS steps are described, where f k is the representative frame of the sequence of the video, assuming the neighbouring pixels share a similar temporal distribution.", [["the BGS steps", "TEST", 10, 23], ["neighbouring pixels", "OBSERVATION", 120, 139], ["similar", "OBSERVATION_MODIFIER", 148, 155], ["temporal", "OBSERVATION_MODIFIER", 156, 164], ["distribution", "OBSERVATION_MODIFIER", 165, 177]]], ["(2): Figure 3 : HOG steps for a sample \"dancing\" action recognition [15] Then A i the background model of the pixel u can be initialised by the background model of all pixels in the i th block:B) BGS and human action identification:This strategy can extract the foreground of selected frames from short video sequences or from embedded devices with limited memory and processing resources.", [["human", "ORGANISM", 204, 209], ["short video sequences", "DNA", 297, 318], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 204, 209], ["short video sequences", "TEST", 297, 318]]], ["Additionally, minimal but efficient size of data is preferred as too large data sizes may result in statistical correlation destruction within the pixels in different locations.", [["too large data sizes", "PROBLEM", 65, 85], ["statistical correlation destruction", "PROBLEM", 100, 135], ["minimal", "OBSERVATION_MODIFIER", 14, 21], ["efficient", "OBSERVATION_MODIFIER", 26, 35], ["size", "OBSERVATION_MODIFIER", 36, 40], ["destruction", "OBSERVATION", 124, 135], ["pixels", "OBSERVATION_MODIFIER", 147, 153], ["different", "OBSERVATION_MODIFIER", 157, 166]]], ["This will also cause the difference between the intensity of each pixel in the current image decreases from the corresponding value in the reference background image.B) BGS and human action identification:An example of a sequence of BGS steps for walking is shown in Figure 2 .", [["human", "ORGANISM", 177, 182], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 177, 182], ["intensity", "OBSERVATION_MODIFIER", 48, 57], ["pixel", "OBSERVATION_MODIFIER", 66, 71]]], ["Human shape plays an important role in recognising human action, which can extract blobs from BGS as shown in Figure 2 , middle and bottom rows.", [["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 51, 56], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 51, 56], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 51, 56]]], ["Several methods based on global features, boundary, and skeletal descriptors have been proposed to illustrate the human shape in a scene [32] .", [["skeletal", "ANATOMY", 56, 64], ["skeletal", "ORGAN", 56, 64], ["human", "ORGANISM", 114, 119], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 114, 119], ["Several methods", "TREATMENT", 0, 15], ["skeletal", "ANATOMY", 56, 64]]], ["After applying the BGS, a series of noise may disappear; however, some other noise may arise in other regions [34] , [35] .", [["some other noise", "PROBLEM", 66, 82]]], ["To remove such artefacts we use erosion and dilation morphological operators, with the structural elements of 3 \u00d7 3.", [["such artefacts", "PROBLEM", 10, 24], ["erosion", "PROBLEM", 32, 39], ["dilation morphological operators", "TREATMENT", 44, 76], ["erosion", "OBSERVATION", 32, 39], ["dilation", "OBSERVATION", 44, 52]]], ["The feature extraction step determines the diagnostic information needed to describe the human silhouette.", [["human", "ORGANISM", 89, 94], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94]]], ["In general, we can say that BGS extracts useful features from an object that increases the performance of our model by decreasing the size of the initial raw data, while maintaining the important parts of the embedded information.B) BGS and human action identification:C) HOG-SKE: Histogram of Oriented Gradients and Skeleton: In our proposed method, four different methods are used to evaluate the performance of the position descriptor: frame voting, global histogram, SVM classification, and dynamic time deviation.", [["human", "ORGANISM", 241, 246], ["human", "SPECIES", 241, 246], ["human", "SPECIES", 241, 246], ["global histogram", "TEST", 453, 469], ["SVM classification", "TEST", 471, 489], ["size", "OBSERVATION_MODIFIER", 134, 138], ["Skeleton", "ANATOMY", 317, 325]]], ["After that, the human body is extracted using complex screws or volumetric models such as cones, elliptical cylinders, and spheres.", [["body", "ANATOMY", 22, 26], ["human", "ORGANISM", 16, 21], ["body", "ORGANISM_SUBDIVISION", 22, 26], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["the human body", "TREATMENT", 12, 26], ["complex screws or volumetric models", "TREATMENT", 46, 81], ["elliptical cylinders, and spheres", "TREATMENT", 97, 130], ["screws", "OBSERVATION", 54, 60]]], ["HOG features can be extracted from the silhouette we made from the BGS stage, as also shown in Figure 3 [15] .", [["silhouette", "ANATOMY", 39, 49]]], ["The technique is a window-based descriptor used to compute points of interest, where the window is divided into an n \u00d7 n frequency grid of the histograms.", [["a window-based descriptor", "TREATMENT", 17, 42], ["an n \u00d7 n frequency grid", "TREATMENT", 112, 135], ["the histograms", "TEST", 139, 153]]], ["The frequency histogram is generated from each grid cell to indicate the magnitude and direction of the edge for every individual cell [36] .", [["grid cell", "ANATOMY", 47, 56], ["cell", "ANATOMY", 130, 134], ["grid cell", "CELL", 47, 56], ["cell", "CELL", 130, 134], ["The frequency histogram", "TEST", 0, 23]]], ["The cells are interconnected and HOG calculates the derivative of each cell (or sub-image), I, with respect to X and Y as shown in Eq.(4) and Eq.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 71, 75], ["cells", "CELL", 4, 9], ["cell", "CELL", 71, 75]]], ["(5):B) BGS and human action identification:where DX = [+1 0 \u2212 1],B) BGS and human action identification:where DY = Figure 4 : The steps of the appropriate frame region selection and extraction of the skeleton motion [16] , [37] I X and I Y , are the derivative of the image with respect to X and Y , respectively.", [["human", "ORGANISM", 15, 20], ["human", "ORGANISM", 76, 81], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 76, 81], ["human action identification", "TEST", 15, 42], ["BGS", "TEST", 68, 71], ["human action identification", "TEST", 76, 103], ["the skeleton motion", "TEST", 196, 215]]], ["In order to obtain these derivatives, horizontal and vertical Sobel filters (i.e. DX and DY ) are convolved on the image.B) BGS and human action identification:Normally, every video consists of hundreds of frames, and using the HOG will lead to an elongated vector and therefore a higher computational cost.", [["human", "ORGANISM", 132, 137], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["these derivatives", "TREATMENT", 19, 36], ["horizontal and vertical Sobel filters", "TREATMENT", 38, 75], ["an elongated vector", "PROBLEM", 245, 264], ["a higher computational cost", "TREATMENT", 279, 306]]], ["For resolving these challenges, an overlap and 6 step frame jumps are used.B) BGS and human action identification:Then magnitude and the angle of each cell is calculated as per the Eq.(6) and Eq.", [["cell", "ANATOMY", 151, 155], ["human", "ORGANISM", 86, 91], ["cell", "CELL", 151, 155], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["6 step frame jumps", "TREATMENT", 47, 65]]], ["Finally histograms of cells will be normalised.B) BGS and human action identification:In this paper, in addition to the HOG method a simple skeleton view is also used for action recognition.", [["cells", "ANATOMY", 22, 27], ["cells", "CELL", 22, 27], ["human", "ORGANISM", 58, 63], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["histograms of cells", "PROBLEM", 8, 27]]], ["This technology allows the fast and easy joints extraction of human body [36] .", [["joints", "ANATOMY", 41, 47], ["body", "ANATOMY", 68, 72], ["joints", "MULTI-TISSUE_STRUCTURE", 41, 47], ["human", "ORGANISM", 62, 67], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["easy joints extraction", "TREATMENT", 36, 58], ["joints", "ANATOMY", 41, 47]]], ["Some studies, only use part of the body in a skeleton method, such as hands.", [["body", "ANATOMY", 35, 39], ["body", "ORGANISM_SUBDIVISION", 35, 39], ["hands", "ORGANISM_SUBDIVISION", 70, 75], ["Some studies", "TEST", 0, 12], ["skeleton", "ANATOMY", 45, 53], ["hands", "ANATOMY", 70, 75]]], ["However, in this research, the whole body is used to increase the overall accuracy.", [["body", "ANATOMY", 37, 41], ["body", "ORGANISM_SUBDIVISION", 37, 41]]], ["Figure 4 -left illustrates a skeletal method on three activities of sitting, standing, and raising hand and Figure 4 right focuses more on hand activity recognition.", [["skeletal", "ANATOMY", 29, 37], ["hand", "ANATOMY", 99, 103], ["hand", "ANATOMY", 139, 143], ["skeletal", "ORGAN", 29, 37], ["hand", "ORGANISM_SUBDIVISION", 99, 103], ["hand", "ORGANISM_SUBDIVISION", 139, 143], ["Figure", "TEST", 0, 6], ["a skeletal method", "PROBLEM", 27, 44], ["left", "ANATOMY_MODIFIER", 10, 14], ["skeletal", "ANATOMY", 29, 37]]], ["One of the advantages of deep data and skeletal data, as compared with traditional RGB data is that, they are less sensitive to changes in lighting conditions [16] .", [["skeletal", "ANATOMY", 39, 47], ["skeletal", "ORGAN", 39, 47], ["deep data", "TEST", 25, 34], ["skeletal data", "TEST", 39, 52], ["traditional RGB data", "TEST", 71, 91], ["skeletal", "ANATOMY", 39, 47]]], ["We use Skeleton and inertia data at both levels of feature and decision making to improve the accuracy of our action recognition model.B) BGS and human action identification:The sequences s k of the skeleton with N F frames are shown as: s k = {f 1 , f 2 , ...f N F }.", [["N F }.", "CHEMICAL", 262, 268], ["human", "ORGANISM", 146, 151], ["N F frames", "DNA", 213, 223], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 146, 151], ["Skeleton and inertia data", "TEST", 7, 32], ["The sequences s", "TEST", 174, 189], ["k", "TEST", 240, 241], ["Skeleton", "ANATOMY", 7, 15], ["skeleton", "ANATOMY", 199, 207]]], ["We use same notations as in [37] .B) BGS and human action identification:To represent spatial and temporal information, the coordinate skeleton sequenceB) BGS and human action identification:where min{C} and max{C} are minima and maxima of all coordinate values.B) BGS and human action identification:The new coordinate space is quantified to integral image representation and three coordinates (X i , Y i , Z i ) are considered as the three components R, G, B of a colour-pixel:B) BGS and human action identification:The steps are shown in Figure 5 .", [["human", "ORGANISM", 45, 50], ["human", "ORGANISM", 163, 168], ["C}", "SIMPLE_CHEMICAL", 212, 214], ["human", "ORGANISM", 273, 278], ["human", "ORGANISM", 490, 495], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 273, 278], ["human", "SPECIES", 490, 495], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 273, 278], ["human", "SPECIES", 490, 495], ["The new coordinate space", "PROBLEM", 301, 325], ["minima", "OBSERVATION", 219, 225], ["new", "OBSERVATION_MODIFIER", 305, 308], ["coordinate space", "OBSERVATION", 309, 325]]], ["Following the above steps and conversions, the raw data of the skeleton sequence changes into 3-D tensors and then is injected into the learning model as inputs.", [["the above steps", "TREATMENT", 10, 25], ["the skeleton sequence changes", "TEST", 59, 88], ["3-D tensors", "TREATMENT", 94, 105]]], ["K denotes the number of joints in each frame and it depends on the deep sensors and data acquisition settings.D) ROI Calculation:During the process of feature extraction to display action, a combination of contour-based distance signal feature, flow-based motion feature [12] , [14] , and uniform rotation local binary patterns can be used to define region of interest for feature extraction [15] , [16] , [17] , [22] .", [["joints", "ANATOMY", 24, 30], ["K", "CHEMICAL", 0, 1], ["joints", "MULTI-TISSUE_STRUCTURE", 24, 30], ["[17]", "SIMPLE_CHEMICAL", 406, 410], ["K", "TEST", 0, 1], ["the deep sensors", "TEST", 63, 79], ["feature extraction", "TREATMENT", 151, 169], ["contour-based distance signal feature", "PROBLEM", 206, 243], ["feature extraction", "TEST", 373, 391], ["number", "OBSERVATION_MODIFIER", 14, 20], ["joints", "ANATOMY", 24, 30], ["deep", "ANATOMY_MODIFIER", 67, 71], ["contour", "OBSERVATION_MODIFIER", 206, 213]]], ["Therefore, at this stage, suitable regions for extraction of the feature are determined.", [["extraction", "TREATMENT", 47, 57]]], ["A similar method is presented in [26] , [38] for extraction of Entropy-based silhouettes.", [["Entropy", "OBSERVATION", 63, 70], ["based", "ANATOMY_MODIFIER", 71, 76], ["silhouettes", "ANATOMY_MODIFIER", 77, 88]]], ["Figure 5 : The stages of converting skeletal sequences to spatio-temporal information to train the model.Feature selectionGiven that in each movie an action is represented by a sequence of frames, we can perform the action recognition by analysing the contents of multiple frames in a sequence.", [["skeletal", "ANATOMY", 36, 44], ["skeletal", "ORGAN", 36, 44], ["the action recognition", "TEST", 212, 234], ["skeletal", "ANATOMY", 36, 44]]], ["We propose a series of techniques and methods to find out activities that are close to human perceptions of activities in real life.Feature selectionOne of the human abilities is to predict the upcoming actions based on the previous action sequences.", [["human", "ORGANISM", 87, 92], ["human", "ORGANISM", 160, 165], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 160, 165], ["a series of techniques", "TREATMENT", 11, 33], ["methods", "TREATMENT", 38, 45], ["the previous action sequences", "TEST", 220, 249]]], ["Therefore, to enable a system with such characteristics, deep neural networks, inspired from natural human neural networks is very appropriate.", [["neural networks", "ANATOMY", 62, 77], ["neural networks", "ANATOMY", 107, 122], ["neural networks", "MULTI-TISSUE_STRUCTURE", 62, 77], ["human", "ORGANISM", 101, 106], ["neural networks", "MULTI-TISSUE_STRUCTURE", 107, 122], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["deep neural networks", "PROBLEM", 57, 77], ["deep", "ANATOMY_MODIFIER", 57, 61], ["neural", "ANATOMY", 62, 68]]], ["These networks include but not limited to CNN, RNN, and LSTM.Feature selectionIn many research works, the CNN streams are fused with RGB frames and skeletal sequences at feature level and decision level.", [["skeletal", "ANATOMY", 148, 156], ["CNN", "GENE_OR_GENE_PRODUCT", 42, 45], ["CNN", "GENE_OR_GENE_PRODUCT", 106, 109], ["skeletal", "ORGAN", 148, 156], ["CNN", "PROTEIN", 42, 45], ["RNN", "PROTEIN", 47, 50], ["LSTM", "PROTEIN", 56, 60], ["CNN streams", "DNA", 106, 117], ["RGB frames", "DNA", 133, 143], ["RGB frames", "TEST", 133, 143], ["skeletal sequences", "TEST", 148, 166], ["selection", "OBSERVATION", 69, 78], ["skeletal", "ANATOMY", 148, 156]]], ["As already mentioned, the existence of multidimensional visual data encourages us to combine all vision cues, such as depth and skeletal as in [16] .", [["skeletal", "ANATOMY", 128, 136], ["skeletal", "ORGAN", 128, 136], ["skeletal", "ANATOMY", 128, 136]]], ["Many studies focus on the improved skeletal display of CNN architecture.", [["skeletal", "ANATOMY", 35, 43], ["skeletal", "ORGAN", 35, 43], ["CNN", "GENE_OR_GENE_PRODUCT", 55, 58], ["CNN", "PROTEIN", 55, 58], ["Many studies", "TEST", 0, 12], ["skeletal", "ANATOMY", 35, 43], ["CNN architecture", "OBSERVATION", 55, 71]]], ["One of the major challenges in exploiting CNN-based methods for detecting skeletal-based action is how to display a temporal skeleton sequence effectively and feed them into a CNN for feature learning and classifications.Feature selectionTo overcome this challenge, we encode the temporal and spatial dynamics of skeleton sequences in 2-D image structures CNN is used to learn the features of the image and its classification to identify the original skeleton sequences [39] .", [["skeletal", "ANATOMY", 74, 82], ["CNN", "GENE_OR_GENE_PRODUCT", 42, 45], ["skeletal", "ORGAN", 74, 82], ["CNN", "DNA", 42, 45], ["the image", "TEST", 393, 402], ["skeletal", "ANATOMY", 74, 82]]], ["CNN generally consists of convolutional layers, pooling layers and fully-connected layers.", [["layers", "TISSUE", 83, 89], ["CNN", "PROTEIN", 0, 3], ["convolutional layers", "PROBLEM", 26, 46], ["pooling layers and fully-connected layers", "PROBLEM", 48, 89], ["convolutional", "OBSERVATION_MODIFIER", 26, 39], ["layers", "OBSERVATION_MODIFIER", 40, 46], ["pooling", "OBSERVATION_MODIFIER", 48, 55], ["layers", "OBSERVATION_MODIFIER", 56, 62], ["connected layers", "OBSERVATION_MODIFIER", 73, 89]]], ["In the convolutional layer, filters are very useful for detecting the edges in the images [40] , [41] , [42] , [43] , [44] .", [["layer", "OBSERVATION_MODIFIER", 21, 26], ["edges", "OBSERVATION_MODIFIER", 70, 75]]], ["The pooling layers are generally used in the Max-type, which is intended to reduce the dimension, and the fully-connected layers are used to convert a cubic dimensional data in to a 1-D vector [45] .Feature selectionBased on a stack of N F input frames, this convolutional network learns to optimise the filters weight; however, it may not be capable of detecting complicated video sequences with complex activities, such as eating or jumping over obstacles.", [["layers", "TISSUE", 122, 128], ["N F input frames", "DNA", 236, 252], ["The pooling layers", "PROBLEM", 0, 18], ["the filters weight", "TEST", 300, 318], ["pooling", "OBSERVATION_MODIFIER", 4, 11], ["layers", "OBSERVATION_MODIFIER", 12, 18], ["dimension", "OBSERVATION_MODIFIER", 87, 96]]], ["RNNs can resolve this problem [12] , [46] , [47] , by storing only the previous step and consequently avoiding the exploding and vanishing gradient issue.", [["RNNs", "SIMPLE_CHEMICAL", 0, 4], ["[46]", "SIMPLE_CHEMICAL", 37, 41], ["[47]", "SIMPLE_CHEMICAL", 44, 48], ["vanishing gradient issue", "PROBLEM", 129, 153]]], ["It can be said that the LSTM network is a kind of RNN, which solves the aforementioned issues by holding up a short memory for a long time.", [["LSTM network", "MULTI-TISSUE_STRUCTURE", 24, 36]]], ["In our research, we combine CNN and LSTM for feature selection and accurate action recognition due to their high performance in visual and sequential data.", [["CNN", "DNA", 28, 31], ["LSTM", "DNA", 36, 40]]], ["AlexNet is also injected into feature selection for identifying hidden patterns of the visual data.", [["Alex", "CHEMICAL", 0, 4], ["the visual data", "TEST", 83, 98]]], ["The feature selection operation is performed in parallel in order to speed up the processing, namely, parallel duplex LSTMs.", [["The feature selection operation", "TREATMENT", 0, 31], ["parallel duplex LSTMs", "TEST", 102, 123], ["selection operation", "OBSERVATION", 12, 31]]], ["A similar approach is considered in [12] , [23] , [48] , [49] , and [50] .", [["[12] , [23]", "SIMPLE_CHEMICAL", 36, 47], ["[48]", "SIMPLE_CHEMICAL", 50, 54], ["[49]", "SIMPLE_CHEMICAL", 57, 61], ["[50]", "SIMPLE_CHEMICAL", 68, 72]]], ["Artificial neural networks and LSTM have greatly gained success in the processing of sequential multimedia data and have obtained advanced results in speech recognition, digital signal processing, image processing, and text data analysis [12] , [39] , [51] .", [["neural networks", "ANATOMY", 11, 26], ["neural networks", "MULTI-TISSUE_STRUCTURE", 11, 26], ["Artificial neural networks", "TREATMENT", 0, 26], ["sequential multimedia data", "TEST", 85, 111], ["speech recognition", "TEST", 150, 168], ["digital signal processing", "TEST", 170, 195], ["image processing", "TEST", 197, 213], ["text data analysis", "TEST", 219, 237]]], ["Figure 6 describes how we use a CNN and dual LSTM networks in our work.", [["LSTM networks", "MULTI-TISSUE_STRUCTURE", 45, 58]]], ["According to research conducted in [12] , [45] , [52] , [37] , [53] , LSTM is capable of learning long-term dependencies, and its special structure includes inputs, outputs and forget gates, which controls long-term sequence recognition.", [["[12] , [45] , [52] , [37] , [53]", "SIMPLE_CHEMICAL", 35, 67], ["long-term sequence", "DNA", 206, 224], ["learning long-term dependencies", "PROBLEM", 89, 120]]], ["The gates are set by the Sigmoid unit opened and closed during the training.", [["Sigmoid unit", "DNA", 25, 37], ["the training", "TREATMENT", 63, 75], ["Sigmoid", "ANATOMY", 25, 32]]], ["Each LSTM unit is calculated as Eq.", [["LSTM unit", "DNA", 5, 14]]], ["(9) to (15) : where x t is the input at time t, f t is the forget gate at time t which clears the information from the memory cell, if needed, and holds a record of the previous frame.", [["memory cell", "ANATOMY", 119, 130], ["memory cell", "CELL", 119, 130], ["memory cell", "CELL_TYPE", 119, 130]]], ["Output gate o t holds the information about the next step, g is the return unit and has the tanh activation function which is computed using the current frame input and the previous s t\u22121 frame status. s t is the RNN output from the current mode.", [["t", "DNA", 14, 15]]], ["The hidden mode is calculated from one RNN stage by activating tanh and c t memory cells.", [["c t memory cells", "ANATOMY", 72, 88], ["tanh and c t memory cells", "CELL_LINE", 63, 88], ["activating tanh and c t memory cells", "PROBLEM", 52, 88], ["memory cells", "OBSERVATION", 76, 88]]], ["W i is the input gate weight, W o is the output gate weight, W f is the forget gate weight and W g is the returning unit weight from the LSTM cell. b i , b o , b f and b g are the biases for input, output, forget and the returning unit gates, respectively.", [["LSTM cell", "ANATOMY", 137, 146], ["LSTM cell", "CELL", 137, 146], ["LSTM cell", "CELL_LINE", 137, 146], ["output", "TEST", 198, 204], ["LSTM cell", "OBSERVATION", 137, 146], ["output", "OBSERVATION_MODIFIER", 198, 204]]], ["As the action recognition does not need the intermediate output of the LSTM, we made a final decision making by applying a Softmax classifier on the final state of the RNN network.", [["RNN network", "MULTI-TISSUE_STRUCTURE", 168, 179], ["LSTM", "DNA", 71, 75], ["RNN network", "PROTEIN", 168, 179]]], ["Training large data with complex sequence patterns (such as video data) can not be identified by a single LSTM cell, so we use stacking multiple LSTM cells to learn long term dependencies in video data.Transfer learning: AlexNetAlexNet is an architecture for solving the challenges of the human action recognition system, trained on the large ImageNet dataset with more than 15 million images.", [["LSTM cell", "ANATOMY", 106, 115], ["LSTM cells", "ANATOMY", 145, 155], ["LSTM cell", "CELL", 106, 115], ["LSTM cells", "CELL", 145, 155], ["human", "ORGANISM", 289, 294], ["LSTM cell", "CELL_LINE", 106, 115], ["LSTM cells", "CELL_LINE", 145, 155], ["human", "SPECIES", 289, 294], ["human", "SPECIES", 289, 294], ["complex sequence patterns", "TEST", 25, 50], ["video data", "TEST", 60, 70], ["a single LSTM cell", "PROBLEM", 97, 115], ["stacking multiple LSTM cells", "TREATMENT", 127, 155], ["long term dependencies", "PROBLEM", 165, 187], ["video data", "TEST", 191, 201], ["AlexNetAlexNet", "TREATMENT", 221, 235]]], ["The model is able to identify hidden patterns in visual data more accurately than many other CNN based architectures [12] , [24] .", [["visual data", "TEST", 49, 60]]], ["Action recognition system requires high training data and computing ability.", [["high training data", "TREATMENT", 35, 53]]], ["AlexNet is embedded in the architecture of our model to extract the higher-performing features because the pre-trained AlexNet does not have any negative impacts on the performance of the system.Transfer learning: AlexNetThe AlexNet architectural parameters are presented in Table 2 .", [["Alex", "CHEMICAL", 0, 4], ["negative", "OBSERVATION_MODIFIER", 145, 153], ["impacts", "OBSERVATION", 154, 161]]], ["It has six layers of convolution, three layers of pooling and three fully-connected layers.", [["layers", "TISSUE", 84, 90], ["pooling", "PROBLEM", 50, 57], ["six", "OBSERVATION_MODIFIER", 7, 10], ["layers", "OBSERVATION_MODIFIER", 11, 17], ["convolution", "OBSERVATION_MODIFIER", 21, 32], ["three", "OBSERVATION_MODIFIER", 34, 39], ["layers", "OBSERVATION_MODIFIER", 40, 46], ["pooling", "OBSERVATION", 50, 57], ["three fully-connected layers", "OBSERVATION_MODIFIER", 62, 90]]], ["Each layer is followed by a non-linear ReLU activation function and the vector of extracted features from the FC8 layer is 1000-dimensional.KNN-Softmax classifierClassification is usually done in deep neural networks based on Softmax function.", [["FC8 layer", "ANATOMY", 110, 119], ["neural networks", "ANATOMY", 201, 216], ["neural networks", "MULTI-TISSUE_STRUCTURE", 201, 216], ["a non-linear ReLU activation function", "PROBLEM", 26, 63], ["Softmax classifierClassification", "TREATMENT", 144, 176], ["layer", "OBSERVATION_MODIFIER", 5, 10], ["activation function", "OBSERVATION", 44, 63]]], ["The Softmax classifier practically is placed after the last layer in the deep neural network.", [["neural network", "ANATOMY", 78, 92], ["neural network", "MULTI-TISSUE_STRUCTURE", 78, 92], ["The Softmax classifier practically", "TREATMENT", 0, 34], ["deep", "ANATOMY_MODIFIER", 73, 77], ["neural network", "ANATOMY", 78, 92]]], ["In fact, the result of the convolutional and pooling layers (a feature vector p l = [p 1 , ..., p I ]) is the input of the Softmax [41] , [43] .", [["the convolutional and pooling layers", "PROBLEM", 23, 59]]], ["After forward propagation, weighs are updated, and errors are minimised through an stochastic gradient descent (SGD) optimisation on several training examples and iterations.", [["an stochastic gradient descent", "PROBLEM", 80, 110]]], ["In case of large number of classes the Softmax does not perform very well.", [["large", "OBSERVATION_MODIFIER", 11, 16]]], ["This is normally due to two main reasons: when the number of parameters is large, the last layer fails to increase the forward-backward speed; furthermore, syncing GPUs will be difficult as well [43] , [44] .KNN-Softmax classifierIn this article we use KNN when the number of classes is high and Softmax fails to perform well.", [["Softmax", "PROTEIN", 296, 303], ["large", "OBSERVATION_MODIFIER", 75, 80]]], ["After classifying by Sofmax, if it fails (that is the probability of closeness of action to two classes or several classes), then KNN should be used.", [["KNN", "TREATMENT", 130, 133]]], ["KNN uses Euclidean distance [54] and Hamming distance to detect the similarity between two feature vectors.", [["KNN", "DNA", 0, 3], ["Hamming distance", "TEST", 37, 53]]], ["We use Euclidean distance in the KNN classifier, with k = 10 and squared inverse distance weights [54] .", [["k", "TEST", 54, 55], ["squared inverse distance weights", "TEST", 65, 97]]], ["Assuming u is a new instance with a label y j , in order to find v + 1 and closest neighbour to u, the distance formula with d(u, x i ) can be determined as Eq.", [["v + 1", "GENE_OR_GENE_PRODUCT", 65, 70], ["d(u, x i", "TREATMENT", 125, 133]]], ["(17).KNN-Softmax classifierwe normalise d(u, x i ) by the kernel function and weighing according to Eq.", [["KNN", "TEST", 5, 8]]], ["(18) .KNN-Softmax classifierThe final membership function of weighted K-nearest neighbour (W-KNN) is formulated as follows:Experimental ResultsIn this section, we will evaluate the proposed method on the UCF101 dataset as a common benchmarking dataset based on the accuracy criterion, followed by discussion on the experimental results.", [["(18) .KNN", "CHEMICAL", 0, 9], ["UCF101 dataset", "DNA", 204, 218]]], ["The dataset is divided into three parts: training, testing, and validation, based on 60%, 20% and 20% splits, respectively.", [["testing", "TEST", 51, 58], ["validation", "TEST", 64, 74]]], ["To implement the proposed model we use Python 3 and TensorFlow deep learning framework.", [["Python 3", "TREATMENT", 39, 47], ["TensorFlow deep learning framework", "TREATMENT", 52, 86]]], ["In our evaluations, we compare the proposed method with six state-of-the-art methods using the accuracy criterion.UCF101 datasetThe UCF101 dataset is a relatively complex dataset due to many action categories.", [["UCF101 dataset", "DNA", 114, 128], ["UCF101 dataset", "DNA", 132, 146], ["our evaluations", "TEST", 3, 18]]], ["One of the major challenges in this dataset is the mixture of natural realistic actions and the actions played by many actors while in other datasets the activities and actions are usually performed by one actor only [12] , [24] , [50] , [54] .", [["major", "OBSERVATION_MODIFIER", 11, 16], ["challenges", "OBSERVATION", 17, 27]]], ["The UCF101 dataset includes 101 action classes, over 13,000 video clips and 27 hours of video data.", [["UCF101 dataset", "DNA", 4, 18], ["The UCF101 dataset", "TEST", 0, 18], ["video clips", "TEST", 60, 71], ["video data", "TEST", 88, 98]]], ["Therefore, UCF101 is considered as a very comprehensive dataset.", [["UCF101", "CHEMICAL", 11, 17], ["UCF101", "GENE_OR_GENE_PRODUCT", 11, 17], ["UCF101", "PROTEIN", 11, 17]]], ["The action categories in this dataset can generally be considered as five major types: Interaction between human and object, body movement, human-to-human interaction, musical instruments, and sport [12] , [55] , [56] .", [["body", "ANATOMY", 125, 129], ["human", "ORGANISM", 107, 112], ["body", "ORGANISM_SUBDIVISION", 125, 129], ["human", "ORGANISM", 140, 145], ["human", "ORGANISM", 149, 154], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 140, 145]]], ["Figure 7 shows one sample frame of three different video clips and actions from the UCF101 dataset.", [["UCF101 dataset", "DNA", 84, 98], ["different video clips", "TREATMENT", 41, 62], ["clips", "OBSERVATION", 57, 62]]], ["Sport category is the largest category of the UCF101 dataset and plays an important role in benchmarking.UCF Sports datasetThis dataset contains 150 videos of sports broadcasts that are captured in cluttered, and dynamic environments.", [["UCF101 dataset", "DNA", 46, 60], ["sports broadcasts", "TREATMENT", 159, 176], ["largest", "OBSERVATION_MODIFIER", 22, 29]]], ["In some research works such as [57] which are based on temporal template matching, the UCF Sports action has been used for benchmarking purposes.", [["temporal template matching", "TREATMENT", 55, 81]]], ["This category is also useful for actions that are related to human body motion such as \"Walk\" or to human-object interaction such as \"Horse-Riding\" [55] .UCF Sports datasetIn the next two sections we discuss about two types of the test and evaluations that we conducted in this research: Table 3 presents the outcome of our experiments for the proposed FR-DL method.", [["body", "ANATOMY", 67, 71], ["human", "ORGANISM", 61, 66], ["body", "ORGANISM_SUBDIVISION", 67, 71], ["human", "ORGANISM", 100, 105], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 100, 105], ["the test and evaluations", "TEST", 227, 251], ["the proposed FR-DL method", "TREATMENT", 340, 365]]], ["The proposed method shows an improve- The proposed hybrid FR-DL method uses a combination of BGS, HOG and Skeleton methods as the preprocessing stage, to extract features that played a major role in the action recognition.", [["The proposed method", "TEST", 0, 19], ["The proposed hybrid FR-DL method", "TREATMENT", 38, 70], ["BGS", "TEST", 93, 96], ["HOG and Skeleton methods", "TREATMENT", 98, 122], ["hybrid FR", "OBSERVATION", 51, 60]]], ["The combination of convolution, pooling, fully-connected and LSTM units are used to achieve a better feature learning, feature selection, and classification.", [["LSTM units", "DNA", 61, 71], ["convolution, pooling", "PROBLEM", 19, 39], ["fully-connected and LSTM units", "TREATMENT", 41, 71], ["convolution", "OBSERVATION_MODIFIER", 19, 30]]], ["Therefore, the probability of error in the classification stage is greatly reduced; and furthermore, complex activities are recognised with higher accuracy rate, as well.Optimum Frame JumpingAs the second experiment we also evaluated the optimum jump length for the proposed FR-DL method.", [["Frame Jumping", "DNA", 178, 191], ["the proposed FR-DL method", "TREATMENT", 262, 287], ["greatly", "OBSERVATION_MODIFIER", 67, 74], ["reduced", "OBSERVATION_MODIFIER", 75, 82]]], ["Table 4 shows the evaluation of the proposed method, based on different frame jumps of 4, 6, and 8 and their impact on the performance of the system.", [["the evaluation", "TEST", 14, 28]]], ["Using the frame jump of J = 6 we achieved nearly 50% improvement in speed and computational cost of the system in comparison with J = 4, while we approximately lost only 1.5% in accuracy rate.", [["accuracy rate", "TEST", 178, 191]]], ["Therefore, considering the speed-accuracy trade-off, we selected the frame jump of 6 as the optimum value for our intended application while it still outperforms the similar state-of-the-art method (DB-LSTM) [12] .Confusion MatrixA confusion matrix contains visualised and quantised information about multiple classifiers using a reference classification system [12] , [49] .", [["confusion", "DISEASE", 232, 241], ["Confusion MatrixA confusion", "PROBLEM", 214, 241]]], ["Each row represents the predicted class, and each column represents instances of the ground truth classes.", [["ground truth", "OBSERVATION", 85, 97]]], ["Figure 8 shows the details of the results on the UCF Sports dataset for the proposed FR-DL method.Confusion MatrixThe confusion matrix results confirms that in overall the FR-DL provides a more consistent confusion matrix comparing the ReHAR method [12] , even for Golf, Run, and Walk actions as our weakest results with the accuracy of 82.6%, 83.42%, and 72.30%, respectively, in contrast to 83.33%, 75.00%, and 57.14% for the ReHAR method.", [["Confusion", "DISEASE", 98, 107], ["confusion", "DISEASE", 118, 127], ["confusion", "DISEASE", 205, 214], ["the proposed FR-DL method", "TREATMENT", 72, 97], ["Confusion Matrix", "PROBLEM", 98, 114], ["the accuracy", "TEST", 321, 333], ["the ReHAR method", "TEST", 424, 440]]], ["This are expectable, as some of these actions have common features that lead to a misclassification.", [["a misclassification", "PROBLEM", 80, 99]]], ["Furthermore, extra objects and people in the background of the scene are among the factors that also leads to a wrong classification.", [["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37]]], ["For example, in one of the examined videos \"walk-front/006RF1-13902-70016.avi\", there is a person who walks on a golf field with a golf pole.", [["person", "SPECIES", 91, 97]]], ["The environment is related to golf field and the motion of the golf pole in the background looks like a person is swinging the pole in front of him [49] .", [["pole", "ANATOMY", 127, 131], ["person", "SPECIES", 104, 110]]], ["This was an examples of mis-classifications by the proposed FR-DL method.DiscussionAccording to summarised performance in Table 3 , the proposed FR-DL method helped us in recognising complex actions using spatio-temporal information, which were hidden in sequential patterns and features.", [["DL", "ANATOMY", 63, 65]]], ["In addition to Softmax, the KNN is used for classification.", [["Softmax", "DNA", 15, 22], ["KNN", "DNA", 28, 31], ["Softmax", "TREATMENT", 15, 22]]], ["These together made the proposed method more precise than the other methods, as seen in Table 3 .DiscussionThe system can reduce the effects of the degradation phenomenon for both training and test phases.", [["the degradation phenomenon", "TREATMENT", 144, 170], ["test phases", "TEST", 193, 204]]], ["It should be noted that degradation phenomena considerably depends on the size of the datasets.", [["degradation phenomena", "PROBLEM", 24, 45], ["phenomena", "OBSERVATION", 36, 45], ["size", "OBSERVATION_MODIFIER", 74, 78]]], ["This is the reason why the networks with too many layers have higher errors than medium-size networks.", [["size", "OBSERVATION_MODIFIER", 88, 92]]], ["The difference between the training error and the test error on the learning curves shows the ability of overfitting prevention.DiscussionWe also extended the skeleton encoding method by exploiting the Euclidean distance and the orientation relationship between the joints.", [["joints", "ANATOMY", 266, 272], ["joints", "MULTI-TISSUE_STRUCTURE", 266, 272], ["the training error", "TEST", 23, 41], ["the test error", "TEST", 46, 60], ["the learning curves", "TEST", 64, 83], ["overfitting prevention", "TREATMENT", 105, 127], ["skeleton", "ANATOMY", 159, 167], ["joints", "ANATOMY", 266, 272]]], ["According to Table 4 , in both methods the accuracy level is slightly higher with J = 4; however, the time complexity of Jump 6 is significantly less than the Jump 4.", [["the accuracy level", "TEST", 39, 57], ["slightly", "OBSERVATION_MODIFIER", 61, 69], ["higher", "OBSERVATION_MODIFIER", 70, 76]]], ["Therefore, the Jump 6 is considered as a better trade-off in terms of accuracy and time complexity.DiscussionAs the table 4 shows, the DB-LSTM method is slightly faster than the FR-DL method but less accurate.", [["the DB-LSTM method", "TEST", 131, 149], ["the FR", "TEST", 174, 180], ["slightly", "OBSERVATION_MODIFIER", 153, 161], ["faster", "OBSERVATION_MODIFIER", 162, 168]]], ["In general, the suggested method of jumping 6 requires 1.6 second in a medium range Cori7 PC to process a 1-second og HD video clip [12] .", [["a medium range Cori7 PC", "TREATMENT", 69, 92], ["a 1-second og HD video clip", "TREATMENT", 104, 131]]], ["Depending on the nature of the application in terms of speed and accuracy requirements, this can be simply converted to a 1-1 real-time action recognition solution either by increasing the jump step, or by improving the CPU speed, or reducing the input video resolution, or by considering a combination of all three factors.ConclusionIn this article, we proposed a new approach including a combination of BGS, HOG and Skeletal to analyse and describe the appropriate frames for the preprocessing phase of the human action recognition.", [["human", "ORGANISM", 509, 514], ["human", "SPECIES", 509, 514], ["human", "SPECIES", 509, 514], ["a new approach", "TREATMENT", 363, 377]]], ["Then a deep convolution neural network and LSTM for the feature selection were implemented, and finally the Softmax-KNN for the labelling and classification of the actions was utilised.", [["neural network", "MULTI-TISSUE_STRUCTURE", 24, 38], ["LSTM", "DNA", 43, 47], ["Softmax", "DNA", 108, 115], ["a deep convolution neural network", "PROBLEM", 5, 38], ["deep", "ANATOMY_MODIFIER", 7, 11]]], ["The accuracy metric, time complexity, and confusion matrix were assessed and analysed, and the overall results showed the proposed FR-DL method outperforms in human action recognition compared with six other state-of-the-art research in the field.", [["confusion", "DISEASE", 42, 51], ["human", "ORGANISM", 159, 164], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 159, 164], ["confusion matrix", "PROBLEM", 42, 58]]], ["Action recognition has many applications, including in smart homes, surveillance systems, autonomous driving, etc. and has already attracted the attention of many researchers that can even remotely monitor people at work, in living environments, or in public places.", [["people", "ORGANISM", 206, 212], ["people", "SPECIES", 206, 212], ["surveillance systems", "TEST", 68, 88]]], ["As future work, we suggest extending this research to improve the current architecture and tp predict the future actions based on spatio-temporal information, current action, and semantic scene segmentation and understanding.", [["semantic scene segmentation", "TEST", 179, 206]]]], "afc2f0a5be2fb3bd3355e04f45d827e9e73419bb": [["IntroductionDespite efforts to reduce the incidence of nosocomial infections by measures such as practicing good hand hygiene and the use of personal protective equipment, hospital-acquired infections are still frequent.", [["hand", "ANATOMY", 113, 117], ["nosocomial infections", "DISEASE", 55, 76], ["infections", "DISEASE", 190, 200], ["hand", "ORGANISM_SUBDIVISION", 113, 117], ["nosocomial infections", "PROBLEM", 55, 76], ["personal protective equipment", "TREATMENT", 141, 170], ["acquired infections", "PROBLEM", 181, 200], ["nosocomial", "OBSERVATION_MODIFIER", 55, 65], ["infections", "OBSERVATION", 66, 76], ["infections", "OBSERVATION", 190, 200]]], ["Two of the largest hospitals in Singapore report that on average, one in seven hospitalized patients acquire a nosocomial infection, 1 with immunocompromised children at greatest risk.", [["nosocomial infection", "DISEASE", 111, 131], ["patients", "ORGANISM", 92, 100], ["children", "ORGANISM", 158, 166], ["patients", "SPECIES", 92, 100], ["children", "SPECIES", 158, 166], ["a nosocomial infection", "PROBLEM", 109, 131], ["largest", "OBSERVATION_MODIFIER", 11, 18], ["nosocomial", "OBSERVATION_MODIFIER", 111, 121], ["infection", "OBSERVATION", 122, 131]]], ["Little is known regarding the transmission of respiratory viruses in clinical environments.", [["respiratory viruses", "DISEASE", 46, 65], ["respiratory viruses", "PROBLEM", 46, 65], ["respiratory viruses", "OBSERVATION", 46, 65]]], ["Theoretically, influenza and other respiratory viruses are transmitted through contact with contagious persons and contaminated fomites.", [["influenza", "DISEASE", 15, 24], ["respiratory viruses", "DISEASE", 35, 54], ["persons", "ORGANISM", 103, 110], ["persons", "SPECIES", 103, 110], ["influenza", "PROBLEM", 15, 24], ["other respiratory viruses", "PROBLEM", 29, 54], ["respiratory viruses", "OBSERVATION", 35, 54]]], ["However, there is an increasing body of evidence supporting the concept of transmis-sion through the inhalation of virus-laden particles.", [["transmis-sion", "PROBLEM", 75, 88], ["increasing", "OBSERVATION_MODIFIER", 21, 31], ["body", "OBSERVATION_MODIFIER", 32, 36], ["virus", "OBSERVATION", 115, 120], ["laden particles", "OBSERVATION", 121, 136]]], ["Specifically, airborne virus-laden particles \u22644\u03bcm are thought to play a significant role in respiratory virus transmission as they can remain in the air for prolonged periods of time and are inhaled deep into the lungs.", [["lungs", "ANATOMY", 213, 218], ["respiratory virus transmission", "DISEASE", 92, 122], ["airborne virus", "ORGANISM", 14, 28], ["respiratory virus", "ORGANISM", 92, 109], ["lungs", "ORGAN", 213, 218], ["airborne virus", "PROBLEM", 14, 28], ["respiratory virus transmission", "TREATMENT", 92, 122], ["airborne virus", "OBSERVATION", 14, 28], ["respiratory virus", "OBSERVATION", 92, 109], ["lungs", "ANATOMY", 213, 218]]], ["2Aerosol samplingAerosol samples were collected in a general pediatric ward at KK Women's and Children's Hospital, Singapore, using three National Institute for Occupational Safety and Health (NIOSH) two-stage cyclone samplers and one SKC filter cassette preloaded with a 37mm polytetrafluoroethylene (PTFE) filter (0.3\u03bcm pore size) designed to sample for severe acute respiratory syndromeassociated coronavirus (SARS-CoV).", [["samples", "ANATOMY", 25, 32], ["pore", "ANATOMY", 322, 326], ["2Aerosol", "CHEMICAL", 0, 8], ["acute respiratory syndromeassociated coronavirus", "DISEASE", 363, 411], ["SARS", "DISEASE", 413, 417], ["polytetrafluoroethylene", "CHEMICAL", 277, 300], ["PTFE", "CHEMICAL", 302, 306], ["Aerosol samples", "CANCER", 17, 32], ["SKC filter cassette", "DNA", 235, 254], ["severe acute respiratory syndromeassociated coronavirus", "SPECIES", 356, 411], ["SARS-CoV", "SPECIES", 413, 421], ["2Aerosol sampling", "TREATMENT", 0, 17], ["Aerosol samples", "TREATMENT", 17, 32], ["two-stage cyclone samplers", "TREATMENT", 200, 226], ["one SKC filter cassette", "TREATMENT", 231, 254], ["a 37mm polytetrafluoroethylene (PTFE) filter (0.3\u03bcm pore size)", "TREATMENT", 270, 332], ["severe acute respiratory syndromeassociated coronavirus", "PROBLEM", 356, 411], ["severe", "OBSERVATION_MODIFIER", 356, 362], ["acute", "OBSERVATION_MODIFIER", 363, 368], ["respiratory syndromeassociated coronavirus", "OBSERVATION", 369, 411]]], ["Aerosol samples were collected once per week for seven weeks in May and June 2017.", [["samples", "ANATOMY", 8, 15], ["Aerosol samples", "CANCER", 0, 15], ["Aerosol samples", "TREATMENT", 0, 15]]], ["The NIOSH samplers were stationed on tripods and placed along the corridor outside the open patient bedding area, and one SKC filter cassette was attached to a mobile computer on wheels (COW) used by doctors and nurses during ward rounds.", [["patient", "ORGANISM", 92, 99], ["SKC filter cassette", "DNA", 122, 141], ["patient", "SPECIES", 92, 99], ["tripods", "TREATMENT", 37, 44], ["one SKC filter cassette", "TREATMENT", 118, 141]]], ["Each sampler was connected to an AirChek\u00ae TOUCH Sample Pump (SKC, Eighty-Four, USA) with Tygon tubing (61 cm length, 0.635 cm diameter) for air collection at a rate of 3.5 L/min.", [["SKC", "TEST", 61, 64], ["Tygon tubing", "TREATMENT", 89, 101], ["air collection", "PROBLEM", 140, 154], ["a rate", "TEST", 158, 164], ["air collection", "OBSERVATION", 140, 154]]], ["A total of 840 L of air was collected during each four-hour sampling period.", [["air", "PROBLEM", 20, 23], ["total", "OBSERVATION_MODIFIER", 2, 7], ["air", "OBSERVATION", 20, 23]]], ["Each NIOSH sampler separates collected particles into three aerodynamic diameters: >4\u03bcm, 1-4\u03bcm, and <1\u03bcm.", [["Each NIOSH sampler", "TREATMENT", 0, 18], ["aerodynamic diameters", "TEST", 60, 81], ["aerodynamic", "OBSERVATION_MODIFIER", 60, 71], ["diameters", "OBSERVATION_MODIFIER", 72, 81], [">4\u03bcm", "OBSERVATION_MODIFIER", 83, 87]]], ["3 Filter cassettes and sample tubes from the NIOSH samplers were stored at -80\u02daC before processing.", [["Filter cassettes", "DNA", 2, 18], ["3 Filter cassettes", "TREATMENT", 0, 18], ["sample tubes", "TREATMENT", 23, 35], ["the NIOSH samplers", "TREATMENT", 41, 59]]], ["Prior to nucleic acid extraction, sample material collected in the 1-4 \u03bcm and <1\u03bcm size fractions were combined (described below).Nucleic acid extractionPTFE filters were removed from the cassettes attached to the NIOSH samplers, transferred to 50 mL falcon tubes and vortexed for 15 s.", [["nucleic acid", "CHEMICAL", 9, 21], ["Nucleic acid", "SIMPLE_CHEMICAL", 130, 142], ["nucleic acid extraction", "TREATMENT", 9, 32], ["sample material", "TEST", 34, 49], ["Nucleic acid extractionPTFE filters", "TREATMENT", 130, 165], ["size", "OBSERVATION_MODIFIER", 83, 87], ["acid", "OBSERVATION_MODIFIER", 138, 142], ["extractionPTFE filters", "OBSERVATION", 143, 165]]], ["One mL of 0.5% bovine serum albumin (BSA) fraction V in molecular grade water was then added to each 50mL falcon tube and vortexed again for 15 s.", [["serum", "ANATOMY", 22, 27], ["bovine", "ORGANISM", 15, 21], ["serum", "ORGANISM_SUBSTANCE", 22, 27], ["albumin", "SIMPLE_CHEMICAL", 28, 35], ["BSA", "SIMPLE_CHEMICAL", 37, 40], ["bovine", "SPECIES", 15, 21], ["bovine", "SPECIES", 15, 21], ["0.5% bovine serum albumin (BSA)", "TREATMENT", 10, 41], ["50mL falcon tube", "TREATMENT", 101, 117]]], ["One mL of 0.5% BSA was added to each 1.5mL conical tube from the NIOSH samplers and vortexed for 15 s.", [["BSA", "CHEMICAL", 15, 18], ["BSA", "SIMPLE_CHEMICAL", 15, 18], ["the NIOSH samplers", "TREATMENT", 61, 79]]], ["These BSA solutions were then pooled into a 2mL cryovial tube.", [["BSA", "SIMPLE_CHEMICAL", 6, 9], ["cryovial tube", "TISSUE", 48, 61], ["These BSA solutions", "TREATMENT", 0, 19], ["a 2mL cryovial tube", "TREATMENT", 42, 61], ["cryovial tube", "OBSERVATION", 48, 61]]], ["Two mL of 0.5% BSA fraction V solution was added to each 15mL falcon tube from the NIOSH samplers, vor-Significance for public healthWe demonstrated the potential for airborne respiratory viruses to circulate among hospitalized children, nursing staff and visitors.", [["BSA", "CHEMICAL", 15, 18], ["airborne respiratory viruses", "DISEASE", 167, 195], ["BSA", "SIMPLE_CHEMICAL", 15, 18], ["children", "ORGANISM", 228, 236], ["children", "SPECIES", 228, 236], ["0.5% BSA fraction V solution", "TREATMENT", 10, 38], ["airborne respiratory viruses", "PROBLEM", 167, 195]]], ["We argue that bioaerosol sampling could serve as a noninvasive and low-cost method to monitor for novel respiratory virus incursions in clinical settings, and better understand the risk of acquiring a respiratory illness during a hospital visit.Significance for public healthArticle texed for 15 s, and transferred to a cryovial tube and stored at -80\u02daC until further used.", [["respiratory", "ANATOMY", 201, 212], ["cryovial tube", "ANATOMY", 320, 333], ["respiratory illness", "DISEASE", 201, 220], ["cryovial tube", "TISSUE", 320, 333], ["bioaerosol sampling", "TREATMENT", 14, 33], ["a noninvasive", "TEST", 49, 62], ["novel respiratory virus incursions", "PROBLEM", 98, 132], ["a respiratory illness", "PROBLEM", 199, 220], ["a cryovial tube", "TREATMENT", 318, 333]]], ["Styrene filters from SKC cassettes were swabbed with FLOQSwabs soaked in 0.5% BSA fraction V solution.", [["Styrene", "CHEMICAL", 0, 7], ["Styrene", "CHEMICAL", 0, 7], ["Styrene", "SIMPLE_CHEMICAL", 0, 7], ["BSA", "SIMPLE_CHEMICAL", 78, 81], ["SKC cassettes", "DNA", 21, 34], ["Styrene filters", "TREATMENT", 0, 15], ["SKC cassettes", "TREATMENT", 21, 34], ["FLOQSwabs", "TREATMENT", 53, 62], ["0.5% BSA fraction V solution", "TREATMENT", 73, 101]]], ["Swabs were then placed in 50mL falcon tubes, vortexed for 15 s, and transferred to cryovials.", [["Swabs", "TREATMENT", 0, 5]]], ["QIAamp viral RNA kit and QIAamp DNA Blood kit (Qiagen) were then used to extract RNA and DNA, respectively, from the sample solutions following the manufacturer's protocol.Real-time RT-PCR/PCRRNA was tested for influenza A, B, and D, 4-6 coronavirus, 7 and enterovirus 8 using Superscript III One-step RT-PCR with Platinum Taq Polymerase.", [["QIAamp", "ORGANISM_SUBSTANCE", 0, 6], ["QIAamp DNA", "ORGANISM_SUBSTANCE", 25, 35], ["Blood", "ORGANISM_SUBSTANCE", 36, 41], ["kit", "ORGANISM_SUBSTANCE", 42, 45], ["Qiagen", "ORGANISM_SUBSTANCE", 47, 53], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["influenza A", "ORGANISM", 211, 222], ["B", "GENE_OR_GENE_PRODUCT", 224, 225], ["D", "ORGANISM", 231, 232], ["4-6 coronavirus", "ORGANISM", 234, 249], ["PCRRNA", "DNA", 189, 195], ["Platinum Taq Polymerase", "PROTEIN", 314, 337], ["influenza A", "SPECIES", 211, 222], ["QIAamp viral RNA kit", "TEST", 0, 20], ["QIAamp DNA Blood kit", "TEST", 25, 45], ["the manufacturer's protocol", "TREATMENT", 144, 171], ["time RT-PCR/PCRRNA", "TEST", 177, 195], ["influenza", "PROBLEM", 211, 220], ["D", "TEST", 231, 232], ["coronavirus", "TEST", 238, 249], ["enterovirus", "TEST", 257, 268], ["Superscript III One-step RT-PCR", "TREATMENT", 277, 308], ["Platinum Taq Polymerase", "TREATMENT", 314, 337]]], ["Extracted DNA was tested for adenovirus by realtime PCR using a QuantiNova Probe PCR kit (Qiagen) ( Table 1 ).", [["DNA", "CELLULAR_COMPONENT", 10, 13], ["adenovirus", "ORGANISM", 29, 39], ["adenovirus", "SPECIES", 29, 39], ["Extracted DNA", "PROBLEM", 0, 13], ["adenovirus", "PROBLEM", 29, 39], ["realtime PCR", "TEST", 43, 55], ["a QuantiNova Probe PCR kit", "TREATMENT", 62, 88]]], ["8ResultsEight (28.5%) of the 28 aerosol samples tested positive for adenovirus and one (3.5%) tested positive for influenza A virus.", [["samples", "ANATOMY", 40, 47], ["influenza A virus", "DISEASE", 114, 131], ["adenovirus", "ORGANISM", 68, 78], ["influenza A virus", "ORGANISM", 114, 131], ["influenza A virus", "SPECIES", 114, 131], ["adenovirus", "SPECIES", 68, 78], ["influenza A virus", "SPECIES", 114, 131], ["the 28 aerosol samples", "TEST", 25, 47], ["adenovirus", "PROBLEM", 68, 78], ["influenza A virus", "PROBLEM", 114, 131]]], ["Aerosol samples with real-time RT-PCR/PCR cycle threshold (Ct) values <40 were considered positive.", [["samples", "ANATOMY", 8, 15], ["Aerosol samples", "TEST", 0, 15], ["PCR/PCR cycle threshold", "TEST", 34, 57], ["Ct) values", "TEST", 59, 69]]], ["All eight adenovirus-positive samples were retrieved from the NIOSH samplers, 3 (37.5%) of which were from particles >4\u03bcm in aerodynamic diameter, and 5 (62.5%) from particles \u22644\u03bcm in aerodynamic diameter.", [["samples", "ANATOMY", 30, 37], ["adenovirus", "ORGANISM", 10, 20], ["aerodynamic diameter", "OBSERVATION", 125, 145], ["aerodynamic diameter", "OBSERVATION", 184, 204]]], ["The captured influenza A virus-positive particles were retrieved from a mobile SKC filter cassette and were therefore \u22650.3\u03bcm.", [["influenza A virus", "ORGANISM", 13, 30], ["mobile SKC filter cassette", "DNA", 72, 98], ["influenza A virus", "SPECIES", 13, 30], ["influenza A virus", "SPECIES", 13, 30], ["The captured influenza A virus", "PROBLEM", 0, 30], ["positive particles", "PROBLEM", 31, 49], ["a mobile SKC filter cassette", "TREATMENT", 70, 98], ["influenza", "OBSERVATION", 13, 22]]], ["None of the aerosol samples tested positive for influenza B or D virus, enterovirus or coronavirus.", [["samples", "ANATOMY", 20, 27], ["influenza B", "DISEASE", 48, 59], ["enterovirus or coronavirus", "DISEASE", 72, 98], ["influenza B", "ORGANISM", 48, 59], ["D virus", "ORGANISM", 63, 70], ["enterovirus", "ORGANISM", 72, 83], ["coronavirus", "ORGANISM", 87, 98], ["D virus", "SPECIES", 63, 70], ["coronavirus", "SPECIES", 87, 98], ["D virus", "SPECIES", 63, 70], ["the aerosol samples", "TEST", 8, 27], ["influenza B", "PROBLEM", 48, 59], ["D virus", "PROBLEM", 63, 70], ["enterovirus", "PROBLEM", 72, 83], ["coronavirus", "PROBLEM", 87, 98]]], ["Attempts to grow viruses in cell culture from positive aerosol samples were unsuccessful.DiscussionOur pilot study provides molecular evidence of airborne respiratory viruses in a general pediatric ward in Singapore.", [["cell culture", "ANATOMY", 28, 40], ["samples", "ANATOMY", 63, 70], ["airborne respiratory viruses", "DISEASE", 146, 174], ["cell", "CELL", 28, 32], ["cell culture", "TEST", 28, 40], ["positive aerosol samples", "TREATMENT", 46, 70], ["DiscussionOur pilot study", "TEST", 89, 114], ["airborne respiratory viruses", "PROBLEM", 146, 174], ["evidence of", "UNCERTAINTY", 134, 145], ["airborne respiratory viruses", "OBSERVATION", 146, 174]]], ["Our results illustrate the potential of airborne respiratory viruses to circulate among hospitalized children, nursing staff and visitors.", [["children", "ORGANISM", 101, 109], ["children", "SPECIES", 101, 109], ["airborne respiratory viruses", "PROBLEM", 40, 68]]], ["Additionally, we detected respirable virus-laden particles (\u22644\u03bcm in diameter) which are thought to play a significant role in respiratory virus transmission.", [["respiratory virus transmission", "DISEASE", 126, 156], ["respiratory virus", "ORGANISM", 126, 143], ["respirable virus", "PROBLEM", 26, 42], ["respiratory virus transmission", "PROBLEM", 126, 156], ["respirable virus", "OBSERVATION", 26, 42], ["laden", "OBSERVATION_MODIFIER", 43, 48], ["particles", "OBSERVATION_MODIFIER", 49, 58], ["thought to play", "UNCERTAINTY", 88, 103], ["significant", "OBSERVATION_MODIFIER", 106, 117], ["respiratory virus", "OBSERVATION", 126, 143]]], ["Aerosol samples testing positive for influenza A virus and adenovirus demonstrates the potential of these viruses to be transmitted via the airborne route.", [["samples", "ANATOMY", 8, 15], ["influenza A virus", "DISEASE", 37, 54], ["Aerosol samples", "CANCER", 0, 15], ["influenza A virus", "ORGANISM", 37, 54], ["adenovirus", "ORGANISM", 59, 69], ["influenza A virus", "SPECIES", 37, 54], ["influenza A virus", "SPECIES", 37, 54], ["adenovirus", "SPECIES", 59, 69], ["Aerosol samples testing", "TEST", 0, 23], ["influenza A virus", "PROBLEM", 37, 54], ["adenovirus", "PROBLEM", 59, 69], ["these viruses", "PROBLEM", 100, 113], ["viruses", "OBSERVATION", 106, 113]]], ["However, we were unable to document the viability of the virus particles and subsequent risk of infection.", [["infection", "DISEASE", 96, 105], ["the virus particles", "PROBLEM", 53, 72], ["infection", "PROBLEM", 96, 105], ["infection", "OBSERVATION", 96, 105]]], ["Additionally, the source of these viruses in the ward is unknown as we did not recruit human subjects nor have access to patient records.", [["human", "ORGANISM", 87, 92], ["patient", "ORGANISM", 121, 128], ["human", "SPECIES", 87, 92], ["patient", "SPECIES", 121, 128], ["human", "SPECIES", 87, 92], ["these viruses", "PROBLEM", 28, 41], ["viruses", "OBSERVATION", 34, 41]]], ["Despite previous successful attempts at using the NIOSH twostage sampler and PCR analyses to collect and detect aerosolized influenza A virus, 9, 10 all samples collected using the NIOSH sampler in this study tested negative for influenza A virus.", [["samples", "ANATOMY", 153, 160], ["influenza A virus", "DISEASE", 124, 141], ["influenza A virus", "DISEASE", 229, 246], ["influenza A virus", "ORGANISM", 124, 141], ["influenza A virus", "ORGANISM", 229, 246], ["influenza A virus", "SPECIES", 124, 141], ["influenza A virus", "SPECIES", 229, 246], ["influenza A virus", "SPECIES", 124, 141], ["influenza A virus", "SPECIES", 229, 246], ["the NIOSH twostage sampler", "TEST", 46, 72], ["PCR analyses", "TEST", 77, 89], ["aerosolized influenza A virus", "PROBLEM", 112, 141], ["the NIOSH sampler", "TEST", 177, 194], ["this study", "TEST", 198, 208], ["influenza A virus", "PROBLEM", 229, 246]]], ["We did capture and detect aerosolized adenovirus using the NIOSH samplers, however, none of the samples from the SKC filter cassettes tested positive for adenovirus.", [["samples", "ANATOMY", 96, 103], ["adenovirus", "ORGANISM", 38, 48], ["adenovirus", "ORGANISM", 154, 164], ["SKC filter cassettes", "DNA", 113, 133], ["adenovirus", "SPECIES", 38, 48], ["adenovirus", "SPECIES", 154, 164], ["aerosolized adenovirus", "PROBLEM", 26, 48], ["the NIOSH samplers", "TEST", 55, 73], ["the samples", "TEST", 92, 103], ["the SKC filter cassettes", "TEST", 109, 133], ["adenovirus", "PROBLEM", 154, 164]]], ["This result is inconsistent with our previous study which successfully recovered adenovirus DNA from aerosol samples collected using the SKC filter cassettes in patient waiting rooms.", [["samples", "ANATOMY", 109, 116], ["adenovirus", "ORGANISM", 81, 91], ["DNA", "CELLULAR_COMPONENT", 92, 95], ["aerosol samples", "ORGANISM_SUBSTANCE", 101, 116], ["patient", "ORGANISM", 161, 168], ["adenovirus DNA", "DNA", 81, 95], ["SKC filter cassettes", "DNA", 137, 157], ["patient", "SPECIES", 161, 168], ["adenovirus", "SPECIES", 81, 91], ["our previous study", "TEST", 33, 51], ["adenovirus DNA", "PROBLEM", 81, 95], ["aerosol samples", "TREATMENT", 101, 116], ["the SKC filter cassettes", "TREATMENT", 133, 157]]], ["11 Sampling sessions in our current study collected 840 L of air using one SKC filter cassette compared to the collection of 900 L of air per each of two SKC filter cassettes in our previous study.", [["SKC filter cassette", "DNA", 75, 94], ["SKC filter cassettes", "DNA", 154, 174], ["our current study", "TEST", 24, 41], ["one SKC filter cassette", "TREATMENT", 71, 94], ["two SKC filter cassettes", "TREATMENT", 150, 174], ["our previous study", "TEST", 178, 196], ["900 L", "OBSERVATION_MODIFIER", 125, 130], ["air", "OBSERVATION", 134, 137]]], ["Additionally, SKC filter cassettes were mobilized in our current study and stationary in our previous study.", [["SKC filter cassettes", "DNA", 14, 34], ["SKC filter cassettes", "TREATMENT", 14, 34], ["our current study", "TEST", 53, 70], ["our previous study", "TEST", 89, 107]]], ["The higher sample volumes collected in our previous study as well as the difference in mobility and location of the samplers might explain the difference in positive sample collections among studies.DiscussionIn addition to bioaerosol sample collection and handling methods, environmental conditions can also influence the viability of airborne viruses and downstream virus recovery.", [["sample", "ANATOMY", 11, 17], ["The higher sample volumes", "TEST", 0, 25], ["our previous study", "TEST", 39, 57], ["the samplers", "TREATMENT", 112, 124], ["positive sample collections", "PROBLEM", 157, 184], ["bioaerosol sample collection", "TREATMENT", 224, 252], ["handling methods", "TREATMENT", 257, 273], ["airborne viruses", "TREATMENT", 336, 352], ["downstream virus recovery", "TREATMENT", 357, 382], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["sample", "OBSERVATION_MODIFIER", 11, 17], ["volumes", "OBSERVATION_MODIFIER", 18, 25], ["mobility", "OBSERVATION_MODIFIER", 87, 95], ["positive", "OBSERVATION_MODIFIER", 157, 165], ["sample", "OBSERVATION_MODIFIER", 166, 172], ["collections", "OBSERVATION", 173, 184], ["airborne viruses", "OBSERVATION", 336, 352]]], ["For example, prolonged sampling periods can compromise stability of virus-laden aerosols and result in decreased viral recovery.", [["prolonged sampling periods", "PROBLEM", 13, 39], ["virus-laden aerosols", "TREATMENT", 68, 88], ["decreased viral recovery", "PROBLEM", 103, 127], ["decreased", "OBSERVATION_MODIFIER", 103, 112], ["viral recovery", "OBSERVATION", 113, 127]]], ["12 Additionally, it has been demonstrated that the survival of airborne influenza virus depends on ambient temperature, relative humidity (RH) and ultraviolet radiation levels.", [["influenza", "DISEASE", 72, 81], ["airborne influenza virus", "ORGANISM", 63, 87], ["airborne influenza virus", "PROBLEM", 63, 87], ["ambient temperature", "TREATMENT", 99, 118], ["relative humidity (RH)", "TREATMENT", 120, 142], ["ultraviolet radiation levels", "TREATMENT", 147, 175]]], ["13 Specifically, infectivity of influenza in a simulated examination room was reported to be the highest at 7-23% RH, moderate at 57% RH and lowest at 43% RH.", [["influenza", "DISEASE", 32, 41], ["influenza", "PROBLEM", 32, 41], ["a simulated examination", "TEST", 45, 68], ["influenza", "OBSERVATION", 32, 41], ["moderate", "OBSERVATION_MODIFIER", 118, 126]]], ["14 Although we did not record temperature and RH at our sampling site, a previous bioaerosol study recorded levels ranging from 54% to 68% RH in three different hospitals in Singapore.", [["a previous bioaerosol study", "TEST", 71, 98], ["levels", "TEST", 108, 114]]], ["11 High RH levels in Singapore could explain the low percentage of influenza A viruspositive aerosol samples in our study.DiscussionOne strength of our bioaerosol sampling method is that it is a quick and non-invasive way to monitor for respiratory viruses without interrupting patients or healthcare professionals.", [["respiratory viruses", "DISEASE", 237, 256], ["patients", "ORGANISM", 278, 286], ["patients", "SPECIES", 278, 286], ["High RH levels", "PROBLEM", 3, 17], ["influenza", "PROBLEM", 67, 76], ["our study", "TEST", 112, 121], ["respiratory viruses", "PROBLEM", 237, 256], ["low percentage", "OBSERVATION_MODIFIER", 49, 63]]], ["Also, it requires little manpower to collect samples and results can be analyzed within a few hours.", [["samples", "ANATOMY", 45, 52]]], ["However, one limitation of our detection method was that we did not measure viral load in our aerosol samples, which makes it difficult to compare our results with quantitative aerosol studies in clinical settings.", [["samples", "ANATOMY", 102, 109], ["our detection method", "TEST", 27, 47], ["our aerosol samples", "TEST", 90, 109], ["quantitative aerosol studies", "TEST", 164, 192]]], ["Additionally, our pilot study was not designed to collect patient data and therefore we were not able to match the virus-positive aerosol samples with individual patients present in the hospital ward at the time of sampling.ConclusionsIn summary, we conducted a 7-week pilot study to monitor for aerosolized respiratory viruses among inpatients in a pediatric ward in Singapore.", [["respiratory viruses", "DISEASE", 308, 327], ["patient", "ORGANISM", 58, 65], ["patients", "ORGANISM", 162, 170], ["patient", "SPECIES", 58, 65], ["patients", "SPECIES", 162, 170], ["our pilot study", "TEST", 14, 29], ["the virus", "TEST", 111, 120], ["pilot study", "TEST", 269, 280], ["aerosolized respiratory viruses", "PROBLEM", 296, 327], ["respiratory viruses", "OBSERVATION", 308, 327]]], ["We found molecular evidence of influenza A virus and adenovirus, demonstrating the potential for airborne transmission.", [["influenza A virus", "DISEASE", 31, 48], ["influenza A virus", "ORGANISM", 31, 48], ["adenovirus", "ORGANISM", 53, 63], ["influenza A virus", "SPECIES", 31, 48], ["influenza A virus", "SPECIES", 31, 48], ["adenovirus", "SPECIES", 53, 63], ["influenza A virus", "PROBLEM", 31, 48], ["adenovirus", "PROBLEM", 53, 63], ["airborne transmission", "PROBLEM", 97, 118], ["evidence of", "UNCERTAINTY", 19, 30], ["influenza", "OBSERVATION", 31, 40], ["virus", "OBSERVATION", 43, 48]]], ["To comprehend this potential risk of transmission, our proof-of-concept project might be expanded in the future to specifically study patients with known positive clinical infections (e.g. through nasopharyngeal swabs) and determine how far away viable viruses can be detected from a patient's bedside.", [["nasopharyngeal swabs", "ANATOMY", 197, 217], ["infections", "DISEASE", 172, 182], ["patients", "ORGANISM", 134, 142], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 197, 217], ["patient", "ORGANISM", 284, 291], ["patients", "SPECIES", 134, 142], ["patient", "SPECIES", 284, 291], ["known positive clinical infections", "PROBLEM", 148, 182], ["nasopharyngeal swabs", "TEST", 197, 217], ["viable viruses", "PROBLEM", 246, 260], ["infections", "OBSERVATION", 172, 182], ["viruses", "OBSERVATION", 253, 260]]], ["Additionally, future studies might involve more comprehensive demographic and clinical risk factor analyses to help us better understand phenomenon such as super-spreading.", [["future studies", "TEST", 14, 28], ["clinical risk factor analyses", "PROBLEM", 78, 107]]], ["Lastly, bioaerosol surveillance might be useful in monitoring clinical populations for incursions of novel respiratory viruses, especially since aerosol sampling in shared clinical spaces often requires no informed consent.", [["respiratory viruses", "DISEASE", 107, 126], ["bioaerosol surveillance", "TEST", 8, 31], ["novel respiratory viruses", "PROBLEM", 101, 126], ["aerosol sampling", "TREATMENT", 145, 161], ["respiratory viruses", "OBSERVATION", 107, 126]]]], "PMC7135244": [], "PMC5456093": [["IntroductionThe advancement of organ transplantation has saved numerous human lives and created enormous welfare gains.", [["organ", "ANATOMY", 31, 36], ["organ", "ORGAN", 31, 36], ["human", "ORGANISM", 72, 77], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["organ transplantation", "TREATMENT", 31, 52], ["organ", "ANATOMY", 31, 36], ["transplantation", "OBSERVATION", 37, 52], ["enormous", "OBSERVATION_MODIFIER", 96, 104], ["welfare gains", "OBSERVATION", 105, 118]]], ["However, in the past two decades, the global organ shortage has led to the development of transplant tourism: the practice of traveling outside one\u2019s own country to obtain organ transplantation, which often involves organ trade or trafficking [1].", [["organ", "ANATOMY", 45, 50], ["organ", "ANATOMY", 172, 177], ["organ", "ANATOMY", 216, 221], ["organ", "ORGAN", 45, 50], ["organ", "ORGAN", 172, 177], ["organ", "ORGAN", 216, 221], ["organ transplantation", "TREATMENT", 172, 193], ["transplant", "OBSERVATION", 90, 100]]], ["Transplant tourism was estimated to account for 10% of organ transplants performed around the world in 2007 [2].", [["organ", "ANATOMY", 55, 60], ["organ", "ORGAN", 55, 60], ["organ transplants", "TREATMENT", 55, 72], ["tourism", "OBSERVATION", 11, 18], ["transplants", "OBSERVATION", 61, 72]]], ["Such practice, though saving lives, has been discouraged by many international organizations because it involves the exploitation of vulnerable groups and the poor [1,3].IntroductionTaiwan\u2019s hepatitis B carrier rate and the country\u2019s prevalence and incidence of renal dialysis are among the world\u2019s highest [4,5].", [["renal", "ANATOMY", 262, 267], ["hepatitis B", "DISEASE", 191, 202], ["hepatitis B", "ORGANISM", 191, 202], ["renal", "ORGAN", 262, 267], ["IntroductionTaiwan", "TREATMENT", 170, 188], ["hepatitis B carrier rate", "TREATMENT", 191, 215], ["renal dialysis", "TREATMENT", 262, 276], ["renal", "ANATOMY", 262, 267], ["dialysis", "OBSERVATION", 268, 276]]], ["Even though Taiwan was one of the first Asian countries to perform renal transplant surgery in 1968, it has suffered from a severe shortage of transplantable organs for more than four decades due to a low organ donation rate.", [["renal transplant", "ANATOMY", 67, 83], ["transplantable organs", "ANATOMY", 143, 164], ["organ", "ANATOMY", 205, 210], ["renal", "ORGAN", 67, 72], ["organs", "ORGAN", 158, 164], ["organ", "ORGAN", 205, 210], ["renal transplant surgery", "TREATMENT", 67, 91], ["a severe shortage of transplantable organs", "PROBLEM", 122, 164], ["a low organ donation rate", "TREATMENT", 199, 224], ["renal", "ANATOMY", 67, 72], ["transplant", "OBSERVATION", 73, 83], ["severe", "OBSERVATION_MODIFIER", 124, 130]]], ["As a result, transplant tourism from Taiwan to China began in the early 1990s and has progressed rapidly as social and economic interaction between the two countries have increased [6,7].", [["progressed", "OBSERVATION_MODIFIER", 86, 96], ["rapidly", "OBSERVATION_MODIFIER", 97, 104]]], ["According to a survey in 2006 by Taiwan\u2019s Department of Health, only 2 of 400 overseas kidney transplant (KT) recipients and 3 of 222 overseas liver transplant (LT) recipients had organ transplantation performed outside of China [8].", [["kidney", "ANATOMY", 87, 93], ["liver", "ANATOMY", 143, 148], ["organ", "ANATOMY", 180, 185], ["kidney", "ORGAN", 87, 93], ["liver", "ORGAN", 143, 148], ["recipients", "ORGANISM", 165, 175], ["organ", "ORGAN", 180, 185], ["kidney transplant", "TREATMENT", 87, 104], ["liver transplant (LT) recipients", "TREATMENT", 143, 175], ["organ transplantation", "TREATMENT", 180, 201], ["kidney", "ANATOMY", 87, 93], ["transplant", "OBSERVATION", 94, 104], ["liver", "ANATOMY", 143, 148], ["transplant", "OBSERVATION", 149, 159], ["organ", "ANATOMY", 180, 185], ["transplantation", "OBSERVATION", 186, 201]]], ["Due to a growing awareness of the ethical controversies and human rights issues, measures were taken to discourage transplant tourism.", [["human", "ORGANISM", 60, 65], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["the ethical controversies", "TREATMENT", 30, 55], ["human rights issues", "TREATMENT", 60, 79], ["growing", "OBSERVATION_MODIFIER", 9, 16]]], ["For example, in 2006, the Taiwanese government announced a guideline prohibiting doctors\u2019 participation in any form of organ brokering [9], and in 2007, requested physicians\u2019 voluntary reporting of overseas transplant patient information to the Taiwan Organ Registry and Sharing Center (TORSC).", [["organ", "ANATOMY", 119, 124], ["organ", "ORGAN", 119, 124], ["patient", "ORGANISM", 218, 225], ["patient", "SPECIES", 218, 225]]], ["Meanwhile, China introduced its Human Organ Transplant Act in 2007 [10]; and in 2008, the Declaration of Istanbul prohibited transplant tourism [1].IntroductionHowever, the practices and the outcomes of international organ tourism have not been well understood.", [["organ", "ANATOMY", 217, 222], ["Human", "ORGANISM", 32, 37], ["organ", "ORGAN", 217, 222], ["Human", "SPECIES", 32, 37]]], ["Nationally-integrated and comprehensive medical and social research concerning transplant tourism is still scant.", [["scant", "OBSERVATION", 107, 112]]], ["Questions to be answered include \u201cHow are patients who engaged in transplant tourism different from other patients?\u201d and \u201cAre there differences in the outcomes for overseas and domestic transplants?\u201d", [["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 106, 114], ["domestic transplants", "TREATMENT", 177, 197]]], ["Since Taiwan\u2019s National Health Insurance (NHI) is a compulsory and universal health insurance program that covers over 99% of the general population and keeps comprehensive healthcare records, an overview of the overseas transplant patient population and the outcomes of the transplants are available [11].", [["patient", "ORGANISM", 232, 239], ["patient", "SPECIES", 232, 239], ["the overseas transplant patient population", "TREATMENT", 208, 250], ["the transplants", "TREATMENT", 271, 286]]], ["Therefore, we investigated trends over the past decade in the numbers and outcomes of overseas kidney and liver transplants and in transplant-related policies in order to create an evidence base for reflection upon ethical/legal implications leading to specific proposals for policy initiatives in the Asian region that may help to resolve relevant important global health, ethics, and human rights issues.Data source ::: Subjects and methodsAll patients in Taiwan who need organ transplantation and/or post-transplantation immunosuppressive therapies are registered in the NHI program so that their costs of treatment can be covered.", [["kidney", "ANATOMY", 95, 101], ["liver", "ANATOMY", 106, 111], ["organ", "ANATOMY", 474, 479], ["kidney", "ORGAN", 95, 101], ["liver", "ORGAN", 106, 111], ["human", "ORGANISM", 386, 391], ["patients", "ORGANISM", 446, 454], ["organ", "ORGAN", 474, 479], ["human", "SPECIES", 386, 391], ["patients", "SPECIES", 446, 454], ["human", "SPECIES", 386, 391], ["overseas kidney", "TREATMENT", 86, 101], ["liver transplants", "TREATMENT", 106, 123], ["ethical/legal implications", "TREATMENT", 215, 241], ["organ transplantation", "TREATMENT", 474, 495], ["post-transplantation immunosuppressive therapies", "TREATMENT", 503, 551], ["treatment", "TREATMENT", 609, 618], ["kidney", "ANATOMY", 95, 101], ["liver", "ANATOMY", 106, 111], ["transplants", "OBSERVATION", 112, 123]]], ["Therefore, all transplant recipients (both domestic and overseas) in Taiwan can be identified from the NHI Research Database (NHIRD), which is derived from NHI reimbursement claims since 1996.Study subjects ::: Subjects and methodsThose who received KT or LT were divided into two groups: \u201cdomestic recipients\u201d (Taiwanese receiving a transplant in Taiwan) and \u201coverseas recipients\u201d (Taiwanese receiving a transplant abroad).", [["recipients", "ORGANISM", 26, 36], ["recipients", "ORGANISM", 299, 309], ["recipients", "ORGANISM", 370, 380], ["all transplant recipients", "TREATMENT", 11, 36], ["KT or LT", "TREATMENT", 250, 258], ["a transplant", "TREATMENT", 332, 344], ["a transplant abroad", "TREATMENT", 403, 422], ["transplant", "OBSERVATION_MODIFIER", 15, 25], ["recipients", "OBSERVATION", 26, 36]]], ["From the NHIRD, we identified 2381 domestic KT via NHI records for the KT procedure between January 1998 and June 2009.", [["the KT procedure", "TREATMENT", 67, 83]]], ["A total of 68 transplants were excluded because of a second KT or with a simultaneous LT.", [["A total of 68 transplants", "TREATMENT", 0, 25]]], ["To make domestic and overseas KT comparable, we further excluded 63 subjects who died or resumed dialysis within 1 month after the domestic KT operation, because only the successful overseas transplantation patients who returned to Taiwan and received anti-rejection therapies could be included in our study.", [["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 207, 215], ["dialysis", "TREATMENT", 97, 105], ["the domestic KT operation", "TREATMENT", 127, 152], ["anti-rejection therapies", "TREATMENT", 252, 276], ["our study", "TEST", 298, 307]]], ["Therefore, the remaining 2250 domestic KT recipients were selected for further analysis.Study subjects ::: Subjects and methodsWe defined overseas KT recipients as patients who were prescribed immunosuppressive medication by Taiwan physicians for kidney transplants (ICD9 = V42.0) but did not have an NHI record for a KT operation.", [["kidney", "ANATOMY", 247, 253], ["recipients", "ORGANISM", 42, 52], ["recipients", "ORGANISM", 150, 160], ["patients", "ORGANISM", 164, 172], ["kidney", "ORGAN", 247, 253], ["patients", "SPECIES", 164, 172], ["domestic KT recipients", "TREATMENT", 30, 52], ["further analysis", "TEST", 71, 87], ["immunosuppressive medication", "TREATMENT", 193, 221], ["kidney transplants", "TREATMENT", 247, 265], ["a KT operation", "TREATMENT", 316, 330], ["kidney", "ANATOMY", 247, 253], ["transplants", "OBSERVATION", 254, 265]]], ["The overseas KT recipients were validated with the NHI-based registry of catastrophic illness to exempt co-payment, and transplantation, cancer and dialysis were all included in the designated categories of catastrophic illness.", [["cancer", "ANATOMY", 137, 143], ["catastrophic illness", "DISEASE", 73, 93], ["cancer", "DISEASE", 137, 143], ["catastrophic illness", "DISEASE", 207, 227], ["recipients", "ORGANISM", 16, 26], ["cancer", "CANCER", 137, 143], ["catastrophic illness", "PROBLEM", 73, 93], ["co-payment", "TREATMENT", 104, 114], ["transplantation", "TREATMENT", 120, 135], ["cancer", "PROBLEM", 137, 143], ["dialysis", "TREATMENT", 148, 156], ["catastrophic illness", "PROBLEM", 207, 227], ["catastrophic", "OBSERVATION_MODIFIER", 73, 85], ["illness", "OBSERVATION", 86, 93], ["cancer", "OBSERVATION", 137, 143], ["catastrophic", "OBSERVATION_MODIFIER", 207, 219], ["illness", "OBSERVATION", 220, 227]]], ["The transplant-related immunosuppressive drugs recognized in this study include cyclosporine, tacrolimus, mycophenolate mofetil, sirolimus, rapamune, and cytotect.", [["cyclosporine", "CHEMICAL", 80, 92], ["tacrolimus", "CHEMICAL", 94, 104], ["mycophenolate mofetil", "CHEMICAL", 106, 127], ["sirolimus", "CHEMICAL", 129, 138], ["rapamune", "CHEMICAL", 140, 148], ["cyclosporine", "CHEMICAL", 80, 92], ["tacrolimus", "CHEMICAL", 94, 104], ["mycophenolate mofetil", "CHEMICAL", 106, 127], ["sirolimus", "CHEMICAL", 129, 138], ["rapamune", "CHEMICAL", 140, 148], ["cyclosporine", "SIMPLE_CHEMICAL", 80, 92], ["tacrolimus", "SIMPLE_CHEMICAL", 94, 104], ["mycophenolate mofetil", "SIMPLE_CHEMICAL", 106, 127], ["sirolimus", "SIMPLE_CHEMICAL", 129, 138], ["rapamune", "SIMPLE_CHEMICAL", 140, 148], ["The transplant", "TREATMENT", 0, 14], ["immunosuppressive drugs", "TREATMENT", 23, 46], ["this study", "TEST", 61, 71], ["cyclosporine", "TREATMENT", 80, 92], ["tacrolimus", "TREATMENT", 94, 104], ["mycophenolate mofetil", "TREATMENT", 106, 127], ["sirolimus", "TREATMENT", 129, 138], ["rapamune", "TREATMENT", 140, 148], ["cytotect", "TREATMENT", 154, 162], ["transplant", "OBSERVATION", 4, 14], ["immunosuppressive drugs", "OBSERVATION", 23, 46]]], ["Among the 2518 overseas KT identified between January 1998 and June 2009, 114 transplants were excluded because of a second KT or with a simultaneous LT.", [["transplants", "TREATMENT", 78, 89]]], ["The remaining 2404 overseas KT recipients were selected for further analysis.", [["recipients", "ORGANISM", 31, 41], ["KT recipients", "TREATMENT", 28, 41], ["further analysis", "TEST", 60, 76]]], ["By applying similar criteria in selecting domestic and overseas LT recipients from the NHIRD, we identified 1658 domestic LT recipients (excluding 84 patients who died within one month after LT and 16 secondary LT) and 540 overseas LT recipients for further analysis between January 1999 and December 2009.", [["recipients", "ORGANISM", 125, 135], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["domestic LT recipients", "TREATMENT", 113, 135], ["LT", "TEST", 191, 193], ["further analysis", "TEST", 250, 266]]], ["We further contacted the TORSC to get the number of overseas and domestic (including deceased and living) transplants beyond the study period.Statistical analysis ::: Subjects and methodsThe distributions of demographic and clinical characteristics of the study subjects were described and compared using mean \u00b1 standard deviation (SD) and Student\u2019s t-tests for continuous variables, and counts/proportions and chi-square tests for categorical variables.", [["transplants", "TREATMENT", 106, 117], ["the study", "TEST", 252, 261], ["Student\u2019s t-tests", "TEST", 340, 357], ["continuous variables", "TEST", 362, 382], ["counts/proportions", "TEST", 388, 406], ["chi-square tests", "TEST", 411, 427], ["categorical variables", "TEST", 432, 453], ["distributions", "OBSERVATION_MODIFIER", 191, 204]]], ["The comorbidity was measured by the D\u2019Hoore\u2019s Charlson comorbidity index (CCI) score [12] using the subjects\u2019 NHI records a year prior to transplantation.", [["The comorbidity", "PROBLEM", 0, 15], ["transplantation", "TREATMENT", 138, 153], ["comorbidity", "OBSERVATION", 4, 15]]], ["The trends of overseas and domestic transplants were compared using Cochran-Armitage trend test.Statistical analysis ::: Subjects and methodsAssociations between domestic and overseas KT recipients and mortality/graft failure (or association between LT groups and mortality) were analyzed using Kaplan\u2013Meier survival curves and log-rank tests.", [["graft", "ANATOMY", 212, 217], ["graft", "TISSUE", 212, 217], ["domestic transplants", "TREATMENT", 27, 47], ["Statistical analysis", "TEST", 96, 116], ["KT recipients", "TREATMENT", 184, 197], ["graft failure", "PROBLEM", 212, 225], ["Meier survival curves", "TEST", 302, 323], ["log-rank tests", "TEST", 328, 342], ["graft failure", "OBSERVATION", 212, 225]]], ["Multivariable Cox proportional hazards models were further conducted to estimate their adjusted associations.", [["Multivariable Cox proportional hazards models", "PROBLEM", 0, 45]]], ["Study entry was defined as the date of transplantation.", [["Study entry", "TEST", 0, 11], ["transplantation", "TREATMENT", 39, 54]]], ["For domestic KT and LT recipients, the date of transplantation was as shown in the NHIRD.", [["recipients", "ORGANISM", 23, 33], ["LT recipients", "TREATMENT", 20, 33], ["transplantation", "TREATMENT", 47, 62]]], ["For overseas KT and LT recipients, the date of transplantation was defined as 14 days and 35 days, respectively, prior to the date the patients took the first prescription of post-transplant immunosuppressant drugs, because the average postoperative hospital stays for overseas KT and LT were 14 days and 35 days, respectively, according to a previous questionnaire survey (8).", [["recipients", "ORGANISM", 23, 33], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["LT recipients", "TREATMENT", 20, 33], ["transplantation", "TREATMENT", 47, 62], ["post-transplant immunosuppressant drugs", "TREATMENT", 175, 214], ["LT", "TEST", 285, 287]]], ["As determined by database availability, the KT and LT cohorts were followed up through the ends of 2009 and 2010, respectively.", [["the KT and LT cohorts", "TEST", 40, 61]]], ["In the models estimating the hazard ratio (HR) of mortality, observations were censored on December 31, 2009, for kidney transplants and December 31, 2010, for liver transplants, or on the date that the patients died, whichever occurred first.", [["kidney", "ANATOMY", 114, 120], ["liver", "ANATOMY", 160, 165], ["kidney", "ORGAN", 114, 120], ["liver", "ORGAN", 160, 165], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["kidney transplants", "TREATMENT", 114, 132], ["liver transplants", "TREATMENT", 160, 177], ["kidney", "ANATOMY", 114, 120], ["transplants", "OBSERVATION", 121, 132], ["liver", "ANATOMY", 160, 165], ["transplants", "OBSERVATION", 166, 177]]], ["In the models estimating the hazard ratio of kidney graft failure, observations were censored on December 31, 2009, on the date that the patients died, or the date on which the subjects resumed persistent dialysis, whichever came first.", [["kidney", "ANATOMY", 45, 51], ["kidney graft failure", "DISEASE", 45, 65], ["kidney graft", "MULTI-TISSUE_STRUCTURE", 45, 57], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["kidney graft failure", "PROBLEM", 45, 65], ["persistent dialysis", "TREATMENT", 194, 213], ["kidney", "ANATOMY", 45, 51], ["graft failure", "OBSERVATION", 52, 65], ["persistent", "OBSERVATION_MODIFIER", 194, 204], ["dialysis", "OBSERVATION", 205, 213]]], ["The pre-transplant characteristics adjusted in the multivariable Cox proportional hazards models for KT recipients included gender, age at KT, CCI score, and time interval between initiation of dialysis and KT.", [["KT recipients", "TREATMENT", 101, 114], ["CCI score", "TEST", 143, 152], ["dialysis", "TREATMENT", 194, 202], ["KT", "TREATMENT", 207, 209]]], ["To assess mortality risk for LT recipients, age, gender, CCI score, and hepatocellular carcinoma, were adjusted in the multivariable models.Statistical analysis ::: Subjects and methodsAnalyses were performed using SAS software, version 9.3 (SAS Institute, Cary, North Carolina, USA).", [["hepatocellular carcinoma", "ANATOMY", 72, 96], ["hepatocellular carcinoma", "DISEASE", 72, 96], ["hepatocellular carcinoma", "CANCER", 72, 96], ["LT recipients", "TREATMENT", 29, 42], ["CCI score", "PROBLEM", 57, 66], ["hepatocellular carcinoma", "PROBLEM", 72, 96], ["Statistical analysis", "TEST", 140, 160], ["Analyses", "TEST", 185, 193], ["SAS software", "TEST", 215, 227], ["version", "TEST", 229, 236], ["hepatocellular", "ANATOMY", 72, 86], ["carcinoma", "OBSERVATION", 87, 96]]], ["A two-sided P value < 0.05 was considered statistically significant.", [["A two-sided P value", "TEST", 0, 19], ["sided", "ANATOMY_MODIFIER", 6, 11]]], ["This study was approved by the Institutional Review Board of the National Health Research Institutes.Numbers of transplants and trends ::: ResultsThe number of patients receiving KT overseas has increased since 2000 and first peaked in 2002 (n = 354) before a decrease in 2003 (Fig 1), the year of the severe acute respiratory syndrome (SARS) epidemic in Southeast Asia [13].", [["acute respiratory syndrome", "DISEASE", 309, 335], ["SARS", "DISEASE", 337, 341], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["This study", "TEST", 0, 10], ["KT overseas", "TREATMENT", 179, 190], ["the severe acute respiratory syndrome", "PROBLEM", 298, 335], ["transplants", "OBSERVATION", 112, 123], ["number", "OBSERVATION_MODIFIER", 150, 156], ["increased", "OBSERVATION_MODIFIER", 195, 204], ["severe", "OBSERVATION_MODIFIER", 302, 308], ["acute", "OBSERVATION_MODIFIER", 309, 314], ["respiratory syndrome", "OBSERVATION", 315, 335]]], ["Meanwhile, the number of overseas LT started to increase in 2000, peaking in 2005 as well (n = 117), and then decreased (P<0.001).", [["increase", "OBSERVATION_MODIFIER", 48, 56], ["decreased", "OBSERVATION_MODIFIER", 110, 119]]], ["The steady decrease of overseas LT after 2012 coincided with an increase of domestic LT, which was mainly from related living donations (S1 Table).Demographic comparison ::: ResultsTable 1 shows that, compared to the domestic KT recipients, the overseas KT recipients were older (47.9 vs 41.2 years, p<0.001), male-dominant (54.8% vs 49.0%, p<0.001), and had a shorter dialysis duration before KT (p<0.001).", [["KT recipients", "ORGANISM", 226, 239], ["recipients", "ORGANISM", 257, 267], ["domestic LT", "TREATMENT", 76, 87], ["p", "TEST", 341, 342], ["a shorter dialysis duration", "TREATMENT", 359, 386], ["KT", "TEST", 394, 396], ["steady", "OBSERVATION_MODIFIER", 4, 10], ["decrease", "OBSERVATION_MODIFIER", 11, 19], ["increase", "OBSERVATION_MODIFIER", 64, 72], ["dominant", "OBSERVATION_MODIFIER", 315, 323]]], ["The overseas KT recipients also suffered from more comorbidities: they had a higher CCI score (1.01 vs 0.73, p<0.001), as well as higher percentages of diabetes (14.2% vs 8.0%, p<0.001) and hypertension (38.6% vs 26.5%, p<0.001).Demographic comparison ::: ResultsAs shown in Table 2, overseas LT recipients were older (50.3 vs 43.0 years, p<0.001), mainly adult (97.4% vs 83.5%, p<0.001), and male-dominant (82.0% vs 69.0%, p<0.001).", [["diabetes", "DISEASE", 152, 160], ["hypertension", "DISEASE", 190, 202], ["recipients", "ORGANISM", 16, 26], ["recipients", "ORGANISM", 296, 306], ["a higher CCI score", "PROBLEM", 75, 93], ["diabetes", "PROBLEM", 152, 160], ["vs", "TEST", 168, 170], ["p", "TEST", 177, 178], ["hypertension", "PROBLEM", 190, 202], ["vs", "TEST", 369, 371], ["p", "TEST", 379, 380], ["p", "TEST", 424, 425], ["diabetes", "OBSERVATION", 152, 160], ["hypertension", "OBSERVATION", 190, 202], ["dominant", "OBSERVATION_MODIFIER", 398, 406]]], ["In addition, more of them had hepatocellular carcinoma compared to their domestic counterparts (64.1% vs 39.9%, p<0.001).Clinical outcome ::: ResultsTable 1 and Fig 2 show the domestic KT recipients had a significantly better crude patient survival rate than the overseas recipients (log rank test p<0.001) but a similar graft survival rate (log rank test p = 0.649).", [["hepatocellular carcinoma", "ANATOMY", 30, 54], ["graft", "ANATOMY", 321, 326], ["hepatocellular carcinoma", "DISEASE", 30, 54], ["hepatocellular carcinoma", "CANCER", 30, 54], ["recipients", "ORGANISM", 188, 198], ["patient", "ORGANISM", 232, 239], ["graft", "TISSUE", 321, 326], ["patient", "SPECIES", 232, 239], ["hepatocellular carcinoma", "PROBLEM", 30, 54], ["p", "TEST", 112, 113], ["a similar graft survival rate", "TREATMENT", 311, 340], ["log rank test p", "TEST", 342, 357], ["hepatocellular", "ANATOMY", 30, 44], ["carcinoma", "OBSERVATION", 45, 54], ["graft", "OBSERVATION", 321, 326]]], ["In Cox proportional hazards model (Table 3), the risk factors of mortality for KT recipients were older age (>65 y/o vs \u226435 y/o, aHR = 5.00 [3.39\u20137.36], p<0.001), male (aHR = 1.35 [1.14\u20131.61], p<0.001), higher CCI score (\u22653 vs 0, aHR = 1.53 [1.20\u20131.94], p<0.001), and longer pre-transplantation dialysis time (\u22651 yr vs no dialysis, aHR = 1.36 [1.01\u20131.81], p = 0.040).", [["KT recipients", "TREATMENT", 79, 92], ["aHR", "TEST", 129, 132], ["p", "TEST", 153, 154], ["aHR", "TEST", 169, 172], ["p", "TEST", 193, 194], ["higher CCI score", "TEST", 203, 219], ["aHR", "TEST", 230, 233], ["dialysis", "TREATMENT", 322, 330], ["aHR", "TEST", 332, 335], ["p", "TEST", 356, 357]]], ["Regarding kidney graft failure, there was no difference between domestic or overseas kidney recipients (aHR = 0.88 [0.77\u20131.01], p = 0.068), but older age (>65 y/0 vs <35 y/o, aHR = 2.15 [1.57\u20132.94], p<0.001), male (aHR = 1.15 [1.02\u20131.31], p = 0.029), higher CCI score (\u22653 vs 0, aHR = 1.41 [1.16\u20131.70], p = 0.001) and longer pre-transplantation dialysis time (>1yr vs no dialysis, aHR = 1.46 [CI 1.16\u20131.82], p = 0.001) were still considered risk factors for graft failure (Table 3).Clinical outcome ::: ResultsRegarding liver transplants, the domestic LT recipients had significantly better survival probabilities than those of the overseas LT recipients in the crude rate (log-rank test p<0.001, Table 2 and Fig 2).", [["kidney graft", "ANATOMY", 10, 22], ["kidney", "ANATOMY", 85, 91], ["graft", "ANATOMY", 457, 462], ["liver", "ANATOMY", 519, 524], ["kidney graft failure", "DISEASE", 10, 30], ["graft failure", "DISEASE", 457, 470], ["kidney graft", "MULTI-TISSUE_STRUCTURE", 10, 22], ["kidney", "ORGAN", 85, 91], ["graft", "TISSUE", 457, 462], ["liver", "ORGAN", 519, 524], ["recipients", "ORGANISM", 554, 564], ["recipients", "ORGANISM", 643, 653], ["kidney graft failure", "PROBLEM", 10, 30], ["aHR", "TEST", 104, 107], ["p", "TEST", 128, 129], ["aHR", "TEST", 175, 178], ["p", "TEST", 199, 200], ["aHR", "TEST", 215, 218], ["p", "TEST", 239, 240], ["higher CCI score", "PROBLEM", 251, 267], ["aHR", "TEST", 278, 281], ["p", "TEST", 302, 303], ["longer pre-transplantation dialysis time", "TREATMENT", 317, 357], ["dialysis", "TREATMENT", 370, 378], ["aHR", "TEST", 380, 383], ["CI", "TEST", 392, 394], ["p", "TEST", 407, 408], ["graft failure", "PROBLEM", 457, 470], ["liver transplants", "TREATMENT", 519, 536], ["the domestic LT recipients", "TREATMENT", 538, 564], ["the crude rate", "TEST", 657, 671], ["kidney", "ANATOMY", 10, 16], ["graft", "OBSERVATION", 17, 22], ["failure", "OBSERVATION", 23, 30], ["no", "UNCERTAINTY", 42, 44], ["kidney", "ANATOMY", 85, 91], ["graft failure", "OBSERVATION", 457, 470], ["liver", "ANATOMY", 519, 524], ["transplants", "OBSERVATION", 525, 536]]], ["Overseas LT recipients with prior hepatocellular carcinoma had the lowest survival rate (Fig 2).", [["hepatocellular carcinoma", "ANATOMY", 34, 58], ["hepatocellular carcinoma", "DISEASE", 34, 58], ["hepatocellular carcinoma", "CANCER", 34, 58], ["prior hepatocellular carcinoma", "PROBLEM", 28, 58], ["hepatocellular", "ANATOMY", 34, 48], ["carcinoma", "OBSERVATION", 49, 58]]], ["In Cox proportional hazards models, due to significant interaction between location of transplantation and history of hepatocellular carcinoma (p<0.001), we separated the subjects into two groups according to their history of hepatocellular carcinoma (Table 4).", [["hepatocellular carcinoma", "ANATOMY", 118, 142], ["hepatocellular carcinoma", "ANATOMY", 226, 250], ["hepatocellular carcinoma", "DISEASE", 118, 142], ["hepatocellular carcinoma", "DISEASE", 226, 250], ["hepatocellular carcinoma", "CANCER", 118, 142], ["hepatocellular carcinoma", "CANCER", 226, 250], ["transplantation", "TREATMENT", 87, 102], ["hepatocellular carcinoma", "PROBLEM", 118, 142], ["hepatocellular carcinoma", "PROBLEM", 226, 250], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["interaction", "OBSERVATION", 55, 66], ["transplantation", "OBSERVATION", 87, 102], ["hepatocellular", "ANATOMY", 118, 132], ["carcinoma", "OBSERVATION", 133, 142], ["hepatocellular", "ANATOMY", 226, 240], ["carcinoma", "OBSERVATION", 241, 250]]], ["In the hepatocellular carcinoma group, overseas LT had a significantly higher hazard ratio for patient mortality (aHR = 2.65 [2.08\u20133.38], p<0.001) after adjusting for age, sex, and CCI score.", [["hepatocellular carcinoma", "ANATOMY", 7, 31], ["hepatocellular carcinoma", "DISEASE", 7, 31], ["hepatocellular carcinoma", "CANCER", 7, 31], ["patient", "ORGANISM", 95, 102], ["patient", "SPECIES", 95, 102], ["the hepatocellular carcinoma", "PROBLEM", 3, 31], ["a significantly higher hazard ratio", "PROBLEM", 55, 90], ["patient mortality", "PROBLEM", 95, 112], ["aHR", "TEST", 114, 117], ["CCI score", "TEST", 181, 190], ["hepatocellular", "ANATOMY", 7, 21], ["carcinoma", "OBSERVATION", 22, 31]]], ["On the other hand, in the non-hepatocellular carcinoma group, the mortality rate of overseas LT was not different from that of domestic LT (aHR = 1.31 [0.94\u20131.82], p = 0.107).", [["non-hepatocellular carcinoma", "ANATOMY", 26, 54], ["non-hepatocellular carcinoma", "DISEASE", 26, 54], ["non-hepatocellular carcinoma", "CANCER", 26, 54], ["the non-hepatocellular carcinoma", "PROBLEM", 22, 54], ["domestic LT", "TEST", 127, 138], ["aHR", "TEST", 140, 143], ["non-hepatocellular", "ANATOMY", 26, 44], ["carcinoma", "OBSERVATION", 45, 54]]], ["Older age (>60 y/o vs \u226418 y/o, aHR = 2.32 [1.37\u20133.93], p = 0.001) was another risk factor for patient mortality.Clinical outcome ::: ResultsWe further identified that post-KT malignancy and liver disease were the two main causes of death for overseas KT recipients compared to those for the domestic KT recipients.", [["KT malignancy", "ANATOMY", 172, 185], ["liver", "ANATOMY", 190, 195], ["malignancy", "DISEASE", 175, 185], ["liver disease", "DISEASE", 190, 203], ["death", "DISEASE", 232, 237], ["patient", "ORGANISM", 94, 101], ["liver", "ORGAN", 190, 195], ["recipients", "ORGANISM", 303, 313], ["patient", "SPECIES", 94, 101], ["aHR", "TEST", 31, 34], ["patient mortality", "PROBLEM", 94, 111], ["post-KT malignancy", "PROBLEM", 167, 185], ["liver disease", "PROBLEM", 190, 203], ["death", "PROBLEM", 232, 237], ["KT recipients", "TREATMENT", 251, 264], ["the domestic KT recipients", "TREATMENT", 287, 313], ["malignancy", "OBSERVATION", 175, 185], ["liver", "ANATOMY", 190, 195], ["disease", "OBSERVATION", 196, 203]]], ["On the other hand, hepatocellular carcinoma was the major cause of death for overseas LT recipients (69.0 per 1000 person-years; IRR = 6.58 [4.69\u20139.23], p<0.001) compared to their domestic counterparts (8.2 per 1000 person-years) (Table 5).Patient and graft survivals ::: Features of transplant tourism from Taiwan to China ::: DiscussionTwo previous studies show that the clinical outcomes of overseas KTs were comparable to those of domestic KTs after 2000 [7,14]; however, those studies had brief follow-up periods (< 5 years) and used only one institution with limited case numbers.", [["hepatocellular carcinoma", "ANATOMY", 19, 43], ["graft", "ANATOMY", 252, 257], ["hepatocellular carcinoma", "DISEASE", 19, 43], ["death", "DISEASE", 67, 72], ["KTs", "DISEASE", 403, 406], ["hepatocellular carcinoma", "CANCER", 19, 43], ["graft", "TISSUE", 252, 257], ["person", "SPECIES", 115, 121], ["person", "SPECIES", 216, 222], ["Patient", "SPECIES", 240, 247], ["hepatocellular carcinoma", "PROBLEM", 19, 43], ["death", "PROBLEM", 67, 72], ["IRR", "TEST", 129, 132], ["previous studies", "TEST", 342, 358], ["those studies", "TEST", 476, 489], ["hepatocellular", "ANATOMY", 19, 33], ["carcinoma", "OBSERVATION", 34, 43], ["graft", "OBSERVATION", 252, 257], ["transplant tourism", "OBSERVATION", 284, 302]]], ["In our study, the crude patient survival rate was better for domestic KT recipients, but there was no difference in graft survival.", [["graft", "ANATOMY", 116, 121], ["patient", "ORGANISM", 24, 31], ["graft", "TISSUE", 116, 121], ["patient", "SPECIES", 24, 31], ["our study", "TEST", 3, 12], ["survival rate", "TEST", 32, 45], ["domestic KT recipients", "TREATMENT", 61, 83], ["graft survival", "TREATMENT", 116, 130], ["no", "UNCERTAINTY", 99, 101], ["graft survival", "OBSERVATION", 116, 130]]], ["The higher mortality rate in overseas KT recipients might have been reduced by a low kidney graft failure rate (overseas vs. domestic: 33.2% vs. 54.5%, Table 1).", [["kidney", "ANATOMY", 85, 91], ["low kidney graft failure", "DISEASE", 81, 105], ["kidney", "ORGAN", 85, 91], ["graft", "TISSUE", 92, 97], ["The higher mortality rate", "PROBLEM", 0, 25], ["a low kidney graft failure rate", "PROBLEM", 79, 110], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["mortality", "OBSERVATION_MODIFIER", 11, 20], ["reduced", "OBSERVATION_MODIFIER", 68, 75], ["low", "OBSERVATION_MODIFIER", 81, 84], ["kidney", "ANATOMY", 85, 91], ["graft", "OBSERVATION", 92, 97]]], ["This is consistent with the general conception that organs procured from executed prisoners (especially young males) in China are similar to organs from living donors, and hence, have better \u201cquality\u201d than the domestic deceased organs which are mainly from brain-dead patients.", [["organs", "ANATOMY", 52, 58], ["organs", "ANATOMY", 141, 147], ["organs", "ANATOMY", 228, 234], ["brain", "ANATOMY", 257, 262], ["organs", "ORGAN", 52, 58], ["organs", "ORGAN", 141, 147], ["donors", "ORGANISM", 160, 166], ["organs", "ORGAN", 228, 234], ["brain", "ORGAN", 257, 262], ["patients", "ORGANISM", 268, 276], ["patients", "SPECIES", 268, 276], ["consistent with", "UNCERTAINTY", 8, 23]]], ["However, after adjusting for covariates, the mortality rate was similar between domestic and overseas KT patients.", [["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["the mortality rate", "TEST", 41, 59]]], ["The poor survival rate in overseas patients is attributed to the characteristics of overseas patients (old age, more comorbidity, and male).Malignancy ::: Features of transplant tourism from Taiwan to China ::: DiscussionWe found that the main causes of death for KT, especially in overseas transplants, were malignancy and liver disease.", [["liver", "ANATOMY", 324, 329], ["Malignancy", "DISEASE", 140, 150], ["death", "DISEASE", 254, 259], ["KT", "DISEASE", 264, 266], ["malignancy", "DISEASE", 309, 319], ["liver disease", "DISEASE", 324, 337], ["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 93, 101], ["liver", "ORGAN", 324, 329], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 93, 101], ["The poor survival rate", "PROBLEM", 0, 22], ["Malignancy", "PROBLEM", 140, 150], ["death", "PROBLEM", 254, 259], ["KT", "PROBLEM", 264, 266], ["malignancy", "PROBLEM", 309, 319], ["liver disease", "PROBLEM", 324, 337], ["poor", "OBSERVATION_MODIFIER", 4, 8], ["survival", "OBSERVATION_MODIFIER", 9, 17], ["transplant tourism", "OBSERVATION", 167, 185], ["malignancy", "OBSERVATION", 309, 319], ["liver", "ANATOMY", 324, 329], ["disease", "OBSERVATION", 330, 337]]], ["The most common malignancies in overseas KT recipients were genitourinary malignancy (kidney or bladder cancer) and hepatocellular carcinoma.", [["malignancies", "ANATOMY", 16, 28], ["genitourinary malignancy", "ANATOMY", 60, 84], ["kidney", "ANATOMY", 86, 92], ["bladder cancer", "ANATOMY", 96, 110], ["hepatocellular carcinoma", "ANATOMY", 116, 140], ["malignancies", "DISEASE", 16, 28], ["genitourinary malignancy", "DISEASE", 60, 84], ["kidney or bladder cancer", "DISEASE", 86, 110], ["hepatocellular carcinoma", "DISEASE", 116, 140], ["malignancies", "CANCER", 16, 28], ["genitourinary malignancy", "CANCER", 60, 84], ["kidney", "ORGAN", 86, 92], ["bladder cancer", "CANCER", 96, 110], ["hepatocellular carcinoma", "CANCER", 116, 140], ["The most common malignancies", "PROBLEM", 0, 28], ["genitourinary malignancy", "PROBLEM", 60, 84], ["bladder cancer", "PROBLEM", 96, 110], ["hepatocellular carcinoma", "PROBLEM", 116, 140], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["malignancies", "OBSERVATION", 16, 28], ["genitourinary", "ANATOMY", 60, 73], ["malignancy", "OBSERVATION", 74, 84], ["kidney", "ANATOMY", 86, 92], ["bladder", "ANATOMY", 96, 103], ["cancer", "OBSERVATION", 104, 110], ["hepatocellular", "ANATOMY", 116, 130], ["carcinoma", "OBSERVATION", 131, 140]]], ["Tsai et al.[15] also reported a high de novo malignancy rate in renal transplant tourism compared to that of domestic renal transplant recipients.", [["renal", "ANATOMY", 64, 69], ["renal", "ANATOMY", 118, 123], ["malignancy", "DISEASE", 45, 55], ["renal", "ORGAN", 64, 69], ["renal", "ORGAN", 118, 123], ["a high de novo malignancy rate", "PROBLEM", 30, 60], ["renal transplant tourism", "TREATMENT", 64, 88], ["domestic renal transplant recipients", "TREATMENT", 109, 145], ["malignancy", "OBSERVATION", 45, 55], ["renal", "ANATOMY", 64, 69], ["transplant", "OBSERVATION", 70, 80], ["renal", "ANATOMY", 118, 123], ["transplant", "OBSERVATION", 124, 134]]], ["The 10-year cumulative cancer incidence of the tourism group (21.5%) was significantly higher than that of the domestic group (6.8%), and the most common cancers were urothelium carcinoma and hepatocellular carcinoma.", [["cancer", "ANATOMY", 23, 29], ["cancers", "ANATOMY", 154, 161], ["urothelium carcinoma", "ANATOMY", 167, 187], ["hepatocellular carcinoma", "ANATOMY", 192, 216], ["cancer", "DISEASE", 23, 29], ["cancers", "DISEASE", 154, 161], ["urothelium carcinoma", "DISEASE", 167, 187], ["hepatocellular carcinoma", "DISEASE", 192, 216], ["cancer", "CANCER", 23, 29], ["cancers", "CANCER", 154, 161], ["urothelium carcinoma", "CANCER", 167, 187], ["hepatocellular carcinoma", "CANCER", 192, 216], ["the most common cancers", "PROBLEM", 138, 161], ["urothelium carcinoma", "PROBLEM", 167, 187], ["hepatocellular carcinoma", "PROBLEM", 192, 216], ["cancer", "OBSERVATION", 23, 29], ["most common", "OBSERVATION_MODIFIER", 142, 153], ["cancers", "OBSERVATION", 154, 161], ["urothelium", "ANATOMY", 167, 177], ["carcinoma", "OBSERVATION", 178, 187], ["hepatocellular carcinoma", "OBSERVATION", 192, 216]]], ["The high cancer incidence in the tourism group might be related to older age, more depleting antibody induction therapy, and omitted pre-transplant cancer screening procedures.Malignancy ::: Features of transplant tourism from Taiwan to China ::: DiscussionIn liver transplants, patient survival was remarkably worse among overseas recipients.", [["cancer", "ANATOMY", 9, 15], ["cancer", "ANATOMY", 148, 154], ["liver", "ANATOMY", 260, 265], ["cancer", "DISEASE", 9, 15], ["cancer", "DISEASE", 148, 154], ["Malignancy", "DISEASE", 176, 186], ["cancer", "CANCER", 9, 15], ["cancer", "CANCER", 148, 154], ["liver", "ORGAN", 260, 265], ["patient", "ORGANISM", 279, 286], ["patient", "SPECIES", 279, 286], ["The high cancer", "PROBLEM", 0, 15], ["antibody induction therapy", "TREATMENT", 93, 119], ["pre-transplant cancer screening procedures", "TREATMENT", 133, 175], ["liver transplants", "TREATMENT", 260, 277], ["high", "OBSERVATION_MODIFIER", 4, 8], ["cancer", "OBSERVATION", 9, 15], ["cancer", "OBSERVATION", 148, 154], ["transplant tourism", "OBSERVATION", 203, 221], ["liver", "ANATOMY", 260, 265], ["transplants", "OBSERVATION", 266, 277]]], ["Overseas hepatocellular carcinoma patients had the worst prognosis compared with other groups.", [["hepatocellular carcinoma", "ANATOMY", 9, 33], ["hepatocellular carcinoma", "DISEASE", 9, 33], ["hepatocellular carcinoma", "CANCER", 9, 33], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["Overseas hepatocellular carcinoma", "PROBLEM", 0, 33], ["hepatocellular", "ANATOMY", 9, 23], ["carcinoma", "OBSERVATION", 24, 33]]], ["In overseas LT, 64.1% had hepatocellular carcinoma before operation compared to 39.9% in domestic groups; but the hepatocellular carcinoma mortality rate was 69.0 compared to 8.2 per 1000 person-years (p<0.001), which implies that most overseas LT recipients were not suitable candidates for LT and inevitably had a high hepatocellular carcinoma recurrence rate and high mortality.", [["hepatocellular carcinoma", "ANATOMY", 26, 50], ["hepatocellular carcinoma", "ANATOMY", 114, 138], ["hepatocellular carcinoma", "ANATOMY", 321, 345], ["hepatocellular carcinoma", "DISEASE", 26, 50], ["hepatocellular carcinoma", "DISEASE", 114, 138], ["hepatocellular carcinoma", "DISEASE", 321, 345], ["hepatocellular carcinoma", "CANCER", 26, 50], ["hepatocellular carcinoma", "CANCER", 114, 138], ["recipients", "ORGANISM", 248, 258], ["hepatocellular carcinoma", "CANCER", 321, 345], ["hepatocellular carcinoma", "PROBLEM", 26, 50], ["the hepatocellular carcinoma", "PROBLEM", 110, 138], ["mortality rate", "TEST", 139, 153], ["LT", "PROBLEM", 292, 294], ["a high hepatocellular carcinoma recurrence rate", "PROBLEM", 314, 361], ["high mortality", "PROBLEM", 366, 380], ["LT", "ANATOMY", 12, 14], ["hepatocellular", "ANATOMY", 26, 40], ["carcinoma", "OBSERVATION", 41, 50], ["hepatocellular", "ANATOMY", 114, 128], ["carcinoma", "OBSERVATION", 129, 138], ["high", "OBSERVATION_MODIFIER", 316, 320], ["hepatocellular", "ANATOMY", 321, 335], ["carcinoma", "OBSERVATION", 336, 345], ["high", "OBSERVATION_MODIFIER", 366, 370], ["mortality", "OBSERVATION_MODIFIER", 371, 380]]], ["Similar to our findings, Allam et al. also reported poor outcomes for LT patients who received transplantation in China, showing one- and three-year cumulative patient survival rates of 83% and 62%, respectively, compared to 92% and 84% in domestic hospitals [18].", [["patients", "ORGANISM", 73, 81], ["patient", "ORGANISM", 160, 167], ["patients", "SPECIES", 73, 81], ["patient", "SPECIES", 160, 167], ["transplantation", "TREATMENT", 95, 110], ["survival rates", "TEST", 168, 182], ["poor", "OBSERVATION_MODIFIER", 52, 56]]], ["The main reason for this discrepancy may be less prudent selection criteria for transplantation in China because 41 (55%) of the patients who received overseas transplantation had been denied liver transplantation at domestic hospitals due to multiple comorbidities, exceeding the age limit, or advanced hepatocellular carcinoma.", [["liver", "ANATOMY", 192, 197], ["hepatocellular carcinoma", "ANATOMY", 304, 328], ["hepatocellular carcinoma", "DISEASE", 304, 328], ["patients", "ORGANISM", 129, 137], ["liver", "ORGAN", 192, 197], ["hepatocellular carcinoma", "CANCER", 304, 328], ["patients", "SPECIES", 129, 137], ["transplantation", "TREATMENT", 80, 95], ["overseas transplantation", "TREATMENT", 151, 175], ["liver transplantation", "TREATMENT", 192, 213], ["multiple comorbidities", "PROBLEM", 243, 265], ["advanced hepatocellular carcinoma", "PROBLEM", 295, 328], ["main", "OBSERVATION_MODIFIER", 4, 8], ["liver", "ANATOMY", 192, 197], ["transplantation", "OBSERVATION", 198, 213], ["multiple", "OBSERVATION_MODIFIER", 243, 251], ["comorbidities", "OBSERVATION", 252, 265], ["advanced", "OBSERVATION_MODIFIER", 295, 303], ["hepatocellular", "ANATOMY", 304, 318], ["carcinoma", "OBSERVATION", 319, 328]]], ["In other words, some LT cases might not be medically indicated and some KT cases were clinically suboptimal for transplantation in the overseas groups, which might contribute to the poorer outcome of the overseas groups.Taiwan and transplant tourism trends ::: Transplant tourism in Asia and organs from executed prisoners ::: DiscussionOverseas transplants increased rapidly after 2000, perhaps due to improved surgical techniques and transplantation outcomes, as well as to increased organ supply and brokering activity in China.", [["organs", "ANATOMY", 292, 298], ["organ", "ANATOMY", 486, 491], ["organs", "ORGAN", 292, 298], ["organ", "ORGAN", 486, 491], ["some LT cases", "PROBLEM", 16, 29], ["some KT cases", "PROBLEM", 67, 80], ["transplantation", "TREATMENT", 112, 127], ["DiscussionOverseas transplants", "TREATMENT", 327, 357], ["improved surgical techniques", "TREATMENT", 403, 431], ["transplantation outcomes", "TREATMENT", 436, 460], ["tourism", "OBSERVATION", 272, 279]]], ["In 2006, China admitted using organs from executed prisoners [10]\u2014a practice prohibited by international professional societies and condemned by human rights groups.", [["organs", "ANATOMY", 30, 36], ["organs", "ORGAN", 30, 36], ["human", "ORGANISM", 145, 150], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 145, 150]]], ["As the public, the media, and NGOs began to better understand the unethical nature of transplant tourism, pressure started to grow in Taiwan.", [["pressure", "TREATMENT", 106, 114], ["transplant", "OBSERVATION", 86, 96]]], ["While international organizations were exercising pressure on China and requesting legal reform on transplantation policy, Taiwan\u2019s government prohibited medical personnel from involvement in any form of organ brokering.", [["organ", "ANATOMY", 204, 209], ["organ", "ORGAN", 204, 209], ["organ brokering", "TREATMENT", 204, 219]]], ["China passed its Human Organ Transplant Act in 2007.", [["Human", "ORGANISM", 17, 22], ["Human", "SPECIES", 17, 22]]], ["Since these policy changes, the number of transplant tourists from Taiwan to China has decreased remarkably.", [["policy", "OBSERVATION", 12, 18], ["transplant tourists", "OBSERVATION", 42, 61], ["decreased", "OBSERVATION_MODIFIER", 87, 96]]], ["This might be due to an increased awareness of related ethical/legal controversies, but also due to the escalated expense of organ trafficking resulting from outlawing the organ trade, which led to reduced availability of organs (prices nearly doubled and even tripled according to the authors\u2019 local survey).Taiwan and transplant tourism trends ::: Transplant tourism in Asia and organs from executed prisoners ::: DiscussionIn June 2015, Taiwan passed amendments to the Human Organ Transplantation Act.", [["organ", "ANATOMY", 125, 130], ["organ", "ANATOMY", 172, 177], ["organs", "ANATOMY", 222, 228], ["organs", "ANATOMY", 381, 387], ["organ", "ORGAN", 125, 130], ["organ", "ORGAN", 172, 177], ["organs", "ORGAN", 222, 228], ["organs", "ORGAN", 381, 387], ["Human", "ORGANISM", 472, 477], ["Human", "SPECIES", 472, 477], ["an increased awareness", "PROBLEM", 21, 43], ["organ trafficking", "PROBLEM", 125, 142], ["the Human Organ Transplantation", "TREATMENT", 468, 499], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["organs", "ANATOMY", 222, 228], ["tourism", "OBSERVATION", 361, 368], ["Organ", "ANATOMY", 478, 483], ["Transplantation", "OBSERVATION", 484, 499]]], ["Organ brokers and patients receiving illegal organ transplants no matter domestically or overseas could face a maximum of five years imprisonment and a fine of up to USD 50,000.", [["Organ", "ANATOMY", 0, 5], ["organ", "ANATOMY", 45, 50], ["patients", "ORGANISM", 18, 26], ["organ", "ORGAN", 45, 50], ["patients", "SPECIES", 18, 26], ["Organ brokers", "TREATMENT", 0, 13], ["illegal organ transplants", "TREATMENT", 37, 62]]], ["Criminalizing \u201cpatients\u201d for illegal transplantation was disputed during the law amendment discussions (2013\u20132015).", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["illegal transplantation", "TREATMENT", 29, 52]]], ["Some transplantation professionals, patient groups and Ministry of Health & Welfare expressed sympathy for patients who receive such transplantation and raised opposing opinion because patients might be desperate and hopeless while so doing.", [["patient", "ORGANISM", 36, 43], ["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 185, 193], ["patient", "SPECIES", 36, 43], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 185, 193], ["such transplantation", "TREATMENT", 128, 148], ["transplantation", "OBSERVATION", 5, 20]]], ["Yet the Ministry of Justice and human right organization supported such amendment based on the principle that human rights protection and punishment should be applied equally to brokers and buyers in an illegal organ trade [26,27].", [["organ", "ANATOMY", 211, 216], ["human", "ORGANISM", 32, 37], ["human", "ORGANISM", 110, 115], ["organ", "ORGAN", 211, 216], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 110, 115], ["Justice and human right organization", "TREATMENT", 20, 56], ["human rights protection", "TREATMENT", 110, 133], ["punishment", "TREATMENT", 138, 148], ["right", "ANATOMY_MODIFIER", 38, 43]]], ["After the Act passed, compulsory registration for overseas transplantation is required, which will promote transparency in transplant tourism and therefore may serve as a deterrent.", [["overseas transplantation", "TREATMENT", 50, 74], ["transplant tourism", "OBSERVATION", 123, 141]]], ["Prohibiting using executed prisoners as organ donors to follow international guideline was implemented.", [["organ", "ANATOMY", 40, 45], ["organ", "ORGAN", 40, 45]]], ["Increased domestic organ donation strategies including \u201cmandatory choice\u201d and \u201crequired request\u201d in deceased organ procurement policy, promoting \u201cdonation after circulatory death,\u201d and allowing \u201cpaired exchange\u201d were all included in the amended law [28].", [["organ", "ANATOMY", 19, 24], ["organ", "ANATOMY", 109, 114], ["circulatory death", "DISEASE", 161, 178], ["organ", "ORGAN", 19, 24], ["organ", "ORGAN", 109, 114], ["Increased domestic organ donation strategies", "TREATMENT", 0, 44], ["circulatory death", "PROBLEM", 161, 178], ["domestic organ donation", "OBSERVATION", 10, 33]]], ["Although it will take time to observe the amendments\u2019 actual effects on transplant tourism, the overall trend has shown a reduction in numbers.Policy suggestion for regulating transplant tourism in Asia ::: DiscussionInternational guidelines concerning organ transplantation all call for adoption of a paradigm that involves governments taking national-level responsibility for fulfilling patients\u2019 needs for organ donation and transplantation, and for ending unethical/illegal organ trafficking and commercialization [29].", [["organ", "ANATOMY", 253, 258], ["organ", "ANATOMY", 409, 414], ["organ", "ANATOMY", 478, 483], ["organ", "ORGAN", 253, 258], ["patients", "ORGANISM", 389, 397], ["organ", "ORGAN", 409, 414], ["organ", "ORGAN", 478, 483], ["patients", "SPECIES", 389, 397], ["transplant tourism", "TREATMENT", 72, 90], ["a reduction in numbers", "PROBLEM", 120, 142], ["organ transplantation", "TREATMENT", 253, 274], ["organ donation", "TREATMENT", 409, 423], ["transplantation", "TREATMENT", 428, 443], ["reduction", "OBSERVATION_MODIFIER", 122, 131]]], ["In 2007, the Philippines prohibited foreigners from travelling to that country for transplantation, which quickly led to a remarkable decrease in such cases [30].", [["transplantation", "TREATMENT", 83, 98], ["a remarkable decrease in such cases", "PROBLEM", 121, 156]]], ["In 2008, Israel passed a law banning the sale, purchase, and brokerage of organs, both in Israel and abroad; and it has arrested brokers.", [["organs", "ANATOMY", 74, 80], ["organs", "ORGAN", 74, 80], ["organs", "ANATOMY", 74, 80]]], ["Despite these regulatory efforts in reducing organ tourism, the issue remains a complex, conflicting, ethical/legal challenge in many Asian countries.", [["organ", "ANATOMY", 45, 50], ["organ", "ORGAN", 45, 50]]], ["Politicians, patients, doctors, brokers, and other stakeholders have engaged in a power struggle to protect their respective interests, which in turn has made ethical and effective legislation difficult to accomplish.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["Comprehensive and enforceable national and international regulatory frameworks within Asian regions, which could be similar to the Convention against Trafficking in Human Organs (2014) by the Council of Europe, are indeed needed yet lacking.", [["Human", "ORGANISM", 165, 170], ["Human", "SPECIES", 165, 170], ["Comprehensive and enforceable national and international regulatory frameworks", "PROBLEM", 0, 78]]], ["The WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation (2010)\u2014requiring relevant transplantation information to be open, accessible, and monitored\u2014could serve as a reference, with enacting principles 10 and 11 (\u201ctraceability\u201d and \u201ctransparency,\u201d respectively) serving as the first step [32].Policy suggestion for regulating transplant tourism in Asia ::: DiscussionWe therefore propose that Asian countries, as well as other countries involved with transplant tourism, adopt practical strategies and legislation so as to effectively reduce transplant tourism and organ trafficking.", [["Cell", "ANATOMY", 36, 40], ["Tissue", "ANATOMY", 42, 48], ["organ", "ANATOMY", 583, 588], ["Human", "ORGANISM", 30, 35], ["Cell", "CELL", 36, 40], ["Tissue", "TISSUE", 42, 48], ["organ", "ORGAN", 583, 588], ["Human", "SPECIES", 30, 35], ["Human", "SPECIES", 30, 35], ["Human Cell", "TREATMENT", 30, 40], ["Tissue and Organ Transplantation", "TREATMENT", 42, 74], ["relevant transplantation", "TREATMENT", 92, 116], ["transplant tourism", "TREATMENT", 469, 487], ["Organ", "ANATOMY", 53, 58]]], ["For example, they should:Strengths and limitations of this research ::: DiscussionA strength of our study is that all the overseas transplant patients were identified and the results can be generalized.", [["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["our study", "TEST", 96, 105]]], ["Additionally, the cohort is larger and with longer follow-up times (an 11-year cohort) than previous studies on transplant tourism (7,18).", [["previous studies", "TEST", 92, 108], ["larger", "OBSERVATION_MODIFIER", 28, 34]]], ["However, this study has several limitations.", [["this study", "TEST", 9, 19]]], ["This is a retrospective study and recruited only overseas transplantation patients who survived, returned to Taiwan, and received anti-rejection therapies.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["a retrospective study", "TEST", 8, 29], ["anti-rejection therapies", "TREATMENT", 130, 154]]], ["Early intra-hospital mortality cases, in which the patients died after transplantation and failed to return to Taiwan, were not available in our research.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["transplantation", "TREATMENT", 71, 86]]], ["To avoid overestimating the outcome of overseas transplants, we excluded domestic recipients who died within one month or who resumed dialysis within one month after the transplant operation to make the overseas and domestic groups more comparable.", [["recipients", "ORGANISM", 82, 92], ["overseas transplants", "TREATMENT", 39, 59], ["dialysis", "TREATMENT", 134, 142], ["the transplant operation", "TREATMENT", 166, 190]]], ["In addition to donor quality, some key variables in the LT models that had affected post-LT survival were not available, including various aspects of donor quality, pre-operative laboratory data, and the characteristics of hepatocellular carcinoma.", [["hepatocellular carcinoma", "ANATOMY", 223, 247], ["hepatocellular carcinoma", "DISEASE", 223, 247], ["hepatocellular carcinoma", "CANCER", 223, 247], ["pre-operative laboratory data", "TEST", 165, 194], ["hepatocellular carcinoma", "PROBLEM", 223, 247], ["LT", "ANATOMY", 56, 58], ["hepatocellular", "ANATOMY", 223, 237], ["carcinoma", "OBSERVATION", 238, 247]]], ["Due to the unethical nature of the transplant tourism sector, overseas transplant patients usually lack such clinical data and return home with only limited medical information, which hinders fair comparison and comprehensive research.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["transplant", "OBSERVATION", 35, 45]]], ["However, the purpose of our study is not to find all the covariates affecting post-transplant survival in order to improve overseas transplants; rather, our study seeks to provide a picture of overseas transplants (trends, patient characteristics, and outcomes) in transplant tourism over the past decade in order to propose possible solutions to this important global health issue.ConclusionOur study gives a basic overview and describes problems of transplant tourism from Taiwan to China.", [["patient", "ORGANISM", 223, 230], ["patient", "SPECIES", 223, 230], ["our study", "TEST", 24, 33], ["post-transplant survival", "TREATMENT", 78, 102], ["overseas transplants", "TREATMENT", 123, 143], ["our study", "TEST", 153, 162], ["overseas transplants", "TREATMENT", 193, 213], ["ConclusionOur study", "TEST", 382, 401]]], ["The overseas transplant group had different demographic and clinical compositions than those of the domestic one; hence, the overseas group\u2019s outcome is inferior.", [["inferior", "OBSERVATION_MODIFIER", 153, 161]]], ["Although transplant tourism has decreased after the increased ethical awareness and establishment of relevant professional guidelines and policies, it still exists in many countries.", [["the increased ethical awareness", "PROBLEM", 48, 79], ["transplant", "OBSERVATION_MODIFIER", 9, 19], ["tourism", "OBSERVATION", 20, 27], ["decreased", "OBSERVATION_MODIFIER", 32, 41], ["increased", "OBSERVATION_MODIFIER", 52, 61]]], ["We have reflected upon the ethical controversies of transplant tourism and proposed strategies for policy and legal reform based on recent professional and governmental efforts, as well as developments in Taiwan; these could be useful references for other Asian countries.", [["transplant tourism", "TREATMENT", 52, 70]]]], "471f3c4076ae57b0a1d0b444d7ac1575922a17de": [["| INTRODUCTIONRotaviruses (RVs) are a major cause of intestinal disease in animals, including weaned piglets and young children (Vlasova, Amimo, & Saif, 2017) .", [["intestinal", "ANATOMY", 53, 63], ["intestinal disease", "DISEASE", 53, 71], ["intestinal", "ORGAN", 53, 63], ["piglets", "ORGANISM", 101, 108], ["children", "ORGANISM", 119, 127], ["piglets", "SPECIES", 101, 108], ["children", "SPECIES", 119, 127], ["intestinal disease", "PROBLEM", 53, 71], ["intestinal", "ANATOMY", 53, 63], ["disease", "OBSERVATION", 64, 71]]], ["RVs form a genus of the Reoviridae family and contain a genome consisting of 11 double-stranded RNA segments.", [["Reoviridae", "GENE_OR_GENE_PRODUCT", 24, 34], ["Reoviridae family", "PROTEIN", 24, 41], ["double-stranded RNA segments", "DNA", 80, 108]]], ["The RV genome encodes six structural viral proteins (VPs; VP1-VP4, VP6 and VP7) and five or six non-structural proteins (NSP1-NSP5/6) (Ramig, 1997) .", [["VPs", "GENE_OR_GENE_PRODUCT", 53, 56], ["VP1-VP4", "GENE_OR_GENE_PRODUCT", 58, 65], ["VP6", "GENE_OR_GENE_PRODUCT", 67, 70], ["VP7", "GENE_OR_GENE_PRODUCT", 75, 78], ["NSP1-NSP5/6", "GENE_OR_GENE_PRODUCT", 121, 132], ["RV genome", "DNA", 4, 13], ["structural viral proteins", "PROTEIN", 26, 51], ["VPs", "PROTEIN", 53, 56], ["VP1", "PROTEIN", 58, 61], ["VP4", "PROTEIN", 62, 65], ["VP6", "PROTEIN", 67, 70], ["VP7", "PROTEIN", 75, 78], ["non-structural proteins", "PROTEIN", 96, 119], ["NSP1", "PROTEIN", 121, 125], ["NSP5/6", "PROTEIN", 126, 132], ["VPs", "TEST", 53, 56], ["VP1", "TEST", 58, 61], ["VP4", "TEST", 62, 65], ["VP6", "TEST", 67, 70], ["VP7", "TEST", 75, 78], ["six non-structural proteins", "TEST", 92, 119], ["NSP1", "TEST", 121, 125], ["RV", "ANATOMY", 4, 6], ["genome", "OBSERVATION", 7, 13], ["six", "OBSERVATION_MODIFIER", 22, 25], ["structural", "OBSERVATION_MODIFIER", 26, 36], ["viral proteins", "OBSERVATION", 37, 51], ["non-structural proteins", "OBSERVATION", 96, 119]]], ["The RV VP6 protein has been used to differentiate RV species by classifying them into 10 groups from group A rotavirus (RVA) to group J rotavirus (RVJ) (Banyai et al., 2017; Matthijnssens et al., 2012; Mihalov-Kovacs et al., 2015) .", [["RV VP6", "GENE_OR_GENE_PRODUCT", 4, 10], ["rotavirus", "ORGANISM", 109, 118], ["RV VP6 protein", "PROTEIN", 4, 18], ["A rotavirus", "SPECIES", 107, 118], ["The RV VP6 protein", "TEST", 0, 18], ["RV species", "PROBLEM", 50, 60], ["A rotavirus (RVA)", "PROBLEM", 107, 124], ["RV", "ANATOMY", 4, 6], ["VP6 protein", "OBSERVATION", 7, 18]]], ["Continuous RV classification is being performed by the Rega Instituut, KU Leuven (Belgium) (https://rega.kuleuven.be/cev/viralmetagenomics/virus-classification/ 7th-RCWG-meeting).", [["Continuous RV classification", "TEST", 0, 28], ["RV", "ANATOMY", 11, 13], ["classification", "OBSERVATION", 14, 28]]], ["The most common group infecting humans and animals is RVA, which causes acute dehydrating diarrhoea (Vlasova et al., 2017) .| INTRODUCTIONTo facilitate the classification of novel RVA strains, a Rotavirus Classification Working Group (RCWG) was established to develop a classification system for RVs (Matthijnssens, Ciarlet, Rahman et al., 2008b) .", [["diarrhoea", "DISEASE", 90, 99], ["Rotavirus", "DISEASE", 195, 204], ["humans", "ORGANISM", 32, 38], ["humans", "SPECIES", 32, 38], ["humans", "SPECIES", 32, 38], ["RVA", "PROBLEM", 54, 57], ["acute dehydrating diarrhoea", "PROBLEM", 72, 99], ["novel RVA strains", "PROBLEM", 174, 191], ["RVs", "PROBLEM", 296, 299], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["infecting", "OBSERVATION", 22, 31], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["dehydrating", "OBSERVATION_MODIFIER", 78, 89], ["diarrhoea", "OBSERVATION", 90, 99]]], ["Due to the high genetic diversity of RVA strains, the dual typing system (G and P genotypes) was extended to a whole-genome sequence classification system with all 11 gene segments (Matthijnssens, Ciarlet, Heiman et al., 2008a) .", [["RVA strains", "PROBLEM", 37, 48], ["RVA strains", "OBSERVATION", 37, 48]]], ["The classification and nomenclature of RVA genes is Gx-P[x]-Ix-Rx-Cx-Mx-Ax-Nx-Tx-Ex-Hx, where x indicates the corresponding number of genotypes (Matthijnssens et al., 2011) .", [["Gx-P[x]-Ix-Rx-Cx-Mx-Ax-Nx-Tx-Ex-Hx", "CHEMICAL", 52, 86], ["Ex-Hx", "SIMPLE_CHEMICAL", 81, 86], ["RVA genes", "DNA", 39, 48], ["Ix", "DNA", 60, 62], ["Rx", "DNA", 63, 65], ["Cx", "DNA", 66, 68], ["Ax", "DNA", 72, 74], ["Nx", "DNA", 75, 77], ["Tx", "DNA", 78, 80], ["Ex", "DNA", 81, 83], ["Hx", "DNA", 84, 86], ["Gx", "TEST", 52, 54], ["Ix", "TEST", 60, 62], ["Rx", "TEST", 63, 65], ["Cx", "TEST", 66, 68], ["Mx-", "TEST", 69, 72], ["Ax", "TEST", 72, 74], ["Nx", "OBSERVATION", 75, 77]]], ["To date, 32 G, 47 P, 24 I, 18 R, 17 C, 17 M, 28 A, 18 N, 19 T, 24 E and 19 H genotypes have been identified among RVAs from humans and animals (Esona et al., 2017) , as described at the 7th RCWG meeting (https://rega.kuleuven.be/cev/ viralmetagenomics/virus-classification/7th-RCWG-meeting) at Rega Instituut, KU Leuven (Belgium).", [["RVAs", "CANCER", 114, 118], ["humans", "ORGANISM", 124, 130], ["humans", "SPECIES", 124, 130], ["humans", "SPECIES", 124, 130], ["P", "TEST", 18, 19], ["A", "TEST", 48, 49], ["H genotypes", "TEST", 75, 86]]], ["In pigs, 12 G genotypes (G1 to G6, and VP8 and the existing RVA isolates using RDP4 software (Martin et al., 2015) .", [["pigs", "ORGANISM", 3, 7], ["VP8", "GENE_OR_GENE_PRODUCT", 39, 42], ["pigs", "SPECIES", 3, 7], ["pigs", "SPECIES", 3, 7], ["VP8", "TEST", 39, 42]]], ["The VP4 sequence of RVA/Pig/China/LNCY/2016/G3P [13] is shown in Figure 5a .", [["VP4", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP4 sequence", "DNA", 4, 16], ["RVA/Pig/China/LNCY/2016/G3P", "SPECIES", 20, 47], ["The VP4 sequence", "TEST", 0, 16], ["RVA", "TEST", 20, 23]]], ["Crossover points for a potential recombination zone were found at nt 456-804 of the VP4 gene (Figure 5b ), but no gene recombination was detected in the other viral proteins.| Sequence analysis of the VP4 geneThe major parental strain for the recombination located in the VP4 [13] genome was successfully sequenced, and evidence of a recombination event was identified.| Sequence analysis of the VP4 geneReassortment events between humans and animal strains have been found previously Doan et al., 2013; Esona et al., 2009 Esona et al., , 2017 Ghosh et al., 2010; He et al., 2013 He et al., , 2017| e323Rotavirus VP7 forms soluble calcium-dependent trimers (Dormitzer, Greenberg, & Harrison, 2000) .", [["calcium", "CHEMICAL", 631, 638], ["calcium", "CHEMICAL", 631, 638], ["VP4", "GENE_OR_GENE_PRODUCT", 84, 87], ["VP4", "GENE_OR_GENE_PRODUCT", 201, 204], ["VP4", "GENE_OR_GENE_PRODUCT", 396, 399], ["humans", "ORGANISM", 432, 438], ["calcium", "SIMPLE_CHEMICAL", 631, 638], ["nt 456-804", "DNA", 66, 76], ["VP4 gene", "DNA", 84, 92], ["viral proteins", "PROTEIN", 159, 173], ["VP4 gene", "DNA", 201, 209], ["VP4 [13] genome", "DNA", 272, 287], ["VP4 geneReassortment", "DNA", 396, 416], ["humans", "SPECIES", 432, 438], ["humans", "SPECIES", 432, 438], ["a potential recombination zone", "PROBLEM", 21, 51], ["nt", "TEST", 66, 68], ["gene recombination", "PROBLEM", 114, 132], ["Sequence analysis", "TEST", 176, 193], ["The major parental strain", "PROBLEM", 209, 234], ["a recombination event", "PROBLEM", 332, 353], ["Sequence analysis", "TEST", 371, 388], ["the VP4 geneReassortment events", "PROBLEM", 392, 423], ["calcium", "TEST", 631, 638]]], ["Protection against RV infection can be mediated by neutralizing antibodies that target epitopes on both VP4 and VP7 (Taniguchi et al., 1991) .", [["RV", "ANATOMY", 19, 21], ["RV infection", "DISEASE", 19, 31], ["RV", "ORGAN", 19, 21], ["VP4", "GENE_OR_GENE_PRODUCT", 104, 107], ["VP7", "GENE_OR_GENE_PRODUCT", 112, 115], ["neutralizing antibodies", "PROTEIN", 51, 74], ["epitopes", "PROTEIN", 87, 95], ["VP4", "PROTEIN", 104, 107], ["VP7", "PROTEIN", 112, 115], ["RV", "SPECIES", 19, 21], ["Protection", "TREATMENT", 0, 10], ["RV infection", "PROBLEM", 19, 31], ["neutralizing antibodies", "PROBLEM", 51, 74], ["target epitopes", "PROBLEM", 80, 95], ["VP4", "TEST", 104, 107], ["RV", "ANATOMY", 19, 21], ["infection", "OBSERVATION", 22, 31]]], ["The structures of the neutralizing epitopes on the VP7 protein have been identified.", [["VP7", "GENE_OR_GENE_PRODUCT", 51, 54], ["neutralizing epitopes", "PROTEIN", 22, 43], ["VP7 protein", "PROTEIN", 51, 62], ["the VP7 protein", "TEST", 47, 62], ["neutralizing", "OBSERVATION", 22, 34]]], ["The epitopes on the exposed surface of the VP7 protein are clustered into two regions: 7-1 (aa 87, 91, 94, 96, 97, 98, 99, 100, 201, 211, 213, 238 and 291) and 7-2 (aa 147, 148, 190, 217, 221, 223, 242 and 264) (Aoki et al., 2009) .", [["surface", "ANATOMY", 28, 35], ["surface", "CELLULAR_COMPONENT", 28, 35], ["VP7", "GENE_OR_GENE_PRODUCT", 43, 46], ["epitopes", "PROTEIN", 4, 12], ["VP7 protein", "PROTEIN", 43, 54], ["the VP7 protein", "TEST", 39, 54], ["aa", "TEST", 92, 94], ["aa", "TEST", 165, 167], ["VP7 protein", "ANATOMY", 43, 54]]], ["The neutralizing epitope of aa 94 to 99 was previously elucidated in the RVA VP7 protein (Mackow et al., 1988) .", [["VP7", "GENE_OR_GENE_PRODUCT", 77, 80], ["aa 94 to 99", "PROTEIN", 28, 39], ["RVA VP7 protein", "PROTEIN", 73, 88], ["The neutralizing epitope", "TEST", 0, 24]]], ["The RV surface is decorated with 60 spikes, each of which is composed of a VP4 dimer (a viral haemagglutinin) (Tihova, Dryden, Bellamy, Greenberg, & Yeager, 2001) .", [["RV surface", "ANATOMY", 4, 14], ["VP4", "GENE_OR_GENE_PRODUCT", 75, 78], ["VP4 dimer", "PROTEIN", 75, 84], ["The RV surface", "TEST", 0, 14], ["60 spikes", "PROBLEM", 33, 42], ["a VP4 dimer", "PROBLEM", 73, 84], ["a viral haemagglutinin", "TREATMENT", 86, 108], ["RV", "ANATOMY", 4, 6], ["surface", "ANATOMY_MODIFIER", 7, 14], ["decorated", "OBSERVATION_MODIFIER", 18, 27], ["60 spikes", "OBSERVATION", 33, 42]]], ["VP4 is a trimer at its base, on the surface only a dimer is exposed while the third monomer is folded away or removed (Settembre, Chen, Dormitzer, Grigorieff, & Harrison, 2011) .", [["surface", "ANATOMY", 36, 43], ["VP4", "GENE_OR_GENE_PRODUCT", 0, 3], ["surface", "CELLULAR_COMPONENT", 36, 43], ["VP4", "PROTEIN", 0, 3], ["dimer", "PROTEIN", 51, 56], ["VP4", "PROBLEM", 0, 3], ["trimer", "OBSERVATION_MODIFIER", 9, 15], ["base", "ANATOMY_MODIFIER", 23, 27], ["surface", "OBSERVATION_MODIFIER", 36, 43], ["dimer", "OBSERVATION", 51, 56], ["folded", "OBSERVATION", 95, 101]]], ["Trypsin cleavage of the RVs VP4 generates two fragments (VP8* and VP5 binds sialic acid (SA), whereas VP5* contains an integrin-binding motif and a hydrophobic region that facilitate cell membrane penetration and integrin-binding (Dowling, Denisova, LaMonica, & Mackow, 2000; Pesavento, Crawford, Estes, & Prasad, 2006) .", [["fragments", "ANATOMY", 46, 55], ["cell membrane", "ANATOMY", 183, 196], ["sialic acid", "CHEMICAL", 76, 87], ["sialic acid", "CHEMICAL", 76, 87], ["Trypsin", "GENE_OR_GENE_PRODUCT", 0, 7], ["VP4", "GENE_OR_GENE_PRODUCT", 28, 31], ["VP8", "GENE_OR_GENE_PRODUCT", 57, 60], ["VP5", "GENE_OR_GENE_PRODUCT", 66, 69], ["sialic acid", "SIMPLE_CHEMICAL", 76, 87], ["VP5", "GENE_OR_GENE_PRODUCT", 102, 105], ["integrin", "GENE_OR_GENE_PRODUCT", 119, 127], ["cell membrane", "CELLULAR_COMPONENT", 183, 196], ["RVs VP4", "PROTEIN", 24, 31], ["VP8", "PROTEIN", 57, 60], ["VP5", "PROTEIN", 66, 69], ["VP5", "PROTEIN", 102, 105], ["integrin-binding motif", "PROTEIN", 119, 141], ["hydrophobic region", "PROTEIN", 148, 166], ["Trypsin cleavage", "TREATMENT", 0, 16], ["two fragments", "PROBLEM", 42, 55], ["VP8", "TEST", 57, 60], ["VP5 binds sialic acid", "TEST", 66, 87], ["an integrin-binding motif", "TREATMENT", 116, 141], ["a hydrophobic region", "PROBLEM", 146, 166], ["cell membrane penetration", "PROBLEM", 183, 208], ["two", "OBSERVATION_MODIFIER", 42, 45], ["fragments", "OBSERVATION", 46, 55], ["sialic", "ANATOMY_MODIFIER", 76, 82], ["cell membrane penetration", "OBSERVATION", 183, 208]]], ["VP8* of RVs mediates cell attachment by interacting with histo-blood group antigens (HBGAs) (Hu et al., 2012; Sun et al., 2016) .", [["cell", "ANATOMY", 21, 25], ["blood", "ANATOMY", 63, 68], ["VP8", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 21, 25], ["histo-blood group antigens", "GENE_OR_GENE_PRODUCT", 57, 83], ["VP8", "PROTEIN", 0, 3], ["histo-blood group antigens", "PROTEIN", 57, 83], ["HBGAs", "PROTEIN", 85, 90], ["HBGAs", "TEST", 85, 90], ["cell attachment", "OBSERVATION", 21, 36]]], ["The structures of the neutralizing epitopes on the VP5* and VP8* proteins have been identified.", [["VP5", "GENE_OR_GENE_PRODUCT", 51, 54], ["VP8", "GENE_OR_GENE_PRODUCT", 60, 63], ["neutralizing epitopes", "PROTEIN", 22, 43], ["VP5* and VP8* proteins", "PROTEIN", 51, 73], ["the VP5* and VP8* proteins", "TEST", 47, 73], ["neutralizing", "OBSERVATION", 22, 34]]], ["The epitopes on VP8* are clustered into four regions (8-1, 8-2, 8-3 and 8-4) (Dormitzer et al., 2004; Naseer et al., 2017) .", [["VP8", "GENE_OR_GENE_PRODUCT", 16, 19], ["epitopes", "PROTEIN", 4, 12], ["VP8", "PROTEIN", 16, 19], ["four", "ANATOMY_MODIFIER", 40, 44], ["regions", "ANATOMY_MODIFIER", 45, 52]]], ["Figure 3 shows minimal dif- Recombination has been shown to be an important means of viral evolution (Simmonds, 2006) .", [["minimal dif", "PROBLEM", 15, 26], ["minimal", "OBSERVATION_MODIFIER", 15, 22], ["viral evolution", "OBSERVATION", 85, 100]]], ["Recombination is considered a potential mechanism for antigenic diversity and a possible mechanism to escape from vaccine-imposed selective pressure but may not contribute to the long-term evolution of RVAs (Woods, 2015) .| e323Several reports have identified sequences with recombination in VP4 (Esona et al., 2017) , VP6 (Jere, Mlera, Page, van Dijk, & O'Neill, 2011; Marthaler et al., 2014) , VP7 (Martinez-Laso et al., 2009; Parra, Bok, Martinez, & Gomez, 2004; Phan et al., 2007a Phan et al., , 2007b Suzuki, Gojobori, & Nakagomi, 1998) , NSP1 (Esona et al., 2017) , NSP2 (Jere et al., 2011) , NSP3 and NSP4 (Donker, Boniface, & Kirkwood, 2011) (Table S4) .", [["NSP4", "GENE_OR_GENE_PRODUCT", 608, 612], ["VP4", "DNA", 292, 295], ["antigenic diversity", "PROBLEM", 54, 73], ["vaccine", "TREATMENT", 114, 121], ["VP6 (Jere", "TREATMENT", 319, 328], ["VP7", "TEST", 396, 399], ["Martinez", "TEST", 401, 409], ["Parra", "TEST", 429, 434], ["Bok", "TEST", 436, 439], ["Martinez", "TEST", 441, 449], ["Gojobori", "TEST", 514, 522], ["NSP1", "TEST", 544, 548], ["NSP2", "TEST", 572, 576], ["NSP3", "PROBLEM", 599, 603], ["NSP4", "PROBLEM", 608, 612]]], ["Intramolecular recombination could contribute to the development of new RVs phenotypes (Ramig, 1997 (Nair et al., 2017) .", [["Intramolecular recombination", "PROBLEM", 0, 28], ["new RVs phenotypes", "PROBLEM", 68, 86], ["new", "OBSERVATION_MODIFIER", 68, 71], ["RVs", "OBSERVATION", 72, 75]]], ["More information is needed to understand the diversity of field strains and to develop an effective polyvalent vaccine as a possible means of PoRV control in China.| e323VP8* is a cleaved product of the VP4 spike protein that contains a shallow groove domain responsible for binding to SAs on cellular glycans (Desselberger, 2014; Lopez & Arias, 2004) or interacting with HBGA for virus particle attachment Sun et al., 2016) .", [["cellular", "ANATOMY", 293, 301], ["PoRV", "GENE_OR_GENE_PRODUCT", 142, 146], ["VP4 spike protein", "GENE_OR_GENE_PRODUCT", 203, 220], ["SAs", "SIMPLE_CHEMICAL", 286, 289], ["cellular", "CELL", 293, 301], ["HBGA", "GENE_OR_GENE_PRODUCT", 372, 376], ["VP4 spike protein", "PROTEIN", 203, 220], ["shallow groove domain", "PROTEIN", 237, 258], ["HBGA", "PROTEIN", 372, 376], ["an effective polyvalent vaccine", "TREATMENT", 87, 118], ["PoRV control", "TREATMENT", 142, 154], ["the VP4 spike protein", "PROBLEM", 199, 220], ["a shallow groove domain", "PROBLEM", 235, 258], ["shallow groove", "OBSERVATION_MODIFIER", 237, 251]]], ["In this study, we reported a six-nt gain in the VP8* protein that resulted in a special structural change, which might affect attachment of the VP8* protein to host cells through interactions with SAs or| e323HBGAs.", [["cells", "ANATOMY", 165, 170], ["VP8", "GENE_OR_GENE_PRODUCT", 48, 51], ["VP8", "GENE_OR_GENE_PRODUCT", 144, 147], ["host cells", "CELL", 160, 170], ["VP8* protein", "PROTEIN", 48, 60], ["VP8* protein", "PROTEIN", 144, 156], ["host cells", "CELL_TYPE", 160, 170], ["e323HBGAs", "PROTEIN", 205, 214], ["this study", "TEST", 3, 13], ["a special structural change", "PROBLEM", 78, 105]]], ["This possibility will be a major focus of our future study.Concurrent infection of a single host cell line by different RVsstrains is a prerequisite for the occurrence of recombination events in nature (Esona et al., 2017 | e325 (Esona et al., 2017) .", [["cell line", "ANATOMY", 97, 106], ["infection", "DISEASE", 70, 79], ["cell line", "CELL", 97, 106], ["host cell line", "CELL_LINE", 92, 106], ["our future study", "TEST", 42, 58], ["Concurrent infection", "PROBLEM", 59, 79], ["a single host cell line", "TREATMENT", 83, 106], ["recombination events", "PROBLEM", 171, 191], ["infection", "OBSERVATION", 70, 79], ["host cell line", "OBSERVATION", 92, 106]]], ["Rotavirus recombination most likely occurs during the genome transcription stage in the viral life cycle (Kojima, Taniguchi, Urasawa, & Urasawa, 1996) .", [["Rotavirus", "ORGANISM", 0, 9], ["Rotavirus recombination", "PROBLEM", 0, 23], ["most likely", "UNCERTAINTY", 24, 35]]]], "54df4dbf91c36ac6a783c34cf23329cc19ad95da": [["-Mahatma GandhiIn a few months, the COVID-19 pandemic has rapidly spread from China, and as it moved west, health-care systems worldwide have been strained facing the worst health crisis of the century.", [["the COVID", "TEST", 32, 41], ["pandemic", "PROBLEM", 45, 53]]], ["COVID-19 has made our ground tremble.", [["COVID-19", "DNA", 0, 8], ["COVID", "TEST", 0, 5]]], ["At the frontline, health-care professionals are exposed not only to the challenge of managing the surge of critically ill patients but also to growing societal pressure from the public and from the media to cure this new viral disease as cases mount.", [["critically ill", "DISEASE", 107, 121], ["viral disease", "DISEASE", 221, 234], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["the media", "TREATMENT", 194, 203], ["this new viral disease", "PROBLEM", 212, 234], ["viral disease", "OBSERVATION", 221, 234]]], ["The mixture of these factors, coupled with economic and political factors, puts at risk the fundamental principle of medicine built on science for patient well-being, and the loss of this may increase the risk of harm to our patients.", [["patient", "ORGANISM", 147, 154], ["patients", "ORGANISM", 225, 233], ["patient", "SPECIES", 147, 154], ["patients", "SPECIES", 225, 233], ["these factors", "PROBLEM", 15, 28], ["economic and political factors", "PROBLEM", 43, 73]]], ["This is particularly true in countries where social pressures may be acute.Eminence-Based Medicine and Unintended ConsequencesWe doctors are humans and, as such, are influenced by our environment (what we hear, read or feel).", [["humans", "ORGANISM", 141, 147], ["humans", "SPECIES", 141, 147], ["humans", "SPECIES", 141, 147], ["acute", "PROBLEM", 69, 74], ["may be", "UNCERTAINTY", 62, 68], ["acute", "OBSERVATION_MODIFIER", 69, 74]]], ["As infections grew dramatically in western countries in early March 2020, some key opinion leaders and prominent researchers developed a series of observations and recommendations that significantly influenced clinicians taking care of the first COVID-19 cases.", [["infections", "DISEASE", 3, 13], ["infections", "PROBLEM", 3, 13], ["dramatically", "OBSERVATION_MODIFIER", 19, 31]]], ["1 Although, to date, no drug has shown to be beneficial for COVID-19 in randomised trials, many advocated for the off-label prescription of many pharmacological treatments, mostly based on anecdotes, small observational studies and biological plausibility: a 'this makes sense' or 'my way to do it' approach.Eminence-Based Medicine and Unintended ConsequencesThis sudden change of practice may have had unintended consequences.", [["COVID", "TEST", 60, 65], ["many pharmacological treatments", "TREATMENT", 140, 171], ["small observational studies", "TEST", 200, 227], ["unintended consequences", "PROBLEM", 403, 426]]], ["When a critically ill patient is admitted to an intensive care unit (ICU), the resulting outcome when discharged is the result of a complex interplay between the insult, the host and us the physicians.", [["critically ill", "DISEASE", 7, 21], ["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29]]], ["Every medical intervention carries the risk of iatrogenic consequences, and they must always be balanced to give our patient a clear benefit.", [["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124], ["Every medical intervention", "TREATMENT", 0, 26], ["iatrogenic consequences", "PROBLEM", 47, 70], ["iatrogenic", "OBSERVATION", 47, 57]]], ["In the first weeks of the SARS-CoV-2 outbreak in Europe and the western world, we did not always adhere to these principles.", [["SARS", "DISEASE", 26, 30], ["SARS-CoV", "SPECIES", 26, 34]]], ["Non-tested therapies are harmful until proven otherwise.", [["Non-tested therapies", "TREATMENT", 0, 20]]], ["The risk application of the particular therapy is uncertain, so we are essentially forced to gamble on the balance between harm and benefit.", [["the particular therapy", "TREATMENT", 24, 46]]], ["Phrases like 'intubation must be prioritized' or 'patients should be left quiet', 1,2 added to the fear of aerosolisation and of non-invasive respiratory support, may have contributed to the crumble of critical care response capacity of many countries and the shortage of mechanical ventilators, beds and common medications.", [["respiratory", "ANATOMY", 142, 153], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["'intubation", "TREATMENT", 13, 24], ["non-invasive respiratory support", "TREATMENT", 129, 161], ["mechanical ventilators", "TREATMENT", 272, 294], ["beds", "TREATMENT", 296, 300], ["common medications", "TREATMENT", 305, 323], ["respiratory support", "OBSERVATION", 142, 161], ["mechanical ventilators", "OBSERVATION", 272, 294]]], ["The tendency towards more aggressive ICU management was mainly based on weak or absent supportive data, fuelled by a secondary pandemic of webinars, press coverage and social media spread of potential golden bullets to treat this new disease.", [["aggressive ICU management", "TREATMENT", 26, 51], ["a secondary pandemic of webinars", "TREATMENT", 115, 147], ["press coverage", "TREATMENT", 149, 163], ["potential golden bullets", "TREATMENT", 191, 215], ["this new disease", "PROBLEM", 225, 241], ["golden bullets", "OBSERVATION", 201, 215]]], ["The early approach to severe COVID-19 was in clear dissonance with the paradigm shift towards evidence-based ICU care over the last decade, with a 'less is more' approach for ventilatory management, resuscitation fluids, transfusions and other interventions.", [["COVID", "DISEASE", 29, 34], ["severe COVID", "PROBLEM", 22, 34], ["ventilatory management", "TREATMENT", 175, 197], ["resuscitation fluids", "TREATMENT", 199, 219], ["transfusions", "TREATMENT", 221, 233], ["other interventions", "TREATMENT", 238, 257], ["severe", "OBSERVATION_MODIFIER", 22, 28]]], ["3 An example is the intubation of hypoxaemic patients.", [["hypoxaemic", "DISEASE", 34, 44], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["hypoxaemic patients", "PROBLEM", 34, 53], ["hypoxaemic patients", "OBSERVATION", 34, 53]]], ["Anecdotal reports suggesting a more favourable outcome with 'early' intubation in COVID-19 led to recommendations to avoid commonly used non-invasive treatments such as continuous positive airway pressure (CPAP), high-flow nasal cannula (HFNC) or non-invasive ventilation (NIV).", [["airway", "ANATOMY", 189, 195], ["nasal", "ANATOMY", 223, 228], ["airway", "MULTI-TISSUE_STRUCTURE", 189, 195], ["'early' intubation", "TREATMENT", 60, 78], ["non-invasive treatments", "TREATMENT", 137, 160], ["continuous positive airway pressure", "TREATMENT", 169, 204], ["CPAP", "TREATMENT", 206, 210], ["high-flow nasal cannula (HFNC", "TREATMENT", 213, 242], ["non-invasive ventilation", "TREATMENT", 247, 271], ["NIV", "TREATMENT", 273, 276], ["airway pressure", "OBSERVATION", 189, 204]]], ["Not surprisingly the first figures showed that NIV was used only in 1 of 10 patients with confirmed COVID-19 infection.", [["infection", "DISEASE", 109, 118], ["NIV", "CHEMICAL", 47, 50], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["NIV", "TREATMENT", 47, 50], ["COVID-19 infection", "PROBLEM", 100, 118], ["infection", "OBSERVATION", 109, 118]]], ["4 Early intubation of a patient with known or suspected COVID-19 with respiratory distress likely resulted in intubating patients who would have otherwise improved on CPAP or NIV.", [["respiratory", "ANATOMY", 70, 81], ["respiratory distress", "DISEASE", 70, 90], ["CPAP", "CHEMICAL", 167, 171], ["NIV", "CHEMICAL", 175, 178], ["patient", "ORGANISM", 24, 31], ["patients", "ORGANISM", 121, 129], ["patient", "SPECIES", 24, 31], ["patients", "SPECIES", 121, 129], ["Early intubation", "TREATMENT", 2, 18], ["COVID", "TEST", 56, 61], ["respiratory distress", "PROBLEM", 70, 90], ["CPAP", "TREATMENT", 167, 171], ["NIV", "TREATMENT", 175, 178], ["respiratory", "ANATOMY", 70, 81], ["distress", "OBSERVATION", 82, 90], ["improved", "OBSERVATION_MODIFIER", 155, 163]]], ["In addition, early intubation may also have denied life-saving treatment for other patients, especially in resource-limited settings.", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["early intubation", "TREATMENT", 13, 29], ["saving treatment", "TREATMENT", 56, 72]]], ["The iatrogenic costs, including ventilator associated pneumonia (VAP), ventilator-induced lung injury (VILI), hemodynamic disturbances, as well as the adverse effects of sedation and immobilisation, could have been avoided in some cases.Eminence-Based Medicine and Unintended ConsequencesThe walk away from evidence-based medicine is not novel.", [["lung", "ANATOMY", 90, 94], ["pneumonia", "DISEASE", 54, 63], ["VAP", "DISEASE", 65, 68], ["ventilator-induced lung injury", "DISEASE", 71, 101], ["VILI", "DISEASE", 103, 107], ["lung", "ORGAN", 90, 94], ["The iatrogenic costs", "PROBLEM", 0, 20], ["ventilator associated pneumonia", "PROBLEM", 32, 63], ["VAP", "PROBLEM", 65, 68], ["ventilator", "TREATMENT", 71, 81], ["lung injury", "PROBLEM", 90, 101], ["hemodynamic disturbances", "PROBLEM", 110, 134], ["sedation", "TREATMENT", 170, 178], ["immobilisation", "TREATMENT", 183, 197], ["iatrogenic", "OBSERVATION_MODIFIER", 4, 14], ["costs", "OBSERVATION", 15, 20], ["pneumonia", "OBSERVATION", 54, 63], ["lung", "ANATOMY", 90, 94], ["injury", "OBSERVATION", 95, 101], ["VILI", "OBSERVATION", 103, 107], ["hemodynamic disturbances", "OBSERVATION", 110, 134]]], ["In medicine, particularly critical care, history has taught us that many initially promising hypotheses, plausible mechanisms and observations failed to pass the test of randomised trials and were found to be no better than prior standards of care.", [["the test", "TEST", 158, 166], ["randomised trials", "TREATMENT", 170, 187]]], ["5 During the first 2 months of the COVID-19 pandemic, emotions and anecdotes prevailed over science, and eminence prevailed over evidence-based medicine.", [["the COVID", "TEST", 31, 40]]], ["6 In these early days of the pandemic, scarcity of data and provocative claims of benefit led to a significant change in practice.", [["a significant change in practice", "PROBLEM", 97, 129], ["significant", "OBSERVATION_MODIFIER", 99, 110], ["change", "OBSERVATION", 111, 117]]], ["This quickly changed the entire playbook of modern critical care medicine.Avoiding Iatrogenic Pandemic for ChildrenPaediatric critical care may be particularly susceptible to threats against evidence-based medicine.", [["modern critical care medicine", "TREATMENT", 44, 73], ["ChildrenPaediatric critical care", "TREATMENT", 107, 139]]], ["There are few randomised trials in critically ill children, and as a result, many of the therapies provided in a paediatric intensive care unit (PICU) are based on extrapolation from adult studies or observational clinical trials.", [["critically ill", "DISEASE", 35, 49], ["children", "ORGANISM", 50, 58], ["children", "SPECIES", 50, 58], ["adult studies", "TEST", 183, 196], ["few", "OBSERVATION_MODIFIER", 10, 13]]], ["As these changes in practice came under scrutiny, 7 paediatricians in PICUs began to ask themselves how they would prepare for critically ill children.", [["critically ill", "DISEASE", 127, 141], ["children", "ORGANISM", 142, 150], ["children", "SPECIES", 142, 150]]], ["Should we change our proven, established current practices to mimic (yet) unproven adults' perspectives?Avoiding Iatrogenic Pandemic for ChildrenViral illnesses are common in PICUs; paediatric intensivists have learned hard lessons from managing critically ill children with viral disease.", [["ChildrenViral illnesses", "DISEASE", 137, 160], ["critically ill", "DISEASE", 246, 260], ["viral disease", "DISEASE", 275, 288], ["children", "ORGANISM", 261, 269], ["children", "SPECIES", 261, 269], ["ChildrenViral illnesses", "PROBLEM", 137, 160], ["viral disease", "PROBLEM", 275, 288], ["viral disease", "OBSERVATION", 275, 288]]], ["Just a couple of decades ago, the standard treatment for respiratory failure was widespread, almost routine, intubation and mechanical ventilation.", [["respiratory", "ANATOMY", 57, 68], ["respiratory failure", "DISEASE", 57, 76], ["the standard treatment", "TREATMENT", 30, 52], ["respiratory failure", "PROBLEM", 57, 76], ["intubation", "TREATMENT", 109, 119], ["mechanical ventilation", "TREATMENT", 124, 146], ["respiratory failure", "OBSERVATION", 57, 76], ["mechanical ventilation", "OBSERVATION", 124, 146]]], ["Currently, the extended use of NIV has reduced the need for intubation, decreasing complications, nosocomial infections, residual morbidity and length of PICU stay.", [["infections", "DISEASE", 109, 119], ["NIV", "CHEMICAL", 31, 34], ["NIV", "TREATMENT", 31, 34], ["intubation", "TREATMENT", 60, 70], ["decreasing complications", "PROBLEM", 72, 96], ["nosocomial infections", "PROBLEM", 98, 119], ["residual morbidity", "PROBLEM", 121, 139], ["residual", "OBSERVATION_MODIFIER", 121, 129], ["morbidity", "OBSERVATION", 130, 139]]], ["8 It is dangerous to divert from well-established and proven therapies during this time of crisis.", [["therapies", "TREATMENT", 61, 70], ["crisis", "PROBLEM", 91, 97], ["dangerous", "OBSERVATION", 8, 17]]], ["Avoiding NIV and applying COVID-19 guidelines to COVID-19 and non-COVID-19 children out of fear is not what is right for our patients and is not consistent with medical evidence.", [["children", "ORGANISM", 75, 83], ["patients", "ORGANISM", 125, 133], ["children", "SPECIES", 75, 83], ["patients", "SPECIES", 125, 133], ["NIV", "TREATMENT", 9, 12], ["COVID", "TREATMENT", 26, 31], ["COVID", "TEST", 49, 54], ["not consistent with", "UNCERTAINTY", 141, 160]]], ["Deviating from core therapies and using unproven therapies 'just to try' could harm children.", [["children", "ORGANISM", 84, 92], ["children", "SPECIES", 84, 92], ["core therapies", "TREATMENT", 15, 29], ["unproven therapies", "TREATMENT", 40, 58]]], ["We have identified several potential causes of the detrimental effects of current pandemic to children (Fig. 1) , which include both medical and nonmedical issues, such as isolation from families.Avoiding Iatrogenic Pandemic for ChildrenWe are aware that it is in our medical nature to prefer intervention to inaction.", [["children", "ORGANISM", 94, 102], ["children", "SPECIES", 94, 102], ["intervention", "TREATMENT", 293, 305]]], ["During these challenging times, it is tempting to abandon routine care in favour of newer and more exciting therapies and clinical approaches.", [["routine care", "TREATMENT", 58, 70], ["exciting therapies", "TREATMENT", 99, 117], ["clinical approaches", "TREATMENT", 122, 141]]], ["However, we must remember that there must always be sufficient justification to administer a medication to a critically ill patient and that this justification must not be anecdotal because the first duty of medicine is 'do no harm'.", [["critically ill", "DISEASE", 109, 123], ["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["a medication", "TREATMENT", 91, 103]]], ["Even in times of crisis, Primum non nocere should prevail.Authors contributionsAC, SG and FD designed and drafted the manuscript.", [["crisis", "PROBLEM", 17, 23], ["crisis", "OBSERVATION", 17, 23]]]], "PMC2949546": [["One of the main reasons was the incomplete definition of the proteome due to the lack of comprehensive genomic information, as well as technical limitations for large scale profiling of proteins.", [["large scale profiling of proteins", "PROBLEM", 161, 194], ["main", "OBSERVATION_MODIFIER", 11, 15]]], ["During the past few decades, improved and novel technologies have emerged as powerful tools for proteomic studies including shotgun proteomics by mass spectrometry technology [1] and protein microarray technology [2].", [["proteomic studies", "TEST", 96, 113], ["shotgun proteomics", "TREATMENT", 124, 142], ["protein microarray technology", "TREATMENT", 183, 212]]], ["Mass spectrometry technology, combined with various sample preparation methods, has been used extensively in biological research such as proteome profiling [3], protein\u2013protein interaction mapping [4], [5] and identification of post-translational modification [6], [7], [8].", [["[7]", "SIMPLE_CHEMICAL", 265, 268], ["Mass spectrometry technology", "PROBLEM", 0, 28], ["various sample preparation methods", "TREATMENT", 44, 78], ["proteome profiling", "TEST", 137, 155], ["protein\u2013protein interaction mapping", "TREATMENT", 161, 196]]], ["The greatest advantage of this technology lies in its capability of high throughput protein identification and quantification.", [["greatest", "OBSERVATION_MODIFIER", 4, 12]]], ["Nevertheless, mass spectrometry still has its limitations, such as the undersampling issue (insufficient coverage of the proteome) [9], [10] as well as bias against low abundant proteins [11].", [["mass spectrometry", "PROBLEM", 14, 31], ["low abundant proteins", "PROBLEM", 165, 186], ["mass", "OBSERVATION", 14, 18]]], ["Protein microarray technology, on the other hand, does not have the above limitations for mass spectrometry owing to its particular platform.", [["Protein microarray technology", "TEST", 0, 29], ["mass spectrometry", "PROBLEM", 90, 107]]], ["Protein microarray technology [12], [13] was developed upon the completion of the genome sequence of multiple organisms, including the budding yeast Saccharomyces cerevisiae[14] and humans (Homo sapiens) [15].", [["budding yeast Saccharomyces cerevisiae", "ORGANISM", 135, 173], ["humans", "ORGANISM", 182, 188], ["Homo sapiens", "ORGANISM", 190, 202], ["yeast", "SPECIES", 143, 148], ["Saccharomyces cerevisiae", "SPECIES", 149, 173], ["humans", "SPECIES", 182, 188], ["Homo sapiens", "SPECIES", 190, 202], ["yeast", "SPECIES", 143, 148], ["Saccharomyces cerevisiae", "SPECIES", 149, 173], ["humans", "SPECIES", 182, 188], ["Homo sapiens", "SPECIES", 190, 202], ["Protein microarray technology", "TEST", 0, 29], ["multiple organisms", "PROBLEM", 101, 119], ["the budding yeast Saccharomyces cerevisiae", "TREATMENT", 131, 173], ["humans (Homo sapiens)", "TREATMENT", 182, 203], ["multiple", "OBSERVATION_MODIFIER", 101, 109], ["organisms", "OBSERVATION", 110, 119]]], ["Determination of genomic sequences leads to the annotation of known and predicted open reading frames (ORFs) in these genomes, which makes it possible to express the full or partial proteome with large-scale cloning and gene expression methods [2].IntroductionProtein microarray typically contains hundreds to thousands of proteins that are arrayed in an addressable format.", [["genomic sequences", "DNA", 17, 34], ["open reading frames", "DNA", 82, 101], ["ORFs", "DNA", 103, 107], ["genomic sequences", "PROBLEM", 17, 34], ["large-scale cloning", "TREATMENT", 196, 215], ["IntroductionProtein microarray", "TEST", 248, 278], ["hundreds", "OBSERVATION_MODIFIER", 298, 306]]], ["Protein microarrays are generally one of two types: analytical/diagnostic microarrays and functional microarrays [16], [17].", [["Protein microarrays", "TEST", 0, 19], ["diagnostic microarrays", "TEST", 63, 85], ["functional microarrays", "TEST", 90, 112]]], ["One form of analytical/diagnostic microarrays is the antibody microarray, in which specific antibodies against defined target proteins are arrayed on the surface of a support material (such as glass slides), and are used for the detection and quantification of their specific antigens [18], [19].", [["surface", "ANATOMY", 154, 161], ["surface", "CELLULAR_COMPONENT", 154, 161], ["target proteins", "PROTEIN", 119, 134], ["diagnostic microarrays", "TEST", 23, 45], ["the antibody microarray", "TEST", 49, 72], ["specific antibodies", "TEST", 83, 102], ["the detection", "TEST", 225, 238]]], ["This type of microarray has great potential for clinical diagnosis and clinical research, and its advantages and disadvantages are reviewed in [17], [20], [21].", [["[17], [20]", "SIMPLE_CHEMICAL", 143, 153], ["[21]", "SIMPLE_CHEMICAL", 155, 159]]], ["The other type of protein microarray is the functional microarray.", [["protein microarray", "OBSERVATION", 18, 36]]], ["These arrays usually contain a large number of individually expressed and purified functional, full-length proteins or peptides printed in a high-density format on support surfaces, and can represent the complete or partial proteome of a given organism [22].", [["full-length proteins", "PROTEIN", 95, 115], ["peptides", "PROBLEM", 119, 127], ["support surfaces", "TREATMENT", 164, 180], ["large", "OBSERVATION_MODIFIER", 31, 36], ["number", "OBSERVATION_MODIFIER", 37, 43], ["high-density", "OBSERVATION_MODIFIER", 141, 153]]], ["This type of protein microarray has been used in studies of protein\u2013protein, protein\u2013DNA, and protein\u2013small molecule interactions as well as protein modifications (Fig. 1) [2], [17], [23], [24], [25].", [["[17], [23]", "SIMPLE_CHEMICAL", 177, 187], ["[24]", "SIMPLE_CHEMICAL", 189, 193], ["[25]", "SIMPLE_CHEMICAL", 195, 199], ["protein microarray", "TEST", 13, 31], ["protein\u2013protein", "TEST", 60, 75], ["protein\u2013DNA", "TEST", 77, 88], ["protein\u2013small molecule interactions", "PROBLEM", 94, 129], ["protein modifications", "TEST", 141, 162]]], ["Many of these studies were done in the budding yeast S. cerevisiae, and will be discussed in detail below.", [["budding yeast S. cerevisiae", "ORGANISM", 39, 66], ["yeast", "SPECIES", 47, 52], ["S. cerevisiae", "SPECIES", 53, 66], ["yeast", "SPECIES", 47, 52], ["S. cerevisiae", "SPECIES", 53, 66], ["these studies", "TEST", 8, 21]]], ["Functional protein microarrays containing human proteins have also been widely applied in various clinical studies of cancer, autoimmune diseases and viral infections [26], [27], [28], [29], [30], [31], [32], which will not be covered here.IntroductionIn this article we will review functional protein microarray technologies in yeast.", [["cancer", "ANATOMY", 118, 124], ["cancer", "DISEASE", 118, 124], ["autoimmune diseases", "DISEASE", 126, 145], ["viral infections", "DISEASE", 150, 166], ["human", "ORGANISM", 42, 47], ["cancer", "CANCER", 118, 124], ["[27], [28], [29], [30], [31], [32]", "SIMPLE_CHEMICAL", 173, 207], ["human proteins", "PROTEIN", 42, 56], ["human", "SPECIES", 42, 47], ["yeast", "SPECIES", 329, 334], ["human", "SPECIES", 42, 47], ["yeast", "SPECIES", 329, 334], ["Functional protein microarrays", "TREATMENT", 0, 30], ["human proteins", "TREATMENT", 42, 56], ["cancer", "PROBLEM", 118, 124], ["autoimmune diseases", "PROBLEM", 126, 145], ["viral infections", "PROBLEM", 150, 166], ["functional protein microarray technologies", "TREATMENT", 283, 325], ["cancer", "OBSERVATION", 118, 124]]], ["We cover the various methods for manufacturing of protein microarray, and discuss their applications in studying protein\u2013protein, protein\u2013DNA, protein\u2013small molecule interactions, and protein post-translational modifications (phosphorylation S-nitrosylation and ubiquitination) (Fig. 1).", [["protein\u2013protein, protein\u2013DNA", "PROTEIN", 113, 141], ["manufacturing of protein microarray", "TREATMENT", 33, 68], ["studying protein\u2013protein", "TEST", 104, 128], ["protein\u2013small molecule interactions", "PROBLEM", 143, 178], ["protein post-translational modifications", "TREATMENT", 184, 224], ["phosphorylation S-nitrosylation and ubiquitination)", "TREATMENT", 226, 277]]], ["We will also discuss the advantages and limitations of this technology.Manufacture of high-density protein microarraySince our group generated the first protein microarray covering 5800 ORFs of the budding yeast S. cerevisiae[2], various methods have been developed in protein microarray production.", [["S. cerevisiae", "ORGANISM", 212, 225], ["5800 ORFs", "DNA", 181, 190], ["yeast", "SPECIES", 206, 211], ["S. cerevisiae", "SPECIES", 212, 225], ["yeast", "SPECIES", 206, 211], ["S. cerevisiae", "SPECIES", 212, 225], ["this technology", "TREATMENT", 55, 70], ["the first protein microarray", "TEST", 143, 171], ["various methods", "TREATMENT", 230, 245], ["high-density", "OBSERVATION_MODIFIER", 86, 98], ["protein microarray", "OBSERVATION", 269, 287]]], ["A diagram of the manufacture of protein microarray is shown in Fig. 2.Manufacture of high-density protein microarrayThere are different support surfaces for making protein microarray, including nanowells [33], solid surfaces (such as glass slides) [2], [34], and absorbent surfaces (such as polyacrylamide gel pads) [35].", [["polyacrylamide", "CHEMICAL", 291, 305], ["[34]", "SIMPLE_CHEMICAL", 253, 257], ["protein microarray", "TEST", 32, 50], ["different support surfaces", "TREATMENT", 126, 152], ["protein microarray", "TEST", 164, 182], ["nanowells", "TEST", 194, 203], ["glass slides", "TEST", 234, 246], ["absorbent surfaces", "TREATMENT", 263, 281], ["polyacrylamide gel pads", "TREATMENT", 291, 314], ["high-density", "OBSERVATION_MODIFIER", 85, 97]]], ["The polyacrylamide gel pad technology has not been applied extensively due to cumbersome slide preparation and inconvenient slide handling (e.g. hard to change buffers); similarly, the nanowell surface is less convenient to make and use [17], [36].", [["nanowell surface", "ANATOMY", 185, 201], ["polyacrylamide gel", "CHEMICAL", 4, 22], ["polyacrylamide", "CHEMICAL", 4, 18], ["The polyacrylamide gel pad technology", "TREATMENT", 0, 37], ["cumbersome slide preparation", "TREATMENT", 78, 106]]], ["Currently, the most popular high-density protein microarrays are manufactured on chemically modified or coated glass microscope slides (e.g. nitrocellulose or amino-silane-coated slides) using a standard contact printer [22], [25].", [["amino-silane", "CHEMICAL", 159, 171], ["nitrocellulose", "CHEMICAL", 141, 155], ["amino-silane", "CHEMICAL", 159, 171], ["amino-silane", "SIMPLE_CHEMICAL", 159, 171], ["amino-silane-coated slides", "TREATMENT", 159, 185], ["density protein microarrays", "OBSERVATION", 33, 60]]], ["This format is compatible with many commercial scanners.", [["compatible with", "UNCERTAINTY", 15, 30]]], ["It is noteworthy that, even within this format, different surface chemistries have different attributes in terms of their protein binding ability, protein function/folding and background, and one has to carefully choose the optimal surface that best fits the specific need of the experiment [21].", [["surface", "ANATOMY", 58, 65], ["surface", "ANATOMY", 232, 239], ["different surface chemistries", "PROBLEM", 48, 77]]], ["For example, stronger protein attachment, such as gold-coated glass surface [37] or reactive surfaces with bifunctional cross-linkers [2] can retain the proteins firmly on the surface with covalent cross-linking, but may decrease their activity due to steric hindrance or disruption of proper folding; however, these surfaces will allow detection methods such as Surface Plasmon Resonance or mass spectrometry to study the dynamics of biochemical reactions on these proteins [21].", [["surface", "ANATOMY", 176, 183], ["gold", "CHEMICAL", 50, 54], ["surface", "CELLULAR_COMPONENT", 176, 183], ["stronger protein attachment", "PROBLEM", 13, 40], ["gold-coated glass surface", "TEST", 50, 75], ["bifunctional cross-linkers", "TREATMENT", 107, 133], ["steric hindrance", "PROBLEM", 252, 268], ["proper folding", "PROBLEM", 286, 300], ["detection methods", "TEST", 337, 354], ["Surface Plasmon Resonance", "TREATMENT", 363, 388], ["mass spectrometry", "PROBLEM", 392, 409], ["biochemical reactions", "PROBLEM", 435, 456], ["these proteins", "TEST", 460, 474], ["reactive", "OBSERVATION_MODIFIER", 84, 92], ["surfaces", "OBSERVATION_MODIFIER", 93, 101], ["steric hindrance", "OBSERVATION", 252, 268], ["proper folding", "OBSERVATION", 286, 300]]], ["In addition, we found that amino-silane-coated glass slides provide the highest signal-to-noise ratio in kinase studies [25].Manufacture of high-density protein microarrayProteins for functional microarrays are either produced individually prior to printing [2] or produced in situ by coupling in vitro transcription and translation of DNA that is printed directly on the surface of the array (e.g. the Nucleic Acid Programmable Protein Array, NAPPA) [38].", [["surface", "ANATOMY", 372, 379], ["amino-silane", "CHEMICAL", 27, 39], ["amino-silane", "CHEMICAL", 27, 39], ["amino-silane", "SIMPLE_CHEMICAL", 27, 39], ["DNA", "CELLULAR_COMPONENT", 336, 339], ["surface", "CELLULAR_COMPONENT", 372, 379], ["amino-silane-coated glass slides", "TREATMENT", 27, 59], ["the highest signal", "TEST", 68, 86], ["kinase studies", "TEST", 105, 119], ["functional microarrays", "PROBLEM", 184, 206], ["vitro transcription", "TREATMENT", 297, 316], ["DNA", "PROBLEM", 336, 339], ["high-density", "OBSERVATION_MODIFIER", 140, 152]]], ["Our group has built two collections of full-length yeast genes cloned in expression plasmids that produce either N-terminal GST (glutathione-S-transferase) -tagged or C-terminal TAP (tandem affinity purification) -tagged fusion proteins [39], [40].", [["plasmids", "ANATOMY", 84, 92], ["glutathione", "CHEMICAL", 129, 140], ["N-", "CHEMICAL", 113, 115], ["glutathione", "CHEMICAL", 129, 140], ["S", "CHEMICAL", 141, 142], ["C-", "CHEMICAL", 167, 169], ["GST", "GENE_OR_GENE_PRODUCT", 124, 127], ["glutathione-S-transferase", "GENE_OR_GENE_PRODUCT", 129, 154], ["TAP", "GENE_OR_GENE_PRODUCT", 178, 181], ["full-length yeast genes", "DNA", 39, 62], ["expression plasmids", "DNA", 73, 92], ["N-terminal GST", "PROTEIN", 113, 127], ["glutathione-S-transferase", "PROTEIN", 129, 154], ["C-terminal TAP", "PROTEIN", 167, 181], ["tandem affinity purification) -tagged fusion proteins", "PROTEIN", 183, 236], ["yeast", "SPECIES", 51, 56], ["yeast", "SPECIES", 51, 56], ["full-length yeast genes", "TREATMENT", 39, 62], ["expression plasmids", "TREATMENT", 73, 92], ["N-terminal GST", "TEST", 113, 127], ["glutathione", "TEST", 129, 140], ["C-terminal TAP (tandem affinity purification", "TREATMENT", 167, 211], ["tagged fusion proteins", "TEST", 214, 236]]], ["The recombinant yeast proteins are expressed in individual yeast clones in a 96-well format, and purified using corresponding affinity tags (GST or TAP).", [["clones", "ANATOMY", 65, 71], ["yeast clones", "CELL", 59, 71], ["GST", "GENE_OR_GENE_PRODUCT", 141, 144], ["TAP", "GENE_OR_GENE_PRODUCT", 148, 151], ["recombinant yeast proteins", "PROTEIN", 4, 30], ["yeast clones", "CELL_LINE", 59, 71], ["GST", "PROTEIN", 141, 144], ["TAP", "PROTEIN", 148, 151], ["yeast", "SPECIES", 16, 21], ["yeast", "SPECIES", 59, 64], ["yeast", "SPECIES", 16, 21], ["yeast", "SPECIES", 59, 64], ["The recombinant yeast proteins", "PROBLEM", 0, 30], ["individual yeast clones", "PROBLEM", 48, 71], ["TAP", "TREATMENT", 148, 151], ["yeast proteins", "OBSERVATION", 16, 30], ["yeast clones", "OBSERVATION", 59, 71]]], ["The purified proteins are then arrayed with a 48-pin ESI contact printer on nitrocellulose or amino-silane-coated glass slides in an addressable, high-density format.", [["amino-silane", "CHEMICAL", 94, 106], ["nitrocellulose", "CHEMICAL", 76, 90], ["amino-silane", "CHEMICAL", 94, 106], ["amino-silane", "SIMPLE_CHEMICAL", 94, 106], ["purified proteins", "PROTEIN", 4, 21], ["nitrocellulose", "TREATMENT", 76, 90], ["amino-silane-coated glass slides", "TREATMENT", 94, 126], ["high-density", "OBSERVATION_MODIFIER", 146, 158]]], ["The detailed protein microarray manufacture protocols can be found in references [22], [25].", [["The detailed protein microarray manufacture protocols", "TREATMENT", 0, 53]]], ["In addition to the yeast functional microarrays, we have also produced an Arabidopsis array [41], [42] and a coronavirus array [26].", [["coronavirus", "ORGANISM", 109, 120], ["yeast", "SPECIES", 19, 24], ["yeast", "SPECIES", 19, 24], ["Arabidopsis", "SPECIES", 74, 85], ["the yeast functional microarrays", "PROBLEM", 15, 47], ["an Arabidopsis array", "TEST", 71, 91], ["a coronavirus array", "TEST", 107, 126]]], ["Invitrogen has produced a human protein array which currently contains more than 9000 proteins (expressed individually using Baculovirus/sf9 expression systems).", [["Invitrogen", "CHEMICAL", 0, 10], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 0, 10], ["human", "ORGANISM", 26, 31], ["Baculovirus", "ORGANISM", 125, 136], ["sf9", "GENE_OR_GENE_PRODUCT", 137, 140], ["9000 proteins", "PROTEIN", 81, 94], ["Baculovirus", "PROTEIN", 125, 136], ["sf9", "PROTEIN", 137, 140], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["a human protein array", "PROBLEM", 24, 45], ["Baculovirus/sf9 expression systems", "TREATMENT", 125, 159]]], ["With a similar method, the group led by Heng Zhu at the Johns Hopkins University also fabricated an Escherichia coli proteome chip containing 4256 proteins encoded by the K12 strain, which is the first reported prokaryotic proteome microarray [43].", [["Escherichia coli", "ORGANISM", 100, 116], ["K12", "GENE_OR_GENE_PRODUCT", 171, 174], ["4256 proteins", "PROTEIN", 142, 155], ["Escherichia coli", "SPECIES", 100, 116], ["Escherichia coli", "SPECIES", 100, 116], ["an Escherichia coli proteome chip", "TREATMENT", 97, 130], ["the K12 strain", "PROBLEM", 167, 181], ["Escherichia coli", "OBSERVATION", 100, 116]]], ["Working with Chuan He's group at the University of Chicago, the authors identified proteins with DNA damage-recognizing activity by probing this array with DNA probes containing a single base-mismatch or an abasic site, which included the known cold-shock DNA-binding protein CspE, and proteins with previous unknown functions, such as YbcN and YbaZ [43].", [["Chuan", "CHEMICAL", 13, 18], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["DNA", "CELLULAR_COMPONENT", 156, 159], ["DNA", "CELLULAR_COMPONENT", 256, 259], ["CspE", "GENE_OR_GENE_PRODUCT", 276, 280], ["YbcN", "GENE_OR_GENE_PRODUCT", 336, 340], ["YbaZ [43]", "GENE_OR_GENE_PRODUCT", 345, 354], ["DNA probes", "DNA", 156, 166], ["abasic site", "DNA", 207, 218], ["cold-shock DNA-binding protein", "PROTEIN", 245, 275], ["CspE", "PROTEIN", 276, 280], ["YbcN", "PROTEIN", 336, 340], ["YbaZ", "PROTEIN", 345, 349], ["Chuan", "SPECIES", 13, 18], ["DNA damage", "PROBLEM", 97, 107], ["DNA probes", "TREATMENT", 156, 166], ["an abasic site", "PROBLEM", 204, 218], ["the known cold-shock DNA", "PROBLEM", 235, 259], ["binding protein CspE", "PROBLEM", 260, 280], ["mismatch", "OBSERVATION", 192, 200], ["abasic site", "OBSERVATION", 207, 218], ["shock DNA", "OBSERVATION", 250, 259]]], ["In this study, the authors further validated the function of YbcN and YbaZ with biochemical analyses, and identified the potential binding partner of YbaZ with the same arrays, demonstrating great potentials of functional protein microarrays.", [["YbcN", "GENE_OR_GENE_PRODUCT", 61, 65], ["YbaZ", "GENE_OR_GENE_PRODUCT", 70, 74], ["YbaZ", "GENE_OR_GENE_PRODUCT", 150, 154], ["YbcN", "PROTEIN", 61, 65], ["YbaZ", "PROTEIN", 70, 74], ["YbaZ", "PROTEIN", 150, 154], ["this study", "TEST", 3, 13], ["YbcN", "TREATMENT", 61, 65], ["biochemical analyses", "TEST", 80, 100], ["functional protein microarrays", "TREATMENT", 211, 241]]], ["The approach of producing proteins and directly spotting them has the following advantages: first of all, in vivo expression of the proteins may help ensure their proper folding and post-translational modifications; second, the individual expression clones allow us to perform single protein quality control, if needed, over the overexpressed collections compared to the coupled transcription-translation method developed by LaBaer et al. [38].", [["the proteins", "TREATMENT", 128, 140], ["single protein quality control", "TREATMENT", 277, 307], ["the overexpressed collections", "PROBLEM", 325, 354], ["the coupled transcription", "TREATMENT", 367, 392], ["translation method", "TREATMENT", 393, 411]]], ["In contrast, the NAPPA method by LaBaer et al. excels in the simplified steps with coupled in vitro, on-slide transcription and translation of the proteins, which saves considerable time and effort [38].Manufacture of high-density protein microarrayVarious detection and data acquisition methods for protein microarray are used to meet different purposes of proteomic studies.", [["the NAPPA method", "TREATMENT", 13, 29], ["protein microarray", "TEST", 300, 318], ["proteomic studies", "TEST", 358, 375], ["high-density", "OBSERVATION_MODIFIER", 218, 230]]], ["For protein\u2013protein, protein\u2013DNA and protein\u2013small molecule interaction studies, these arrays are usually probed with fluorescently labeled molecules and the signals are then acquired with a confocal laser scanner [2], [44], [45].", [["protein\u2013DNA", "SIMPLE_CHEMICAL", 21, 32], ["fluorescently labeled molecules", "PROTEIN", 118, 149], ["protein\u2013protein", "TEST", 4, 19], ["protein\u2013DNA", "TEST", 21, 32], ["protein\u2013small molecule interaction studies", "TEST", 37, 79]]], ["These interactions can also be detected with oligonucleotide-conjugated probes followed by Rolling Circle Amplification [46].", [["oligonucleotide-conjugated probes", "TREATMENT", 45, 78]]], ["For kinase assays, isotope-labeled ATP and autoradiography film exposure are often used for data acquisition [25], [33], [47].Detection of protein\u2013protein, protein\u2013dna and protein\u2013small molecule interactions using protein microarrayBecause of its unique features, protein microarrays provide a powerful and convenient platform to study protein\u2013protein, protein\u2013nucleic acid and protein\u2013small molecule interaction networks.", [["ATP", "CHEMICAL", 35, 38], ["protein\u2013nucleic acid", "CHEMICAL", 353, 373], ["ATP", "CHEMICAL", 35, 38], ["ATP", "SIMPLE_CHEMICAL", 35, 38], ["protein\u2013dna", "GENE_OR_GENE_PRODUCT", 156, 167], ["protein\u2013nucleic acid", "SIMPLE_CHEMICAL", 353, 373], ["protein\u2013protein, protein\u2013dna and protein\u2013small molecule", "PROTEIN", 139, 194], ["protein\u2013protein, protein\u2013nucleic acid and protein\u2013small molecule interaction networks", "PROTEIN", 336, 421], ["kinase assays", "TEST", 4, 17], ["isotope-labeled ATP", "TEST", 19, 38], ["autoradiography film exposure", "TEST", 43, 72], ["Detection", "TEST", 126, 135], ["protein\u2013protein", "TEST", 139, 154], ["protein\u2013dna", "TEST", 156, 167], ["protein\u2013small molecule interactions", "PROBLEM", 172, 207], ["protein microarrays", "TEST", 264, 283], ["study protein\u2013protein", "TEST", 330, 351], ["protein\u2013nucleic acid", "TREATMENT", 353, 373], ["protein\u2013small molecule interaction networks", "PROBLEM", 378, 421]]], ["Unlike DNA and RNA, whose functional information depends mainly on the sequence of individual molecules (with the exception of ribozymes), the function and proper regulation of proteins often requires their 3-dimensional conformation and post-translational modifications.", [["DNA", "CELLULAR_COMPONENT", 7, 10], ["Unlike DNA and RNA", "PROBLEM", 0, 18], ["ribozymes", "TREATMENT", 127, 136], ["post-translational modifications", "TREATMENT", 238, 270]]], ["Moreover, the function of proteins also depends heavily on their binding partners in the functional complexes.", [["functional complexes", "PROTEIN", 89, 109]]], ["Therefore, to completely understand the function of a given protein, it is critical to know the information on its interaction to various molecular species in the living cells, whether they are other proteins, nucleic acids, and small molecules.Detection of protein\u2013protein, protein\u2013dna and protein\u2013small molecule interactions using protein microarrayMuch of the potential protein\u2013protein interaction information in yeast was obtained by yeast two-hybrid approaches [48], [49], which is very labor-intensive.", [["cells", "ANATOMY", 170, 175], ["nucleic acids", "CHEMICAL", 210, 223], ["cells", "CELL", 170, 175], ["nucleic acids", "SIMPLE_CHEMICAL", 210, 223], ["protein\u2013dna", "GENE_OR_GENE_PRODUCT", 275, 286], ["living cells", "CELL_TYPE", 163, 175], ["protein\u2013dna", "PROTEIN", 275, 286], ["yeast", "SPECIES", 416, 421], ["yeast", "SPECIES", 438, 443], ["yeast", "SPECIES", 416, 421], ["yeast", "SPECIES", 438, 443], ["nucleic acids", "TEST", 210, 223], ["small molecules", "PROBLEM", 229, 244], ["Detection", "TEST", 245, 254], ["protein\u2013protein", "TEST", 258, 273], ["protein\u2013dna", "TEST", 275, 286], ["protein\u2013small molecule interactions", "PROBLEM", 291, 326], ["protein microarrayMuch", "TEST", 333, 355], ["very labor", "PROBLEM", 487, 497], ["small molecules", "OBSERVATION", 229, 244], ["very", "OBSERVATION_MODIFIER", 487, 491], ["labor", "OBSERVATION", 492, 497]]], ["Currently the most comprehensive protein\u2013protein binary interaction data in S. cerevisiae were obtained by Yu et al. [50], by performing high-throughput yeast two-hybrid screening with 3917 bait proteins and 5246 prey proteins, which yielded 1809 interactions among 1278 proteins.", [["S. cerevisiae", "ORGANISM", 76, 89], ["3917 bait proteins", "PROTEIN", 185, 203], ["5246 prey proteins", "PROTEIN", 208, 226], ["1278 proteins", "PROTEIN", 266, 279], ["S. cerevisiae", "SPECIES", 76, 89], ["yeast", "SPECIES", 153, 158], ["S. cerevisiae", "SPECIES", 76, 89], ["hybrid screening", "TEST", 163, 179], ["bait proteins", "TEST", 190, 203], ["prey proteins", "TEST", 213, 226]]], ["Ninety-four randomly chosen interactions were validated with a precision rate of 94\u2013100% in this study.", [["a precision rate", "TEST", 61, 77], ["this study", "TEST", 92, 102]]], ["In addition, a high quality binary protein interaction map was generated in combination with other available data sets including the \u201cUetz-screen\u201d by Uetz et al. [49], the \u201cIto-score\u201d by Ito et al. [51], and high-throughput affinity purification/mass spectrometry data sets by Gavin et al. [4] and Krogan et al. [5].Detection of protein\u2013protein, protein\u2013dna and protein\u2013small molecule interactions using protein microarrayProtein microarray has many advantages over the yeast two-hybrid method in studying protein interactions.", [["protein\u2013dna", "GENE_OR_GENE_PRODUCT", 346, 357], ["yeast", "SPECIES", 470, 475], ["yeast", "SPECIES", 470, 475], ["a high quality binary protein interaction map", "PROBLEM", 13, 58], ["et al.", "TEST", 191, 197], ["mass spectrometry data sets", "PROBLEM", 246, 273], ["Detection", "TEST", 316, 325], ["protein\u2013protein", "TEST", 329, 344], ["protein\u2013dna", "TEST", 346, 357], ["protein\u2013small molecule interactions", "PROBLEM", 362, 397], ["protein microarray", "TEST", 404, 422], ["Protein microarray", "TEST", 422, 440]]], ["First, once made, its in vitro nature does not require yeast culture, transformation and mating, which greatly saves time and effort.", [["yeast", "SPECIES", 55, 60], ["yeast", "SPECIES", 55, 60], ["yeast culture", "TEST", 55, 68]]], ["Second, it uses fluorescently labeled probes instead of reporter genes, therefore the interaction signal can be readily quantified with a laser scanner in a matter of minutes, and the relative fluorescence intensity can also reflect the binding strength of the two interacting proteins.", [["reporter genes", "DNA", 56, 70], ["interacting proteins", "PROTEIN", 265, 285], ["a laser scanner", "TREATMENT", 136, 151], ["the relative fluorescence intensity", "PROBLEM", 180, 215]]], ["Moreover, protein microarray also allows many types of molecules to be used as probes (e.g. DNA and small molecules) besides proteins or peptides as compared with the yeast two-hybrid method which only allows detection of protein\u2013protein interactions.Detection of protein\u2013protein, protein\u2013dna and protein\u2013small molecule interactions using protein microarraySince its inception, our group has long been interested in pursuing protein\u2013protein and protein\u2013small molecule interaction networks [2].", [["DNA", "CELLULAR_COMPONENT", 92, 95], ["protein\u2013dna", "GENE_OR_GENE_PRODUCT", 281, 292], ["protein\u2013protein, protein\u2013dna and protein\u2013small molecule", "PROTEIN", 264, 319], ["yeast", "SPECIES", 167, 172], ["yeast", "SPECIES", 167, 172], ["protein microarray", "TEST", 10, 28], ["many types of molecules", "PROBLEM", 41, 64], ["probes (e.g. DNA and small molecules", "PROBLEM", 79, 115], ["proteins or peptides", "PROBLEM", 125, 145], ["protein\u2013protein interactions", "PROBLEM", 222, 250], ["Detection", "TEST", 251, 260], ["protein\u2013protein", "TEST", 264, 279], ["protein\u2013dna", "TEST", 281, 292], ["protein\u2013small molecule interactions", "PROBLEM", 297, 332], ["protein microarraySince", "TREATMENT", 339, 362], ["protein\u2013protein", "TREATMENT", 425, 440]]], ["We obtained the binding profile of calmodulin by probing the array with biotinylated calmodulin and Cy3-labeled streptavidin.", [["Cy3", "CHEMICAL", 100, 103], ["calmodulin", "GENE_OR_GENE_PRODUCT", 35, 45], ["calmodulin", "GENE_OR_GENE_PRODUCT", 85, 95], ["Cy3", "SIMPLE_CHEMICAL", 100, 103], ["streptavidin", "GENE_OR_GENE_PRODUCT", 112, 124], ["calmodulin", "PROTEIN", 35, 45], ["calmodulin", "PROTEIN", 85, 95], ["Cy3-labeled streptavidin", "PROTEIN", 100, 124], ["biotinylated calmodulin", "TREATMENT", 72, 95], ["Cy3-labeled streptavidin", "TREATMENT", 100, 124]]], ["Calmodulin is an important calcium binding protein which is highly conserved between species and participates in the regulation of many signaling pathways [52].", [["calcium", "CHEMICAL", 27, 34], ["calcium", "CHEMICAL", 27, 34], ["Calmodulin", "GENE_OR_GENE_PRODUCT", 0, 10], ["calcium", "SIMPLE_CHEMICAL", 27, 34], ["Calmodulin", "PROTEIN", 0, 10], ["calcium binding protein", "PROTEIN", 27, 50], ["Calmodulin", "TREATMENT", 0, 10], ["an important calcium binding protein", "PROBLEM", 14, 50]]], ["With this high throughput method, we identified 33 previously unknown potential binding partners of calmodulin, as well as a novel binding-motif, (I/L)QXXK(K/X)GB for this protein (Fig. 2 in ref.", [["calmodulin", "GENE_OR_GENE_PRODUCT", 100, 110], ["K/X)GB", "GENE_OR_GENE_PRODUCT", 156, 162], ["calmodulin", "PROTEIN", 100, 110], ["novel binding-motif", "PROTEIN", 125, 144], ["Fig. 2", "PROTEIN", 181, 187], ["this protein", "PROBLEM", 167, 179]]], ["Meanwhile, to test the possibility of detecting protein\u2013small molecule interactions, we also probed these arrays with phosphoinositide (PI), a well known secondary messenger lipid.", [["phosphoinositide", "CHEMICAL", 118, 134], ["phosphoinositide", "CHEMICAL", 118, 134], ["phosphoinositide", "SIMPLE_CHEMICAL", 118, 134], ["PI", "SIMPLE_CHEMICAL", 136, 138], ["lipid", "SIMPLE_CHEMICAL", 174, 179], ["protein\u2013small molecule interactions", "PROBLEM", 48, 83], ["phosphoinositide (PI)", "TREATMENT", 118, 139], ["molecule interactions", "OBSERVATION", 62, 83], ["secondary messenger lipid", "OBSERVATION", 154, 179]]], ["We identified 150 novel lipid-binding proteins, which include membrane-associated proteins as well as proteins involved in glucose metabolism [2].", [["membrane", "ANATOMY", 62, 70], ["glucose", "CHEMICAL", 123, 130], ["glucose", "CHEMICAL", 123, 130], ["lipid-binding proteins", "GENE_OR_GENE_PRODUCT", 24, 46], ["membrane", "CELLULAR_COMPONENT", 62, 70], ["glucose", "SIMPLE_CHEMICAL", 123, 130], ["lipid-binding proteins", "PROTEIN", 24, 46], ["membrane-associated proteins", "PROTEIN", 62, 90], ["novel lipid-binding proteins", "TEST", 18, 46], ["membrane-associated proteins", "PROBLEM", 62, 90]]], ["Our study was the first to show the capability of protein microarray technology to pursue protein\u2013protein and protein\u2013small molecule interactions.Detection of protein\u2013protein, protein\u2013dna and protein\u2013small molecule interactions using protein microarraySince its first debut a decade ago, protein microarray technology has been used to discover protein interacting partners/networks in a wide range of applications.", [["protein\u2013dna", "GENE_OR_GENE_PRODUCT", 176, 187], ["protein interacting partners", "PROTEIN", 344, 372], ["Our study", "TEST", 0, 9], ["protein microarray technology", "TREATMENT", 50, 79], ["protein\u2013protein", "TREATMENT", 90, 105], ["protein\u2013small molecule interactions", "PROBLEM", 110, 145], ["Detection", "TEST", 146, 155], ["protein\u2013protein", "TEST", 159, 174], ["protein\u2013dna", "TEST", 176, 187], ["protein\u2013small molecule interactions", "PROBLEM", 192, 227], ["protein microarray", "TEST", 234, 252], ["protein microarray technology", "TEST", 288, 317], ["protein\u2013small molecule interactions", "OBSERVATION", 110, 145]]], ["For detecting protein\u2013protein interactions, Hesselberth et al. identified interacting proteins of the WW domain in S. cerevisiae[53].", [["S. cerevisiae", "ORGANISM", 115, 128], ["interacting proteins", "PROTEIN", 74, 94], ["WW domain", "PROTEIN", 102, 111], ["S. cerevisiae", "SPECIES", 115, 128], ["S. cerevisiae", "SPECIES", 115, 128]]], ["The WW domain is a highly conserved domain in many organisms including yeast and human.", [["human", "ORGANISM", 81, 86], ["WW domain", "PROTEIN", 4, 13], ["yeast", "SPECIES", 71, 76], ["human", "SPECIES", 81, 86], ["yeast", "SPECIES", 71, 76], ["human", "SPECIES", 81, 86], ["The WW domain", "PROBLEM", 0, 13], ["yeast", "PROBLEM", 71, 76]]], ["Proteins containing these domains are involved in many cellular processes including cell cycle regulation, targeted protein degradation and transcription activation [54], [55], [56].", [["cellular", "ANATOMY", 55, 63], ["cell", "ANATOMY", 84, 88], ["cellular", "CELL", 55, 63], ["cell", "CELL", 84, 88], ["Proteins containing these domains", "PROBLEM", 0, 33], ["cell cycle regulation", "TEST", 84, 105], ["targeted protein degradation", "PROBLEM", 107, 135], ["transcription activation", "TEST", 140, 164], ["cellular processes", "OBSERVATION", 55, 73], ["cell cycle", "OBSERVATION", 84, 94]]], ["There are 10 WW domain-containing proteins (with 13 WW domains) in S. cerevisiae, including Prp40 which is involved in mRNA splicing, the ubiquitin ligases Rsp5 and SSm4, the histone methyltransferase Set2, the peptidyl-prolyl isomerase Ess1, and proteins with still unknown functions such as YPR152C, Wwm1, Aus1, Vid30 and Alg9 [53].", [["prolyl", "CHEMICAL", 220, 226], ["S. cerevisiae", "ORGANISM", 67, 80], ["Prp40", "GENE_OR_GENE_PRODUCT", 92, 97], ["Rsp5", "GENE_OR_GENE_PRODUCT", 156, 160], ["SSm4", "GENE_OR_GENE_PRODUCT", 165, 169], ["histone methyltransferase", "GENE_OR_GENE_PRODUCT", 175, 200], ["Set2", "GENE_OR_GENE_PRODUCT", 201, 205], ["peptidyl-prolyl isomerase", "GENE_OR_GENE_PRODUCT", 211, 236], ["Ess1", "GENE_OR_GENE_PRODUCT", 237, 241], ["YPR152C", "GENE_OR_GENE_PRODUCT", 293, 300], ["Wwm1", "GENE_OR_GENE_PRODUCT", 302, 306], ["Aus1", "GENE_OR_GENE_PRODUCT", 308, 312], ["Vid30", "GENE_OR_GENE_PRODUCT", 314, 319], ["Alg9 [53]", "GENE_OR_GENE_PRODUCT", 324, 333], ["WW domain-containing proteins", "PROTEIN", 13, 42], ["13 WW domains", "PROTEIN", 49, 62], ["Prp40", "PROTEIN", 92, 97], ["ubiquitin ligases", "PROTEIN", 138, 155], ["Rsp5", "PROTEIN", 156, 160], ["SSm4", "PROTEIN", 165, 169], ["histone methyltransferase", "PROTEIN", 175, 200], ["Set2", "PROTEIN", 201, 205], ["peptidyl-prolyl isomerase", "PROTEIN", 211, 236], ["Ess1", "PROTEIN", 237, 241], ["YPR152C", "PROTEIN", 293, 300], ["Wwm1", "PROTEIN", 302, 306], ["Aus1", "PROTEIN", 308, 312], ["Vid30", "PROTEIN", 314, 319], ["Alg9", "PROTEIN", 324, 328], ["S. cerevisiae", "SPECIES", 67, 80], ["S. cerevisiae", "SPECIES", 67, 80], ["Prp40", "TREATMENT", 92, 97], ["the ubiquitin ligases Rsp5", "TEST", 134, 160], ["SSm4", "TEST", 165, 169], ["the histone methyltransferase", "TEST", 171, 200], ["the peptidyl-prolyl isomerase Ess1", "TEST", 207, 241], ["Aus1", "TEST", 308, 312], ["Vid30", "TEST", 314, 319], ["Alg9", "TEST", 324, 328]]], ["Hesselberth et al. determined the binding partners of 12 of the 13 WW domains by probing them on the yeast protein arrays, and identified 587 high-confidence interactions with 207 proteins [53].", [["13 WW domains", "PROTEIN", 64, 77], ["207 proteins", "PROTEIN", 176, 188], ["yeast", "SPECIES", 101, 106], ["yeast", "SPECIES", 101, 106], ["the yeast protein arrays", "TEST", 97, 121]]], ["These WW-domain interaction proteins are enriched in cofactor metabolism, peroxisome localization, and ER localization with Gene Ontology annotation classifications, suggesting their potential functions.", [["peroxisome", "CELLULAR_COMPONENT", 74, 84], ["ER", "GENE_OR_GENE_PRODUCT", 103, 105], ["WW-domain interaction proteins", "PROTEIN", 6, 36], ["ER", "PROTEIN", 103, 105], ["These WW", "TEST", 0, 8], ["domain interaction proteins", "PROBLEM", 9, 36], ["peroxisome localization", "TEST", 74, 97], ["cofactor metabolism", "OBSERVATION", 53, 72]]], ["They compared their protein microarray findings with yeast two-hybrid and affinity-purification/mass spectrometry data available at that time and identified 19 unreported interacting partners.", [["yeast", "SPECIES", 53, 58], ["yeast", "SPECIES", 53, 58], ["yeast", "TEST", 53, 58], ["purification/mass spectrometry data", "TEST", 83, 118]]], ["Interestingly they also found that some WW-domain containing proteins, such as Rsp5, Alg9, Wwm1 and Ssm4 also have conserved WW-domain binding motifs, which suggested possible multimerization between these proteins.", [["Rsp5", "GENE_OR_GENE_PRODUCT", 79, 83], ["Alg9", "GENE_OR_GENE_PRODUCT", 85, 89], ["Wwm1", "GENE_OR_GENE_PRODUCT", 91, 95], ["Ssm4", "GENE_OR_GENE_PRODUCT", 100, 104], ["WW-domain containing proteins", "PROTEIN", 40, 69], ["Rsp5", "PROTEIN", 79, 83], ["Alg9", "PROTEIN", 85, 89], ["Wwm1", "PROTEIN", 91, 95], ["Ssm4", "PROTEIN", 100, 104], ["WW-domain binding motifs", "PROTEIN", 125, 149], ["some WW-domain containing proteins", "PROBLEM", 35, 69], ["Rsp5", "TEST", 79, 83], ["domain binding motifs", "PROBLEM", 128, 149], ["multimerization between these proteins", "PROBLEM", 176, 214], ["possible", "UNCERTAINTY", 167, 175], ["multimerization", "OBSERVATION", 176, 191]]], ["Using a similar approach, Galindo et al. also identified 4 binding partners for the Aeromonas hydrophila cytotoxic enterotoxin Act in yeast, one of which was the vesicle tethering protein Vsp52, indicating that Act might mediate its function through interfering with vesicle transport of the host cells [57].", [["vesicle", "ANATOMY", 162, 169], ["vesicle", "ANATOMY", 267, 274], ["cells", "ANATOMY", 297, 302], ["Aeromonas hydrophila", "ORGANISM", 84, 104], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 115, 126], ["vesicle", "CELLULAR_COMPONENT", 162, 169], ["Vsp52", "GENE_OR_GENE_PRODUCT", 188, 193], ["vesicle", "CELLULAR_COMPONENT", 267, 274], ["cells", "CELL", 297, 302], ["Aeromonas hydrophila cytotoxic enterotoxin", "PROTEIN", 84, 126], ["vesicle tethering protein", "PROTEIN", 162, 187], ["Vsp52", "PROTEIN", 188, 193], ["Act", "PROTEIN", 211, 214], ["host cells", "CELL_TYPE", 292, 302], ["Aeromonas hydrophila", "SPECIES", 84, 104], ["yeast", "SPECIES", 134, 139], ["Aeromonas hydrophila", "SPECIES", 84, 104], ["yeast", "SPECIES", 134, 139], ["a similar approach", "TREATMENT", 6, 24], ["Galindo et al", "TREATMENT", 26, 39], ["the Aeromonas hydrophila cytotoxic enterotoxin", "TREATMENT", 80, 126]]], ["Protein microarray technology can also be used for specific protein quantification.", [["Protein microarray technology", "TEST", 0, 29], ["specific protein quantification", "TEST", 51, 82]]], ["Park et al. fabricated an antibody protein microarray (named by the authors as \u201creverse-phase protein microarray\u201d), and quantified the protein N-myc Downstream Regulated Gene 2 (NDRG2) in hepatocellular carcinoma patients and normal controls and observed significant lower expression of this protein in cancerous tissues [58].Detection of protein\u2013protein, protein\u2013dna and protein\u2013small molecule interactions using protein microarrayProtein microarrays have also been used to identify protein-nucleic acid interactions.", [["hepatocellular carcinoma", "ANATOMY", 188, 212], ["cancerous tissues", "ANATOMY", 303, 320], ["hepatocellular carcinoma", "DISEASE", 188, 212], ["N-myc Downstream Regulated Gene 2", "GENE_OR_GENE_PRODUCT", 143, 176], ["NDRG2", "GENE_OR_GENE_PRODUCT", 178, 183], ["hepatocellular carcinoma", "CANCER", 188, 212], ["patients", "ORGANISM", 213, 221], ["cancerous tissues", "TISSUE", 303, 320], ["protein\u2013dna", "GENE_OR_GENE_PRODUCT", 356, 367], ["nucleic acid", "SIMPLE_CHEMICAL", 492, 504], ["antibody protein", "PROTEIN", 26, 42], ["protein N-myc Downstream Regulated Gene 2", "PROTEIN", 135, 176], ["NDRG2", "DNA", 178, 183], ["patients", "SPECIES", 213, 221], ["an antibody protein microarray", "TEST", 23, 53], ["the protein N", "TEST", 131, 144], ["myc Downstream", "TEST", 145, 159], ["hepatocellular carcinoma", "PROBLEM", 188, 212], ["this protein in cancerous tissues", "PROBLEM", 287, 320], ["Detection", "TEST", 326, 335], ["protein\u2013protein", "TEST", 339, 354], ["protein\u2013dna", "TEST", 356, 367], ["protein\u2013small molecule interactions", "PROBLEM", 372, 407], ["protein microarray", "TEST", 414, 432], ["Protein microarrays", "TEST", 432, 451], ["protein", "TEST", 484, 491], ["nucleic acid interactions", "PROBLEM", 492, 517], ["hepatocellular", "ANATOMY", 188, 202], ["carcinoma", "OBSERVATION", 203, 212], ["significant", "OBSERVATION_MODIFIER", 255, 266], ["lower expression", "OBSERVATION_MODIFIER", 267, 283], ["cancerous tissues", "OBSERVATION", 303, 320]]], ["Our group probed the yeast protein microarray with Cy3-labeled single-stranded (ssDNA) or double-stranded (dsDNA) yeast genomic DNA and identified 84 ssDNA-binding, 58 dsDNA binding, and 131 ssDNA and dsDNA-binding proteins (schematic design shown in Fig. 1 as well as Fig. 1 in ref.", [["Cy3", "CHEMICAL", 51, 54], ["Cy3", "SIMPLE_CHEMICAL", 51, 54], ["DNA", "CELLULAR_COMPONENT", 128, 131], ["Cy3-labeled single-stranded (ssDNA) or double-stranded (dsDNA) yeast genomic DNA", "DNA", 51, 131], ["dsDNA-binding proteins", "PROTEIN", 201, 223], ["yeast", "SPECIES", 21, 26], ["yeast", "SPECIES", 114, 119], ["yeast", "SPECIES", 21, 26], ["yeast", "SPECIES", 114, 119], ["the yeast protein microarray", "TEST", 17, 45], ["Cy3", "TEST", 51, 54], ["double-stranded (dsDNA) yeast genomic DNA", "PROBLEM", 90, 131], ["ssDNA", "TEST", 150, 155], ["dsDNA binding", "TEST", 168, 181], ["ssDNA", "TEST", 191, 196], ["dsDNA", "TEST", 201, 206], ["binding proteins", "TEST", 207, 223], ["Fig", "OBSERVATION", 269, 272]]], ["We chose 8 proteins previously unreported for their DNA-binding activity for further validation, and 3 proteins were confirmed by Chromatin-Immunoprecipitation followed by probing genomic DNA microarrays (ChIP-Chip; [60]).", [["DNA", "CELLULAR_COMPONENT", 52, 55], ["Chromatin", "CELLULAR_COMPONENT", 130, 139], ["DNA", "CELLULAR_COMPONENT", 188, 191], ["further validation", "TEST", 77, 95], ["genomic DNA microarrays (ChIP-Chip", "TREATMENT", 180, 214]]], ["Of the 3 validated proteins, Arg5,6 was found to bind both mitochondrial (15 S ribosomal DNA, COX1, COX3, and COB1) and nuclear genes (PUF4, PHO23 and THI13), and participate in both transcription elongation and RNA-processing.", [["mitochondrial", "ANATOMY", 59, 72], ["nuclear", "ANATOMY", 120, 127], ["Arg5,6", "GENE_OR_GENE_PRODUCT", 29, 35], ["mitochondrial", "CELLULAR_COMPONENT", 59, 72], ["ribosomal", "CELLULAR_COMPONENT", 79, 88], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["COX1", "GENE_OR_GENE_PRODUCT", 94, 98], ["COX3", "GENE_OR_GENE_PRODUCT", 100, 104], ["COB1", "GENE_OR_GENE_PRODUCT", 110, 114], ["nuclear", "CELLULAR_COMPONENT", 120, 127], ["PUF4", "GENE_OR_GENE_PRODUCT", 135, 139], ["PHO23", "GENE_OR_GENE_PRODUCT", 141, 146], ["THI13", "GENE_OR_GENE_PRODUCT", 151, 156], ["Arg5,6", "PROTEIN", 29, 35], ["mitochondrial (15 S ribosomal DNA", "DNA", 59, 92], ["COX1", "DNA", 94, 98], ["COX3", "DNA", 100, 104], ["COB1", "DNA", 110, 114], ["nuclear genes", "DNA", 120, 133], ["PUF4", "DNA", 135, 139], ["PHO23", "DNA", 141, 146], ["THI13", "DNA", 151, 156], ["S ribosomal DNA", "TEST", 77, 92], ["COX1", "TEST", 94, 98], ["COX3", "TEST", 100, 104], ["PHO23", "TEST", 141, 146], ["elongation", "OBSERVATION_MODIFIER", 197, 207]]], ["Using a similar approach, Hu et al. identified conserved DNA motif-binding proteins using a protein microarray containing 4191 human proteins [61].", [["DNA", "CELLULAR_COMPONENT", 57, 60], ["human", "ORGANISM", 127, 132], ["conserved DNA motif-binding proteins", "PROTEIN", 47, 83], ["4191 human proteins", "PROTEIN", 122, 141], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["a similar approach", "TREATMENT", 6, 24], ["a protein microarray", "TEST", 90, 110], ["human proteins", "TEST", 127, 141]]], ["Interestingly, besides known transcription factors, they also identified over 300 previously unknown or unexpected DNA-binding proteins, including ERK2, a multifaceted mitogen-activated protein kinase [62], which also acts as a transcription repressor in the interferon gamma signaling pathway.", [["DNA", "CELLULAR_COMPONENT", 115, 118], ["ERK2", "GENE_OR_GENE_PRODUCT", 147, 151], ["mitogen-activated protein kinase [62", "GENE_OR_GENE_PRODUCT", 168, 204], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 259, 275], ["transcription factors", "PROTEIN", 29, 50], ["DNA-binding proteins", "PROTEIN", 115, 135], ["ERK2", "PROTEIN", 147, 151], ["multifaceted mitogen-activated protein kinase", "PROTEIN", 155, 200], ["transcription repressor", "PROTEIN", 228, 251], ["interferon gamma", "PROTEIN", 259, 275], ["known transcription factors", "PROBLEM", 23, 50], ["unexpected DNA-binding proteins", "PROBLEM", 104, 135], ["ERK2", "TEST", 147, 151], ["a multifaceted mitogen", "TEST", 153, 175], ["activated protein kinase", "TEST", 176, 200], ["a transcription repressor", "TREATMENT", 226, 251], ["the interferon gamma signaling pathway", "TREATMENT", 255, 293], ["transcription factors", "OBSERVATION", 29, 50]]], ["Another interesting study was reported by Zhu et al. on the identification and validation of binding proteins to the clamped adenine motif (CAM) of Brome mosaic virus (BMV), a model positive-strand RNA plant virus [63].", [["adenine", "CHEMICAL", 125, 132], ["adenine", "CHEMICAL", 125, 132], ["adenine", "SIMPLE_CHEMICAL", 125, 132], ["CAM", "MULTI-TISSUE_STRUCTURE", 140, 143], ["Brome mosaic virus", "ORGANISM", 148, 166], ["BMV", "ORGANISM", 168, 171], ["binding proteins", "PROTEIN", 93, 109], ["clamped adenine motif", "DNA", 117, 138], ["Brome mosaic virus", "SPECIES", 148, 166], ["BMV", "SPECIES", 168, 171], ["Another interesting study", "TEST", 0, 25], ["the identification", "TEST", 56, 74], ["binding proteins", "TREATMENT", 93, 109], ["the clamped adenine motif (CAM", "TREATMENT", 113, 143], ["Brome mosaic virus", "PROBLEM", 148, 166], ["a model positive-strand RNA plant virus", "PROBLEM", 174, 213]]], ["As BMV can also replicate in S. cerevisiae, the authors probed the yeast proteome array (containing ~ 5000 purified proteins) with both Cy3-labeled CAM-containing RNA and a Cy5-labeled control, and identified 12 hits that showed equal or stronger signals than BMV's own capsid protein (CP).", [["BMV", "ORGANISM", 3, 6], ["S. cerevisiae", "ORGANISM", 29, 42], ["Cy3", "SIMPLE_CHEMICAL", 136, 139], ["CAM", "MULTI-TISSUE_STRUCTURE", 148, 151], ["Cy5", "SIMPLE_CHEMICAL", 173, 176], ["BMV's own capsid protein", "GENE_OR_GENE_PRODUCT", 260, 284], ["purified proteins", "PROTEIN", 107, 124], ["Cy3-labeled CAM-containing RNA", "RNA", 136, 166], ["capsid protein", "PROTEIN", 270, 284], ["CP", "PROTEIN", 286, 288], ["S. cerevisiae", "SPECIES", 29, 42], ["yeast", "SPECIES", 67, 72], ["BMV", "SPECIES", 3, 6], ["S. cerevisiae", "SPECIES", 29, 42], ["yeast", "SPECIES", 67, 72], ["BMV", "SPECIES", 260, 263], ["Cy3-labeled CAM", "TREATMENT", 136, 151], ["RNA", "TREATMENT", 163, 166], ["a Cy5-labeled control", "TREATMENT", 171, 192]]], ["The authors focused on 2 of the 3 strongest binders, Pus4 and App1, and found that they could also inhibit positive-strand RNA accumulation and systemic viral infection in vivo.", [["viral infection", "DISEASE", 153, 168], ["Pus4", "GENE_OR_GENE_PRODUCT", 53, 57], ["App1", "GENE_OR_GENE_PRODUCT", 62, 66], ["Pus4", "PROTEIN", 53, 57], ["App1", "PROTEIN", 62, 66], ["positive-strand RNA accumulation", "PROBLEM", 107, 139], ["systemic viral infection in vivo", "PROBLEM", 144, 176], ["strand RNA accumulation", "OBSERVATION", 116, 139], ["systemic", "OBSERVATION_MODIFIER", 144, 152], ["viral infection", "OBSERVATION", 153, 168]]], ["Their further investigation demonstrated that Pus4 inhibited in vivo viral systemic spread by affecting virion formation through a direct competition with CP.", [["virion", "ANATOMY", 104, 110], ["Pus4", "CHEMICAL", 46, 50], ["Pus4", "CHEMICAL", 46, 50], ["Pus4", "SIMPLE_CHEMICAL", 46, 50], ["virion", "CELLULAR_COMPONENT", 104, 110], ["Their further investigation", "TEST", 0, 27], ["Pus4", "PROBLEM", 46, 50], ["vivo viral systemic spread", "PROBLEM", 64, 90], ["CP", "PROBLEM", 155, 157], ["virion formation", "OBSERVATION", 104, 120]]], ["This study shows a good example of the capability of functional protein microarray in the discovery of interactions of in vivo physiological importance, and in this case, components involved in antiviral response.Detection of protein\u2013protein, protein\u2013dna and protein\u2013small molecule interactions using protein microarrayBesides protein\u2013protein and protein\u2013DNA/RNA discoveries, protein microarrays were also used to identify protein\u2013small molecule interactions.", [["protein\u2013dna", "GENE_OR_GENE_PRODUCT", 243, 254], ["This study", "TEST", 0, 10], ["functional protein microarray", "PROBLEM", 53, 82], ["Detection", "TEST", 213, 222], ["protein\u2013protein", "TEST", 226, 241], ["protein\u2013dna", "TEST", 243, 254], ["protein\u2013small molecule interactions", "PROBLEM", 259, 294], ["protein microarray", "TEST", 301, 319], ["protein\u2013protein", "TEST", 327, 342], ["protein\u2013DNA", "TEST", 347, 358], ["protein microarrays", "TEST", 376, 395], ["protein\u2013small molecule interactions", "PROBLEM", 423, 458], ["antiviral response", "OBSERVATION", 194, 212]]], ["Rapamycin is a small molecule drug that can induce starvation response and inhibit cell growth through its target TOR (Target of Rapamycin), a highly conserved kinase regulating cell proliferation and metabolism, in yeast and humans [64].", [["cell", "ANATOMY", 83, 87], ["cell", "ANATOMY", 178, 182], ["Rapamycin", "CHEMICAL", 0, 9], ["Rapamycin", "CHEMICAL", 129, 138], ["Rapamycin", "CHEMICAL", 0, 9], ["Rapamycin", "CHEMICAL", 129, 138], ["Rapamycin", "SIMPLE_CHEMICAL", 0, 9], ["cell", "CELL", 83, 87], ["TOR", "GENE_OR_GENE_PRODUCT", 114, 117], ["Target of Rapamycin", "GENE_OR_GENE_PRODUCT", 119, 138], ["cell", "CELL", 178, 182], ["humans", "ORGANISM", 226, 232], ["TOR", "PROTEIN", 114, 117], ["Target of Rapamycin", "PROTEIN", 119, 138], ["yeast", "SPECIES", 216, 221], ["humans", "SPECIES", 226, 232], ["yeast", "SPECIES", 216, 221], ["humans", "SPECIES", 226, 232], ["Rapamycin", "TREATMENT", 0, 9], ["a small molecule drug", "TREATMENT", 13, 34], ["starvation response", "PROBLEM", 51, 70], ["inhibit cell growth", "PROBLEM", 75, 94], ["Rapamycin", "TREATMENT", 129, 138], ["a highly conserved kinase regulating cell proliferation", "PROBLEM", 141, 196], ["kinase regulating cell proliferation", "OBSERVATION", 160, 196]]], ["Rapamycin analogs are promising chemotherapeutic drugs to treat cancer [65].", [["cancer", "ANATOMY", 64, 70], ["Rapamycin", "CHEMICAL", 0, 9], ["cancer", "DISEASE", 64, 70], ["Rapamycin", "CHEMICAL", 0, 9], ["Rapamycin", "SIMPLE_CHEMICAL", 0, 9], ["cancer", "CANCER", 64, 70], ["Rapamycin analogs", "TREATMENT", 0, 17], ["chemotherapeutic drugs", "TREATMENT", 32, 54], ["cancer", "PROBLEM", 64, 70]]], ["Jiang et al. identified small molecules that could enhance (small-molecule enhancers of rapamycin, or SMERs) or inhibit (small-molecule inhibitors of rapamycin, or SMIRs) rapamycin effects in yeast, and discovered intracellular protein targets of two SMIRs, SMIR3 and SMIR4, by probing the yeast protein microarray with biotinylated SMIRs [66].", [["intracellular", "ANATOMY", 214, 227], ["rapamycin", "CHEMICAL", 88, 97], ["rapamycin", "CHEMICAL", 150, 159], ["rapamycin", "CHEMICAL", 171, 180], ["rapamycin", "CHEMICAL", 88, 97], ["rapamycin", "CHEMICAL", 150, 159], ["rapamycin", "CHEMICAL", 171, 180], ["rapamycin", "SIMPLE_CHEMICAL", 88, 97], ["SMERs", "SIMPLE_CHEMICAL", 102, 107], ["rapamycin", "SIMPLE_CHEMICAL", 150, 159], ["SMIRs", "GENE_OR_GENE_PRODUCT", 164, 169], ["rapamycin", "SIMPLE_CHEMICAL", 171, 180], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 214, 227], ["SMIRs", "GENE_OR_GENE_PRODUCT", 251, 256], ["SMIR3", "GENE_OR_GENE_PRODUCT", 258, 263], ["SMIR4", "GENE_OR_GENE_PRODUCT", 268, 273], ["SMIRs", "PROTEIN", 251, 256], ["SMIR3", "PROTEIN", 258, 263], ["SMIR4", "PROTEIN", 268, 273], ["yeast", "SPECIES", 192, 197], ["yeast", "SPECIES", 290, 295], ["yeast", "SPECIES", 192, 197], ["yeast", "SPECIES", 290, 295], ["small molecules", "PROBLEM", 24, 39], ["small-molecule enhancers", "PROBLEM", 60, 84], ["rapamycin", "TREATMENT", 88, 97], ["SMERs", "PROBLEM", 102, 107], ["small-molecule inhibitors", "TREATMENT", 121, 146], ["rapamycin", "TREATMENT", 150, 159], ["SMIRs", "TREATMENT", 164, 169], ["rapamycin effects in yeast", "PROBLEM", 171, 197], ["SMIR4", "TREATMENT", 268, 273], ["the yeast protein microarray", "TEST", 286, 314], ["biotinylated SMIRs", "TEST", 320, 338], ["small", "OBSERVATION_MODIFIER", 24, 29], ["molecules", "OBSERVATION", 30, 39], ["small", "OBSERVATION_MODIFIER", 60, 65], ["small", "OBSERVATION_MODIFIER", 121, 126]]], ["Among the strongest protein targets identified in this study, two proteins, Tep1p and Nir1p, were shown to be components of the TOR signaling pathway, suggesting that the protein array method is capable of detecting specific protein\u2013small molecule interactions.", [["Tep1p", "GENE_OR_GENE_PRODUCT", 76, 81], ["Nir1p", "GENE_OR_GENE_PRODUCT", 86, 91], ["TOR", "GENE_OR_GENE_PRODUCT", 128, 131], ["Tep1p", "PROTEIN", 76, 81], ["Nir1p", "PROTEIN", 86, 91], ["TOR", "PROTEIN", 128, 131], ["this study", "TEST", 50, 60], ["Tep1p", "TEST", 76, 81], ["Nir1p", "TREATMENT", 86, 91], ["the protein array method", "TEST", 167, 191], ["protein\u2013small molecule interactions", "OBSERVATION", 225, 260]]], ["By probing the protein arrays with biotinylated polyanions (two proteins, two compounds, and DNA) Salamat-Miller et al. also identified a total of 893 polyanion-binding proteins in S. cerevisiae[67].", [["DNA", "CELLULAR_COMPONENT", 93, 96], ["S. cerevisiae", "ORGANISM", 181, 194], ["893 polyanion-binding proteins", "PROTEIN", 147, 177], ["S. cerevisiae", "SPECIES", 181, 194], ["S. cerevisiae", "SPECIES", 181, 194], ["the protein arrays", "TREATMENT", 11, 29], ["biotinylated polyanions (two proteins", "TREATMENT", 35, 72]]], ["Interestingly, the polyanions and their binding proteins are found to form a network that is involved in maintaining the structure and activity of the yeast cells.Detection of post-translational modifications using protein microarrayThe proteome ultimately carries out most cellular functions, and is regulated by many different types of post-translational modifications.", [["yeast cells", "ANATOMY", 151, 162], ["cellular", "ANATOMY", 274, 282], ["yeast cells", "CELL", 151, 162], ["cellular", "CELL", 274, 282], ["binding proteins", "PROTEIN", 40, 56], ["yeast cells", "CELL_TYPE", 151, 162], ["yeast", "SPECIES", 151, 156], ["yeast", "SPECIES", 151, 156], ["the polyanions and their binding proteins", "PROBLEM", 15, 56], ["post-translational modifications", "TREATMENT", 176, 208], ["protein microarray", "TEST", 215, 233], ["post-translational modifications", "TREATMENT", 338, 370], ["yeast cells", "OBSERVATION", 151, 162], ["out most", "OBSERVATION_MODIFIER", 265, 273], ["cellular functions", "OBSERVATION", 274, 292], ["many", "OBSERVATION_MODIFIER", 314, 318], ["different types", "OBSERVATION_MODIFIER", 319, 334], ["post-translational modifications", "OBSERVATION", 338, 370]]], ["These modifications include phosphorylation, glycosylation, acetylation, ubiquitination, SUMOylation, and S-nitrilation [68], [69], [70].", [["S-nitrilation [68]", "SIMPLE_CHEMICAL", 106, 124], ["phosphorylation, glycosylation", "TREATMENT", 28, 58], ["acetylation", "TREATMENT", 60, 71], ["ubiquitination", "TREATMENT", 73, 87], ["SUMOylation", "TREATMENT", 89, 100]]], ["Therefore, the status of post-translational modification of the proteome is a snapshot of the dynamic activities of the living cell.Detection of post-translational modifications using protein microarrayThe specific platform of protein microarray makes it ideal to identify proteome-wide potential targets for protein post-translational modification enzymes.", [["cell", "ANATOMY", 127, 131], ["cell", "CELL", 127, 131], ["protein post-translational modification enzymes", "PROTEIN", 309, 356], ["post-translational modifications", "TREATMENT", 145, 177], ["protein microarray", "TEST", 184, 202], ["protein microarray", "TEST", 227, 245], ["protein", "TEST", 309, 316], ["translational modification enzymes", "TEST", 322, 356], ["living cell", "OBSERVATION", 120, 131]]], ["The high throughput format enables screening of potential substrates in the whole or partial proteome in a single assay, and its in vitro nature allows fine and accurate controls over the assay conditions.Detection of post-translational modifications using protein microarrayOf all post-translational modifications, phosphorylation is the most studied.", [["the assay conditions", "TEST", 184, 204], ["post-translational modifications", "TREATMENT", 218, 250], ["protein microarrayOf", "TREATMENT", 257, 277], ["translational modifications", "TREATMENT", 287, 314], ["phosphorylation", "TREATMENT", 316, 331], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["The kinome, or collection of all kinases in the cell, is responsible for the dynamic phosphorylation of proteins and controls many different cellular processes.", [["cell", "ANATOMY", 48, 52], ["cellular", "ANATOMY", 141, 149], ["cell", "CELL", 48, 52], ["cellular", "CELL", 141, 149], ["kinases", "PROTEIN", 33, 40], ["all kinases in the cell", "PROBLEM", 29, 52], ["the dynamic phosphorylation of proteins", "PROBLEM", 73, 112], ["many different cellular processes", "PROBLEM", 126, 159], ["kinome", "OBSERVATION_MODIFIER", 4, 10], ["all", "OBSERVATION_MODIFIER", 29, 32], ["kinases", "OBSERVATION_MODIFIER", 33, 40], ["cell", "ANATOMY", 48, 52], ["responsible for", "UNCERTAINTY", 57, 72], ["cellular processes", "OBSERVATION", 141, 159]]], ["Levels of kinase activities are likely to be very tightly controlled; indeed Sopko et al. examined the influence of individual overexpression of more than 80% of all yeast genes and observed enrichment of kinases and phosphatases in the list of \u201ctoxic gene set\u201d; a set of genes whose overexpression significantly slowed yeast growth [71].", [["yeast genes", "DNA", 166, 177], ["kinases", "PROTEIN", 205, 212], ["phosphatases", "PROTEIN", 217, 229], ["yeast", "SPECIES", 166, 171], ["yeast", "SPECIES", 320, 325], ["yeast", "SPECIES", 166, 171], ["yeast", "SPECIES", 320, 325], ["Levels of kinase activities", "TEST", 0, 27], ["all yeast genes", "PROBLEM", 162, 177], ["kinases", "TEST", 205, 212], ["phosphatases", "TEST", 217, 229], ["yeast growth", "PROBLEM", 320, 332], ["yeast genes", "OBSERVATION", 166, 177]]], ["Several groups including ours have carried out large-scale studies to identify the substrates of yeast kinases at the proteomic level.", [["yeast kinases", "GENE_OR_GENE_PRODUCT", 97, 110], ["yeast kinases", "PROTEIN", 97, 110], ["yeast", "SPECIES", 97, 102], ["yeast", "SPECIES", 97, 102], ["large-scale studies", "TEST", 47, 66], ["yeast kinases", "PROBLEM", 97, 110], ["yeast kinases", "OBSERVATION", 97, 110]]], ["In 2000 our group screened 119 of the 122 yeast kinases with 17 different substrates (including the kinases themselves for monitoring autophosphorylation) on a prototype of protein microarray [33].", [["122 yeast kinases", "PROTEIN", 38, 55], ["kinases", "PROTEIN", 100, 107], ["yeast", "SPECIES", 42, 47], ["yeast", "SPECIES", 42, 47], ["yeast kinases", "TEST", 42, 55], ["17 different substrates", "PROBLEM", 61, 84], ["the kinases themselves", "TREATMENT", 96, 118], ["monitoring autophosphorylation", "TEST", 123, 153], ["a prototype of protein microarray", "TREATMENT", 158, 191]]], ["The substrates were immobilized onto nanowell protein chips and phosphorylation events were identified by adding 33P-\u03b3-ATP and a specific yeast kinase and exposing the chip to a phosphoimager.", [["33P-\u03b3-ATP", "CHEMICAL", 113, 122], ["33P-\u03b3-ATP", "CHEMICAL", 113, 122], ["33P-\u03b3-ATP", "SIMPLE_CHEMICAL", 113, 122], ["33P", "PROTEIN", 113, 116], ["yeast kinase", "PROTEIN", 138, 150], ["yeast", "SPECIES", 138, 143], ["yeast", "SPECIES", 138, 143], ["The substrates", "TREATMENT", 0, 14], ["nanowell protein chips", "TREATMENT", 37, 59], ["phosphorylation events", "PROBLEM", 64, 86], ["a phosphoimager", "TREATMENT", 176, 191]]], ["We discovered that more than 60% of the kinases autophosphorylated themselves, and 94% of the tested kinases had at least one substrate in vitro, with 32 of them specifically phosphorylating one or two substrates.", [["kinases", "PROTEIN", 40, 47], ["kinases", "PROTEIN", 101, 108], ["the kinases autophosphorylated themselves", "TEST", 36, 77], ["the tested kinases", "TEST", 90, 108]]], ["Twenty-seven kinases were found to phosphorylate poly(Tyr-Glu), which quadrupled the number of identified tyrosine kinases (seven) reported at that time.", [["poly(Tyr-Glu", "CHEMICAL", 49, 61], ["tyrosine", "CHEMICAL", 106, 114], ["poly(Tyr-Glu)", "CHEMICAL", 49, 62], ["tyrosine", "CHEMICAL", 106, 114], ["Tyr-Glu", "SIMPLE_CHEMICAL", 54, 61], ["kinases", "PROTEIN", 13, 20], ["tyrosine kinases", "PROTEIN", 106, 122], ["phosphorylate poly", "TEST", 35, 53], ["tyrosine kinases", "TEST", 106, 122], ["tyrosine kinases", "OBSERVATION", 106, 122]]], ["Moreover, these tyrosine kinases preferentially contain 3 conserved lysines and one conserved methionine near the catalytic region, indicating their potential roles in substrate selection.", [["tyrosine", "CHEMICAL", 16, 24], ["methionine", "CHEMICAL", 94, 104], ["tyrosine", "CHEMICAL", 16, 24], ["lysines", "CHEMICAL", 68, 75], ["methionine", "CHEMICAL", 94, 104], ["methionine", "AMINO_ACID", 94, 104], ["tyrosine kinases", "PROTEIN", 16, 32], ["catalytic region", "PROTEIN", 114, 130], ["these tyrosine kinases", "TREATMENT", 10, 32], ["catalytic", "ANATOMY", 114, 123], ["region", "ANATOMY_MODIFIER", 124, 130], ["substrate selection", "OBSERVATION", 168, 187]]], ["The same method was later used to identify Hrr25p as a kinase for the zinc-finger transcription factor Crz1, which turned out to negatively regulate Crz1 activity and nuclear localization by phosphorylation in vivo [72].", [["nuclear", "ANATOMY", 167, 174], ["zinc", "CHEMICAL", 70, 74], ["Hrr25p", "GENE_OR_GENE_PRODUCT", 43, 49], ["Crz1", "GENE_OR_GENE_PRODUCT", 103, 107], ["Crz1", "GENE_OR_GENE_PRODUCT", 149, 153], ["nuclear", "CELLULAR_COMPONENT", 167, 174], ["Hrr25p", "PROTEIN", 43, 49], ["zinc-finger transcription factor", "PROTEIN", 70, 102], ["Crz1", "PROTEIN", 103, 107], ["Crz1", "PROTEIN", 149, 153], ["the zinc-finger transcription", "TREATMENT", 66, 95], ["nuclear localization", "TEST", 167, 187]]], ["Our group later expanded the study to search for the substrates of 87 different S. cerevisiae kinases in a large set of more than 4400 full-length, functional yeast proteins with a yeast protein microarray containing 4400 yeast proteins [47].", [["S. cerevisiae", "ORGANISM", 80, 93], ["S. cerevisiae kinases", "PROTEIN", 80, 101], ["functional yeast proteins", "PROTEIN", 148, 173], ["4400 yeast proteins", "PROTEIN", 217, 236], ["S. cerevisiae", "SPECIES", 80, 93], ["yeast", "SPECIES", 159, 164], ["yeast", "SPECIES", 181, 186], ["yeast", "SPECIES", 222, 227], ["S. cerevisiae", "SPECIES", 80, 93], ["yeast", "SPECIES", 159, 164], ["yeast", "SPECIES", 181, 186], ["yeast", "SPECIES", 222, 227], ["the study", "TEST", 25, 34], ["the substrates", "TEST", 49, 63], ["cerevisiae kinases", "TEST", 83, 101], ["functional yeast proteins", "PROBLEM", 148, 173], ["a yeast protein microarray", "TEST", 179, 205], ["yeast proteins", "TEST", 222, 236]]], ["In this study we discovered about 4200 phosphorylation events affecting 1325 proteins and generated the first version of the phosphorylation network in yeast (schematic design shown in Fig. 3).", [["1325 proteins", "PROTEIN", 72, 85], ["yeast", "SPECIES", 152, 157], ["yeast", "SPECIES", 152, 157], ["this study", "TEST", 3, 13], ["4200 phosphorylation events", "PROBLEM", 34, 61], ["the phosphorylation network", "TREATMENT", 121, 148]]], ["We found that each kinase had a unique substrate profile and most phosphorylation substrates were recognized by 3 or fewer kinases.", [["kinases", "PROTEIN", 123, 130], ["a unique substrate profile", "PROBLEM", 30, 56], ["most phosphorylation substrates", "PROBLEM", 61, 92]]], ["Even within closely related kinases such as Tpk1, Tpk2 and Tpk3, there seem to be a low overlap between their substrate profiles (only 12.3% of all their identified substrates could be recognized by more than one of the three kinases).", [["Tpk1", "GENE_OR_GENE_PRODUCT", 44, 48], ["Tpk2", "GENE_OR_GENE_PRODUCT", 50, 54], ["Tpk3", "GENE_OR_GENE_PRODUCT", 59, 63], ["kinases", "PROTEIN", 28, 35], ["Tpk1", "PROTEIN", 44, 48], ["Tpk2", "PROTEIN", 50, 54], ["Tpk3", "PROTEIN", 59, 63], ["kinases", "PROTEIN", 226, 233], ["Tpk1", "TEST", 44, 48], ["Tpk2", "TEST", 50, 54], ["Tpk3", "TEST", 59, 63], ["a low overlap between their substrate profiles", "PROBLEM", 82, 128], ["low", "OBSERVATION", 84, 87]]], ["Moreover, we also found that kinases might display distinct substrate preferences when they form complexes with different proteins.", [["kinases", "PROTEIN", 29, 36], ["different proteins", "PROBLEM", 112, 130]]], ["We determined the consensus motifs for 11 kinases in this study using a method developed by Jonassen et al. [73], and further investigated this in a larger scale in a separate study with a rapid peptide screening approach (schematic design shown in Fig. 3), in which we determined the consensus phosphorylation motifs for 61 kinases [74].", [["consensus motifs", "DNA", 18, 34], ["kinases", "PROTEIN", 42, 49], ["consensus phosphorylation motifs", "PROTEIN", 285, 317], ["61 kinases", "PROTEIN", 322, 332], ["this study", "TEST", 53, 63], ["a method", "TREATMENT", 70, 78], ["a separate study", "TEST", 165, 181], ["a rapid peptide screening approach", "TREATMENT", 187, 221]]], ["Lastly, by combining our profiling data with available transcription factor binding and protein interaction data sets [49], [51], [75], [76], [77], [78], [79], we discovered 8 regulatory modules in the phosphorylation network.", [["[51], [75], [76], [77], [78]", "SIMPLE_CHEMICAL", 124, 152], ["[79]", "SIMPLE_CHEMICAL", 154, 158], ["transcription factor", "PROTEIN", 55, 75], ["protein interaction data sets", "TEST", 88, 117]]], ["All of the above indicated that kinases have evolved to have their unique, specific roles in carrying out molecular and cellular functions in the eukaryotic cells.Detection of post-translational modifications using protein microarrayBesides protein microarrays, large-scale profiling of the protein phosphorylation networks was also approached with other methods.", [["cellular", "ANATOMY", 120, 128], ["cells", "ANATOMY", 157, 162], ["cellular", "CELL", 120, 128], ["cells", "CELL", 157, 162], ["kinases", "PROTEIN", 32, 39], ["eukaryotic cells", "CELL_TYPE", 146, 162], ["protein phosphorylation networks", "PROTEIN", 291, 323], ["post-translational modifications", "TREATMENT", 176, 208], ["protein microarray", "TEST", 215, 233], ["protein microarrays", "TEST", 241, 260], ["the protein phosphorylation networks", "PROBLEM", 287, 323], ["cellular functions", "OBSERVATION", 120, 138], ["eukaryotic cells", "OBSERVATION", 146, 162], ["large", "OBSERVATION_MODIFIER", 262, 267]]], ["Instead of direct proteomic approaches, Fiedler et al. determined the epistasis of binary interactions between all yeast kinases, phosphatases and key cellular regulators by building an epistatic miniarray profile (E-MAP) through the generation of double mutants [80].", [["cellular", "ANATOMY", 151, 159], ["cellular", "CELL", 151, 159], ["E-MAP", "GENE_OR_GENE_PRODUCT", 215, 220], ["yeast kinases", "PROTEIN", 115, 128], ["phosphatases", "PROTEIN", 130, 142], ["cellular regulators", "PROTEIN", 151, 170], ["yeast", "SPECIES", 115, 120], ["yeast", "SPECIES", 115, 120], ["direct proteomic approaches", "TREATMENT", 11, 38], ["the epistasis of binary interactions", "PROBLEM", 66, 102], ["all yeast kinases", "TEST", 111, 128], ["phosphatases", "TEST", 130, 142], ["an epistatic miniarray profile", "TEST", 183, 213], ["double mutants", "PROBLEM", 248, 262], ["epistasis", "OBSERVATION", 70, 79]]], ["In this study, by analyzing \u201cTriplet Genetic Motifs\u201d, the authors detected both known (such as Cak1 and its substrates Ctk1 and Smk1) and previously undiscovered (e.g. involvement of Cak1 and Fus3 in the Set2/Rpd3C(S) pathway) interactions with this method.", [["Cak1", "GENE_OR_GENE_PRODUCT", 95, 99], ["Ctk1", "GENE_OR_GENE_PRODUCT", 119, 123], ["Smk1", "GENE_OR_GENE_PRODUCT", 128, 132], ["Cak1", "GENE_OR_GENE_PRODUCT", 183, 187], ["Fus3", "GENE_OR_GENE_PRODUCT", 192, 196], ["Set2", "GENE_OR_GENE_PRODUCT", 204, 208], ["Rpd3C(S)", "GENE_OR_GENE_PRODUCT", 209, 217], ["Cak1", "PROTEIN", 95, 99], ["Ctk1", "PROTEIN", 119, 123], ["Smk1", "PROTEIN", 128, 132], ["Cak1", "PROTEIN", 183, 187], ["Fus3", "PROTEIN", 192, 196], ["Set2", "PROTEIN", 204, 208], ["this study", "TEST", 3, 13], ["Cak1", "TEST", 183, 187], ["Fus3", "TEST", 192, 196], ["this method", "TREATMENT", 245, 256]]], ["Moreover, Korf et al. generated an antibody-based protein microarray, which can be used to monitor time-dependent quantitative changes in the phosphorylation states of individual kinases [81].", [["an antibody", "TEST", 32, 43], ["protein microarray", "TEST", 50, 68], ["dependent quantitative changes", "PROBLEM", 104, 134], ["individual kinases", "TEST", 168, 186]]], ["This method could be applied potentially to monitor many targets at the same time; however, like other antibody protein microarrays, this method significantly depends on the quality and specificity of the antibody pairs for each protein [21].", [["antibody pairs", "PROTEIN", 205, 219], ["This method", "TREATMENT", 0, 11], ["other antibody protein microarrays", "TEST", 97, 131], ["this method", "TEST", 133, 144], ["the antibody pairs", "TEST", 201, 219], ["each protein", "TEST", 224, 236]]], ["Alternatively, the phospho-proteome can also be profiled with quantitative mass spectrometry [82], [83].", [["quantitative mass spectrometry", "TEST", 62, 92]]], ["Soufi et al. identified 5534 unique phospho-peptides associated with the osmotic response of S. cerevisiae with a quantitative high-resolution mass spectrometry of their phospho-proteome, and observed that greater than 15% of these changes occured within 5 min after the start of the treatment, suggesting that phosphorylation of a group of specific proteins is part of the early response to osmotic changes [82].Detection of post-translational modifications using protein microarrayOther post-translational modifications have also been investigated with protein microarray technology.", [["phospho", "CHEMICAL", 36, 43], ["phospho", "CHEMICAL", 170, 177], ["phospho-peptides", "GENE_OR_GENE_PRODUCT", 36, 52], ["S. cerevisiae", "ORGANISM", 93, 106], ["phospho", "PROTEIN", 170, 177], ["S. cerevisiae", "SPECIES", 93, 106], ["S. cerevisiae", "SPECIES", 93, 106], ["unique phospho-peptides", "TREATMENT", 29, 52], ["the treatment", "TREATMENT", 280, 293], ["phosphorylation of a group of specific proteins", "PROBLEM", 311, 358], ["osmotic changes", "PROBLEM", 392, 407], ["post-translational modifications", "TREATMENT", 426, 458], ["protein microarrayOther", "TREATMENT", 465, 488], ["translational modifications", "TREATMENT", 494, 521], ["protein microarray technology", "TREATMENT", 555, 584], ["greater", "OBSERVATION_MODIFIER", 206, 213]]], ["By probing the yeast protein microarray with Concanavalin A or Wheat-Germ Agglutinin, both of which are lectins that bind glycans on proteins, Kung et al. identified 534 glycosylated yeast proteins including 30 mitochondrial proteins and a number of nuclear proteins; 406 of the glycosylated protein were unreported previously [84].", [["mitochondrial", "ANATOMY", 211, 224], ["nuclear", "ANATOMY", 250, 257], ["Concanavalin A", "GENE_OR_GENE_PRODUCT", 45, 59], ["Wheat-Germ Agglutinin", "GENE_OR_GENE_PRODUCT", 63, 84], ["mitochondrial", "CELLULAR_COMPONENT", 211, 224], ["nuclear", "CELLULAR_COMPONENT", 250, 257], ["534 glycosylated yeast proteins", "PROTEIN", 166, 197], ["mitochondrial proteins", "PROTEIN", 211, 233], ["nuclear proteins", "PROTEIN", 250, 266], ["glycosylated protein", "PROTEIN", 279, 299], ["yeast", "SPECIES", 15, 20], ["yeast", "SPECIES", 183, 188], ["yeast", "SPECIES", 15, 20], ["yeast", "SPECIES", 183, 188], ["the yeast protein microarray", "TEST", 11, 39], ["Concanavalin A", "TREATMENT", 45, 59], ["Germ Agglutinin", "PROBLEM", 69, 84], ["glycosylated yeast proteins", "TEST", 170, 197], ["mitochondrial proteins", "TEST", 211, 233], ["nuclear proteins", "TEST", 250, 266], ["the glycosylated protein", "TEST", 275, 299], ["yeast proteins", "OBSERVATION", 183, 197]]], ["Interestingly, they also found that inhibition of glycosylation by N-linked glycosylation inhibitor tunicamycin affected the localization of some mitochondrial proteins, such as Ydr065wp and Lpe10p, which suggests that proper protein glycosylation is important for their normal localization and function.", [["mitochondrial", "ANATOMY", 146, 159], ["tunicamycin", "CHEMICAL", 100, 111], ["N", "CHEMICAL", 67, 68], ["tunicamycin", "CHEMICAL", 100, 111], ["tunicamycin", "SIMPLE_CHEMICAL", 100, 111], ["mitochondrial", "CELLULAR_COMPONENT", 146, 159], ["Ydr065wp", "GENE_OR_GENE_PRODUCT", 178, 186], ["Lpe10p", "GENE_OR_GENE_PRODUCT", 191, 197], ["mitochondrial proteins", "PROTEIN", 146, 168], ["Ydr065wp", "PROTEIN", 178, 186], ["Lpe10p", "PROTEIN", 191, 197], ["glycosylation", "TREATMENT", 50, 63], ["N-linked glycosylation inhibitor tunicamycin", "TREATMENT", 67, 111], ["some mitochondrial proteins", "PROBLEM", 141, 168], ["proper protein glycosylation", "PROBLEM", 219, 247], ["mitochondrial proteins", "OBSERVATION", 146, 168], ["protein glycosylation", "OBSERVATION", 226, 247]]], ["In addition to glycosylation, Tao et al. used an analogous approach to examine poly(ADP-ribosyl)ation in yeast with protein microarray [85].", [["poly(ADP-ribosyl", "CHEMICAL", 79, 95], ["poly(ADP-ribosyl)", "CHEMICAL", 79, 96], ["poly(ADP-ribosyl)", "GENE_OR_GENE_PRODUCT", 79, 96], ["yeast", "SPECIES", 105, 110], ["yeast", "SPECIES", 105, 110], ["glycosylation", "TREATMENT", 15, 28], ["Tao et al", "TREATMENT", 30, 39], ["an analogous approach", "TREATMENT", 46, 67], ["poly(ADP-ribosyl)ation", "TREATMENT", 79, 101], ["protein microarray", "TEST", 116, 134]]], ["Poly(ADP-ribosyl)ation of proteins is usually carried out by the enzyme poly(ADP-ribose) polymerase-1 (PARP-1), a pluripotent enzyme involved in both DNA damage sensing mechanism and regulation of gene expression [86], [87].", [["Poly", "CHEMICAL", 0, 4], ["ADP", "CHEMICAL", 5, 8], ["poly(ADP-ribose", "CHEMICAL", 72, 87], ["Poly(ADP-ribosyl)", "CHEMICAL", 0, 17], ["poly(ADP-ribose)", "CHEMICAL", 72, 88], ["Poly(ADP-ribosyl)", "GENE_OR_GENE_PRODUCT", 0, 17], ["poly(ADP-ribose) polymerase-1", "GENE_OR_GENE_PRODUCT", 72, 101], ["PARP-1", "GENE_OR_GENE_PRODUCT", 103, 109], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["poly(ADP-ribose) polymerase-1 (PARP-1", "PROTEIN", 72, 109], ["pluripotent enzyme", "PROTEIN", 114, 132], ["Poly(ADP-ribosyl)ation of proteins", "TREATMENT", 0, 34], ["the enzyme poly", "TEST", 61, 76], ["ADP-ribose) polymerase", "TEST", 77, 99], ["PARP", "TEST", 103, 107], ["a pluripotent enzyme", "TEST", 112, 132], ["gene expression", "TEST", 197, 212]]], ["The authors identified 33 PARP-1 substrates in this study, including six proteins involved in ribosome biogenesis, indicating that poly(ADP-ribosyl)ation may be required for the normal biogenesis process of the ribosomes.Detection of post-translational modifications using protein microarrayAcetylation and deacetylation of the lysine residues in proteins, especially histones are important events in regulating chromatin-related processes and gene expression, although not much was known for the non-chromatin-associated substrates of these histone acetyltransferases and deacetylases [88], [89].", [["ribosome", "ANATOMY", 94, 102], ["ribosomes", "ANATOMY", 211, 220], ["chromatin", "ANATOMY", 412, 421], ["poly(ADP-ribosyl", "CHEMICAL", 131, 147], ["lysine", "CHEMICAL", 328, 334], ["poly(ADP-ribosyl)", "CHEMICAL", 131, 148], ["lysine", "CHEMICAL", 328, 334], ["PARP-1", "GENE_OR_GENE_PRODUCT", 26, 32], ["ribosome", "CELLULAR_COMPONENT", 94, 102], ["poly(ADP-ribosyl)ation", "GENE_OR_GENE_PRODUCT", 131, 153], ["ribosomes", "CELLULAR_COMPONENT", 211, 220], ["histones", "GENE_OR_GENE_PRODUCT", 368, 376], ["chromatin", "CELLULAR_COMPONENT", 412, 421], ["histone acetyltransferases", "GENE_OR_GENE_PRODUCT", 542, 568], ["PARP", "PROTEIN", 26, 30], ["histones", "PROTEIN", 368, 376], ["chromatin", "DNA", 412, 421], ["histone acetyltransferases", "PROTEIN", 542, 568], ["deacetylases", "PROTEIN", 573, 585], ["this study", "TEST", 47, 57], ["poly(ADP-ribosyl)ation", "TREATMENT", 131, 153], ["post-translational modifications", "TREATMENT", 234, 266], ["protein microarrayAcetylation", "TREATMENT", 273, 302], ["deacetylation", "TREATMENT", 307, 320], ["the lysine residues in proteins", "TREATMENT", 324, 355], ["especially histones", "PROBLEM", 357, 376], ["gene expression", "PROBLEM", 444, 459], ["these histone acetyltransferases", "TREATMENT", 536, 568], ["deacetylases", "TEST", 573, 585], ["ribosome biogenesis", "OBSERVATION", 94, 113], ["post-translational modifications", "OBSERVATION", 234, 266]]], ["Of the many different histone acetyltransferases, only the catalytic enzyme Esa1p in the essential nucleosome acetyltransferase of H4 (NuA4) complex was found required for the viability of the cells, indicating this complex may have additional roles beyond gene expression regulation [90].", [["cells", "ANATOMY", 193, 198], ["histone acetyltransferases", "GENE_OR_GENE_PRODUCT", 22, 48], ["Esa1p", "GENE_OR_GENE_PRODUCT", 76, 81], ["nucleosome", "CELLULAR_COMPONENT", 99, 109], ["acetyltransferase of H4", "GENE_OR_GENE_PRODUCT", 110, 133], ["NuA4", "GENE_OR_GENE_PRODUCT", 135, 139], ["cells", "CELL", 193, 198], ["histone acetyltransferases", "PROTEIN", 22, 48], ["catalytic enzyme", "PROTEIN", 59, 75], ["Esa1p", "PROTEIN", 76, 81], ["essential nucleosome acetyltransferase", "PROTEIN", 89, 127], ["H4 (NuA4) complex", "PROTEIN", 131, 148], ["the catalytic enzyme", "TEST", 55, 75], ["histone acetyltransferases", "OBSERVATION", 22, 48], ["nucleosome acetyltransferase", "OBSERVATION", 99, 127]]], ["By incubating the NuA4 complex with yeast proteome microarrays in the presence of 14C labeled Acetyl-CoA, Lin et al. discovered a large number of novel non-histone substrates for NuA4 and confirmed 13 of them with standard in vitro activity assays [88]; and more importantly, the authors also validated these substrates with in vivo experiments [91]: the levels of acetylated substrates were found decreased dramatically in ESA1 Ts (esa1-531) mutant cells when they were grown at the nonpermissive temperature, which proved that these proteins are real in vivo targets of Esa1p.", [["cells", "ANATOMY", 450, 455], ["14C", "CHEMICAL", 82, 85], ["Acetyl-CoA", "CHEMICAL", 94, 104], ["14C", "CHEMICAL", 82, 85], ["Acetyl-CoA", "CHEMICAL", 94, 104], ["NuA4", "GENE_OR_GENE_PRODUCT", 18, 22], ["14C", "SIMPLE_CHEMICAL", 82, 85], ["Acetyl-CoA", "SIMPLE_CHEMICAL", 94, 104], ["NuA4", "GENE_OR_GENE_PRODUCT", 179, 183], ["esa1-531", "GENE_OR_GENE_PRODUCT", 433, 441], ["Esa1p", "GENE_OR_GENE_PRODUCT", 572, 577], ["NuA4 complex", "PROTEIN", 18, 30], ["non-histone substrates", "PROTEIN", 152, 174], ["NuA4", "PROTEIN", 179, 183], ["ESA1 Ts (esa1-531) mutant cells", "CELL_LINE", 424, 455], ["Esa1p", "PROTEIN", 572, 577], ["yeast", "SPECIES", 36, 41], ["yeast", "SPECIES", 36, 41], ["yeast proteome microarrays", "TREATMENT", 36, 62], ["novel non-histone substrates", "TREATMENT", 146, 174], ["NuA4", "TEST", 179, 183], ["standard in vitro activity assays", "TEST", 214, 247], ["acetylated substrates", "PROBLEM", 365, 386], ["esa1", "TEST", 433, 437], ["mutant cells", "PROBLEM", 443, 455], ["these proteins", "PROBLEM", 529, 543], ["CoA", "ANATOMY", 101, 104], ["large", "OBSERVATION_MODIFIER", 130, 135], ["decreased", "OBSERVATION_MODIFIER", 398, 407], ["nonpermissive temperature", "OBSERVATION_MODIFIER", 484, 509]]], ["The authors then focused on Pck1p (phosphoenolpyruvate carboxykinase), a metabolic enzyme involved in gluconeogenesis, and found that the acetylation of Pck1p is essential for its enzymatic activity and the life span of yeast.", [["phosphoenolpyruvate", "CHEMICAL", 35, 54], ["Pck1p", "GENE_OR_GENE_PRODUCT", 28, 33], ["phosphoenolpyruvate carboxykinase", "GENE_OR_GENE_PRODUCT", 35, 68], ["Pck1p", "GENE_OR_GENE_PRODUCT", 153, 158], ["Pck1p", "PROTEIN", 28, 33], ["phosphoenolpyruvate carboxykinase", "PROTEIN", 35, 68], ["metabolic enzyme", "PROTEIN", 73, 89], ["Pck1p", "PROTEIN", 153, 158], ["yeast", "SPECIES", 220, 225], ["yeast", "SPECIES", 220, 225], ["Pck1p (phosphoenolpyruvate carboxykinase", "TREATMENT", 28, 68], ["a metabolic enzyme", "TEST", 71, 89], ["the acetylation of Pck1p", "PROBLEM", 134, 158], ["its enzymatic activity", "PROBLEM", 176, 198], ["yeast", "PROBLEM", 220, 225]]], ["This study is one of the first to examine an important acetyltransferase complex for non-histone-related regulatory functions in the cell and suggests that histone acetyltransferases and deacetylases may also have other important cellular roles besides chromatin-related processes.", [["cell", "ANATOMY", 133, 137], ["cellular", "ANATOMY", 230, 238], ["chromatin", "ANATOMY", 253, 262], ["acetyltransferase complex", "GENE_OR_GENE_PRODUCT", 55, 80], ["cell", "CELL", 133, 137], ["histone acetyltransferases", "GENE_OR_GENE_PRODUCT", 156, 182], ["cellular", "CELL", 230, 238], ["chromatin", "CELLULAR_COMPONENT", 253, 262], ["acetyltransferase complex", "PROTEIN", 55, 80], ["histone acetyltransferases", "PROTEIN", 156, 182], ["deacetylases", "PROTEIN", 187, 199], ["chromatin", "DNA", 253, 262], ["This study", "TEST", 0, 10], ["histone acetyltransferases", "TREATMENT", 156, 182], ["deacetylases", "TREATMENT", 187, 199], ["histone acetyltransferases", "OBSERVATION", 156, 182]]], ["Moreover, in vivo validation of the acetylation targets of the NuA4 complex suggested that using enzyme complexes instead of individual proteins in protein microarray studies may help identify substrates that are more physiologically relevant.Detection of post-translational modifications using protein microarrayUbiquitination is another critical post-translational modification involved in various cellular processes.", [["cellular", "ANATOMY", 400, 408], ["NuA4", "GENE_OR_GENE_PRODUCT", 63, 67], ["cellular", "CELL", 400, 408], ["NuA4 complex", "PROTEIN", 63, 75], ["enzyme complexes", "PROTEIN", 97, 113], ["enzyme complexes", "TEST", 97, 113], ["protein microarray studies", "TEST", 148, 174], ["post-translational modifications", "PROBLEM", 256, 288], ["protein microarrayUbiquitination", "TREATMENT", 295, 327], ["post-translational modifications", "OBSERVATION", 256, 288], ["cellular processes", "OBSERVATION", 400, 418]]], ["It facilitates proteosome-mediated protein degradation/recycling [92] as well as activation of cell signaling molecules [93].", [["cell", "ANATOMY", 95, 99], ["proteosome", "GENE_OR_GENE_PRODUCT", 15, 25], ["cell", "CELL", 95, 99], ["proteosome", "PROTEIN", 15, 25], ["cell signaling molecules", "PROTEIN", 95, 119], ["mediated protein degradation", "PROBLEM", 26, 54], ["cell signaling molecules", "TEST", 95, 119]]], ["Gupta et al. identified the substrates of Rsp5, a ubiquitin-protein ligase (E3) in yeast by both in vitro ubiquitination and protein interaction assays [94].", [["Rsp5", "GENE_OR_GENE_PRODUCT", 42, 46], ["E3", "GENE_OR_GENE_PRODUCT", 76, 78], ["Rsp5", "PROTEIN", 42, 46], ["ubiquitin-protein ligase", "PROTEIN", 50, 74], ["E3", "PROTEIN", 76, 78], ["yeast", "SPECIES", 83, 88], ["yeast", "SPECIES", 83, 88], ["Rsp5", "TEST", 42, 46], ["a ubiquitin-protein ligase", "TEST", 48, 74], ["protein interaction assays", "TEST", 125, 151]]], ["To identify substrates that could be ubiquitinated by Rsp5, the authors incubated the yeast protein microarrays with Rsp5 and FITC-labeled ubiquitin; alternatively, the arrays were probed with Alexa Fluor 647-labeled Rsp5 to identify interacting proteins.", [["FITC", "CHEMICAL", 126, 130], ["Alexa Fluor 647", "CHEMICAL", 193, 208], ["Rsp5", "GENE_OR_GENE_PRODUCT", 54, 58], ["Rsp5", "GENE_OR_GENE_PRODUCT", 117, 121], ["FITC", "GENE_OR_GENE_PRODUCT", 126, 130], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 139, 148], ["Alexa Fluor 647", "SIMPLE_CHEMICAL", 193, 208], ["Rsp5", "GENE_OR_GENE_PRODUCT", 217, 221], ["Rsp5", "PROTEIN", 54, 58], ["Rsp5", "PROTEIN", 117, 121], ["FITC-labeled ubiquitin", "PROTEIN", 126, 148], ["Alexa Fluor 647-labeled Rsp5", "PROTEIN", 193, 221], ["interacting proteins", "PROTEIN", 234, 254], ["yeast", "SPECIES", 86, 91], ["yeast", "SPECIES", 86, 91], ["the yeast protein microarrays", "TEST", 82, 111], ["Rsp5", "TEST", 117, 121], ["FITC", "TEST", 126, 130], ["Alexa Fluor", "TEST", 193, 204], ["interacting proteins", "PROBLEM", 234, 254]]], ["One hundred and fifty proteins were identified in the ubiquitination assay and 155 in the interaction assay, of which 64 proteins were identified in both sets of experiments.", [["fifty proteins", "TEST", 16, 30], ["the ubiquitination assay", "TEST", 50, 74], ["the interaction assay", "TEST", 86, 107], ["ubiquitination assay", "OBSERVATION", 54, 74]]], ["Of these identified substrates, the authors discovered more details of the known PY motif for Rsp5 binding.", [["Rsp5", "GENE_OR_GENE_PRODUCT", 94, 98], ["PY motif", "PROTEIN", 81, 89], ["Rsp5", "PROTEIN", 94, 98], ["Rsp5 binding", "PROBLEM", 94, 106]]], ["They found that Prolines, Serines and Alanines were enriched in the (L/P)PxY motif (at position x) which may also contribute to substrate specificity.Detection of post-translational modifications using protein microarrayProtein microarray technology was also used for the discovery of other protein post-translational modifications such as S-nitrosylation [95].", [["Prolines", "CHEMICAL", 16, 24], ["Serines", "CHEMICAL", 26, 33], ["Alanines", "CHEMICAL", 38, 46], ["Prolines", "CHEMICAL", 16, 24], ["Serines", "CHEMICAL", 26, 33], ["Alanines", "CHEMICAL", 38, 46], ["Prolines", "SIMPLE_CHEMICAL", 16, 24], ["Serines", "SIMPLE_CHEMICAL", 26, 33], ["Alanines", "SIMPLE_CHEMICAL", 38, 46], ["Serines and Alanines", "TREATMENT", 26, 46], ["the (L/P)PxY motif (at position x)", "TREATMENT", 64, 98], ["post-translational modifications", "TREATMENT", 163, 195], ["protein microarray", "TEST", 202, 220], ["Protein microarray technology", "TEST", 220, 249], ["other protein", "PROBLEM", 285, 298], ["translational modifications", "TREATMENT", 304, 331]]], ["This type of post-translational modification plays an important role in nitric oxide (NO) and endogenous S-nitrosothiol (SNO) signaling, abnormal regulation of which is associated with diseases such as neurological dysfunction and cancer [95], [96], [97].", [["neurological", "ANATOMY", 202, 214], ["cancer", "ANATOMY", 231, 237], ["nitric oxide", "CHEMICAL", 72, 84], ["NO", "CHEMICAL", 86, 88], ["S-nitrosothiol", "CHEMICAL", 105, 119], ["SNO", "CHEMICAL", 121, 124], ["neurological dysfunction", "DISEASE", 202, 226], ["cancer", "DISEASE", 231, 237], ["nitric oxide", "CHEMICAL", 72, 84], ["NO", "CHEMICAL", 86, 88], ["S-nitrosothiol", "CHEMICAL", 105, 119], ["SNO", "CHEMICAL", 121, 124], ["nitric oxide", "SIMPLE_CHEMICAL", 72, 84], ["NO", "SIMPLE_CHEMICAL", 86, 88], ["S-nitrosothiol", "SIMPLE_CHEMICAL", 105, 119], ["SNO", "SIMPLE_CHEMICAL", 121, 124], ["cancer", "CANCER", 231, 237], ["post-translational modification", "TREATMENT", 13, 44], ["nitric oxide", "TREATMENT", 72, 84], ["endogenous S-nitrosothiol (SNO)", "TREATMENT", 94, 125], ["abnormal regulation", "PROBLEM", 137, 156], ["diseases", "PROBLEM", 185, 193], ["neurological dysfunction", "PROBLEM", 202, 226], ["cancer", "PROBLEM", 231, 237], ["post-translational modification", "OBSERVATION", 13, 44]]], ["Using a biotin switch technique that converts SNO to S-biotinylated Cys [98], which is then readily detectable with anti-biotin antibody, Foster et al. identified several hundred SNO-proteins after S-nitrosocysteine treatment of the yeast protein microarrays [95].", [["biotin", "CHEMICAL", 8, 14], ["SNO", "CHEMICAL", 46, 49], ["S-biotinylated Cys", "CHEMICAL", 53, 71], ["S-nitrosocysteine", "CHEMICAL", 198, 215], ["biotin", "CHEMICAL", 8, 14], ["SNO", "CHEMICAL", 46, 49], ["Cys", "CHEMICAL", 68, 71], ["anti-biotin", "CHEMICAL", 116, 127], ["S-nitrosocysteine", "CHEMICAL", 198, 215], ["biotin", "SIMPLE_CHEMICAL", 8, 14], ["SNO", "SIMPLE_CHEMICAL", 46, 49], ["S-biotinylated Cys [98]", "SIMPLE_CHEMICAL", 53, 76], ["anti-biotin", "SIMPLE_CHEMICAL", 116, 127], ["S-nitrosocysteine", "SIMPLE_CHEMICAL", 198, 215], ["anti-biotin antibody", "PROTEIN", 116, 136], ["hundred SNO-proteins", "PROTEIN", 171, 191], ["yeast", "SPECIES", 233, 238], ["yeast", "SPECIES", 233, 238], ["a biotin switch technique", "TREATMENT", 6, 31], ["S-biotinylated Cys", "TEST", 53, 71], ["anti-biotin antibody", "PROBLEM", 116, 136], ["S-nitrosocysteine treatment", "TREATMENT", 198, 225], ["the yeast protein microarrays", "TEST", 229, 258], ["several", "OBSERVATION_MODIFIER", 163, 170], ["hundred SNO", "OBSERVATION_MODIFIER", 171, 182]]], ["These proteins were enriched with proteins with active-site Cys thiols, however, neither secondary structures nor Cys thiol nucleophilicity could explain substrate specificity.", [["Cys thiol", "CHEMICAL", 114, 123], ["Cys", "CHEMICAL", 60, 63], ["thiols", "CHEMICAL", 64, 70], ["Cys", "CHEMICAL", 114, 117], ["thiol", "CHEMICAL", 118, 123], ["Cys thiols", "SIMPLE_CHEMICAL", 60, 70], ["Cys thiol nucleophilicity", "SIMPLE_CHEMICAL", 114, 139], ["These proteins", "TEST", 0, 14], ["Cys thiol nucleophilicity", "PROBLEM", 114, 139], ["thiol nucleophilicity", "OBSERVATION", 118, 139]]], ["The authors then found out that S-nitrosylation efficiency might depend on the stereochemistry and structure of the NO-donor as well as allosteric effectors.Advantages and limitations of protein microarray technologyAs reviewed above, protein microarray technology serves as a powerful and convenient tool in a large-scale, high-throughput manner for proteomic studies such as protein interactions and modifications.", [["NO", "CHEMICAL", 116, 118], ["NO", "CHEMICAL", 116, 118], ["NO", "SIMPLE_CHEMICAL", 116, 118], ["allosteric effectors", "PROTEIN", 136, 156], ["S-nitrosylation efficiency", "PROBLEM", 32, 58], ["protein microarray technology", "TREATMENT", 187, 216], ["proteomic studies", "TEST", 351, 368], ["protein interactions", "TREATMENT", 377, 397], ["S-nitrosylation efficiency", "OBSERVATION", 32, 58], ["allosteric effectors", "OBSERVATION", 136, 156]]], ["The advantages of the protein microarray technology are (also refer to review by Zhu et al. [17]): its convenient and straightforward probing using a wide variety of standard detection platforms, the ability to control and fine-tune experimental conditions, and its unbiased protein target selection (regardless of their endogenous cellular abundance) due to its particular fashion of manufacture.", [["cellular", "ANATOMY", 332, 340], ["cellular", "CELL", 332, 340], ["manufacture", "OBSERVATION", 385, 396]]], ["The latter enables the inclusion of normally underrepresented proteins such as low abundant proteins, membrane and secreted proteins, and conditionally expressed proteins.Advantages and limitations of protein microarray technologyProtein microarray technology also have limitations.", [["membrane", "ANATOMY", 102, 110], ["membrane", "CELLULAR_COMPONENT", 102, 110], ["low abundant proteins", "PROTEIN", 79, 100], ["membrane and secreted proteins", "PROTEIN", 102, 132], ["conditionally expressed proteins", "PROTEIN", 138, 170], ["low abundant proteins", "PROBLEM", 79, 100], ["membrane and secreted proteins", "PROBLEM", 102, 132], ["protein microarray technology", "TREATMENT", 201, 230], ["Protein microarray technology", "TEST", 230, 259]]], ["First, the scope of protein microarray relies heavily on the availability of genomic information of the specific organisms.", [["protein microarray", "TEST", 20, 38]]], ["Therefore, this technology is not capable of covering unknown ORFs/splicing variants, and is unavailable for organisms whose genome information is unknown.", [["ORFs", "DNA", 62, 66], ["splicing variants", "DNA", 67, 84], ["unknown ORFs/splicing variants", "PROBLEM", 54, 84], ["organisms", "PROBLEM", 109, 118], ["splicing variants", "OBSERVATION", 67, 84]]], ["Second, as proteins are purified from the cells, they may contain mixed post-translational modifications or even co-purified interacting proteins, which may interfere with the protein binding, kinase assays and post-translational modification detection.", [["cells", "ANATOMY", 42, 47], ["cells", "CELL", 42, 47], ["co-purified interacting proteins", "PROTEIN", 113, 145], ["mixed post-translational modifications", "PROBLEM", 66, 104], ["co-purified interacting proteins", "PROBLEM", 113, 145], ["the protein binding", "TEST", 172, 191], ["kinase assays", "TEST", 193, 206], ["post-translational modification detection", "TEST", 211, 252], ["mixed", "OBSERVATION_MODIFIER", 66, 71]]], ["In vitro expression methods may avoid contamination from other tightly interacting proteins; however, proteins produced this way may not be properly folded or modified.", [["tightly interacting proteins", "PROTEIN", 63, 91], ["contamination", "PROBLEM", 38, 51], ["other tightly interacting proteins", "PROBLEM", 57, 91]]], ["Third, as protein microarray-based studies are in vitro studies, off-target interactions and modifications that do not normally happen in cell may also occur.", [["cell", "ANATOMY", 138, 142], ["cell", "CELL", 138, 142], ["protein microarray", "TEST", 10, 28], ["based studies", "TEST", 29, 42], ["vitro studies", "TEST", 50, 63]]], ["For this reason protein microarray findings should be validated with more direct methods such as immunoprecipitation, immunoblotting and in vitro and in vivo activity assays.", [["protein microarray findings", "PROBLEM", 16, 43], ["immunoprecipitation", "TREATMENT", 97, 116], ["immunoblotting", "TREATMENT", 118, 132]]], ["Furthermore, as the cost for manufacturing protein microarrays is still high, it can be expensive to study large proteomes such as the human proteome.", [["human", "ORGANISM", 135, 140], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 135, 140], ["manufacturing protein microarrays", "TEST", 29, 62]]], ["Lastly, the specific platform of protein microarray usually allows only one or two probes/enzymes per each assay on a single proteome array, which, with the cost of manufacturing the protein microarrays, limits researchers to investigate only one or a few probes/enzymes at a time.", [["enzymes", "PROTEIN", 90, 97], ["enzymes", "PROTEIN", 263, 270], ["protein microarray", "TEST", 33, 51], ["enzymes", "TEST", 90, 97], ["manufacturing the protein microarrays", "TREATMENT", 165, 202]]], ["This limitation will be significantly alleviated, however, with the drop of manufacturing cost as well as improvements in multiplexing technologies.Closing remarksSince its debut a decade ago, protein microarray technology has evolved into a powerful tool in proteomic studies.", [["manufacturing cost", "TREATMENT", 76, 94], ["protein microarray technology", "TEST", 193, 222], ["proteomic studies", "TEST", 259, 276]]], ["Application of this technology in the model organism S. cerevisiae has led to numerous significant scientific findings at the proteomic level, including protein\u2013protein, protein\u2013DNA and protein\u2013small molecule interactions as well as post-translational modifications.", [["S. cerevisiae", "ORGANISM", 53, 66], ["S. cerevisiae", "SPECIES", 53, 66], ["S. cerevisiae", "SPECIES", 53, 66], ["this technology", "TREATMENT", 15, 30], ["protein\u2013protein", "TEST", 153, 168], ["protein\u2013DNA", "TREATMENT", 170, 181], ["protein\u2013small molecule interactions", "PROBLEM", 186, 221], ["numerous", "OBSERVATION_MODIFIER", 78, 86], ["significant", "OBSERVATION_MODIFIER", 87, 98], ["protein\u2013small molecule interactions", "OBSERVATION", 186, 221], ["post-translational modifications", "OBSERVATION", 233, 265]]], ["Since many of these mechanisms are conserved through evolution, some of these findings are expected to be relevant to those occurring in other organisms, such as plant and human [99].", [["human", "ORGANISM", 172, 177], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 172, 177]]], ["In fact, multiple studies mentioned above have already confirmed the counterparts of their findings in humans [57], [85], [88].Closing remarksThe proteome is only a part of the complex network in a living organism.", [["humans", "ORGANISM", 103, 109], ["humans", "SPECIES", 103, 109], ["humans", "SPECIES", 103, 109], ["multiple studies", "TEST", 9, 25]]], ["It coordinates with the other systems including the genome, the transcriptome, and the metabolome, to carry out complex cellular functions and intercellular communication [100].", [["cellular", "ANATOMY", 120, 128], ["intercellular", "ANATOMY", 143, 156], ["cellular", "CELL", 120, 128]]], ["With the emergence of new high throughput technologies such as next generation high-throughput sequencing [101] and improved mass spectrometry technologies [1], it becomes possible to simultaneously generate integrated networks at the systems level from the same sample sets in a time dependent manner, if desired.", [["new high throughput technologies", "TREATMENT", 22, 54], ["improved mass spectrometry technologies", "PROBLEM", 116, 155]]], ["Time-resolved global networks generated from quantitative data sets of the proteome, the genome, the methylome, the transcriptome and the metabolome, with environmental factors such as the microbiome (Fig. 4), will enable a comprehensive view of miscellaneous biological processes, as well as their roles in natural courses such as development and aging, and in pathogenesis of human diseases such as cancer.", [["cancer", "ANATOMY", 401, 407], ["cancer", "DISEASE", 401, 407], ["human", "ORGANISM", 378, 383], ["cancer", "CANCER", 401, 407], ["human", "SPECIES", 378, 383], ["human", "SPECIES", 378, 383], ["environmental factors", "TREATMENT", 155, 176], ["human diseases", "PROBLEM", 378, 392], ["cancer", "PROBLEM", 401, 407], ["cancer", "OBSERVATION", 401, 407]]]], "PMC7294903": [["IntroductionCoronavirus 2019 (COVID-19) pneumonia is caused by a novel virus from the Coronaviridae family, from which the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) viruses also originated, causing two epidemics in 2002 and 2012, respectively.", [["COVID-19", "CHEMICAL", 30, 38], ["pneumonia", "DISEASE", 40, 49], ["acute respiratory syndrome", "DISEASE", 130, 156], ["SARS", "DISEASE", 158, 162], ["Middle East respiratory syndrome (MERS) viruses", "DISEASE", 168, 215], ["COVID-19", "ORGANISM", 30, 38], ["Middle East respiratory", "ORGANISM", 168, 191], ["IntroductionCoronavirus 2019 (COVID-19", "SPECIES", 0, 38], ["Middle East respiratory syndrome (MERS) viruses", "SPECIES", 168, 215], ["IntroductionCoronavirus", "TEST", 0, 23], ["COVID", "TEST", 30, 35], ["pneumonia", "PROBLEM", 40, 49], ["a novel virus", "PROBLEM", 63, 76], ["the severe acute respiratory syndrome", "PROBLEM", 119, 156], ["SARS)", "PROBLEM", 158, 163], ["Middle East respiratory syndrome (MERS) viruses", "PROBLEM", 168, 215], ["pneumonia", "OBSERVATION", 40, 49], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["respiratory syndrome", "OBSERVATION", 136, 156], ["Middle", "ANATOMY_MODIFIER", 168, 174], ["respiratory syndrome", "OBSERVATION", 180, 200], ["epidemics", "OBSERVATION_MODIFIER", 245, 254]]], ["According to the previous study, the disease develops in three phases: early (Days 1-3), intermediate (Days 4-6), late (after Day 6) [1].", [["the previous study", "TEST", 13, 31], ["the disease", "PROBLEM", 33, 44], ["disease", "OBSERVATION", 37, 44]]], ["Even if chest CT can detect lung anomalies before symptom onset, the findings follow a temporal pattern and are consistent with clinicopathological development: the first and most common feature is ground-glass opacity (GGO), which represents early alveolar damage, with bilateral subpleural distribution in the lower lobes; then, areas of consolidation appear and tend to coalesce on the underlying GGOs.", [["chest", "ANATOMY", 8, 13], ["lung", "ANATOMY", 28, 32], ["alveolar", "ANATOMY", 249, 257], ["subpleural", "ANATOMY", 281, 291], ["lower lobes", "ANATOMY", 312, 323], ["lung anomalies", "DISEASE", 28, 42], ["GGO", "DISEASE", 220, 223], ["alveolar damage", "DISEASE", 249, 264], ["chest", "ORGAN", 8, 13], ["lung", "ORGAN", 28, 32], ["alveolar", "TISSUE", 249, 257], ["lower lobes", "ORGAN", 312, 323], ["GGOs", "PATHOLOGICAL_FORMATION", 400, 404], ["chest CT", "TEST", 8, 16], ["lung anomalies", "PROBLEM", 28, 42], ["ground-glass opacity", "PROBLEM", 198, 218], ["early alveolar damage", "PROBLEM", 243, 264], ["bilateral subpleural distribution in the lower lobes", "PROBLEM", 271, 323], ["consolidation", "PROBLEM", 340, 353], ["the underlying GGOs", "PROBLEM", 385, 404], ["chest", "ANATOMY", 8, 13], ["lung", "ANATOMY", 28, 32], ["anomalies", "OBSERVATION", 33, 42], ["consistent with", "UNCERTAINTY", 112, 127], ["most common", "OBSERVATION_MODIFIER", 175, 186], ["ground", "OBSERVATION", 198, 204], ["glass opacity", "OBSERVATION", 205, 218], ["GGO", "OBSERVATION_MODIFIER", 220, 223], ["early", "OBSERVATION_MODIFIER", 243, 248], ["alveolar", "ANATOMY_MODIFIER", 249, 257], ["damage", "OBSERVATION", 258, 264], ["bilateral", "ANATOMY_MODIFIER", 271, 280], ["subpleural", "ANATOMY_MODIFIER", 281, 291], ["distribution", "OBSERVATION_MODIFIER", 292, 304], ["lower lobes", "ANATOMY", 312, 323], ["areas", "OBSERVATION_MODIFIER", 331, 336], ["consolidation", "OBSERVATION", 340, 353], ["coalesce", "OBSERVATION_MODIFIER", 373, 381]]], ["Later, in this background, the \u201ccrazy paving\u201d pattern can be seen, with thickened interlobular septa and intralobular lines.", [["interlobular septa", "ANATOMY", 82, 100], ["intralobular lines", "ANATOMY", 105, 123], ["interlobular septa", "TISSUE", 82, 100], ["intralobular lines", "CELL", 105, 123], ["thickened interlobular septa", "PROBLEM", 72, 100], ["intralobular lines", "PROBLEM", 105, 123], ["can be seen", "UNCERTAINTY", 54, 65], ["thickened", "OBSERVATION", 72, 81], ["interlobular", "ANATOMY_MODIFIER", 82, 94], ["septa", "ANATOMY_MODIFIER", 95, 100], ["intralobular lines", "OBSERVATION", 105, 123]]], ["Lymphadenopathies and pleural effusion are rarely seen [2].IntroductionChest CT plays a pivotal role in the detection and early management of COVID-19 pneumonia; despite its sensitivity, it lacks specificity because of the wide spectrum of pathologies that can show GGO.", [["pleural effusion", "ANATOMY", 22, 38], ["Lymphadenopathies", "DISEASE", 0, 17], ["pleural effusion", "DISEASE", 22, 38], ["pneumonia", "DISEASE", 151, 160], ["GGO", "DISEASE", 266, 269], ["pleural effusion", "CANCER", 22, 38], ["COVID-19", "SPECIES", 142, 150], ["Lymphadenopathies", "PROBLEM", 0, 17], ["pleural effusion", "PROBLEM", 22, 38], ["IntroductionChest CT", "TEST", 59, 79], ["the detection", "TEST", 104, 117], ["early management", "TREATMENT", 122, 138], ["COVID-19 pneumonia", "PROBLEM", 142, 160], ["the wide spectrum of pathologies", "PROBLEM", 219, 251], ["GGO", "PROBLEM", 266, 269], ["pleural", "ANATOMY", 22, 29], ["effusion", "OBSERVATION", 30, 38], ["pneumonia", "OBSERVATION", 151, 160], ["pathologies", "OBSERVATION", 240, 251], ["GGO", "OBSERVATION", 266, 269]]], ["The aim of our study is to show chest CT findings that could mimic COVID-19 pneumonia; in the COVID-19 era, we should not forget other lung diseases that could be misinterpreted in our experience.", [["chest", "ANATOMY", 32, 37], ["lung", "ANATOMY", 135, 139], ["pneumonia", "DISEASE", 76, 85], ["lung diseases", "DISEASE", 135, 148], ["lung", "ORGAN", 135, 139], ["our study", "TEST", 11, 20], ["chest CT", "TEST", 32, 40], ["COVID", "TEST", 67, 72], ["pneumonia", "PROBLEM", 76, 85], ["other lung diseases", "PROBLEM", 129, 148], ["chest", "ANATOMY", 32, 37], ["pneumonia", "OBSERVATION", 76, 85], ["lung", "ANATOMY", 135, 139], ["diseases", "OBSERVATION", 140, 148]]], ["It is, therefore, fundamental to correlate CT findings with clinical history and lab data to achieve the correct diagnosis and an integrated scenario for every patient [3].IntroductionGround-glass opacity is de\ufb01ned as hazy opacity that does not obscure underlying bronchial structures or pulmonary vessels at computed tomography (CT).", [["bronchial structures", "ANATOMY", 264, 284], ["pulmonary vessels", "ANATOMY", 288, 305], ["patient", "ORGANISM", 160, 167], ["bronchial structures", "MULTI-TISSUE_STRUCTURE", 264, 284], ["pulmonary vessels", "MULTI-TISSUE_STRUCTURE", 288, 305], ["patient", "SPECIES", 160, 167], ["CT findings", "TEST", 43, 54], ["lab data", "TEST", 81, 89], ["Ground-glass opacity", "PROBLEM", 184, 204], ["hazy opacity", "PROBLEM", 218, 230], ["underlying bronchial structures", "PROBLEM", 253, 284], ["computed tomography", "TEST", 309, 328], ["CT", "TEST", 330, 332], ["glass opacity", "OBSERVATION", 191, 204], ["hazy", "OBSERVATION_MODIFIER", 218, 222], ["opacity", "OBSERVATION", 223, 230], ["does not obscure", "UNCERTAINTY", 236, 252], ["bronchial", "ANATOMY", 264, 273], ["pulmonary vessels", "ANATOMY", 288, 305]]], ["It represents many histopathological processes because the underlying mechanism may be partial airspace \ufb01lling; interstitial thickening with in\ufb02ammation, edema, \ufb01brosis; and neoplastic proliferation.", [["airspace", "ANATOMY", 95, 103], ["interstitial", "ANATOMY", 112, 124], ["edema", "ANATOMY", 154, 159], ["neoplastic", "ANATOMY", 174, 184], ["in\ufb02ammation", "DISEASE", 141, 152], ["edema", "DISEASE", 154, 159], ["\ufb01brosis", "DISEASE", 161, 168], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 124], ["edema", "PATHOLOGICAL_FORMATION", 154, 159], ["many histopathological processes", "PROBLEM", 14, 46], ["partial airspace \ufb01lling", "PROBLEM", 87, 110], ["interstitial thickening", "PROBLEM", 112, 135], ["in\ufb02ammation", "PROBLEM", 141, 152], ["edema", "PROBLEM", 154, 159], ["\ufb01brosis", "PROBLEM", 161, 168], ["neoplastic proliferation", "PROBLEM", 174, 198], ["many", "OBSERVATION_MODIFIER", 14, 18], ["histopathological", "OBSERVATION", 19, 36], ["may be", "UNCERTAINTY", 80, 86], ["partial", "OBSERVATION_MODIFIER", 87, 94], ["airspace", "OBSERVATION", 95, 103], ["interstitial", "ANATOMY_MODIFIER", 112, 124], ["thickening", "OBSERVATION", 125, 135], ["edema", "OBSERVATION", 154, 159], ["\ufb01brosis", "OBSERVATION_MODIFIER", 161, 168], ["neoplastic proliferation", "OBSERVATION", 174, 198]]], ["GGO is a frequent focal lung finding representing cancer; it can also represent lung infections, lung edema, or interstitial diseases (where GGO can represent disease activity and may precede irreversible fibrosis).", [["lung", "ANATOMY", 24, 28], ["cancer", "ANATOMY", 50, 56], ["lung", "ANATOMY", 80, 84], ["lung", "ANATOMY", 97, 101], ["interstitial", "ANATOMY", 112, 124], ["GGO", "DISEASE", 0, 3], ["cancer", "DISEASE", 50, 56], ["lung infections", "DISEASE", 80, 95], ["lung edema", "DISEASE", 97, 107], ["interstitial diseases", "DISEASE", 112, 133], ["GGO", "DISEASE", 141, 144], ["fibrosis", "DISEASE", 205, 213], ["lung", "ORGAN", 24, 28], ["cancer", "CANCER", 50, 56], ["lung", "ORGAN", 80, 84], ["lung", "ORGAN", 97, 101], ["GGO", "PROBLEM", 0, 3], ["a frequent focal lung finding", "PROBLEM", 7, 36], ["cancer", "PROBLEM", 50, 56], ["lung infections", "PROBLEM", 80, 95], ["lung edema", "PROBLEM", 97, 107], ["interstitial diseases", "PROBLEM", 112, 133], ["GGO", "PROBLEM", 141, 144], ["disease activity", "PROBLEM", 159, 175], ["irreversible fibrosis", "PROBLEM", 192, 213], ["frequent", "OBSERVATION_MODIFIER", 9, 17], ["focal", "OBSERVATION_MODIFIER", 18, 23], ["lung", "ANATOMY", 24, 28], ["cancer", "OBSERVATION", 50, 56], ["can also represent", "UNCERTAINTY", 61, 79], ["lung", "ANATOMY", 80, 84], ["infections", "OBSERVATION", 85, 95], ["lung", "ANATOMY", 97, 101], ["edema", "OBSERVATION", 102, 107], ["interstitial", "ANATOMY_MODIFIER", 112, 124], ["diseases", "OBSERVATION", 125, 133], ["may precede", "UNCERTAINTY", 180, 191], ["irreversible", "OBSERVATION_MODIFIER", 192, 204], ["fibrosis", "OBSERVATION", 205, 213]]], ["Since it is a non-specific radiological finding, it is fundamental to know the underlying physiopathology to narrow the differential diagnosis [4].Materials and methodsWe retrospectively enrolled 33 patients aged between 19 and 88 years (20 males and 13 females), admitted to Verona A.O.U.I. - Policlinico Universitario G. B. Rossi, who underwent non-contrast-enhanced (NCE) and contrast-enhanced (CE) chest CT between March 12 and April 12.", [["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 199, 207], ["a non-specific radiological finding", "PROBLEM", 12, 47], ["chest CT", "TEST", 402, 410], ["non-specific", "OBSERVATION_MODIFIER", 14, 26], ["chest", "ANATOMY", 402, 407]]], ["When CE-CT was performed, we used a high iodine concentration contrast agent (Ultravist 370, Bayer Schering Pharma AG, Berlin, Germany).", [["CE", "CHEMICAL", 5, 7], ["iodine", "CHEMICAL", 41, 47], ["iodine", "CHEMICAL", 41, 47], ["iodine", "SIMPLE_CHEMICAL", 41, 47], ["CE-CT", "TEST", 5, 10], ["a high iodine concentration contrast agent", "TREATMENT", 34, 76]]], ["We included all patients with CT images positive for GGO.", [["GGO", "DISEASE", 53, 56], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["CT images", "TEST", 30, 39], ["GGO", "PROBLEM", 53, 56], ["GGO", "OBSERVATION", 53, 56]]], ["COVID-19 patients were excluded from this study.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["this study", "TEST", 37, 47]]], ["Patients tested for COVID-19 underwent a reverse transcription-polymerase chain reaction RT-PCR assay on a nasopharyngeal swab.", [["nasopharyngeal swab", "ANATOMY", 107, 126], ["Patients", "ORGANISM", 0, 8], ["nasopharyngeal swab", "CANCER", 107, 126], ["COVID-19", "DNA", 20, 28], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 20, 25], ["a reverse transcription", "TEST", 39, 62], ["polymerase chain reaction", "TEST", 63, 88], ["PCR assay", "TEST", 92, 101], ["a nasopharyngeal swab", "TEST", 105, 126], ["nasopharyngeal", "ANATOMY", 107, 121], ["swab", "OBSERVATION", 122, 126]]], ["Patients with other infective pneumonia were confirmed with bronchoalveolar lavage (BAL), viral panel, serologic tests, or blood cultures.Materials and methodsCTs were performed with the patient supine at full inspiration, using a 64-row MDCT scanner (Brilliance iCT, Philips Healthcare, Amsterdam, Netherlands).", [["bronchoalveolar lavage", "ANATOMY", 60, 82], ["BAL", "ANATOMY", 84, 87], ["blood cultures", "ANATOMY", 123, 137], ["pneumonia", "DISEASE", 30, 39], ["Patients", "ORGANISM", 0, 8], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 60, 82], ["blood", "ORGANISM_SUBSTANCE", 123, 128], ["patient", "ORGANISM", 187, 194], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 187, 194], ["other infective pneumonia", "PROBLEM", 14, 39], ["bronchoalveolar lavage", "TEST", 60, 82], ["viral panel", "TEST", 90, 101], ["serologic tests", "TEST", 103, 118], ["blood cultures", "TEST", 123, 137], ["methodsCTs", "TEST", 152, 162], ["infective", "OBSERVATION_MODIFIER", 20, 29], ["pneumonia", "OBSERVATION", 30, 39], ["bronchoalveolar lavage", "OBSERVATION", 60, 82]]], ["Scanning parameters were tube voltage 120 kV and tube current modulation 100 mA.", [["tube", "TISSUE", 49, 53], ["Scanning parameters", "TEST", 0, 19], ["tube voltage", "TEST", 25, 37], ["tube current modulation", "TREATMENT", 49, 72]]], ["Images were reconstructed with a slice thickness of 1 mm or 2 mm.", [["Images", "TEST", 0, 6], ["a slice thickness", "TEST", 31, 48]]], ["All images were reconstructed on both lung (width, 1500 HU; level: -700 HU) and mediastinal (width, 350 HU; level: 40 HU) settings.ResultsThe number of symptomatic patients was 25/33 (75.7%).", [["lung", "ANATOMY", 38, 42], ["mediastinal", "ANATOMY", 80, 91], ["lung", "ORGAN", 38, 42], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["All images", "TEST", 0, 10], ["level", "TEST", 60, 65], ["level", "TEST", 108, 113], ["both", "ANATOMY_MODIFIER", 33, 37], ["lung", "ANATOMY", 38, 42], ["700 HU", "OBSERVATION_MODIFIER", 68, 74], ["mediastinal", "ANATOMY", 80, 91], ["350 HU", "OBSERVATION_MODIFIER", 100, 106], ["40 HU", "OBSERVATION_MODIFIER", 115, 120], ["symptomatic", "OBSERVATION_MODIFIER", 152, 163]]], ["At clinical presentation, they reported fever and dry cough, and six out of 25 (24%) cases also reported dyspnea.", [["fever", "DISEASE", 40, 45], ["dry cough", "DISEASE", 50, 59], ["dyspnea", "DISEASE", 105, 112], ["fever", "PROBLEM", 40, 45], ["dry cough", "PROBLEM", 50, 59], ["dyspnea", "PROBLEM", 105, 112], ["fever", "OBSERVATION", 40, 45], ["dry", "OBSERVATION_MODIFIER", 50, 53], ["cough", "OBSERVATION", 54, 59], ["dyspnea", "OBSERVATION", 105, 112]]], ["Thirty-three (33; 100%) showed GGO at CT; 15/33 (45.45%) presented pure GGO and 18/33 (54.54%) presented GGO with consolidation.", [["GGO", "DISEASE", 72, 75], ["GGO", "DISEASE", 105, 108], ["GGO at CT", "TEST", 31, 40], ["GGO", "PROBLEM", 105, 108], ["consolidation", "PROBLEM", 114, 127], ["GGO", "OBSERVATION", 31, 34], ["GGO", "OBSERVATION", 72, 75], ["GGO", "OBSERVATION", 105, 108], ["consolidation", "OBSERVATION", 114, 127]]], ["COVID-19 pneumonia was suspected because of the CT report and clinical presentation so an RT-PCR assay by nasopharyngeal swab was performed; interestingly, the virus was not detected in any patient.", [["nasopharyngeal swab", "ANATOMY", 106, 125], ["pneumonia", "DISEASE", 9, 18], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 106, 125], ["patient", "ORGANISM", 190, 197], ["patient", "SPECIES", 190, 197], ["COVID", "TEST", 0, 5], ["pneumonia", "PROBLEM", 9, 18], ["the CT report", "TEST", 44, 57], ["an RT-PCR assay", "TEST", 87, 102], ["nasopharyngeal swab", "TEST", 106, 125], ["the virus", "PROBLEM", 156, 165], ["pneumonia", "OBSERVATION", 9, 18]]], ["We investigated other potential underlying diseases: neoplastic causes (8/33, 24.24%) and non-neoplastic causes, in particular, infectious pneumonias (16/33, 48,48 %, viral and fungal), interstitial pneumonias (4/33, 12,12%), and cardio-pulmonary disease (5/33, 15,15%).", [["neoplastic", "ANATOMY", 53, 63], ["non-neoplastic", "ANATOMY", 90, 104], ["interstitial", "ANATOMY", 186, 198], ["pulmonary", "ANATOMY", 237, 246], ["pneumonias", "DISEASE", 139, 149], ["interstitial pneumonias", "DISEASE", 186, 209], ["cardio-pulmonary disease", "DISEASE", 230, 254], ["pulmonary", "ORGAN", 237, 246], ["neoplastic causes", "PROBLEM", 53, 70], ["non-neoplastic causes", "PROBLEM", 90, 111], ["infectious pneumonias", "PROBLEM", 128, 149], ["viral and fungal)", "PROBLEM", 167, 184], ["interstitial pneumonias", "PROBLEM", 186, 209], ["cardio-pulmonary disease", "PROBLEM", 230, 254], ["diseases", "OBSERVATION", 43, 51], ["neoplastic", "OBSERVATION", 53, 63], ["non-neoplastic", "OBSERVATION", 90, 104], ["infectious", "OBSERVATION_MODIFIER", 128, 138], ["pneumonias", "OBSERVATION", 139, 149], ["fungal", "OBSERVATION_MODIFIER", 177, 183], ["interstitial", "ANATOMY_MODIFIER", 186, 198], ["pneumonias", "OBSERVATION", 199, 209], ["cardio", "ANATOMY", 230, 236], ["pulmonary", "ANATOMY", 237, 246], ["disease", "OBSERVATION", 247, 254]]], ["The different meaning of GGO in every category was also investigated.DiscussionSince GGO lesions can be caused by a wide spectrum of pathologies, a GGO is a non-specific radiological finding.", [["GGO lesions", "ANATOMY", 85, 96], ["GGO", "DISEASE", 25, 28], ["GGO", "DISEASE", 148, 151], ["GGO lesions", "CANCER", 85, 96], ["GGO", "PROBLEM", 25, 28], ["GGO lesions", "PROBLEM", 85, 96], ["a wide spectrum of pathologies", "PROBLEM", 114, 144], ["a GGO", "PROBLEM", 146, 151], ["a non-specific radiological finding", "PROBLEM", 155, 190], ["different", "OBSERVATION_MODIFIER", 4, 13], ["GGO", "OBSERVATION", 25, 28], ["lesions", "OBSERVATION", 89, 96], ["pathologies", "OBSERVATION", 133, 144], ["non-specific", "OBSERVATION_MODIFIER", 157, 169]]], ["It does not represent a confirmed diagnosis, even in the Covid-19 era.", [["the Covid", "TEST", 53, 62], ["does not represent", "UNCERTAINTY", 3, 21]]], ["It is, therefore, necessary to understand the underlying histopathology and to integrate imaging with clinical and lab data to achieve the correct diagnosis.", [["integrate imaging", "TEST", 79, 96], ["clinical and lab data", "TEST", 102, 123]]], ["According to our experience, in the current paper, we distinguished between the neoplastic and non-neoplastic causes of GGO.", [["neoplastic", "ANATOMY", 80, 90], ["non-neoplastic", "ANATOMY", 95, 109], ["GGO", "DISEASE", 120, 123], ["the neoplastic and non-neoplastic causes of GGO", "PROBLEM", 76, 123], ["neoplastic", "OBSERVATION", 80, 90], ["non-neoplastic", "OBSERVATION", 95, 109], ["GGO", "OBSERVATION", 120, 123]]], ["For each category, we analyzed the diagnostic pitfalls and discussed management during radiological practice.DiscussionLung adenocarcinomaDiscussionA 39-year-old male patient, a health worker, presented to the emergency department, with a history of dry cough.", [["dry cough", "DISEASE", 250, 259], ["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 167, 174], ["dry cough", "PROBLEM", 250, 259], ["cough", "OBSERVATION", 254, 259]]], ["He did not report any significant comorbidity, nor malignancies in his clinical history.", [["malignancies", "ANATOMY", 51, 63], ["malignancies", "DISEASE", 51, 63], ["malignancies", "CANCER", 51, 63], ["any significant comorbidity", "PROBLEM", 18, 45], ["malignancies", "PROBLEM", 51, 63], ["malignancies", "OBSERVATION", 51, 63]]], ["In suspicion of COVID-19 pneumonia (clinical and epidemiological criteria), an RT-PCR assay on nasopharyngeal swab was performed.", [["nasopharyngeal swab", "ANATOMY", 95, 114], ["pneumonia", "DISEASE", 25, 34], ["nasopharyngeal swab", "CANCER", 95, 114], ["COVID-19 pneumonia", "PROBLEM", 16, 34], ["an RT-PCR assay", "TEST", 76, 91], ["nasopharyngeal swab", "TEST", 95, 114], ["suspicion of", "UNCERTAINTY", 3, 15], ["pneumonia", "OBSERVATION", 25, 34], ["nasopharyngeal", "ANATOMY", 95, 109]]], ["Later, he underwent a chest CT scan.", [["a chest CT scan", "TEST", 20, 35], ["chest", "ANATOMY", 22, 27]]], ["The report showed a pure ground-glass nodule in the apical segment of the left superior lobe (Figures 1-2).", [["apical segment", "ANATOMY", 52, 66], ["left superior lobe", "ANATOMY", 74, 92], ["apical segment", "MULTI-TISSUE_STRUCTURE", 52, 66], ["superior lobe", "MULTI-TISSUE_STRUCTURE", 79, 92], ["a pure ground-glass nodule", "PROBLEM", 18, 44], ["pure", "OBSERVATION_MODIFIER", 20, 24], ["glass nodule", "OBSERVATION", 32, 44], ["apical", "ANATOMY_MODIFIER", 52, 58], ["segment", "ANATOMY_MODIFIER", 59, 66], ["left superior lobe", "ANATOMY", 74, 92]]], ["The result of the RT-PCR was negative.DiscussionConsidering the mild symptomatology and the presence of pure GGO, early-stage COVID-19 pneumonia could have been diagnosed; nevertheless, it is important to consider lung cancer as an incidental finding.", [["lung cancer", "ANATOMY", 214, 225], ["GGO", "DISEASE", 109, 112], ["pneumonia", "DISEASE", 135, 144], ["lung cancer", "DISEASE", 214, 225], ["lung cancer", "CANCER", 214, 225], ["the RT-PCR", "TEST", 14, 24], ["the mild symptomatology", "PROBLEM", 60, 83], ["pure GGO", "PROBLEM", 104, 112], ["early-stage COVID", "PROBLEM", 114, 131], ["pneumonia", "PROBLEM", 135, 144], ["lung cancer", "PROBLEM", 214, 225], ["negative", "OBSERVATION", 29, 37], ["GGO", "OBSERVATION", 109, 112], ["pneumonia", "OBSERVATION", 135, 144], ["lung", "ANATOMY", 214, 218], ["cancer", "OBSERVATION", 219, 225]]], ["According to the Fleischner Society Guidelines, a 12-months follow-up was recommended [5].DiscussionGGO is a common sign of lung cancer.", [["lung cancer", "ANATOMY", 124, 135], ["lung cancer", "DISEASE", 124, 135], ["lung cancer", "CANCER", 124, 135], ["lung cancer", "PROBLEM", 124, 135], ["lung", "ANATOMY", 124, 128], ["cancer", "OBSERVATION", 129, 135]]], ["According to the World Health Organization (WHO) classification, adenocarcinoma and its precursors are classified into preinvasive lesions (atypical adenomatous hyperplasia (AAH) and adenocarcinoma in situ (AIS)), minimally invasive adenocarcinoma (MIA), typically presenting as a pure GGO nodule greater than 10 mm in diameter, and invasive adenocarcinoma.", [["adenocarcinoma", "ANATOMY", 65, 79], ["preinvasive lesions", "ANATOMY", 119, 138], ["atypical adenomatous hyperplasia", "ANATOMY", 140, 172], ["AAH", "ANATOMY", 174, 177], ["adenocarcinoma in situ", "ANATOMY", 183, 205], ["AIS", "ANATOMY", 207, 210], ["invasive adenocarcinoma", "ANATOMY", 224, 247], ["MIA", "ANATOMY", 249, 252], ["GGO nodule", "ANATOMY", 286, 296], ["invasive adenocarcinoma", "ANATOMY", 333, 356], ["adenocarcinoma", "DISEASE", 65, 79], ["adenomatous hyperplasia", "DISEASE", 149, 172], ["AAH", "DISEASE", 174, 177], ["adenocarcinoma", "DISEASE", 183, 197], ["AIS", "DISEASE", 207, 210], ["adenocarcinoma", "DISEASE", 233, 247], ["MIA", "DISEASE", 249, 252], ["adenocarcinoma", "DISEASE", 342, 356], ["adenocarcinoma", "CANCER", 65, 79], ["preinvasive lesions", "CANCER", 119, 138], ["atypical adenomatous hyperplasia", "CANCER", 140, 172], ["AAH", "CANCER", 174, 177], ["adenocarcinoma", "CANCER", 183, 197], ["adenocarcinoma", "CANCER", 233, 247], ["MIA", "CANCER", 249, 252], ["GGO nodule", "CANCER", 286, 296], ["adenocarcinoma", "CANCER", 342, 356], ["adenocarcinoma", "PROBLEM", 65, 79], ["preinvasive lesions", "PROBLEM", 119, 138], ["atypical adenomatous hyperplasia (AAH)", "PROBLEM", 140, 178], ["adenocarcinoma in situ (AIS)", "PROBLEM", 183, 211], ["minimally invasive adenocarcinoma (MIA)", "PROBLEM", 214, 253], ["a pure GGO nodule", "PROBLEM", 279, 296], ["invasive adenocarcinoma", "PROBLEM", 333, 356], ["adenocarcinoma", "OBSERVATION", 65, 79], ["preinvasive", "OBSERVATION_MODIFIER", 119, 130], ["lesions", "OBSERVATION", 131, 138], ["atypical", "OBSERVATION_MODIFIER", 140, 148], ["adenomatous", "OBSERVATION_MODIFIER", 149, 160], ["hyperplasia", "OBSERVATION", 161, 172], ["adenocarcinoma", "OBSERVATION", 183, 197], ["minimally", "OBSERVATION_MODIFIER", 214, 223], ["invasive", "OBSERVATION_MODIFIER", 224, 232], ["adenocarcinoma", "OBSERVATION", 233, 247], ["GGO", "OBSERVATION_MODIFIER", 286, 289], ["nodule", "OBSERVATION", 290, 296], ["greater", "OBSERVATION_MODIFIER", 297, 304], ["than 10 mm", "OBSERVATION_MODIFIER", 305, 315], ["diameter", "OBSERVATION_MODIFIER", 319, 327], ["invasive", "OBSERVATION_MODIFIER", 333, 341], ["adenocarcinoma", "OBSERVATION", 342, 356]]], ["In general, lung adenocarcinomas are thought to follow a path in which AAH progresses to AIS, followed by invasive adenocarcinoma.", [["lung adenocarcinomas", "ANATOMY", 12, 32], ["invasive adenocarcinoma", "ANATOMY", 106, 129], ["lung adenocarcinomas", "DISEASE", 12, 32], ["AAH", "DISEASE", 71, 74], ["AIS", "DISEASE", 89, 92], ["adenocarcinoma", "DISEASE", 115, 129], ["lung adenocarcinomas", "CANCER", 12, 32], ["AAH", "CANCER", 71, 74], ["adenocarcinoma", "CANCER", 115, 129], ["lung adenocarcinomas", "PROBLEM", 12, 32], ["AAH", "PROBLEM", 71, 74], ["AIS", "PROBLEM", 89, 92], ["invasive adenocarcinoma", "PROBLEM", 106, 129], ["lung", "ANATOMY", 12, 16], ["adenocarcinomas", "OBSERVATION", 17, 32], ["invasive", "OBSERVATION_MODIFIER", 106, 114], ["adenocarcinoma", "OBSERVATION", 115, 129]]], ["Most pure ground-glass nodules (GGN - without solid component) are preinvasive adenocarcinomas, often behaving as indolent tumors; semisolid nodules tend to be adenocarcinomas, as well as invasive because of the intrinsic histological difference in the solid component: the more they grow, the more invasive they are [6].DiscussionThe GGOs of AIS usually manifest as regions of slightly higher attenuation relative to the opacity of AAH due to the histopathologic difference in the number of cellular components within the nodule or the thickness of alveolar walls.", [["GGN", "ANATOMY", 32, 35], ["preinvasive adenocarcinomas", "ANATOMY", 67, 94], ["tumors", "ANATOMY", 123, 129], ["semisolid nodules", "ANATOMY", 131, 148], ["adenocarcinomas", "ANATOMY", 160, 175], ["cellular", "ANATOMY", 492, 500], ["nodule", "ANATOMY", 523, 529], ["alveolar walls", "ANATOMY", 550, 564], ["adenocarcinomas", "DISEASE", 79, 94], ["tumors", "DISEASE", 123, 129], ["adenocarcinomas", "DISEASE", 160, 175], ["AIS", "DISEASE", 343, 346], ["AAH", "DISEASE", 433, 436], ["ground-glass nodules", "CANCER", 10, 30], ["GGN", "CANCER", 32, 35], ["preinvasive adenocarcinomas", "CANCER", 67, 94], ["indolent tumors", "CANCER", 114, 129], ["semisolid nodules", "CANCER", 131, 148], ["adenocarcinomas", "CANCER", 160, 175], ["AAH", "CANCER", 433, 436], ["cellular", "CELL", 492, 500], ["nodule", "CANCER", 523, 529], ["alveolar walls", "MULTI-TISSUE_STRUCTURE", 550, 564], ["Most pure ground-glass nodules", "PROBLEM", 0, 30], ["GGN", "TEST", 32, 35], ["solid component", "PROBLEM", 46, 61], ["preinvasive adenocarcinomas", "PROBLEM", 67, 94], ["indolent tumors", "PROBLEM", 114, 129], ["semisolid nodules", "PROBLEM", 131, 148], ["adenocarcinomas", "PROBLEM", 160, 175], ["the intrinsic histological difference in the solid component", "PROBLEM", 208, 268], ["AIS", "PROBLEM", 343, 346], ["slightly higher attenuation", "PROBLEM", 378, 405], ["the opacity of AAH", "PROBLEM", 418, 436], ["the histopathologic difference", "PROBLEM", 444, 474], ["the nodule", "PROBLEM", 519, 529], ["glass nodules", "OBSERVATION", 17, 30], ["without", "UNCERTAINTY", 38, 45], ["solid component", "OBSERVATION_MODIFIER", 46, 61], ["preinvasive", "OBSERVATION_MODIFIER", 67, 78], ["adenocarcinomas", "OBSERVATION", 79, 94], ["indolent", "OBSERVATION_MODIFIER", 114, 122], ["tumors", "OBSERVATION", 123, 129], ["semisolid", "OBSERVATION_MODIFIER", 131, 140], ["nodules", "OBSERVATION", 141, 148], ["adenocarcinomas", "OBSERVATION", 160, 175], ["solid component", "OBSERVATION_MODIFIER", 253, 268], ["slightly", "OBSERVATION_MODIFIER", 378, 386], ["higher attenuation", "OBSERVATION_MODIFIER", 387, 405], ["opacity", "OBSERVATION", 422, 429], ["histopathologic", "OBSERVATION_MODIFIER", 448, 463], ["difference", "OBSERVATION_MODIFIER", 464, 474], ["number", "OBSERVATION_MODIFIER", 482, 488], ["cellular", "OBSERVATION_MODIFIER", 492, 500], ["components", "OBSERVATION_MODIFIER", 501, 511], ["nodule", "OBSERVATION", 523, 529], ["thickness", "OBSERVATION_MODIFIER", 537, 546], ["alveolar", "ANATOMY_MODIFIER", 550, 558], ["walls", "ANATOMY_MODIFIER", 559, 564]]], ["Pure GGNs greater than 16.4 mm in diameter have been reported to represent invasive adenocarcinoma [7-8].DiscussionInfectious disease: viral pneumoniaDiscussionA 32-year-old male presented with a two-week history of high fever (T-max 39.5\u00b0C), cough, and muscle ache.", [["invasive adenocarcinoma", "ANATOMY", 75, 98], ["muscle", "ANATOMY", 254, 260], ["adenocarcinoma", "DISEASE", 84, 98], ["DiscussionInfectious disease", "DISEASE", 105, 133], ["viral pneumoniaDiscussionA", "DISEASE", 135, 161], ["fever", "DISEASE", 221, 226], ["cough", "DISEASE", 243, 248], ["muscle ache", "DISEASE", 254, 265], ["GGNs", "GENE_OR_GENE_PRODUCT", 5, 9], ["invasive adenocarcinoma", "CANCER", 75, 98], ["male", "ORGANISM", 174, 178], ["muscle", "ORGAN", 254, 260], ["ache", "ORGANISM_SUBDIVISION", 261, 265], ["Pure GGNs", "TEST", 0, 9], ["invasive adenocarcinoma", "PROBLEM", 75, 98], ["high fever", "PROBLEM", 216, 226], ["T", "TEST", 228, 229], ["cough", "PROBLEM", 243, 248], ["muscle ache", "PROBLEM", 254, 265], ["greater", "OBSERVATION_MODIFIER", 10, 17], ["16.4 mm", "OBSERVATION_MODIFIER", 23, 30], ["reported to represent", "UNCERTAINTY", 53, 74], ["invasive", "OBSERVATION_MODIFIER", 75, 83], ["adenocarcinoma", "OBSERVATION", 84, 98], ["cough", "OBSERVATION", 243, 248], ["muscle", "ANATOMY", 254, 260], ["ache", "OBSERVATION", 261, 265]]], ["Blood tests showed mild lymphopenia (900/mmc) and high C-reactive protein (CRP) levels (56 mg/L, normal value <5); therefore, an ongoing infective process was suspected.", [["Blood", "ANATOMY", 0, 5], ["lymphopenia", "DISEASE", 24, 35], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 55, 73], ["CRP", "GENE_OR_GENE_PRODUCT", 75, 78], ["C-reactive protein", "PROTEIN", 55, 73], ["CRP", "PROTEIN", 75, 78], ["Blood tests", "TEST", 0, 11], ["mild lymphopenia", "PROBLEM", 19, 35], ["mmc", "TEST", 41, 44], ["high C-reactive protein", "PROBLEM", 50, 73], ["CRP", "TEST", 75, 78], ["levels", "TEST", 80, 86], ["an ongoing infective process", "PROBLEM", 126, 154], ["mild", "OBSERVATION_MODIFIER", 19, 23], ["lymphopenia", "OBSERVATION", 24, 35], ["infective", "OBSERVATION", 137, 146]]], ["Considering the possibility of COVID-19 pneumonia, RT-PCR was performed twice for the persistence of typical symptoms and because of chest CT findings, highly suspect for viral pneumonia.", [["chest", "ANATOMY", 133, 138], ["pneumonia", "DISEASE", 40, 49], ["viral pneumonia", "DISEASE", 171, 186], ["COVID-19", "SPECIES", 31, 39], ["COVID", "TEST", 31, 36], ["pneumonia", "PROBLEM", 40, 49], ["RT-PCR", "TEST", 51, 57], ["typical symptoms", "PROBLEM", 101, 117], ["chest CT findings", "TEST", 133, 150], ["viral pneumonia", "PROBLEM", 171, 186], ["pneumonia", "OBSERVATION", 40, 49], ["chest", "ANATOMY", 133, 138], ["highly suspect for", "UNCERTAINTY", 152, 170], ["viral", "OBSERVATION_MODIFIER", 171, 176], ["pneumonia", "OBSERVATION", 177, 186]]], ["The CT scan reported a consolidating area in the medial segment of the middle lobe and GGOs in the lower left lobe (Figures 3-4).", [["medial segment", "ANATOMY", 49, 63], ["middle lobe", "ANATOMY", 71, 82], ["GGOs", "ANATOMY", 87, 91], ["lower left lobe", "ANATOMY", 99, 114], ["medial segment", "MULTI-TISSUE_STRUCTURE", 49, 63], ["middle lobe", "MULTI-TISSUE_STRUCTURE", 71, 82], ["GGOs", "CANCER", 87, 91], ["left lobe", "MULTI-TISSUE_STRUCTURE", 105, 114], ["The CT scan", "TEST", 0, 11], ["GGOs in the lower left lobe", "PROBLEM", 87, 114], ["Figures", "TEST", 116, 123], ["consolidating", "OBSERVATION", 23, 36], ["medial", "ANATOMY_MODIFIER", 49, 55], ["segment", "ANATOMY_MODIFIER", 56, 63], ["middle lobe", "ANATOMY", 71, 82], ["lower", "ANATOMY_MODIFIER", 99, 104], ["left lobe", "ANATOMY", 105, 114]]], ["Since the RT-PCR persisted negative, a BAL was performed and influenza A virus detected by multiplex PCR.", [["BAL", "ANATOMY", 39, 42], ["influenza A virus", "ORGANISM", 61, 78], ["influenza A virus", "SPECIES", 61, 78], ["influenza A virus", "SPECIES", 61, 78], ["the RT-PCR", "TEST", 6, 16], ["a BAL", "TEST", 37, 42], ["influenza A virus", "PROBLEM", 61, 78], ["multiplex PCR", "TEST", 91, 104]]], ["The differential diagnosis among viral pneumonias appears to be extremely difficult: there is a significant overlap in the imaging appearance and overlapping with other inflammatory lung diseases; furthermore, blood exams are highly unspecific, too, showing generally lymphopenia and slightly increased CRP.DiscussionThe CT patterns of viral pneumonia are related to the pathogenesis of the viral infection and are affected by the immune status of the host and the underlying pathophysiology of the viral pathogen.", [["lung", "ANATOMY", 182, 186], ["blood", "ANATOMY", 210, 215], ["viral pneumonias", "DISEASE", 33, 49], ["lung diseases", "DISEASE", 182, 195], ["lymphopenia", "DISEASE", 268, 279], ["viral pneumonia", "DISEASE", 336, 351], ["viral infection", "DISEASE", 391, 406], ["lung", "ORGAN", 182, 186], ["blood", "ORGANISM_SUBSTANCE", 210, 215], ["CRP", "GENE_OR_GENE_PRODUCT", 303, 306], ["CRP", "PROTEIN", 303, 306], ["viral pneumonias", "PROBLEM", 33, 49], ["a significant overlap in the imaging appearance", "PROBLEM", 94, 141], ["other inflammatory lung diseases", "PROBLEM", 163, 195], ["blood exams", "TEST", 210, 221], ["generally lymphopenia", "PROBLEM", 258, 279], ["slightly increased CRP", "PROBLEM", 284, 306], ["The CT", "TEST", 317, 323], ["viral pneumonia", "PROBLEM", 336, 351], ["the viral infection", "PROBLEM", 387, 406], ["the viral pathogen", "PROBLEM", 495, 513], ["viral", "OBSERVATION_MODIFIER", 33, 38], ["pneumonias", "OBSERVATION", 39, 49], ["significant", "OBSERVATION_MODIFIER", 96, 107], ["overlap", "OBSERVATION", 108, 115], ["inflammatory", "OBSERVATION_MODIFIER", 169, 181], ["lung", "ANATOMY", 182, 186], ["diseases", "OBSERVATION", 187, 195], ["lymphopenia", "OBSERVATION", 268, 279], ["slightly", "OBSERVATION_MODIFIER", 284, 292], ["increased", "OBSERVATION_MODIFIER", 293, 302], ["CRP", "OBSERVATION_MODIFIER", 303, 306], ["viral", "OBSERVATION_MODIFIER", 336, 341], ["pneumonia", "OBSERVATION", 342, 351], ["viral", "OBSERVATION_MODIFIER", 391, 396], ["infection", "OBSERVATION", 397, 406], ["viral pathogen", "OBSERVATION", 499, 513]]], ["Moreover, viruses of the same family have similar pathogenesis; consequently, viral pneumonia caused by different viruses from the same virus family exhibits a similar pattern on chest CT images [9-10].", [["viral pneumonia", "DISEASE", 78, 93], ["similar pathogenesis", "PROBLEM", 42, 62], ["viral pneumonia", "PROBLEM", 78, 93], ["different viruses", "PROBLEM", 104, 121], ["chest CT images", "TEST", 179, 194], ["viruses", "OBSERVATION", 10, 17], ["similar", "OBSERVATION_MODIFIER", 42, 49], ["pathogenesis", "OBSERVATION", 50, 62], ["viral", "OBSERVATION_MODIFIER", 78, 83], ["pneumonia", "OBSERVATION", 84, 93], ["different", "OBSERVATION_MODIFIER", 104, 113], ["viruses", "OBSERVATION", 114, 121], ["chest", "ANATOMY", 179, 184]]], ["GGOs represent areas of alveolar damage and, in patients developing acute respiratory distress syndrome (ARDS), fluid-refilled alveoli.", [["alveolar", "ANATOMY", 24, 32], ["respiratory", "ANATOMY", 74, 85], ["alveoli", "ANATOMY", 127, 134], ["alveolar damage", "DISEASE", 24, 39], ["acute respiratory distress syndrome", "DISEASE", 68, 103], ["ARDS", "DISEASE", 105, 109], ["GGOs", "SIMPLE_CHEMICAL", 0, 4], ["alveolar", "TISSUE", 24, 32], ["patients", "ORGANISM", 48, 56], ["alveoli", "MULTI-TISSUE_STRUCTURE", 127, 134], ["patients", "SPECIES", 48, 56], ["alveolar damage", "PROBLEM", 24, 39], ["acute respiratory distress syndrome", "PROBLEM", 68, 103], ["ARDS", "PROBLEM", 105, 109], ["fluid-refilled alveoli", "PROBLEM", 112, 134], ["areas", "OBSERVATION_MODIFIER", 15, 20], ["alveolar damage", "OBSERVATION", 24, 39], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory distress syndrome", "OBSERVATION", 74, 103], ["ARDS", "OBSERVATION", 105, 109], ["fluid", "OBSERVATION", 112, 117], ["refilled alveoli", "OBSERVATION", 118, 134]]], ["COVID-19 is a new type of viral pneumonia; previous studies have demonstrated frequent CT findings, in particular, bilateral GGO and interstitial thickening, similar to other viral pneumonias, specifically SARS, and MERS, belonging to the same Viridae.", [["interstitial", "ANATOMY", 133, 145], ["viral pneumonia", "DISEASE", 26, 41], ["GGO", "DISEASE", 125, 128], ["viral pneumonias", "DISEASE", 175, 191], ["SARS", "DISEASE", 206, 210], ["COVID", "TEST", 0, 5], ["viral pneumonia", "PROBLEM", 26, 41], ["previous studies", "TEST", 43, 59], ["frequent CT findings", "PROBLEM", 78, 98], ["bilateral GGO", "PROBLEM", 115, 128], ["interstitial thickening", "PROBLEM", 133, 156], ["other viral pneumonias", "PROBLEM", 169, 191], ["SARS", "PROBLEM", 206, 210], ["new", "OBSERVATION_MODIFIER", 14, 17], ["viral", "OBSERVATION_MODIFIER", 26, 31], ["pneumonia", "OBSERVATION", 32, 41], ["bilateral", "ANATOMY_MODIFIER", 115, 124], ["GGO", "OBSERVATION", 125, 128], ["interstitial", "ANATOMY_MODIFIER", 133, 145], ["thickening", "OBSERVATION", 146, 156], ["viral", "OBSERVATION_MODIFIER", 175, 180], ["pneumonias", "OBSERVATION", 181, 191]]], ["SARS and MERS outbreaks were also due to a coronavirus: consequently, studying and understanding those epidemics may be helpful in managing the current pandemics [11].DiscussionA and B influenza viruses belong to the Orthomyxoviridae family.", [["SARS", "DISEASE", 0, 4], ["coronavirus", "DISEASE", 43, 54], ["B influenza viruses", "ORGANISM", 183, 202], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 217, 233], ["Orthomyxoviridae family", "PROTEIN", 217, 240], ["B influenza viruses", "SPECIES", 183, 202], ["B influenza viruses", "SPECIES", 183, 202], ["SARS", "PROBLEM", 0, 4], ["MERS outbreaks", "PROBLEM", 9, 23], ["a coronavirus", "PROBLEM", 41, 54], ["B influenza viruses", "PROBLEM", 183, 202]]], ["In individuals with chronic comorbidities (diabetes, cardiac failure), severe complications leading to ARDS may occur.DiscussionChest CT shows bilateral reticular areas of opacity, sometimes with focal areas of consolidation, usually in the lower lobes.", [["cardiac", "ANATOMY", 53, 60], ["reticular areas", "ANATOMY", 153, 168], ["lower lobes", "ANATOMY", 241, 252], ["chronic comorbidities", "DISEASE", 20, 41], ["diabetes", "DISEASE", 43, 51], ["cardiac failure", "DISEASE", 53, 68], ["ARDS", "DISEASE", 103, 107], ["opacity", "DISEASE", 172, 179], ["cardiac", "ORGAN", 53, 60], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 241, 252], ["chronic comorbidities", "PROBLEM", 20, 41], ["diabetes", "PROBLEM", 43, 51], ["cardiac failure", "PROBLEM", 53, 68], ["severe complications", "PROBLEM", 71, 91], ["ARDS", "PROBLEM", 103, 107], ["DiscussionChest CT", "TEST", 118, 136], ["bilateral reticular areas of opacity", "PROBLEM", 143, 179], ["consolidation", "PROBLEM", 211, 224], ["chronic", "OBSERVATION_MODIFIER", 20, 27], ["comorbidities", "OBSERVATION", 28, 41], ["cardiac", "ANATOMY", 53, 60], ["failure", "OBSERVATION", 61, 68], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["complications", "OBSERVATION", 78, 91], ["ARDS", "OBSERVATION", 103, 107], ["bilateral", "ANATOMY_MODIFIER", 143, 152], ["reticular", "ANATOMY_MODIFIER", 153, 162], ["opacity", "OBSERVATION", 172, 179], ["focal", "OBSERVATION_MODIFIER", 196, 201], ["areas", "OBSERVATION_MODIFIER", 202, 207], ["consolidation", "OBSERVATION", 211, 224], ["lower lobes", "ANATOMY", 241, 252]]], ["Patchy GGOs can be associated with the areas of consolidation.", [["Patchy GGOs", "PROBLEM", 0, 11], ["consolidation", "PROBLEM", 48, 61], ["GGOs", "OBSERVATION", 7, 11], ["areas", "OBSERVATION_MODIFIER", 39, 44], ["consolidation", "OBSERVATION", 48, 61]]], ["Pleural effusion is rare.DiscussionInterstitial pneumoniasDiscussionA 39-year-old female affected by Sj\u00f6gren syndrome underwent a scheduled chest CT scan to assess lung involvement.", [["Pleural", "ANATOMY", 0, 7], ["chest", "ANATOMY", 140, 145], ["lung", "ANATOMY", 164, 168], ["Pleural effusion", "DISEASE", 0, 16], ["Interstitial pneumoniasDiscussionA", "DISEASE", 35, 69], ["Sj\u00f6gren syndrome", "DISEASE", 101, 117], ["female", "ORGANISM", 82, 88], ["lung", "ORGAN", 164, 168], ["Pleural effusion", "PROBLEM", 0, 16], ["Interstitial pneumoniasDiscussionA", "PROBLEM", 35, 69], ["Sj\u00f6gren syndrome", "PROBLEM", 101, 117], ["a scheduled chest CT scan", "TEST", 128, 153], ["lung involvement", "PROBLEM", 164, 180], ["effusion", "OBSERVATION", 8, 16], ["chest", "ANATOMY", 140, 145], ["lung", "ANATOMY", 164, 168], ["involvement", "OBSERVATION", 169, 180]]], ["GGOs were reported bilaterally, predominantly in the lower lobes, along with interstitial thickening (Figures 5-6).", [["lower lobes", "ANATOMY", 53, 64], ["interstitial", "ANATOMY", 77, 89], ["GGOs", "GENE_OR_GENE_PRODUCT", 0, 4], ["lower", "ORGANISM_SUBDIVISION", 53, 58], ["lobes", "ORGAN", 59, 64], ["interstitial thickening", "PROBLEM", 77, 100], ["Figures", "TEST", 102, 109], ["bilaterally", "ANATOMY_MODIFIER", 19, 30], ["predominantly", "OBSERVATION_MODIFIER", 32, 45], ["lower lobes", "ANATOMY", 53, 64], ["interstitial", "ANATOMY_MODIFIER", 77, 89], ["thickening", "OBSERVATION", 90, 100]]], ["Despite the typical imaging features and the onset of mild symptoms, the report excluded COVID-19 pneumonia; interstitial inflammatory involvement was correctly diagnosed.", [["interstitial", "ANATOMY", 109, 121], ["pneumonia", "DISEASE", 98, 107], ["mild symptoms", "PROBLEM", 54, 67], ["COVID", "TEST", 89, 94], ["pneumonia", "PROBLEM", 98, 107], ["interstitial inflammatory involvement", "PROBLEM", 109, 146], ["mild", "OBSERVATION_MODIFIER", 54, 58], ["pneumonia", "OBSERVATION", 98, 107], ["interstitial", "ANATOMY_MODIFIER", 109, 121], ["inflammatory", "OBSERVATION", 122, 134]]], ["CT findings, along with clinical history, led to the correct diagnosis: it could have been misinterpreted since, in the COVID-19 era, every patient should be considered positive until proven negative.", [["patient", "ORGANISM", 140, 147], ["patient", "SPECIES", 140, 147], ["CT findings", "TEST", 0, 11]]], ["RT-PCR confirmed negative.DiscussionInterstitial pneumonias are a heterogeneous group of diffuse parenchymal lung diseases caused by a combination of inflammation and fibrosis.", [["Interstitial", "ANATOMY", 36, 48], ["parenchymal lung", "ANATOMY", 97, 113], ["Interstitial pneumonias", "DISEASE", 36, 59], ["parenchymal lung diseases", "DISEASE", 97, 122], ["inflammation", "DISEASE", 150, 162], ["fibrosis", "DISEASE", 167, 175], ["lung", "ORGAN", 109, 113], ["RT-PCR", "TEST", 0, 6], ["Interstitial pneumonias", "PROBLEM", 36, 59], ["diffuse parenchymal lung diseases", "PROBLEM", 89, 122], ["inflammation", "PROBLEM", 150, 162], ["fibrosis", "PROBLEM", 167, 175], ["negative", "OBSERVATION", 17, 25], ["Interstitial", "OBSERVATION_MODIFIER", 36, 48], ["pneumonias", "OBSERVATION", 49, 59], ["heterogeneous", "OBSERVATION_MODIFIER", 66, 79], ["diffuse", "OBSERVATION_MODIFIER", 89, 96], ["parenchymal", "ANATOMY_MODIFIER", 97, 108], ["lung", "ANATOMY", 109, 113], ["diseases", "OBSERVATION", 114, 122], ["inflammation", "OBSERVATION", 150, 162], ["fibrosis", "OBSERVATION", 167, 175]]], ["The primary site of injury is the interstitium, which includes the space between the epithelial and endothelial membranes; airspaces, airways, and vessels are often affected [12].", [["interstitium", "ANATOMY", 34, 46], ["epithelial", "ANATOMY", 85, 95], ["endothelial membranes", "ANATOMY", 100, 121], ["airspaces", "ANATOMY", 123, 132], ["airways", "ANATOMY", 134, 141], ["vessels", "ANATOMY", 147, 154], ["interstitium", "TISSUE", 34, 46], ["epithelial", "TISSUE", 85, 95], ["endothelial membranes", "CELLULAR_COMPONENT", 100, 121], ["airspaces", "MULTI-TISSUE_STRUCTURE", 123, 132], ["airways", "MULTI-TISSUE_STRUCTURE", 134, 141], ["vessels", "MULTI-TISSUE_STRUCTURE", 147, 154], ["injury", "PROBLEM", 20, 26], ["airspaces, airways, and vessels", "PROBLEM", 123, 154], ["injury", "OBSERVATION", 20, 26], ["interstitium", "OBSERVATION", 34, 46], ["space", "ANATOMY_MODIFIER", 67, 72], ["epithelial", "ANATOMY_MODIFIER", 85, 95], ["endothelial membranes", "ANATOMY", 100, 121], ["airspaces", "ANATOMY_MODIFIER", 123, 132], ["airways", "ANATOMY", 134, 141], ["vessels", "ANATOMY", 147, 154]]], ["Interstitial pneumonias may be idiopathic or secondary to a variety of other causes, including collagen vascular diseases, pneumoconiosis, infection, and smoking.", [["Interstitial", "ANATOMY", 0, 12], ["vascular", "ANATOMY", 104, 112], ["Interstitial pneumonias", "DISEASE", 0, 23], ["idiopathic", "DISEASE", 31, 41], ["collagen vascular diseases", "DISEASE", 95, 121], ["pneumoconiosis", "DISEASE", 123, 137], ["infection", "DISEASE", 139, 148], ["smoking", "CHEMICAL", 154, 161], ["collagen", "GENE_OR_GENE_PRODUCT", 95, 103], ["vascular", "MULTI-TISSUE_STRUCTURE", 104, 112], ["Interstitial pneumonias", "PROBLEM", 0, 23], ["idiopathic", "PROBLEM", 31, 41], ["other causes", "PROBLEM", 71, 83], ["collagen vascular diseases", "PROBLEM", 95, 121], ["pneumoconiosis", "PROBLEM", 123, 137], ["infection", "PROBLEM", 139, 148], ["pneumonias", "OBSERVATION", 13, 23], ["may be", "UNCERTAINTY", 24, 30], ["idiopathic", "OBSERVATION", 31, 41], ["variety", "OBSERVATION_MODIFIER", 60, 67], ["collagen", "OBSERVATION_MODIFIER", 95, 103], ["vascular", "ANATOMY", 104, 112], ["diseases", "OBSERVATION", 113, 121], ["pneumoconiosis", "OBSERVATION", 123, 137], ["infection", "OBSERVATION", 139, 148]]], ["The American Thoracic Society and European Respiratory Society classification includes seven clinicopathologic entities: idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia, acute interstitial pneumonia (AIP), respiratory bronchiolitis (RB)-associated interstitial lung disease (ILD), desquamative interstitial pneumonia (DIP), and lymphoid interstitial pneumonia (LIP) [13].DiscussionLIP is regarded as a variant of diffuse pulmonary lymphoid hyperplasia primarily affecting the interstitium and it is distinguished from low-grade malignant lymphoproliferative diseases with immunohistochemical analysis.", [["pulmonary", "ANATOMY", 132, 141], ["respiratory", "ANATOMY", 271, 282], ["interstitial lung", "ANATOMY", 313, 330], ["lymphoid interstitial", "ANATOMY", 393, 414], ["pulmonary lymphoid hyperplasia", "ANATOMY", 486, 516], ["interstitium", "ANATOMY", 541, 553], ["idiopathic pulmonary fibrosis", "DISEASE", 121, 150], ["IPF", "DISEASE", 152, 155], ["interstitial pneumonia", "DISEASE", 170, 192], ["NSIP", "DISEASE", 194, 198], ["pneumonia", "DISEASE", 224, 233], ["interstitial pneumonia", "DISEASE", 241, 263], ["AIP", "DISEASE", 265, 268], ["respiratory bronchiolitis", "DISEASE", 271, 296], ["RB", "DISEASE", 298, 300], ["interstitial lung disease", "DISEASE", 313, 338], ["ILD", "DISEASE", 340, 343], ["interstitial pneumonia", "DISEASE", 359, 381], ["DIP", "DISEASE", 383, 386], ["lymphoid interstitial pneumonia", "DISEASE", 393, 424], ["pulmonary lymphoid hyperplasia", "DISEASE", 486, 516], ["malignant lymphoproliferative diseases", "DISEASE", 593, 631], ["pulmonary", "ORGAN", 132, 141], ["lung", "ORGAN", 326, 330], ["pulmonary lymphoid hyperplasia", "PATHOLOGICAL_FORMATION", 486, 516], ["interstitium", "TISSUE", 541, 553], ["low-grade malignant lymphoproliferative", "CANCER", 583, 622], ["idiopathic pulmonary fibrosis", "PROBLEM", 121, 150], ["IPF)", "PROBLEM", 152, 156], ["nonspecific interstitial pneumonia (NSIP)", "PROBLEM", 158, 199], ["cryptogenic organizing pneumonia", "PROBLEM", 201, 233], ["acute interstitial pneumonia (AIP)", "PROBLEM", 235, 269], ["respiratory bronchiolitis (RB)", "PROBLEM", 271, 301], ["interstitial lung disease", "PROBLEM", 313, 338], ["ILD)", "PROBLEM", 340, 344], ["desquamative interstitial pneumonia (DIP)", "PROBLEM", 346, 387], ["lymphoid interstitial pneumonia (LIP)", "PROBLEM", 393, 430], ["diffuse pulmonary lymphoid hyperplasia", "PROBLEM", 478, 516], ["low-grade malignant lymphoproliferative diseases", "PROBLEM", 583, 631], ["immunohistochemical analysis", "TEST", 637, 665], ["Thoracic", "ANATOMY", 13, 21], ["Society", "OBSERVATION", 22, 29], ["idiopathic", "OBSERVATION_MODIFIER", 121, 131], ["pulmonary", "ANATOMY", 132, 141], ["fibrosis", "OBSERVATION", 142, 150], ["IPF", "OBSERVATION", 152, 155], ["nonspecific", "OBSERVATION_MODIFIER", 158, 169], ["interstitial", "ANATOMY_MODIFIER", 170, 182], ["pneumonia", "OBSERVATION", 183, 192], ["NSIP", "OBSERVATION", 194, 198], ["cryptogenic", "OBSERVATION_MODIFIER", 201, 212], ["organizing", "OBSERVATION_MODIFIER", 213, 223], ["pneumonia", "OBSERVATION", 224, 233], ["acute", "OBSERVATION_MODIFIER", 235, 240], ["interstitial", "ANATOMY_MODIFIER", 241, 253], ["pneumonia", "OBSERVATION", 254, 263], ["respiratory", "ANATOMY", 271, 282], ["bronchiolitis", "OBSERVATION", 283, 296], ["interstitial", "ANATOMY_MODIFIER", 313, 325], ["lung", "ANATOMY", 326, 330], ["disease", "OBSERVATION", 331, 338], ["desquamative", "OBSERVATION_MODIFIER", 346, 358], ["interstitial", "ANATOMY_MODIFIER", 359, 371], ["pneumonia", "OBSERVATION", 372, 381], ["DIP", "OBSERVATION_MODIFIER", 383, 386], ["lymphoid", "ANATOMY", 393, 401], ["interstitial", "ANATOMY_MODIFIER", 402, 414], ["pneumonia", "OBSERVATION", 415, 424], ["LIP", "ANATOMY", 426, 429], ["diffuse", "OBSERVATION_MODIFIER", 478, 485], ["pulmonary", "ANATOMY", 486, 495], ["lymphoid hyperplasia", "OBSERVATION", 496, 516], ["interstitium", "ANATOMY", 541, 553], ["low-grade", "OBSERVATION_MODIFIER", 583, 592], ["malignant", "OBSERVATION_MODIFIER", 593, 602], ["lymphoproliferative diseases", "OBSERVATION", 603, 631]]], ["LIP is frequently associated with systemic disorders (Sj\u00f6gren syndrome, acquired immunodeficiency virus (AIDS), Hashimoto thyroiditis) [14].DiscussionAbnormalities on CT in patients with LIP are usually bilateral and may be diffuse or have lower lung predominance.", [["lung", "ANATOMY", 246, 250], ["systemic disorders", "DISEASE", 34, 52], ["Sj\u00f6gren syndrome", "DISEASE", 54, 70], ["acquired immunodeficiency virus", "DISEASE", 72, 103], ["AIDS", "DISEASE", 105, 109], ["Hashimoto thyroiditis", "DISEASE", 112, 133], ["acquired immunodeficiency virus", "ORGANISM", 72, 103], ["patients", "ORGANISM", 173, 181], ["LIP", "CANCER", 187, 190], ["lung", "ORGAN", 246, 250], ["immunodeficiency virus", "SPECIES", 81, 103], ["patients", "SPECIES", 173, 181], ["systemic disorders", "PROBLEM", 34, 52], ["Sj\u00f6gren syndrome", "PROBLEM", 54, 70], ["acquired immunodeficiency virus (AIDS)", "PROBLEM", 72, 110], ["Hashimoto thyroiditis", "PROBLEM", 112, 133], ["CT", "TEST", 167, 169], ["lower lung predominance", "PROBLEM", 240, 263], ["Hashimoto thyroiditis", "OBSERVATION", 112, 133], ["LIP", "ANATOMY", 187, 190], ["bilateral", "ANATOMY_MODIFIER", 203, 212], ["may be", "UNCERTAINTY", 217, 223], ["diffuse", "OBSERVATION_MODIFIER", 224, 231], ["lower", "ANATOMY_MODIFIER", 240, 245], ["lung", "ANATOMY", 246, 250], ["predominance", "OBSERVATION", 251, 263]]], ["A typical finding is GGO, representing diffuse interstitial phlogistic involvement, along with interlobular thickening.", [["interstitial phlogistic", "ANATOMY", 47, 70], ["interlobular", "ANATOMY", 95, 107], ["GGO", "DISEASE", 21, 24], ["interstitial phlogistic", "PATHOLOGICAL_FORMATION", 47, 70], ["interlobular", "MULTI-TISSUE_STRUCTURE", 95, 107], ["GGO", "PROBLEM", 21, 24], ["diffuse interstitial phlogistic involvement", "PROBLEM", 39, 82], ["interlobular thickening", "PROBLEM", 95, 118], ["GGO", "OBSERVATION", 21, 24], ["diffuse", "OBSERVATION_MODIFIER", 39, 46], ["interstitial", "ANATOMY_MODIFIER", 47, 59], ["phlogistic involvement", "OBSERVATION", 60, 82], ["interlobular", "ANATOMY_MODIFIER", 95, 107], ["thickening", "OBSERVATION", 108, 118]]], ["Centrilobular nodules and perivascular cysts are also common, representing inflammatory infiltration of the peribronchiolar interstitium [15].DiscussionChronic obstructive pulmonary disease (COPD): emphysemaDiscussionA 54-year-old male underwent a heart transplant due to severe dilatative cardiomyopathy associated with mitral failure.", [["Centrilobular nodules", "ANATOMY", 0, 21], ["perivascular cysts", "ANATOMY", 26, 44], ["peribronchiolar interstitium", "ANATOMY", 108, 136], ["pulmonary", "ANATOMY", 172, 181], ["heart", "ANATOMY", 248, 253], ["mitral", "ANATOMY", 321, 327], ["perivascular cysts", "DISEASE", 26, 44], ["Chronic obstructive pulmonary disease", "DISEASE", 152, 189], ["COPD", "DISEASE", 191, 195], ["cardiomyopathy", "DISEASE", 290, 304], ["mitral failure", "DISEASE", 321, 335], ["Centrilobular nodules", "PATHOLOGICAL_FORMATION", 0, 21], ["perivascular cysts", "PATHOLOGICAL_FORMATION", 26, 44], ["peribronchiolar interstitium", "TISSUE", 108, 136], ["pulmonary", "ORGAN", 172, 181], ["male", "ORGANISM", 231, 235], ["heart", "ORGAN", 248, 253], ["mitral", "MULTI-TISSUE_STRUCTURE", 321, 327], ["Centrilobular nodules", "PROBLEM", 0, 21], ["perivascular cysts", "PROBLEM", 26, 44], ["inflammatory infiltration of the peribronchiolar interstitium", "PROBLEM", 75, 136], ["Chronic obstructive pulmonary disease", "PROBLEM", 152, 189], ["a heart transplant", "TREATMENT", 246, 264], ["severe dilatative cardiomyopathy", "PROBLEM", 272, 304], ["mitral failure", "PROBLEM", 321, 335], ["nodules", "OBSERVATION", 14, 21], ["perivascular", "ANATOMY_MODIFIER", 26, 38], ["cysts", "OBSERVATION", 39, 44], ["inflammatory", "OBSERVATION_MODIFIER", 75, 87], ["infiltration", "OBSERVATION", 88, 100], ["peribronchiolar", "ANATOMY_MODIFIER", 108, 123], ["interstitium", "ANATOMY_MODIFIER", 124, 136], ["Chronic", "OBSERVATION_MODIFIER", 152, 159], ["obstructive", "OBSERVATION_MODIFIER", 160, 171], ["pulmonary", "ANATOMY", 172, 181], ["disease", "OBSERVATION", 182, 189], ["COPD", "OBSERVATION", 191, 195], ["heart", "ANATOMY", 248, 253], ["transplant", "OBSERVATION", 254, 264], ["severe", "OBSERVATION_MODIFIER", 272, 278], ["cardiomyopathy", "OBSERVATION", 290, 304], ["mitral", "ANATOMY", 321, 327], ["failure", "OBSERVATION", 328, 335]]], ["He also reported centrilobular emphysema in his clinical history.", [["centrilobular emphysema", "ANATOMY", 17, 40], ["emphysema", "DISEASE", 31, 40], ["centrilobular emphysema", "PATHOLOGICAL_FORMATION", 17, 40], ["centrilobular emphysema", "PROBLEM", 17, 40], ["centrilobular", "OBSERVATION_MODIFIER", 17, 30], ["emphysema", "OBSERVATION", 31, 40]]], ["During hospitalization and rehabilitation, direct contact with a COVID-19-positive patient was reported.", [["COVID-19", "CHEMICAL", 65, 73], ["COVID-19", "GENE_OR_GENE_PRODUCT", 65, 73], ["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90], ["rehabilitation", "TREATMENT", 27, 41], ["a COVID", "TEST", 63, 70]]], ["Since the patient developed a cough, a chest CT scan was performed, reporting patchy bilateral ground-glass opacities affecting both the superior and inferior lobes, along with mild bronchiectasis (Figure 7).DiscussionA careful review of the previous CT showed diffuse ground-glass opacities bilaterally, completely similar to the most recent lung findings: COVID-19 pneumonia was excluded (Figure 8).", [["superior", "ANATOMY", 137, 145], ["inferior lobes", "ANATOMY", 150, 164], ["lung", "ANATOMY", 343, 347], ["cough", "DISEASE", 30, 35], ["bronchiectasis", "DISEASE", 182, 196], ["pneumonia", "DISEASE", 367, 376], ["patient", "ORGANISM", 10, 17], ["superior", "CANCER", 137, 145], ["inferior lobes", "MULTI-TISSUE_STRUCTURE", 150, 164], ["lung", "ORGAN", 343, 347], ["patient", "SPECIES", 10, 17], ["a cough", "PROBLEM", 28, 35], ["a chest CT scan", "TEST", 37, 52], ["patchy bilateral ground-glass opacities", "PROBLEM", 78, 117], ["mild bronchiectasis", "PROBLEM", 177, 196], ["the previous CT", "TEST", 238, 253], ["diffuse ground-glass opacities bilaterally", "PROBLEM", 261, 303], ["COVID", "TEST", 358, 363], ["pneumonia", "PROBLEM", 367, 376], ["cough", "OBSERVATION", 30, 35], ["chest", "ANATOMY", 39, 44], ["patchy", "OBSERVATION_MODIFIER", 78, 84], ["bilateral", "ANATOMY_MODIFIER", 85, 94], ["ground-glass opacities", "OBSERVATION", 95, 117], ["both", "ANATOMY_MODIFIER", 128, 132], ["superior", "ANATOMY_MODIFIER", 137, 145], ["inferior lobes", "ANATOMY", 150, 164], ["mild", "OBSERVATION_MODIFIER", 177, 181], ["bronchiectasis", "OBSERVATION", 182, 196], ["diffuse", "OBSERVATION_MODIFIER", 261, 268], ["ground-glass opacities", "OBSERVATION", 269, 291], ["bilaterally", "ANATOMY_MODIFIER", 292, 303], ["lung", "ANATOMY", 343, 347], ["pneumonia", "OBSERVATION", 367, 376]]], ["The RT-PCR negative swab confirmed the radiological report.DiscussionCT in centrilobular-emphysema shows small, well-defined or poorly defined areas of low attenuation surrounded by normal lung; centrilobular pulmonary arteries or arterioles mark the center of each lobule.", [["centrilobular-emphysema", "ANATOMY", 75, 98], ["lung", "ANATOMY", 189, 193], ["centrilobular pulmonary arteries", "ANATOMY", 195, 227], ["arterioles", "ANATOMY", 231, 241], ["lobule", "ANATOMY", 266, 272], ["emphysema", "DISEASE", 89, 98], ["centrilobular-emphysema", "PATHOLOGICAL_FORMATION", 75, 98], ["lung", "ORGAN", 189, 193], ["centrilobular pulmonary arteries", "MULTI-TISSUE_STRUCTURE", 195, 227], ["arterioles", "MULTI-TISSUE_STRUCTURE", 231, 241], ["lobule", "MULTI-TISSUE_STRUCTURE", 266, 272], ["The RT-PCR", "TEST", 0, 10], ["centrilobular-emphysema", "PROBLEM", 75, 98], ["small, well-defined or poorly defined areas of low attenuation", "PROBLEM", 105, 167], ["centrilobular pulmonary arteries", "PROBLEM", 195, 227], ["centrilobular", "OBSERVATION_MODIFIER", 75, 88], ["emphysema", "OBSERVATION", 89, 98], ["small", "OBSERVATION_MODIFIER", 105, 110], ["well-defined", "OBSERVATION_MODIFIER", 112, 124], ["poorly defined", "OBSERVATION_MODIFIER", 128, 142], ["areas", "OBSERVATION_MODIFIER", 143, 148], ["low attenuation", "OBSERVATION", 152, 167], ["normal", "OBSERVATION", 182, 188], ["lung", "ANATOMY", 189, 193], ["centrilobular", "ANATOMY_MODIFIER", 195, 208], ["pulmonary arteries", "ANATOMY", 209, 227], ["arterioles", "OBSERVATION", 231, 241], ["center", "OBSERVATION_MODIFIER", 251, 257], ["lobule", "OBSERVATION_MODIFIER", 266, 272]]], ["The low-attenuation areas may range from 1-3 mm.", [["The low-attenuation areas", "PROBLEM", 0, 25], ["low", "OBSERVATION_MODIFIER", 4, 7], ["-attenuation", "OBSERVATION_MODIFIER", 7, 19], ["areas", "OBSERVATION_MODIFIER", 20, 25], ["range", "OBSERVATION_MODIFIER", 30, 35], ["from 1-3 mm", "OBSERVATION_MODIFIER", 36, 47]]], ["Small airway disease is often a component of both emphysema-predominant disease and airway-predominant disease involving larger airways.", [["airway", "ANATOMY", 6, 12], ["airway", "ANATOMY", 84, 90], ["airways", "ANATOMY", 128, 135], ["airway disease", "DISEASE", 6, 20], ["emphysema", "DISEASE", 50, 59], ["airway", "MULTI-TISSUE_STRUCTURE", 6, 12], ["airway", "MULTI-TISSUE_STRUCTURE", 84, 90], ["airways", "MULTI-TISSUE_STRUCTURE", 128, 135], ["Small airway disease", "PROBLEM", 0, 20], ["both emphysema", "PROBLEM", 45, 59], ["predominant disease", "PROBLEM", 60, 79], ["airway-predominant disease involving larger airways", "PROBLEM", 84, 135], ["airway", "ANATOMY", 6, 12], ["disease", "OBSERVATION", 13, 20], ["component", "OBSERVATION_MODIFIER", 32, 41], ["both", "OBSERVATION_MODIFIER", 45, 49], ["emphysema", "OBSERVATION", 50, 59], ["predominant", "OBSERVATION_MODIFIER", 60, 71], ["disease", "OBSERVATION", 72, 79], ["airway", "ANATOMY", 84, 90], ["predominant", "OBSERVATION_MODIFIER", 91, 102], ["disease", "OBSERVATION", 103, 110], ["larger", "OBSERVATION_MODIFIER", 121, 127], ["airways", "ANATOMY", 128, 135]]], ["Isolated small airway disease can also occur as a primary expression of COPD [16].DiscussionIn addition to centrilobular nodules, CT in cigarette smokers could show the typical imaging features of infiltrative lung disease, including GGOs and reticular anomalies, which likely correspond to variable combinations of respiratory bronchiolitis, airspace enlargement with fibrosis, and smoking-related interstitial fibrosis [17].", [["airway", "ANATOMY", 15, 21], ["centrilobular nodules", "ANATOMY", 107, 128], ["infiltrative lung", "ANATOMY", 197, 214], ["reticular", "ANATOMY", 243, 252], ["respiratory", "ANATOMY", 316, 327], ["airspace", "ANATOMY", 343, 351], ["interstitial", "ANATOMY", 399, 411], ["airway disease", "DISEASE", 15, 29], ["COPD", "DISEASE", 72, 76], ["lung disease", "DISEASE", 210, 222], ["GGOs", "DISEASE", 234, 238], ["reticular anomalies", "DISEASE", 243, 262], ["respiratory bronchiolitis", "DISEASE", 316, 341], ["airspace enlargement", "DISEASE", 343, 363], ["fibrosis", "DISEASE", 369, 377], ["smoking", "CHEMICAL", 383, 390], ["interstitial fibrosis", "DISEASE", 399, 420], ["airway", "MULTI-TISSUE_STRUCTURE", 15, 21], ["centrilobular nodules", "PATHOLOGICAL_FORMATION", 107, 128], ["lung", "ORGAN", 210, 214], ["GGOs", "CANCER", 234, 238], ["reticular", "PATHOLOGICAL_FORMATION", 243, 252], ["airspace", "MULTI-TISSUE_STRUCTURE", 343, 351], ["Isolated small airway disease", "PROBLEM", 0, 29], ["COPD", "PROBLEM", 72, 76], ["centrilobular nodules", "PROBLEM", 107, 128], ["CT", "TEST", 130, 132], ["infiltrative lung disease", "PROBLEM", 197, 222], ["GGOs", "PROBLEM", 234, 238], ["reticular anomalies", "PROBLEM", 243, 262], ["respiratory bronchiolitis", "PROBLEM", 316, 341], ["airspace enlargement", "PROBLEM", 343, 363], ["fibrosis", "PROBLEM", 369, 377], ["interstitial fibrosis", "PROBLEM", 399, 420], ["small airway disease", "OBSERVATION", 9, 29], ["COPD", "OBSERVATION", 72, 76], ["centrilobular", "OBSERVATION_MODIFIER", 107, 120], ["nodules", "OBSERVATION", 121, 128], ["infiltrative", "OBSERVATION_MODIFIER", 197, 209], ["lung", "ANATOMY", 210, 214], ["disease", "OBSERVATION", 215, 222], ["reticular", "ANATOMY_MODIFIER", 243, 252], ["anomalies", "OBSERVATION", 253, 262], ["respiratory bronchiolitis", "OBSERVATION", 316, 341], ["airspace", "ANATOMY_MODIFIER", 343, 351], ["enlargement", "OBSERVATION", 352, 363], ["fibrosis", "OBSERVATION", 369, 377], ["interstitial", "ANATOMY_MODIFIER", 399, 411], ["fibrosis", "OBSERVATION", 412, 420]]], ["In these findings, the histopathological mechanism underlying GGO is small airway obstruction or fibrosis, which causes vasoconstriction in that area of the lung, shunting blood away from areas of impaired gas exchange, with hyperperfusion of the adjacent normal lung, leading to relatively increased attenuation with a subsequent \u201cmosaic attenuation\u201d aspect [18-19].DiscussionGGO seen on CT can represent a wide spectrum of pathologic conditions, such as inflammatory disease and lung neoplasms.", [["airway", "ANATOMY", 75, 81], ["lung", "ANATOMY", 157, 161], ["blood", "ANATOMY", 172, 177], ["lung", "ANATOMY", 263, 267], ["lung neoplasms", "ANATOMY", 481, 495], ["GGO", "DISEASE", 62, 65], ["airway obstruction", "DISEASE", 75, 93], ["fibrosis", "DISEASE", 97, 105], ["hyperperfusion", "DISEASE", 225, 239], ["lung neoplasms", "DISEASE", 481, 495], ["airway", "MULTI-TISSUE_STRUCTURE", 75, 81], ["lung", "ORGAN", 157, 161], ["blood", "ORGANISM_SUBSTANCE", 172, 177], ["lung", "ORGAN", 263, 267], ["lung neoplasms", "CANCER", 481, 495], ["GGO", "PROBLEM", 62, 65], ["small airway obstruction", "PROBLEM", 69, 93], ["fibrosis", "PROBLEM", 97, 105], ["vasoconstriction", "PROBLEM", 120, 136], ["shunting blood", "PROBLEM", 163, 177], ["impaired gas exchange", "PROBLEM", 197, 218], ["hyperperfusion of the adjacent normal lung", "PROBLEM", 225, 267], ["relatively increased attenuation", "PROBLEM", 280, 312], ["a subsequent \u201cmosaic attenuation\u201d aspect", "PROBLEM", 318, 358], ["CT", "TEST", 389, 391], ["pathologic conditions", "PROBLEM", 425, 446], ["inflammatory disease", "PROBLEM", 456, 476], ["lung neoplasms", "PROBLEM", 481, 495], ["GGO", "OBSERVATION", 62, 65], ["small", "OBSERVATION_MODIFIER", 69, 74], ["airway", "ANATOMY", 75, 81], ["obstruction", "OBSERVATION", 82, 93], ["fibrosis", "OBSERVATION", 97, 105], ["vasoconstriction", "OBSERVATION_MODIFIER", 120, 136], ["lung", "ANATOMY", 157, 161], ["shunting", "OBSERVATION", 163, 171], ["areas", "OBSERVATION_MODIFIER", 188, 193], ["impaired", "OBSERVATION_MODIFIER", 197, 205], ["gas exchange", "OBSERVATION", 206, 218], ["hyperperfusion", "OBSERVATION", 225, 239], ["normal", "OBSERVATION", 256, 262], ["lung", "ANATOMY", 263, 267], ["relatively", "OBSERVATION_MODIFIER", 280, 290], ["increased", "OBSERVATION_MODIFIER", 291, 300], ["attenuation", "OBSERVATION_MODIFIER", 301, 312], ["mosaic", "OBSERVATION_MODIFIER", 332, 338], ["attenuation", "OBSERVATION_MODIFIER", 339, 350], ["pathologic", "OBSERVATION", 425, 435], ["inflammatory", "OBSERVATION_MODIFIER", 456, 468], ["lung", "ANATOMY", 481, 485], ["neoplasms", "OBSERVATION", 486, 495]]], ["The analysis of several parameters, such as bilateral/unilateral involvement localization in the lung parenchyma, superimposed consolidation, and the presence of lymphadenopathies and pleural effusion and associated abnormalities will avoid most pitfalls, indicating a possible diagnosis of the underlying cause and offering a consistent differential diagnosis.", [["lung parenchyma", "ANATOMY", 97, 112], ["lymphadenopathies", "ANATOMY", 162, 179], ["pleural effusion", "ANATOMY", 184, 200], ["lymphadenopathies", "DISEASE", 162, 179], ["pleural effusion", "DISEASE", 184, 200], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 97, 112], ["lymphadenopathies", "CANCER", 162, 179], ["pleural", "ORGAN", 184, 191], ["The analysis", "TEST", 0, 12], ["several parameters", "TEST", 16, 34], ["bilateral/unilateral involvement localization in the lung parenchyma", "PROBLEM", 44, 112], ["superimposed consolidation", "PROBLEM", 114, 140], ["lymphadenopathies", "PROBLEM", 162, 179], ["pleural effusion", "PROBLEM", 184, 200], ["associated abnormalities", "PROBLEM", 205, 229], ["bilateral", "ANATOMY_MODIFIER", 44, 53], ["unilateral", "OBSERVATION_MODIFIER", 54, 64], ["involvement", "OBSERVATION", 65, 76], ["lung", "ANATOMY", 97, 101], ["parenchyma", "ANATOMY_MODIFIER", 102, 112], ["superimposed", "OBSERVATION_MODIFIER", 114, 126], ["consolidation", "OBSERVATION", 127, 140], ["lymphadenopathies", "OBSERVATION", 162, 179], ["pleural", "ANATOMY", 184, 191], ["effusion", "OBSERVATION", 192, 200]]], ["Nevertheless, GGO remains a diagnostic challenge and, therefore, a systematic approach is necessary to ensure an optimal workup.ConclusionsCOVID-19 pneumonia is a novel disease, therefore, special attention to differential diagnoses with clinical and radiological presentations that may mimic it is recommended.", [["GGO", "DISEASE", 14, 17], ["pneumonia", "DISEASE", 148, 157], ["GGO", "PROBLEM", 14, 17], ["a systematic approach", "TEST", 65, 86], ["an optimal workup", "TEST", 110, 127], ["ConclusionsCOVID", "TEST", 128, 144], ["pneumonia", "PROBLEM", 148, 157], ["a novel disease", "PROBLEM", 161, 176], ["pneumonia", "OBSERVATION", 148, 157]]], ["Although CT represents a fundamental diagnostic tool because of its sensitivity, it still needs to be integrated with clinical data to achieve the best clinical management.", [["CT", "TEST", 9, 11], ["clinical data", "TEST", 118, 131]]], ["However, in the presence of typical imaging features (e.g. GGO and consolidation), the radiologist should focus his attention on the pandemic and manage a suspect patient as COVID-19 positive until proven to be negative since it is of primary importance to manage COVID-19 pneumonia as early as possible in order to prevent the contagion from continuing to spread.", [["pneumonia", "DISEASE", 273, 282], ["patient", "ORGANISM", 163, 170], ["patient", "SPECIES", 163, 170], ["GGO", "PROBLEM", 59, 62], ["consolidation", "PROBLEM", 67, 80], ["COVID", "TEST", 174, 179], ["COVID", "TEST", 264, 269], ["pneumonia", "PROBLEM", 273, 282], ["the contagion", "PROBLEM", 324, 337], ["consolidation", "OBSERVATION", 67, 80], ["pneumonia", "OBSERVATION", 273, 282]]]]}